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Abstract 
 
The physical complications of Type 1 diabetes mellitus (T1DM) 
have been understood as an accelerated ageing process (Morley, 2008). 
Do people with T1DM also experience accelerated cognitive and brain 
ageing? Using findings from research of the normal cognitive and brain 
ageing process and conceptualized in theories of the functional brain 
changes in cognitive ageing, a combination of cognitive testing and 
functional magnetic resonance imaging (fMRI) techniques were used to 
evaluate evidence of accelerated cognitive and brain ageing in middle-
aged adults with T1DM. 
The first part of this thesis comprises a cognitive study of 94 
adults (≥  45 years of age) with long duration (≥  10 years) of T1DM. 
Participants completed cognitive assessment and questionnaires on 
general mood and feelings about living with diabetes. Findings 
highlighted the importance of microvascular disease (specifically 
retinopathy) as an independent predictor of cognitive function. The 
incidence and predictors of mild cognitive impairment (MCI) were then 
explored. Results indicate a higher percentage of the group met criteria 
for MCI than expected based on incidence rates in the general 
population, providing initial evidence of accelerated cognitive ageing. 
Psychological factors were explored next. The relationship between the 
measures of well-being, diabetes health, and cognitive function 
highlighted the need for attention to patient’s psychological well-being 
in diabetes care. Finally, a subgroup of 30 participants between the 
ii  
ages of 45 and 65 who differed on severity of retinopathy were selected 
to take part in an fMRI study. Blood oxygen level dependent (BOLD) 
activity was evaluated while participants were engaged in cognitive 
tasks and during rest.  The findings provided evidence that the pattern 
of BOLD activation and functional connectivity for those with high 
severity of retinopathy are similar to patterns found in adults over the 
age of 65. In line with the theories of cognitive ageing, functional 
brain changes appear to maintain a level of cognitive function. 
Evidence of accelerated brain ageing in this primarily middle-aged 
group, emphasizes the importance of treatments and regimens to 
prevent or minimize microvascular complications.   
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                                                           Chapter 1
INTRODUCTION 
 
Type 1 diabetes mellitus (T1DM) is a chronic metabolic condition 
that commonly develops in childhood or adolescence. The physical 
complications of T1DM are well documented. What is less well 
understood is the heightened risk of cognitive dysfunction associated 
with T1DM. In this thesis I investigate the diabetes health predictors of 
cognitive and brain function in middle-aged and older adults with 
T1DM. The aim is to understand how and why T1DM affects cognitive 
and brain function, which aspects are most vulnerable and how this 
relates to cognitive and brain function in normal ageing.  
1.1.  Type 1 Diabetes Mellitus 
Diabetes affects almost 1 in 20 people in the U.K. population, 
with 2.8 million people diagnosed (Diabetes UK, 2011a) and estimates 
of this number rising up to 4 million by 2025 (Diabetes UK, 2010). 
T1DM affects 10% of people with diabetes, approximately 1 in 700 to 
1000, and it  is also on the rise (Diabetes UK, 2010).  TIDM is a 
disorder that occurs when the body is unable to produce insulin. This 
happens when insulin-producing beta cells in the pancreas are 
destroyed by the body’s immune system leading to a disruption in the 
body’s ability to use glucose that is present in the blood. 
 People with T1DM need to administer insulin and maintain a 
careful balance between eating and exercise to keep blood glucose 
values near normal levels. This is referred to as maintaining glycaemic 
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control,  which is essential for preventing extremes of low blood 
glucose (hypoglycaemia) and high blood glucose (hyperglycaemia) and 
related complications. In the course of treatment, a patient’s glycaemic 
control is tested through the HbA1c value. This is a measure of 
glycosylated hemoglobin level,  a product of glucose binding to 
hemoglobin in red blood cells.  The higher an individual’s blood 
glucose level,  the more HbA1c is produced, and the higher percentage 
value of HbA1c (Michigan Diabetes Research and Training Center, 
2009). The HbA1c value is affected by glucose levels over an 8 to 12 
week period and is an established predictor for diabetes complications 
(Nathan, Turgeon, & Regan, 2007). The target HbA1c value for 
individuals with T1DM is 6.5% an HbA1c level at 8.5% or above is 
considered high (Diabetes UK, 2009).  
The brain requires a constant supply of glucose to function 
(McCall,  2004). As a result,  acute hypoglycaemia causes immediate 
impairment of brain function and cognitive processing (McAulay, 
Deary, Sommerfield, & Frier,  2006; Sommerfield, McAulay, Deary, & 
Frier,  2003; Strachan, Ewing, Frier,  McCrimmon & Deary, 2003). 
There is also some evidence that normal cognitive function is disrupted 
when there is an overload of glucose available, or acute 
hyperglycaemia (Cox et al. ,  2005). In the long term, hyperglycaemia 
causes damage to small blood vessels (microvascular diseases) that can 
damage the eyes (retinopathy) kidneys (nephropathy) and peripheral 
nerves (neuropathy; Diabetes UK, 2010). Individuals with T1DM are 
also at elevated risk of damage to large blood vessels (atherosclerosis) 
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leading to an increased risk of early onset of hypertension, heart 
disease and stroke, (Morley, 2008).  
1.2.  Accelerated Ageing in T1DM 
The physical changes due to hyperglycaemia have been 
characterized as an accelerated ageing process (Morley, 2008). This 
process is related to increasing levels of blood glucose (McNay, 2005), 
but other factors are also important (Cheitlin, 2003) including insulin 
resistance, dyslipidaemia, hypertension, and arterial stiffness 
(Aronson, 2003; O'Rourke & Hashimoto, 2007). Given the accelerated 
physiological ageing in T1DM (Aronson, 2003) it  may be possible to 
observe signs of accelerated cognitive ageing in middle-age groups 
with T1DM. 
There is little research available focused on older adults with 
T1DM, and limited information available about cognitive ageing in this 
group. What research does exist shows the same primary areas of 
cognitive processing deficits that have been identified in research with 
younger adults (Brands et al. ,  2006), specifically processing speed and 
cognitive flexibility (switching between tasks). On tasks involving 
information processing speed, older adults showed greater cognitive 
decline prospectively than controls (Van Duinkerken et al. ,  2011), and 
weaker performance compared with controls (Brands et al. ,  2006).  
There is some debate over the evidence of accelerated cognitive 
ageing in T1DM.  Ryan, Geckle, and Orchard (2003) found a 
significant decline in psychomotor speed over a relatively short period 
of time (7 years) in young to middle age adults (age 18-55) with no 
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corresponding decline in a control group, suggesting early decline in 
this particular area. However, in his comparison of older and younger 
groups with T1DM, Ryan (2005) argues that he found no evidence for 
accelerated cognitive ageing because he only found early cognitive 
decline in the area of processing speed and the rate of decline was not 
steeper for older adults in comparison to younger adults.  Although in a 
more recent review of the lieterature, the similarities between the 
normal ageing process and the pattern of cognitive deficits identified 
in adult groups with T1DM have been emphasized (Brands, Kessels, & 
Ryan, 2009). 
Park & Reuter-Lorenz (2009) indicate that the cognitive 
processes most often implicated in normal ageing are working memory 
(short-term storage and mental manipulation of information), executive 
function (inhibition of one thought/action to follow another) and 
processing speed (time to complete a simple cognitive task). Given that 
processing speed is one of the key deficits identified in the normal 
ageing process, it  could be that cognitive processing within the T1DM 
group is a sign of accelerated cognitive ageing and decline in these 
processes may be mitigated by functional brain changes that have not 
been investigated in earlier studies of cognition in T1DM.  
1.3.  Mild Cognitive Impairment and Diabetes 
Another indicator of accelerated cognitive ageing would be a 
heightened and/or earlier incidence of mild cognitive impairment 
(MCI). MCI is generally defined by memory or other cognitive 
impairments out of the normal range for age, with preserved 
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functioning with respect to age in general cognitive function, with 
problems noticeable to the person themselves and others, however 
these problems do not significantly impact daily functioning (Chertkow 
et al. ,  2008; Petersen, 2004; Gauthier et al. ,  2006). In some studies of 
T1DM, the incidence of MCI was not higher in those with and without 
diabetes, however the presence of MCI was associated with longer 
duration, insulin treatment, younger age of onset and diabetes 
complications (Roberts et al. ,  2008). In adults over age 65, Type 2 
diabetes was associated with a 1.4 times higher risk of MCI than for 
those without diabetes (Luchsinger et al. ,  2007). Some studies noted a 
particular deficit  in processing speed in the nature of the MCI noted in 
the diabetes population (Arvanitakis, Wilson, Bienias, Evans, & 
Bennett,  2004; Toro, Schonknecht, & Schroder, 2009), however others 
have reported that memory type (amnestic) MCI is more prevalent than 
non-amnestic types of MCI when controlling for factors such as years 
of education (Luchsinger et al. ,  2007). It  has also been found that older 
adults (over age 50) with T1DM indicate more subjective cognitive 
complaints than those without diabetes of the same age (Brands et al. ,  
2006). Other researchers (Brismar et al. ,  2007) have also found a high 
level of participants reporting a subjective experience of cognitive 
decline (39%) even in a relatively younger group with T1DM (mean 
age = 43.3).  A higher incidence of MCI compared to the normal 
population would provide support of an accelerated cognitive ageing 
process in T1DM. 
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1.4.  Psychological Variables 
People with T1DM need to administer insulin and maintain a 
careful balance between eating and exercise to keep blood glucose 
values near normal levels. With much of the treatment of those with 
diabetes reliant on optimal self-management, psychological variables 
like anxiety, depression and general well being may impact on the 
effective management of diabetes, overall health, and likelihood of 
developing microvascular complications. Depression or other emotional 
factors may then have a negative impact on control and have an 
indirect influence on the incidence of microvascular complications 
(Lustman & Clouse, 2005; Shaban, Fosbury, Cavan, Kerr, & Skinner, 
2009). It  is important to take psychological variables into account 
given the link with control and microvascular disease. Positive 
psychological characteristics could be one factor that contributes to 
better outcomes through the cognitive ageing process. 
1.5.  Functional Brain Imaging in Type 1 diabetes 
Before a case for accelerated ageing can be made or definitively 
ruled-out, it  is necessary to investigate what is happening functionally 
within the brains of indiviuduals with T1DM to sustain cognitive 
processing. To date, functional imaging has been used infrequently in 
the study of cognitive function in T1DM. Results of these studies 
indicate a pattern of altered brain activation for individuals with T1DM 
and retinopathy indicating less task-related deactivation sites 
associated with resting state (Wessels et al. ,  2006) and less 
connectivity in resting state (Van Duinkerken et al,  2011).  
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Neuroimaging studies have revealed some structural differences 
between groups of individuals with T1DM, but these are not often areas 
indicated through cognitive testing. Functional MRI is ideal because it  
l inks cognitive performance and brain function and can answer the 
question of whether there is evidence of accelerated ageing in adults 
with T1DM. 
1.6.  Study Aims and Questions 
1.6.1.  Cognitive Study 
The aim of the cognitive study was to determine whether there is 
evidence of cognitive processing issues in groups who differ on 
diabetes health variables or general health variables and whether these 
differences could be considered signs of accelerated ageing within 
these subgroups. Comparing the outcomes for those with T1DM and 
diabetes health variables (e.g.,  chronic hyperglycaemia, greater 
microvascular disease, recurrent severe hypoglycaemia) to those with 
T1DM and optimal health provides an indication of factors that 
differentiate group performance. Understanding the relationship of 
these factors to cognitive processing can help determine interventions 
that may promote maintenance of cognitive function in ageing. The 
strongest diabetes health predictor of cognitive function that emerged 
from the cognitive study was used in creating comparison groups for 
the neuroimaging study as this factor was considered most likely to 
have influence on brain function within this group.  
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1. Do individuals who differ on diabetes health variables (e.g.,  
glycaemic control,  microvascular complications) show 
significantly different scores on measures of cognitive 
processes?  
2. Is cognitive function related to general health variables and 
health promoting habits (e.g. BMI, blood pressure, cholesterol,  
exercise, cognitive activity)? 
3. Which diabetes health variables have the strongest predictive 
value on cognitive function? 
1.6.2.  Mild Cognitive Impairment 
Although diagnosed MCI was an exclusion criteria for the cognitive 
study, there were some individuals who showed significant cognitive 
deficits on tests used in the cognitive study. The aim of this study was 
to determine the incidence and predictors of MCI. This was used as an 
initial technique to determine the evidence of early cognitive ageing in 
this group with T1DM. High incidence of MCI in middle-aged adults 
was regarded as evidence of early cognitive ageing in this group. 
1. What is the incidence and nature of MCI in the study sample?  
How does this compare to the incidence of MCI the general 
population? 
2. Are there differences in the age, education or general intelligence 
of the participants in the study sample who show MCI in 
comparison to those who show lower levels of cognitive 
impairment?  
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3. Are there differences in general health variables and health habits 
in those who show MCI in comparison to those who show lower 
levels of cognitive impairment?  
4. Are there differences in diabetes health variables for those with 
MCI and in comparison to those who show lower levels of 
cognitive impairment? What are the strongest predictors of MCI? 
1.6.3.  Psychological Variables 
The aim of the investigation of psychological variables was to 
determine whether measures of well-being (e.g.,  anxiety, depression) 
relate to diabetes health variables and cognitive function and what this 
relationship could suggest in optimizing positive outcomes for 
individuals with T1DM. Identification of potential modifiable factors 
may provide targets for promoting maintenance of cognitive function in 
ageing. 
1. What percentage of the study group are classified within each 
category on the HADS anxiety and depression scale?  
2. Do measures of well-being relate to demographic variables? 
3. Do measures of well-being relate to diabetes health variables? 
4. Do measures of well-being relate to cognitive function? 
1.6.4.  Neuroimaging Study 
The aim of the functional neuroimaging study was to determine 
whether there were notable differences in brain function between 
groups with low and high severity of diabetes microvascular 
complications that may suggest early brain ageing in this group.  Use 
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of functional brain imaging provides the ability to determine whether 
cognitive function in groups with greater microvascular complications 
is maintained by brain function typically identified in ageing groups, 
providing evidence of accelerated ageing. 
1. Does neural activation (as indicated by the blood oxygen level 
dependent (BOLD) response in fMRI), when completing a cognitive 
task and at rest,  differ between groups with high severity 
retinopathy and those with low severity retinopathy?  
2. Does BOLD activation in the high severity retinopathy group 
resemble patterns found in normal ageing? 
1.7.  Thesis Outline 
 Although cognitive changes are expected within the normal 
ageing process, chronic disease can also have an influence on these 
cognitive and brain changes. The study of cognitive ageing in T1DM 
provides the opportunity to investigate the impact of different disease 
variables within a group that has had long-standing chronic disease and 
to evaluate evidence of accelerated ageing. The inclusion of personal 
characteristics and psychological variables provides a focus on 
protective and modifiable factors that is typically not included in 
T1DM research and can inform recommendations that help preserve 
cognitive function in ageing. 
This thesis examines cognitive and brain function in middle age 
to older adults with T1DM who differ on aspects of diabetes and to 
determine whether there is evidence of early cognitive and brain ageing 
within this group and the identification of modifiable protective factors 
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of cognitive function in ageing. Initially, cognitive testing was used to 
investigate the relationship of long-term glycaemic control,  diabetes 
complications (e.g. microvascular diseases), as well as general health 
variables and health promoting habits on cognitive performance.  This 
was followed by an examination of the incidence, nature and predictors 
MCI in the study group. Next, the influence of general and diabetes 
specific well-being were examined in their influence on diabetes health 
variables. Finally, functional neuroimaging techniques were used to 
determine whether signs of accelerated brain ageing could be identified 
in individuals with and without microvascular disease.  
Chapter 2 provides an overview of research and theory related to 
the normal cognitive ageing process. Chapter 3 provides detailed 
information on the cognitive processes that appear to be most affected 
in T1DM and within the normal cognitive ageing process. These are the 
cognitive processes that are a focus of this thesis. This chapter also 
includes information on the relationship of these cognitive processes 
diabetes complications These are the key diabetes health variables used 
in the cognitive study and the investigation of MCI. The final part of 
the chapter provides a review of the psychological factors that may 
influence self-management and mitigate the diabetes complications that 
have been related to the cognitive processing deficits identified in 
groups with T1DM and are the focus of the study of psychological 
variables. 
The studies undertaken for this thesis are described in the 
following chapters. Details of the participant group and recruitment are 
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provided in Chapter 4. The cognitive study is described in Chapter 5. 
In this study, a clinic sample of self-referred middle aged and older 
adults with T1DM were asked to complete a battery sampling various 
cognitive processes along with a questionnaire regarding health habits 
and diabetes history and well-being questionnaires. This chapter 
concerns the identification of the strongest diabetes health predictors 
of cognitive function and cognitive change to determine those most 
likely to impact functional brain ageing. Chapter 6 is a closer 
investigation of the sub-group within the sample that met criteria for 
the identification of MCI. This includes comparison to the UK 
incidence statistics and identification of predictors of MCI in the study 
group. In Chapter 7, an investigation of the relationship between 
personal and psychological factors on diabetes and general health 
variables is explored. 
A functional MRI study, is presented in Chapter 8. In this 
neuroimaging study a subgroup of 30 people, who took part in the 
cognitive study, completed functional magnetic resonance imaging 
scans of the brain. Based on results of the cognitive study and MCI 
investigation that microvascular disease (retinopathy) was most 
consistently predictive of cognitive function, participants were placed 
in two groups, those with low severity of retinopathy and those with 
high severity of retinopathy. Brain function was compared when 
completing cognitive tasks and in resting state between these groups 
and compared with results of research in normal ageing populations. 
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Finally, Chapter 9 provides a general discussion of the 
conclusions of the two studies in the thesis evaluating the evidence for 
accelerated ageing in middle aged and older adults with T1DM and the 
potential factors that could protect cognitive function through the 
ageing process. 
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                                                                       Chapter 2
Cognitive Ageing  
 
2.1.  Cognitive Ageing in Healthy Adults 
The cognitive ageing process affects, “people’s abilities to 
activate, to represent and maintain information in mind, to attend to 
relevant but ignore irrelevant information, and to process information 
promptly” (Li, Lindenberger, & Sikström, 2001, p. 479). Results of 
research on normal cognitive ageing indicate that abilities in different 
cognitive domains deteriorate at different rates. Some cognitive 
functions such as processing speed begin to deteriorate early in 
adulthood and others, such as verbal knowledge, remain intact into late 
adulthood. In his cross-sectional studies, Salthouse (2004) found that 
several cognitive processes including immediate verbal memory, 
processing speed, and fluid reasoning decreased steadily from the early 
twenties. In contrast,  he found that crystallized intelligence peaked in 
the forties or fifties and remained stable until  the 70s. It  is thought that 
weakening processing efficiency places limits on the expression of 
both fluid and crystallized intelligence (Li et al. ,  2004).  
Results of the Seattle Longitudinal Study on ageing indicate that 
decrease in functioning in certain domains foreshadow cognitive 
impairment by showing earlier decline (Willis & Schaie, 2005). These 
include immediate and delayed verbal recall,  word fluency and 
psychomotor speed. They found that greater decline of these domains 
in midlife was an effective indicator of future cognitive impairment.  
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Brain structure also changes with age along with changes in 
cognitive performance seen in ageing. The structural brain imaging 
research of Sowell and colleagues (2003) supports findings from 
longitudinal cognitive ageing research. These researchers found that 
between the ages of 7 and 60 there is a decrease in gray matter density 
in dorsal frontal,  parietal lobes, and orbitofrontal cortex that was 
accompanied by increases in white matter volume until  age 40. They 
suggest that this pattern indicates a trade off between gray matter 
volume and myelination of white matter tracks until  this time. After 
age 40 there is a neurodegenerative process with a corresponding 
decrease in brain weight and increase in volume of cerebral spinal 
fluid. The temporal lobes show a gain in gray matter until  the 30s and 
stay stable, only declining in old age, which is consistent with the 
findings for maintenance of crystallized intelligence and vocabulary 
skills well into late adulthood.  
2.2.  Theories of Cognitive Ageing 
Although brain insults and structural changes occur in the normal 
ageing process, cognitive performance may be maintained well for 
some individuals. Two theories that provide explanatory models 
include Cognitive Reserve (Stern, 2002) and Scaffolding Theory of 
Ageing and Cognition (STAC; Park & Reuter-Lorenz, 2009).  
2.2.1.  Cognitive Reserve (CR) 
In the cognitive reserve (CR) model, Stern (2002) suggests that 
the brain adapts to damage through both cognitive processing strategies 
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and compensation. It  is hypothesized that the higher CR of an 
individual, the higher threshold for adapting to brain insults and 
maintaining cognitive performance. In this way the same brain 
pathology may lead to different cognitive outcomes for different 
individuals with more or less cognitive reserve. Tucker and Stern 
(2011) maintain that CR is not a fixed characteristic and that the more 
modifiable factors have independent and combined positive impact on 
CR even when introduced later in life. Increased cognitive reserve can 
be measured by a number of inate and modifiable factors including 
higher intelligence quotient (IQ), professional occupation level, socio-
economic status, literacy, educational attainment, exercise, leisure 
activities, social experiences and cognitive engagement. It  is 
hypothesized that two neural processes underly CR, neural reserve and 
neural compensation (Stern, 2009). Neural reserve is the use of neural 
networks for cognitive processing that have more sustainability, are 
more efficient, and have more capacity to deal with damage or 
demands. Neural compensation is the use of alternate brain networks 
for cognitive processing not usually used to compensate for brain 
damage.  This is supported by research showing that some individuals 
can have more Alzheimer’s Disease (AD) pathology in the brain and 
appear cognitively similar to individuals with less AD pathology and 
the differences observed in the brain networks used by younger and 
older adults to obtain the same performance on a cognitive task (Stern, 
2006; Stern, 2009).  
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2.2.2.  Scaffolding Theory of Ageing and Cognition (STAC) 
Even though a number of cognitive processing abilities are 
changing, alterations in brain function are believed to compensate for 
these changes. Through the Scaffolding Theory of Ageing and 
Cognition (STAC), Park and Reuter-Lorenz (2009) argue that cognitive 
ageing occurs through a combination of neurocognitive declines and 
compensatory neural mechanisms, which are predictive of cognitive 
function. In ageing, scaffolding includes the functional brain changes 
that promote and preserve optimal cognitive function.  They believe 
that the ageing process is adaptive, allowing us to maintain our daily 
functioning and independence even though a number of our cognitive 
processing abilities are changing (Park & Reuter-Lorenz, 2009). 
According to the Park and Reuter-Lorenz (2009), greater degrees of 
functional brain ageing can occur due to some chronic diseases. The 
STAC theory suggests that middle-aged adults who show signs of 
pervasive scaffolding are at risk of early decline in cognitive 
performance. This may manifest in greater incidence and earlier onset 
of mild cognitive impairment (MCI) an intermediate stage between 
normal cognitive ageing and dementia, characterized by cognitive 
processing significantly below age expectations, often in the area of 
memory. Functional neuroimaging studies suggest particular patterns 
evident in ageing. These patterns differentiate older adults from 
younger adults and support cognitive function in ageing. These include 
over-activation in frontal regions, lack of deactivation in areas 
associated with rest (i .e. ,  default mode network) when there are 
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increasing task demands and less connectivity between regions when at 
rest (Reuter-Lorenz & Park, 2010). 
2.3.  Summary 
The cognitive impairments common in normal ageing (deficits in 
processing speed, working memory, and inhibition) are mediated by 
structural and functional brain changes. Two complementary theories 
that are used to understand the maintenance of cognitive performance 
despite brain damage related to aging or disease. Both CR and STAC 
indicate that there are neural networks that compensate for brain 
insults.  CR places emphasis on the inate and modifiable factors that 
can be used to predict better cognitive outcomes and the relation with 
higher neural reserve. STAC focuses on the scaffolding processes, or 
functional changes themselves and how these compensatory 
mechanisms can be enhanced.  Both theories suggest that outcomes in 
cognitive ageing are not fixed and can be influenced through 
modifiable factors across the lifespan. Both of these theories provide 
an understanding of how cognitive processes can be maintained through 
functional brain changes and modified through lifestyle choices . 
Looking at the cognitive performance and brain function through the 
lens of cognitive ageing is important to determine whether ageing in 
the T1DM population appears the same, accelerated, or on a unique 
path to that described in research and theories of healthy cognitive 
ageing. 
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                                                                        Chapter 3
COGNITIVE PROCESSES AND DIABETES HEALTH 
VARIABLES 
 
3.1.  Cognitive Processes Identified in T1DM Research 
A meta-analysis of large group studies has revealed that 
individuals with T1DM show mild to moderate deficits in certain 
cognitive domains in comparison to control groups without diabetes 
(Brands et al. ,  2005). These include crystallized and fluid intelligence, 
psychomotor efficiency, cognitive flexibility, sustained attention, and 
selective attention. Other areas were not significantly affected 
including verbal learning and memory, working memory and language. 
Brands and colleagues (2005) suggest that the lower scores in 
crystallized and fluid intelligence reflected impairments in primary 
mental abilities including efficiency and flexibility, rather than a 
deficit  in general intelligence per se. Since this review was published, 
further studies have also shown a specific deficit in psychomotor 
efficiency and cognitive flexibility for those with T1DM (Brismar et 
al. ,  2007; Jacobson et al. ,  2007; Ryan, 2005). 
The studies of cognition it  T1DM have mainly focused on adults 
under the age of 50 (Brands et al. ,  2005). Results of available research 
regarding older adults are inconclusive. Only small groups have been 
studied primarily representing a healthy group in the Netherlands. 
Brands and colleagues (2006) studied group of 40 individuals with 
T1DM. Although they found a trend for relative deficits in all  
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cognitive domains, the T1DM group only showed a significant 
difference in psychomotor efficiency and cognitive flexibility, the 
same areas typically found in the T1DM research with younger adults.  
They also determined that the level of brain abnormalities were in the 
normal range for age. They concluded that although this older group 
with T1DM did somewhat worse on all cognitive tasks, it  was not 
significant and not related to any structural brain changes. They 
suggested that because their sample drew from a particularly well-
controlled cohort in terms of glucose management, that these factors 
might have diminished the potential to find any other differences 
between the group with T1DM and control groups. In a prospective 
study of the same sample, only on tasks involving information 
processing speed did older adults show greater cognitive decline 
prospectively than controls (Van Duinkerken et al. ,  2011). 
There has also been one study from the United States, with a small 
sample of middle-aged adults.  Ryan (2005) directly compared a cohort 
of individuals with T1DM and controls over a wide age range (18 to 
64) to address the question of whether cognitive changes in the group 
with diabetes resembled that of cognitive ageing. He concluded that the 
answer was no because cognitive impairments for this group were 
primarily in the area of “psychomotor slowing” rather than across 
cognitive domains.  
3.1.1.  Description of Cognitive Processes 
The following is an overview of the key cognitive processes 
identified in T1DM research along with the neuropsychological tests 
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commonly used to assess function in these areas. These cognitive 
processes will be included in the cognitive study test battery. The 
cognitive battery used in this thesis covers all  the cognitive processes 
and tests identified in this chapter.  More specific details of the 
cognitive battery are provided in Chapter 4. 
Fluid and Crystallized Intelligence 
Intelligence has been traditionally conceptualized in terms of a 
contrast between fluid problem solving ability and crystallized 
knowledge. Cattell  (1971) classifies fluid intelligence as inductive and 
deductive reasoning abilities with biological and neurological 
underpinnings affected by incidental learning determined by the 
environment. In contrast crystallized intelligence consists of acquired 
knowledge resulting from cultural experiences. The Raven’s 
Progressive Matrices is a common measure of fluid intelligence and 
vocabulary or general knowledge tests are measures of crystallized 
intelligence (Deary, Whalley, & Crawford, 2004). Given that 
crystallized intelligence is stable into later adulthood, these types of 
tests are used to estimate a person’s past intellectual ability. Premorbid 
intelligence is an estimate or actual baseline cognitive function before 
disease or injury. Evidence from studies on the Scottish Mental Survey 
cohorts indicated a high correlation between a common test of 
premorbid intelligence, the National Adult Reading Test (NART) and 
intelligence tested at age 11(Crawford, Deary, Starr,  & Whalley, 2001).  
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Processing Speed 
Processing speed is a multifaceted cognitive domain that 
encompasses many subdomains. There have been six distinct types of 
speed measures identified by Salthouse (2000). Some include a 
measure of time to complete a task, and others focus on the number of 
items completed within a time limit.  These vary in the relative 
difficulty of the cognitive task and the complexity of the motor 
response. Three distinctions from Salthouse (2000) are helpful in 
understanding past cognitive research with T1DM groups and the 
cognitive tasks used in the current study. These include psychomotor 
speed, perceptual speed, and psychophysical speed. These are 
summarized in Table 3.1. The tasks of processing speed used in the 
cognitive study, Symbol Digit Modalities and Trail Making Test A, are 
types of perceptual speed tasks according to Salthouse’s (2000) 
distinction. Measures of perceptual speed have been related to decision 
accuracy rather than time working on a problem or time to make the 
response (Salthouse, 2000). Across this variety of different measures, 
processing speed has a strong relation with age (Salthouse, 2000). The 
processing speed task used in the neuroimaging study, inspection time, 
is a psychophysical speed task. The processing speed tasks used by 
some researchers are psychomotor speed tasks with a more complex 
motor component, such as the grooved pegboard test used in a study by 
Ryan (2005).  
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Table 3.1 Summary Of Three Types Of Processing Speed Tasks Used In 
T1DM Research And The Current Study (Salthouse, 2000).  
 
 
Executive Function 
Executive functions encompass a number of  related processes. 
Royall and colleagues (2002) define executive functions as a “set of 
cognitive skills responsible for planning, initiating, sequencing and 
Processing 
Speed Task  
Test  Type Measurement Cognit ive 
Diff iculty  
Motor 
Diff iculty  
Psychomotor  
Speed 
Repet i t ive  motor  
movement  or  
manipulat ion 
Time to  complete  
a  motor  task 
Simple –  
performance 
perfect   
Moderate  –  
dependent  
on dexter i ty ,  
hand-eye 
coordinat ion 
Psycho-
physical   
Speed 
Discr iminat ion 
between visual  or  
auditory s t imuli  
presented for  
under  one second 
Correct  
Responses  to  
barely  
perceivable  
visual  or  
auditory s t imulus  
Simple –  
perfect  i f  
s t imulus on 
for  long 
enough 
Simple –  
but ton press  
Perceptual   
Speed 
Visual  search for  
matching i tems,  
complet ing i tems 
using a  code,     
Correct  
responses  within  
a  t ime l imit  to  
s imple content  
Simple –  
perfect  i f  no 
t ime l imit  
Simple –  
paper  and 
penci l  
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monitoring of complex goal-directed behaviour” (p. 378). Miyake and 
colleagues (2000), indicate that the three most studied executive 
functions include “shifting mental set,  monitoring and updating 
working memory, and inhibition of preponent responses” (p. 50) which 
they consider lower level executive functions that underlie more 
complex executive functions such as planning.  
Brands and colleagues (2005) defined cognitive flexibility as the 
ability to shift concepts and problem-solving strategies, fitting with the 
definition of an executive function task, and found that this was a key 
area of cognitive deficit in T1DM. These tasks require set shifting or 
switching from one mode of response to another or determining 
changes in task rules. The executive task used in this study, Trail 
Making Test B (TMT-B; Army Individual Test Battery, 1944), requires 
the participant to switch focus between numbers and letters as quickly 
as possible.  
3.1.2.  Critique of Cognitive Tests used in T1DM Research 
The conclusions of recent research in this area are uncertain due 
to choices of tests for certain cognitive domains. For example, Brismar 
and colleagues (2007) found a broader array of cognitive domains to be 
deficient in individuals with T1DM than some other researchers have 
(Ryan, 2005). However, several of the tests or combinations of tests 
overlap on two or three domains. For example Trail Making B is 
included as a measure of executive function, information processing 
speed and psychomotor efficiency. Digit Symbol Coding and Trail 
Making B were part of the battery for psychomotor speed and speed of 
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information processing with the addition of the Paced Auditory Serial 
Addition Test for speed of information processing. Brismar and 
colleagues (2007) argue that this is because these tests cover several 
different domains, however, this leads to cognitive domains that are 
highly interrelated without clear distinction for some variables.  
There has also been an example of uncertainty in the conclusions 
because there are multiple processes involved in certain cognitive tasks 
that may better explain results.  For example, Ryan et al. ,  (2003) and 
Ryan (2005) suggest that psychomotor speed is the primary deficit  in 
T1DM. However, the main test that Ryan (2005) has classified under 
the heading psychomotor speed is Grooved Pegboard. Ryan (2005) and 
others have found that individuals with T1DM do more poorly on 
Grooved Pegboard than control groups and show decline with age. 
Given that others have suggested that the main component of Grooved 
pegboard is motor performance, manual dexterity and strength (Lezak, 
1995), this emphasizes the significant sex differences that occur in 
scores on this test.  Due to smaller relative hand size, women do better 
than men. The difference in psychomotor speed may have more to do 
with motor than cognitive deficiencies in individuals with T1DM given 
the physical complications that can affect nerve functioning in this 
disease.  
3.2.  Cognitive Processes Identified in Research on Ageing 
There are some areas of cognitive function that have been 
highlighted in research in cognitive ageing that will also be included in 
the cognitive battery given the goal to investigate evidence of early 
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cognitive ageing including two measures of memory - working 
memory, identified as one of the key cognitive processes in the ageing 
process (Park & Reuter-Lorenz, 2009) and episodic memory, an 
impairment common in diagnosis of mild cognitive impairment 
(Petersen, 2011). 
3.2.1.  Working Memory 
Working memory is a “system typically involving attentional 
control and allowing the manipulation of information held in short-
term storage” (Baddeley, 2007, p. 7), whereas short-term memory 
refers to the “immediate recall of small amounts of information” 
(Baddeley, 2007, p. 7). The model of working memory proposed by 
Baddeley and Logie (1999) includes a number of memory subsystems 
of the phonological loop, the visuo-spatial sketchpad, the central 
executive, and the episodic buffer. Working and short-term memory 
have been studied in research on healthy ageing. Tests include 
immediate recall of small amounts of auditory or visual information or 
complex recall with a component of further processing. The task used 
for this research, Digit Span (Wechsler, 1997), is a simple test of 
working memory that includes both storage and processing. Lezak 
(1995) based on evidence from neuropsychological patient performance 
on forward and backward Digit Span contends that backward Digit 
Span requires holding information and mentally rearranging, which is 
more effortful than the more passive task of forward Digit Span. In 
their work with children and adolescents, Gathercole, Pickering, 
Ambridge and Wearing (2004) classified forward Digit Span as a 
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verbal storage task and backward Digit Span as a storage and 
processing task or complex memory span task.  
3.2.2.  Episodic memory 
Episodic memory involves memory for events from the past from 
a specific time and place (Tulving, 1972). There are a number of sub 
processes involved in episodic memory involved in the familiarity and 
recollection of past events (Purves et al. ,  2008). Typical tests that are 
used in the assessment of episodic memory include word list learning 
and story recall.  These include either recall or recognition of learned 
information. These are classified as item memory tests that focus only 
on the content of the memory, with other tests that focus on the 
context, order, space or source in which the information was learned 
(Purves et al. ,  2008). This aspect of memory has not been related to 
T1DM, however is known to decline in healthy ageing (Salthouse, 
2004). 
3.3.  Diabetes Health Variables and Cognitive Processes 
The link between diabetes and specific deficits in cognitive 
processing has been studied by examining diabetes health variables that 
are proposed to underlie these cognitive changes related to the 
dysregulation of glucose levels in the body.  
3.3.1.  Repeated Severe Hypoglycaemia and Cognition 
Findings from the Diabetes Control and Complications Trial 
(DCCT) and the Epidemiology of Diabetes Interventions and 
Complications (EDIC), longitudinal studies of over 1000 patients 
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which followed a group with T1DM for 18 years, found that repeated 
episodes of severe hypoglycaemia were not associated with cognitive 
decline over the long-term (Jacobson et al. ,  2007). This finding has 
generally been replicated in some cross-sectional studies as well 
(Brismar et al. ,  2007) and in brain imaging research (Ferguson et al. ,  
2003). Contradictory evidence has been found in a study of older 
adults,  with severe hypoglycaemia performing worse on overall 
cognitive processing and information processing speed and who were 
more susceptible to cognitive decline (Van Duinkerken et al. ,  2011). 
The researchers suggest that older adults may be more vulnerable to the 
long-term effects of hypoglycaemia than younger adults.  This variable 
may be of higher importance when exploring the reasons for cognitive 
function in older adult groups than in younger adult groups.  
3.3.2.  Chronic Hyperglycaemia and Cognition 
There is conflicting evidence about the relationship of chronic 
hyperglycaemia, as measured by HbA1c percentage, and cognitive 
function. Various summary measures of high HbA1c have been used as 
a measure of chronic hyperglycaemia in studies of cognitive function 
and diabetes. Results of the DCCT/EDIC longitudinal study showed 
that patients with poor glycaemic control or mean HbA1c >8.8% (18 
year mean value) were slower on measures of psychomotor efficiency 
and motor speed than those with better control or mean HbA1c<7.4% 
(Jacobson et al. ,  2007). Conversely, Brismar and colleagues (2007) 
using a more restricted measure of HbA1c (using on average of 5 years 
of values) found that this measure was only weakly correlated to 
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cognitive impairment and had no value as a predictor of cognitive 
function. Similarly, Zihl, Schaaf, and Zillmer (2010) using a single, 
current value of HbA1c did not find a difference in cognitive function 
between groups based on glycaemic control.  One reason for these 
contradictory results may be the differences in the use of a long-term 
or short-term measure of HbA1c. Brismar and colleagues (2007) 
suggested that their value for mean HbA1c was not ideal,  as it  did not 
reflect lifetime glycaemic control or glucose instability. Since HbA1c 
levels vary within the same person for a variety of treatment and 
personal reasons, a restricted measurement may give a false or skewed 
value that does not best characterize glucose control over the long 
term. A mean HbA1c sampled over several years is needed to acquire a 
long-term measure of blood glucose control.   
 T1DM is often first diagnosed in childhood or adolescence. 
Given the brain is refining itself through adolescence and into the 
twenties (Casey, Tottenham, Liston, & Durston, 2005; Giedd, 2008), 
chronic hyperglycaemia during this period of continuing brain 
development may impact brain structure or function. Indeed, there is 
evidence of structural brain differences in children and adolescents 
compared with controls (Perantie et al.  2007), extending into adulthood 
(Musen et al. ,  2006). Brain imaging research has also provided 
evidence that implicates chronic hyperglycaemia in these structural 
differences. A study of children and adolescents (Perantie et al. ,  2007) 
showed hyperglycaemic exposure to be related to differences in gray 
and white matter density, years before the expected development of 
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microvascular complications. Musen and colleagues (2006) found 
evidence of reduced gray matter density in brain areas associated with 
memory (hippocampus, parahippocampal gyrus) language (superior 
temporal and angular gyrus) and attention (left posterior cingulate) for 
adults with a higher lifetime HbA1c average. Kodl and colleagues 
(2008) using Diffusion Tensor Imaging (DTI) analysis showed 
abnormalities in white matter structure for those with T1DM in 
comparison to controls in the posterior corona radiata and the optic 
radiation. Results indicated that chronic hyperglycaemia might have an 
independent effect on cognition. In contrast,  when comparing groups 
that differed in glycaemic control or presence of microvascular disease 
(retinopathy), Weinger and colleagues (2008) showed that these groups 
did not differ in deep white matter or periventricular white matter 
lesions. The results of this study along with the results of the cognitive 
studies by Brismar and colleagues (2007) as well as Zihl and 
colleagues (2010) suggest that evidence on the influence of chronic 
hyperglycaemia on cognitive function is not conclusive. 
3.3.3.  Microvascular Complications and Cognition 
Ryan (2005) found that complications including retinopathy, 
polyneuropathy and peripheral vascular disease were predictive of 
decline in psychomotor efficiency scores. Similarly, Ferguson and 
colleagues (2003) found that only those patients with T1DM who 
presented with background retinopathy showed differences in white 
matter and cognitive function. In a study assessing cognitive change 
after seven years for 103 middle age adults with childhood onset 
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diabetes, Ryan and colleagues (2003), found that changes in 
psychomotor efficiency over this period were strongly related to 
diabetic complications. A more recent study (Brismar et al. ,  2007) 
found that diabetes duration, age at diagnosis , and peripheral nerve 
conduction deficits (neuropathy) showed the strongest correlation with 
measures of psychomotor speed and visual – perception. Unlike the 
other studies, Brismar and colleagues (2007) did not find that 
retinopathy was predictive of cognitive decline. It  is possible that the 
effects of retinopathy may have been masked by another variable 
correlated with retinopathy such as diabetes duration, which was 
identified as a primary predictor of cognitive deficit.  The presence of 
retinopathy was correlated with many of the cognitive domains studied 
and was correlated with many of the other diabetes health variables 
studied. 
Brain imaging studies show evidence of the importance of 
microvascular complications on cognition in T1DM. Ferguson and 
colleagues (2003) studied a group of individuals with T1DM with and 
without retinopathy under the age of 45. Those who developed 
retinopathy showed a significantly higher percentage of small 
punctuate white matter lesions than those without retinopathy in the 
basal ganglia. They suggested that this finding is consistent with the 
presence of enlarged perivascular spaces attributed to diabetic 
microangiopathy. They suggested that retinopathy is a marker of 
suboptimal control of diabetes and that cerebrovascular responsiveness 
in cognitive tasks may be compromised by retinopathy. There was no 
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decline in cognitive performance related to the presence of lesions, 
however the retinopathy group showed weaker cognitive performance 
on processing speed, attention and concentration, and fluid 
intelligence. They suggest cognitive differences stem from vascular 
cause and that impaired cerebrovascular responsiveness may be 
responsible for differences in cognitive functioning. Musen and 
colleagues (2006) associated the structural brain changes that they 
found to be related to hyperglycaemia exposure (a score combining 
median HbA1c and diabetes duration) as evidence for early 
microvascular damage. They suggest that changes in microvasculature 
due to retinopathy decreases vasoreactivity and blood flow, which 
causes deficits in cognitive function in T1DM.  
Using functional Magnetic Resonance Imaging (fMRI) Wessels 
and colleagues (2006) showed a pattern of altered brain activation for 
individuals with T1DM and retinopathy on a working memory task (n-
back) during induced hypoglycemia. The researchers found that there 
was no significant difference in task performance and reaction time 
between the groups with and without retinopathy. When comparing 
performance on the hard and easy version of the task during 
hypoglycaemia, the group with retinopathy showed greater activation 
(left occipital lobe) and no deactivation. The group without retinopathy 
showed deactivation in the anterior and posterior cingulate gyrus and 
left medial frontal gyrus. The group with retinopathy also showed 
increased activation during normal glycaemic values (euglycaemia) in 
the superior frontal gyrus. As well,  the group with retinopathy showed 
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less deactivation when in hypoglycaemia compared with euglycaemia 
in the left anterior cingulate, right orbital frontal gyrus, and left 
parietal lobe. Finally there was an interaction with less deactivation in 
the right orbital frontal gyrus and left anterior cingulate cortex (ACC) 
in the group with retinopathy during hypoglycaemia. These two areas 
are part of the default mode network, which is active in rest and shows 
deactivation in cognitive tasks. They note that some proposed roles for 
the ACC including turning intentions into actions, willed control of 
behaviour and suppression of inappropriate responses. They note that 
the orbitofrontal cortex is involved in voluntary goal-directed 
behaviour and executive function. 
Another study used resting state analysis to compare resting state 
neural connectivity in those with and without microvascular disease 
(Van Duinkerken et al. ,  2011). The researchers used independent 
component analysis and compared differences between those with 
severe microvascular disease (proliferative retinopathy) and without 
microvascular disease (no retinopathy) and controls between the ages 
of 18 and 56.  Those with microvascular disease showed decreased 
connectivity in a variety of networks including attention, working 
memory, auditory, language, motor and visual processes.  
 
Hyperglycaemia or microvascular complications? 
 Individuals with T1DM may sustain chronically high blood 
glucose for years before the signs of microvascular complications are 
evident. Chronic hyperglycaemia does show evidence of effects that are 
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independent of microvascular complications. Results of research with 
children and young adults,  well before the onset of microvascular 
complications, also suggest that chronic hyperglycaemia has an 
independent effect on cognitive functioning (Perantie et al. ,  2007) that 
can be dissociated from that of microvascular disease. With an ageing 
group of individuals with T1DM with long duration, most will be 
affected by retinopathy to some degree (Diabetes UK, 2010). Young 
groups with T1DM have relatively lower rates of microvascular disease 
than older groups with T1DM, with small group size for comparison.  It  
is therefore important to include both measures of mean HbA1c and 
microvascular complications, primarily retinopathy, when evaluating 
predictors of cognitive function. 
 
3.3.4.  Insulin Action 
Insulin action is an emerging area of study in T1DM literature. 
Brismar and his colleagues (2007) theorized that cognitive impairment 
occurs because of a loss of neuro-protective effects of insulin. 
Biessels, Staekenborg, Brunner, Brayne, and Scheltens (2006) suggest 
that hyperinsulinaemia and insulin resistance play a role in the 
development of Alzheimer pathology of amyloid plaques given the 
number of insulin receptors found in crucial brain areas such as the 
hippocampus and cortex. High insulin, related to increased risk of 
strokes, also affects amyloid metabolism by changes in brain of insulin 
and its receptor and formation of advanced glycation end-products 
implicated in both normal ageing and dementia. Study of an older 
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group with long diabetes duration may allow the opportunity to 
investigate the importance of insulin resistance to understanding 
cognitive decline in this group. 
3.4.  Psychological Factors and Diabetes Health 
Although there are a number of possible physical links to the 
deficits in cognitive function there are also personal characteristics and 
psychological variables that influence glycaemic control,  which could 
influence the relationship between T1DM and cognition and these 
diabetes health variables. 
3.4.1.  Self-Management 
In a prospective study, Skinner and Hampson (2001) investigated 
the impact of personal models of diabetes on diabetes self-care. They 
suggest that a personal model of diabetes or a person’s illness beliefs 
can predict self-care, well-being and glycaemic control affecting a 
person’s behaviour and emotions and is influenced by past experiences.  
A change in perceived impact of diabetes was positively correlated 
with anxiety and change in perceived effectiveness of treatment was 
positively correlated with dietary self-care. Watkins and colleagues 
(2000) found that when perception of control and understanding 
increased, this led to better dietary behaviours, less social and personal 
burden and fewer negative feelings regarding the disease and a more 
positive attitude in general.  Better self-management can lead to better 
health outcomes in diabetes by improving glycaemic control and limit 
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the onset and severity of microvascular complications that have been 
related to deficits in cognitive deficits. 
3.4.2.  Intelligence 
It may also be that a person’s level of intelligence influences blood 
glucose control with lower intelligence leading to poorer ability to 
manage diabetes control.  Gottfredson & Deary (2004) found that 
intelligence quotient (IQ) scores in childhood predicted adult morbidity 
and mortality and they suggest that this may be influenced by better 
ability for self-care. Taylor, Frier,  Gold, & Deary (2003) found that 
those with more years of education had a better understanding of their 
diabetes at 4 and 12 months after diagnosis. Those with better 
knowledge early on had lower HbA1c at 12 months after diagnosis and 
this knowledge accounted for 5% of variance in glycaemic control.  
Premorbid IQ measured using the NART accounted for 11% of the 
variance in knowledge of diabetes at 12 months. However, they believe 
that psychosocial factors are more strongly associated with subjective 
outcomes such as quality of life, than objective outcomes such as 
HbA1c. IQ is an important indicator of cognitive reserve and a 
protective factor in the cognitive ageing process (Stern, 2002). 
3.4.3.  Depression and Anxiety 
People with diabetes experience a higher rate of depression than 
those without diabetes (Ciechanowski, Katon, Russo, & Hirsch, 2003; 
Eaton, 2002; Heckbert et al. ,  2010). One study indicates a prevalence 
rate for depression of more than twice that of age and sex matched 
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controls based on cut-off score on questionnaire (Gendelman et al. ,  
2009) and an increase in depression and anxiety symptoms overall 
(Collins, Corcorant, & Perry, 2009). A review of literature found that 
40% of participants in clinic studies had elevated anxiety levels with 
14% having Generalized Anxiety Disorder (Grigsby, Anderson, 
Feedland, Clouse, & Lustman, 2002). In a clinic setting, more than a 
quarter of patients with T1DM (age 18-80) indicate levels of anxiety 
and/or depression within a moderate to severe range using the Hospital 
Anxiety and Depression Scale (HADS; Lloyd, Dyert,  & Barnett,  2000) 
with anxiety symptoms most prevalent at these levels. However, they 
found that the older adults (>33years of age) in the T1DM group 
exclusively reported moderate to severe symptoms of depression. In 
larger clinic study (n=259) of people between the ages of 16 and 60 
with T1DM (Shaban et al. ,  2009) using the HADS, the mean anxiety 
rating was slightly higher than the mean depression. In comparison, 
values obtained for a normative non-clinic sample in the UK indicated 
that 12.6% showed moderate to severe levels of anxiety and 3.6 % 
moderate to severe depression (Crawford, Henry, Crombie, & Taylor, 
2001). According to conclusions of a systematic review of the 
literature, the prevalence for depression, particularly in T1DM, has not 
been established due to limited number of well-designed studies and 
focus on symptom cut-off scores in self-report questionnaire (Barnard, 
Skinner & Peveler, 2006).  
Van Tilburg and colleagues (2001) found that depressed mood was 
significantly related with sub-optimal glycaemic control in T1DM and 
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may be related to differences in self-care of diabetes. Anxiety has also 
been related to processing efficiency for control of inhibiting and 
switching attention (Derakshan & Eysenck, 2009). Results of a meta-
analysis suggests that there may be a reciprocal relationship with poor 
glycaemic control leading to depressed mood and depressed mood 
influencing glycaemic control (Lustman et al. ,  2000). However, there is 
evidence that improvement in depression scores does not lead to better 
glycaemic control over time (Georgiades et al. ,  2007). Lloyd and 
colleagues (2000) found that those with retinopathy reported moderate 
to severe levels of anxiety more often than those with no retinopathy 
and those with neuropathy were more likely to report depression. They 
found that all  those with T1DM and moderate to severe depression had 
poor glycaemic control.  Given the higher incidence and link with 
poorer glycaemic control and microvascular complications, anxiety and 
depression are important considerations in the link between diabetes 
health variables and cognition. 
3.5.  Summary 
There have been a few key areas of cognitive processing deficit 
identified in studies of younger adults with T1DM. These have 
included processing speed, executive function (cognitive flexibility) 
and both general and fluid intelligence. Other cognitive processes have 
been highlighted in ageing research including working memory and 
immediate and delayed episodic memory. Tasks that sample these 
cognitive processes will be used in the thesis studies. The cognitive 
processes identified are included in the current study reported in 
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Chapter 5. Evaluation of the incidence of MCI in the study group 
reported in Chapter 6 is based on participant performance across these 
cognitive processes. 
Measures of blood glucose control and diabetes complications have 
been linked to cognitive functioning in T1DM. Some contradictory 
results may be due to the differing measures of HbA1c (long-term mean 
vs. single value or measure based on few years of data) and the low 
levels of microvascular complications present in younger age groups. 
There is evidence that measures such as repeated severe hypoglycaemia 
may have more importance in an ageing group though it  has been 
dismissed as a significant factor in younger groups with T1DM. The 
influence of insulin resistance has not been studied in younger T1DM 
groups, but this factor is also more prevalent and may have more 
importance in an ageing group. These diabetes health variables will be 
used as predictors in the cognitive study reported in Chapter 5, and the 
study of the incidence and predictors of MCI reported in Chapter 6, in 
the study group. The psychological characteristics highlighted here that 
may have an added influence on diabetes control,  complications and 
cognitive function are highlighted in Chapter 7.  
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                                                           Chapter 4
METHODOLOGY 
 
This chapter provides information about the common methodology 
pertaining to all  participants throughout the studies described in this 
thesis.  
4.1.  Participants 
4.1.1.   Recruitment 
Participants were recruited between June 2009 and March 2011 
from secondary care facilities hosting regular diabetes clinics within 
the Tayside region of Scotland. Clinics included those operating at 
Ninewells Hospital in Dundee, the Perth Royal Infirmary, and the 
Arbroath Royal Infirmary. Potential participants with upcoming clinic 
appointments who met diabetes type, diabetes duration, and age criteria 
(see Table 4.1) were sent a research invitation letter from the 
Consultant supervising the research (Appendix A), an introductory 
letter (Appendix B), participant information sheet (Appendix C), and 
response card (Appendix D) to indicate agreement or disagreement to 
be contacted by the researcher for more information about the study. In 
addition, patients listed on the Scottish Diabetes Research Network 
(SDRN) Research Register,  who had given agreement to be contacted 
for any diabetes study, were contacted directly by the researcher to ask 
if they would like to receive information about the study.  
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4.1.2.   Inclusion and Exclusion Criteria 
The researcher went through a brief inclusion/exclusion 
questionnaire with participants over the phone to determine eligibility 
to take part in the study (Appendix E). The inclusion and exclusion 
criteria are presented in Table 4.1. 
 
Table 4.1 Inclusion and Exclusion Criteria for Study 1  
 
Inclusion Criteria Exclusion Criteria 
• Age 45 and over 
• Diabetes duration  
of 10 years since diagnosis. 
• English-Speaker  
 
Conditions or characteristics that would 
affect results of cognitive assessment 
including: 
• Diagnosed disease or injury affecting 
brain (stroke, brain injury, dementia, 
mild cognitive impairment confirmed 
through medical diagnosis)  
• Diagnosis of major psychiatric 
disorder (e.g. schizophrenia, major 
depression or anxiety disorder)  
• self-identified or doctor-identified 
alcohol or drug use problem/addiction  
• visual impairment or hearing deficits  
• non-English speaker. 
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4.2.  Sample Size Feasibility 
To check the feasibility of the sample size, a query was conducted 
by the Managed Clinical Network (MCN) data facilitator using 
information from the Scottish Care Information – Diabetes 
Collaboration (SCI-DC) clinical management system (McAlpine, 
November 2008). The results of the query revealed that,  in Tayside 
there were 625 individuals over 40 with a diabetes duration of 10 years 
or more and 331 over the age of 50. An age cut-off of 45 was chosen as 
optimal to focus on older patients as much as possible and maximize 
the number of potential participants for the study (see Table 4.2). 
Table 4.2 Tayside Patients with Type 1 diabetes Grouped by Average 
HbA1c  
 
 Age > 40  Age > 50  
HbA1c  Number Percentage Number Percentage 
</= 7 48  8  21 6 
7.1 to 9 378  60 218 66 
> 9 199  32  92 28 
All 625 100 331 100 
 
As this is a sample of convenience, ultimately the groups were divided 
based on actual mean HbA1c of the participants in tertiles to create 
groups that are similar in size for comparison. Assuming about half the 
individuals between 40 and 50 are 45 and over, there will be about 470 
patients aged 45 and above. The goal was to recruit a sample of 150 or 
32% of potential participants based on the results of the sample size 
feasibility and power analysis detailed below.  
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4.2.1.  Participant Recruitment Statistics 
 In practice 451 potential participants were contacted and the 
final response decisions, numbers, and percentages are detailed in 
Table 4.3. The targeted recruitment level of 150 was not achieved due 
to exhausting the clinic lists and research register for the three Tayside 
clinic sites. Although application was made to add another clinic site 
outside of the Tayside region (St. Andrews in Fife) to increase patient 
recruitment, approval came too late (March 2011) to allow recruitment 
at this site.  
 Out of the 451 research invitations sent, just over 27% expressed 
a willingness to take part in the study. Of those who responded yes to 
the research invitation (n=124), over three quarters were included 
(n=94). One fifth of the group who said yes was excluded due to 
incorrect diagnosis, short duration of diabetes, visual or hearing 
impairments, or onset of hypoglycaemia during testing (Table 4.3). The 
majority was excluded due to the existence of a medical condition that 
may affect cognition including stroke, transient ischemic attack (TIA), 
epilepsy, or encephalopathy or diagnosed anxiety or depression. Those 
with limited acute or past use of anti-depressant medications and no 
self-identified concerns with depression were permitted to participate. 
Only 4 people who originally consented withdrew themselves from the 
study. Of these, only one person asked to discontinue after the start of 
testing. Of the other three, one did not show up for the appointment, 
and two cancelled their appointments. 
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Table 4.3  Participant Recruitment Statistics  
 
 Total (n) Percent of Total (%) 
Participant Invitations  451 100 
No Response 244 54.1 
Response Total 207 45.9 
No 84 18.6 
Yes 124 27.5 
Included  94 75.8 
Excluded  30 24.2 
Type 2 diabetes 1 4 
Duration <10 years 2 8 
Medical condition 10 40 
Anxiety/Depression  7 28 
Inconvenient to attend 2 8 
Hypo during testing 3 11.5 
Uncorrected vision 1 4 
Elected to Withdraw 4 3.25 
  
There was no specific information available on the exclusions 
regarding diabetes health as only limited patient information was 
accessed to contact potential participants. Those who withdrew from 
the study did not systematically differ from those who were included in 
the study. The majority were male (n=18), they had a wide age range 
(48 – 74 years) and from short to long duration of diabetes (7 – 52 
years).  The information available is provided in Table 4.4 
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Table 4.4 Excluded Participants  
Total Number Gender  
(Number) 
Age Mean (SD) 
Range 
Duration of 
Diabetes (SD) 
Range 
 Male Female   
30 18 12 57.8 (8.27)  
48 - 74 
29.1 (14.75) 
7-52 
 
4.3.  Independent Variables:  
4.3.1.  General and Diabetes Health Variables 
The following general and diabetes health variables were collected 
along with demographic information (age, gender, education) for all 
participants through medical records including SCI-DC, and 
questionnaires completed before the cognitive testing session (see 
Appendix I & Appendix J).  Each measure of diabetes health, general 
health variables and health promoting habits along with the method to 
obtain or derive the variable is listed in Table 4.5. More detailed 
information about the measures of diabetes control and complications 
is provided below. 
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Table 4.5 Participant Health Information Collected for Study 1  
 
Information Derived Variable 
1. Age at Diagnosis Age in years when diagnosed 
2. Duration of Diagnosis Years since first diagnosis 
3. Waist/Hip Ratio Calculated from waist/hip measurements 
taken at testing session 
4. Body Mass Index Value on record at time of study 
5. Blood Pressure a. Systolic BP at time of study 
b. Diastolic BP at time of study 
6. Cholesterol a. Total Cholesterol at time of study 
b. HDL Cholesterol at time of study 
c. Triglycerides 
7. Exercise a. Rate Less/Same/More than age peers 
b. Rate of Perceived Exertion (RPE)  - 
self-rating on 10 point Likert-type 
scale from Low to Strong 
8. Cognitive Activity a. Rate Less/Same/More than age peers 
9. HbA1c  a. Frequency weighted mean HbA1c  
b. Current HbA1c – HbA1c at testing 
c. Recent HbA1c–5 year mean HbA1c 
d. HbA1c SD – HbA1c Standard Deviation 
based on mean HbA1c  
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Table 4.5 (cont.) 
 
Information Derived Variable 
10. Retinopathy Rating based on Scottish Diabetic 
Retinopathy Grading Scheme of 
retinopathy and maculopathy 
11. Neuropathy Rating based on foot risk score  
12. Nephropathy Rating based on albuminuria level 
13. Microvascular Total Combination of retinopathy, maculopathy, 
neuropathy and nephropathy ratings  
14. Hypoglycaemic Events Average hypos per year determined by 
number of events/duration of diabetes  
15. Insulin Resistance Estimated Glucose Disposal Rate (eGDR) 
 
1. Age at Diagnosis 
Self-report of the participant’s age at first diagnosis 
2. Duration of Diagnosis  
Participant age at diagnosis subtracted from current age 
3. Waist/Hip ratio 
The researcher took participant waist and hip measurements at the 
testing session. The waist/hip ratio was calculated from these values.  
4. Body Mass Index (BMI) 
BMI is calculated at the participant’s clinic appointment and 
reported through SCI-DC. 
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5. Blood Pressure (BP) 
Systolic BP and Diastolic BP values are taken by the nurse at the 
participant’s clinic appointment and reported through SCI-DC. 
6. Cholesterol 
Values for High-Density Lipoprotein (HDL), Total Cholesterol and 
Triglycerides taken at the participant’s clinic appointment and reported 
through SCI-DC 
7. Exercise 
Level of physical activity: A global rating of daily physical 
activity based on Sternfeld, Cauley, Harlow, Liu, & Lee (2000) asks 
participants to compare their own physical activity to that of their age 
peers and rate their level of physical activity as “much less”, “less”, 
“the same as”, “more” or “much more” than others of their age.    
Rate of Perceived Exertion (RPE): Self-rating of usual exercise 
intensity using the 10-point Rate of Perceived Exertion (RPE) scale 
(American Council on Exercise, 2001). 
8. Cognitive Activity 
A global rating of daily cognitive activity, using the same rating 
scale for the global rating of physical activity described above, will be 
used to rate participant engagement in cognitive activities.   
9. Measures of HbA1c 
Frequency weighted mean HbA1c:  Based on 10 years or more of 
HbA1c values with a range from 7 to 20 years of values ( x¯ =16.3, 
SD=4). Although all participants were diagnosed with diabetes for at 
least 10 years, for a small number of participants (n=4), this mean is 
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based on 7 to 9 years of values due to missing records from previous 
secondary care clinics within England. The researcher requested past 
records from clinics in England; however, this was not always 
successful.  One participant had HbA1c scores for only 5 years. This 
participant was excluded from analyses using weighted mean HbA1c 
only.  
The method of determining frequency weighted HbA1c and 
frequency weighted standard deviation of HbA1c was developed in 
consultation with Dr. Christie Marr (May 2010), who at the time was 
Head of the Mathematics Support Centre at the University of St 
Andrews. It  was decided that a frequency weighted mean based on the 
number of days between readings would be most accurate for this data 
set as there were not always an even number of days between readings 
(e.g.,  2 HbA1c readings for 2005 could be within 1 month of each other 
and for 2007 could be within 6 months of one another). It  was assumed 
that HbA1c values taken closer in time would be more similar and 
therefore should have lower weighting in the overall mean than those 
readings taken further apart in time. Given that the SCI-DC record 
includes entries from both secondary and primary care facilities, 
HbA1c tests could be either more frequent for some participants, or the 
same data may have been entered more than once, on different days 
(McAlpine, October 21, 2009).  
Each HbA1c value was multiplied by the value for days between 
readings. These values were then summed and divided by the sum of 
days between readings shown in Equation 4.1. Step by step details of 
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the method for deriving frequency weighted HbA1c can be found in 
Appendix K. 
Equation 4.1 
             ∑  xi  wi   
      ∑  wi  
x= HbA1c Value ;  w= Number of days between readings  
 
Frequency Weighted HbA1c SD: These values used to calculate mean 
HbA1c were also used to determine a frequency weighted standard 
deviation of HbA1c scores shown in Equation 4.2.  
 
Equation 4.2 
 ∑  xi 2  wi   
                         
                                                               ∑   wi  /  n 
 
x= HbA1c Value ;  w= Number of days between readings; n=number of 
readings 
Current HbA1c: HbA1c value at time of study participation  
Recent HbA1c: Frequency weighted mean HbA1c over past 5 years 
 
10. Retinopathy  
 
Retinopathy ratings were taken from the SCI-DC or paper 
medical record based on the Scottish Diabetic Retinopathy Grading  
(SDRG) Scheme 2007 v1.1 (Scottish Diabetic Retinopathy Screening 
Collaborative, 2007). The SDRG is the hierarchical grading system 
used to assess severity of retinopathy. This results in 5 levels of 
Frequency Weighted Mean HbA1c  = 
Frequency Weighted HbA1c SD = 
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retinopathy severity from lowest - 0 (no retinopathy) to highest - 4 
(proliferative retinopathy). Retinopathy grading is subject to 
improvement  (i .e. ,  decrease from higher to lower severity) if 
participants received laser treatment. Retinopathy was graded as the 
highest rating on record for either eye. Given the small number of 
participants with no retinopathy in the sample (n=3) this group was 
combined with the mild retinopathy group in analyses. In some 
analyses the Referable and Proliferative groups were combined as a 
High Severity Retinopathy group given that all  are referred for 
ophthalmology and/or laser treatment. Laser treated retinopathy or 
maculopathy was included in the proliferative retinopathy category. as 
indicated in Table 4.6.  
 
Table 4.6 Retinopathy Coding and Frequency in Study 1 Sample  
 
 
Retinopathy Severity 
 
Code 
Frequency in 
Total Sample 
No Ret inopathy  0 3 
Mild  Background Diabet ic  Ret inopathy  1 15 
Observable  Background Diabet ic  Ret inopathy  or  
Observable  Maculopathy  
2 22 
Referable  Background Diabet ic  Ret inopathy  or  
Referable  Maculopathy  
3 21 
Prol i fe ra t ive  Diabet ic  Ret inopathy  or   
Laser  Trea ted  Ret inopathy/Maculopathy  
4 33 
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11. Neuropathy 
The grading for neuropathy was based on the foot risk score 
provided in SCI-DC. The most current risk score was used. Frequency 
analysis indicated that 75% of the study 1 participants were considered 
to be in the lowest risk category, 15% moderate risk and 10% high risk.  
12. Nephropathy 
Nephropathy was rated based on albuminuria level.  Most 
participants had normal albuminuria levels (87%) with an even split  
between those with microalbuminuria and macro or clinical 
albuminuria (13%). Given the limited numbers with elevated 
neuropathy and nephropathy risk in this sample, these variables were 
not considered independently in analysis, but combined with 
retinopathy severity to get a microvascular total score. 
13. Microvascular Total  
A combined rating of microvascular burden derived by adding 
retinopathy, neuropathy and nephropathy ratings together weighted by 
the number of rating levels within each variable, shown in Equation 4.3 
Equation 4.3 
 
Microvascular Total = 
 
Retinopathy Level/5 + Neuropathy Level/3 + Nephropathy Level/3 
14. Hypoglycaemic Events 
Participants were asked to rate how frequently they had 
experienced hypoglycaemic events (requiring assistance or 
hospitalization). This was estimated by questions on the Diabetes 
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Questionnaire (Appendix I) based on a method used by Brismar and 
colleagues (2007). Participants gave the absolute number of these 
events or an estimate of the number they typically experience per year. 
The number of hypoglycaemic events was divided by duration of 
diabetes to get an estimate of hypoglycaemia exposure based on 
duration, “average hypos per year”. Eighty-eight percent of the sample 
had values indicating they experience an average of less than 1 hypo 
per year. The average hypos per year value ranged from 0 to 12. Given 
the wide variation and non-normal distribution in average hypos per 
year, these values were coded for severity (0 = never; 1=less than 
0.06/year; 2= more than 0.06 per year) to make similar sized groups for 
comparison. 
15. Insulin Resistance 
Insulin resistance can be estimated through the calculation of 
estimated glucose disposal rate (eGDR). Olson and colleagues (2002) 
provide the equation to calculate eGDR based on their earlier work 
(Williams, Erbey, Becker, Arslanian, & Orchard, 2000) shown in 
Equation 4 .4. There is an inverse relationship between eGDR and 
insulin resistance with lower eGDR scores related to higher levels of 
insulin resistance (Williams et al. ,  2000). Therefore, higher eGDR 
scores relate to better diabetes health. 
 
Equat ion 4 .4   
 
eGDR=24.31-(12.22*Waist-Hip Ratio)  –(3.29 Hypertension)-(0 .57*HbA1c) 
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4.4.  Dependent Variables: Cognitive Battery 
 Each participant completed the following cognitive battery 
administered by the researcher. These were used as predictors and/or 
covariates in the analyses. Table 4.7 displays the tests in the cognitive 
battery listed in order of administration and the average time to 
complete each test.  
Table 4.7  Cognitive Battery  
 
Cognitive Tests in Administration Order Average 
Administration Time 
in Minutes 
1. National Adult Reading Test  3 
2. Adult Memory and Information Processing 
Battery Story Recall – Immediate 
 
5 
3. Raven’s Standard Progressive Matrices  25 
4. Adult Memory and Information Processing 
Battery Story Recall – Delayed 
 
2 
5. Symbol Digit Modalities Test – Written 
and Oral 
5 
6. Digit Span Forward and Backward 5 
7. Trail Making A & B  5 
Total of 7 cognitive tests 50 
 
The tests used for the cognitive battery in relation to the cognitive 
domain are presented in Table 4.8. 
The cognitive domains were chosen based on the domains with 
the largest effect sizes in the meta-analysis of T1DM and cognition 
research (Brands et al. ,  2005) including processing speed, executive 
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function (i.e.,  set shifting) and indices of general intelligence. Tests of 
working memory and episodic memory were also included as these 
processes are important in cognitive ageing research (Hedden & 
Gabrieli,  2004). The test(s) chosen for each domain are discussed in 
turn. A sample of the type of material presented for all  the cognitive 
tests with a visual presentation format is provided in Appendix L. 
Scoring details for raw score to standard score conversion for each 
cognitive test are provided in Appendix M.  
1. Processing Speed : Symbol Digit Modalities Test 
The Symbol Digit Modalities Test (SDMT;  Smith, 1982) is a test 
of processing speed and more specifically meets Salthouse’s (2000) 
criteria for a test of perceptual speed. It  is a simple paper-and-pencil 
cognitive task with a time limit.  At the top of the page there is a key 
that pairs a symbol with each number from one to nine. At the bottom 
of the page are several rows of these symbols with the numbers missing 
(Appendix L). Participants are asked to fill  in the correct number for 
each symbol for as many symbols as possible within a 90 second time 
limit.  Using what should be a well-practiced motor skill ,  writing of 
single digit numbers, minimizes the motor component of this task. This 
task draws on processes including attention, visual scanning and motor 
speed (Sheridan et al. ,  2006). This test was administered in both a 
written and oral format as physical motor speed may influence the 
deficits that T1DM groups have on this type of task. Scoring was based 
on the number correct within 90 seconds. This test was presented and 
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scored according to the standard administration procedures and norms 
provided (Smith, 1982). 
 
Table 4.8 Cognitive Tests Used Within Selected Cognitive Domain  
 
2. Processing Speed and Set Shifting: Trail Making Test  A & B 
The Trail Making Test (TMT; Army Individual Test Battery, 
1944) is widely used in neuropsychological testing. The TMT A, is a 
Cognitive Domain Test 
Processing Speed: Perceptual 
Speed 
Symbol Digit Modalities Written & 
Oral ;  Trail Making A 
Executive Function: Set  
Shifting 
Trail Making B 
 
Crystalized (Premorbid) IQ National Adult Reading Test 
 
Fluid Reasoning Ravens Standard Progressive Matrices 
 
Estimated Lifetime Cognitive 
Change (ELCC) 
NART-Ravens Regression 
 
Age-Adjusted Lifetime 
Cognitive Change (A-ELCC) 
 Age-ELCC Regression 
Episodic Memory  
 
Adult Memory and Information 
Processing Battery Story Recall 
Immediate & Delayed  
 
Short-term/Working Memory  WAIS-III Digit Span  
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paper-and-pencil task in which participants are asked to draw a line to 
connect numbers starting at 1 in consecutive order as quickly as 
possible (Appendix L). This task meets Salthouse’s (2000) definition 
of a test of perceptual speed given the low cognitive complexity and 
timed response. On the TMT-B, participants are presented with another 
sheet of paper including both numbers and letters. They are asked to 
alternate between making a trail  connecting numbers (starting from 1) 
and letters (starting from A) as quickly as possible (Appendix L). This 
task involves an executive component as participants must alternate or 
shift between two tasks. Scores will include the amount of time in 
seconds required to complete each task. The TMT A & B were 
administered and scored using the guidelines and normative data 
developed by Spreen, and Strauss (1998).  
 
3. Premorbid IQ: National Adult Reading Test (2nd edition).  
The National Adult Reading Test-2n d edition (NART; Nelson & 
Willison, 1991) is a measure of vocabulary knowledge that is resistant 
to neurological impairment processes and has strong correlation  with 
standard measures of verbal IQ (Lezak, 1995) and provides an estimate 
of premorbid IQ. The NART is therefore a measure of crystallized 
intelligence and scholarly knowledge (Brands et al. ,  2005). Participants 
are asked to read a list of progressively difficult and phonetically 
irregular English words. The scores include the total number of errors 
(for conversion to Full Scale IQ equivalent) and the total number 
correct out of 50 (for the calculation or the Estimate of Lifetime 
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Cognitive Change). The NART was administered according to standard 
procedures (Nelson & Willison, 1991). 
 
4. Fluid Reasoning: Raven’s Standard Progressive Matrices 
For the Raven’s Standard Progressive Matrices (Raven's SPM; 
Raven, Raven, & Court,  2003), the participant is asked to choose from 
a group of pictures to best complete a missing piece of a pattern or 
matrix (Appendix L). This test was administered following the standard 
administration procedures (Raven et al. ,  2003) with a time limit of 20 
minutes for calculation of the Estimate of Lifetime Cognitive Change 
score (Deary et al. ,  2004). The score is the number of items correct 
within the time limit.  There were no norms available for the 20-minute 
administration. 
 
5. Estimate of Lifetime Cognitive Change  
To get an estimate of change in cognitive functioning across time 
without having a previous IQ score, Deary et al. ,  (2004) studied the 
Scottish Mental Survey cohort of 1932 to establish the validity of an 
Estimate of Lifetime Cognitive Change (ELCC). The ELCC score is the 
standardized residual score (z score) that is calculated using linear 
regression. Using the regression-based difference between raw scores 
on the NART and Raven’s (20min time limit) to adjust current ability 
(Raven’s) with an estimate of prior ability (NART number correct).  
The standardized residual difference scores (z scores) provide an 
estimate of cognitive change with a positive score indicating a relative 
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positive change in estimated cognitive function and a negative score 
indicating a relative decline in cognitive function. Deary and his 
colleagues (2004) found a strong relationship between IQ scores at age 
11 and IQ scores at age 77 and 78, a measure of actual cognitive 
change in the 1932 cohort.  Pearson correlation revealed that the ELCC 
score had a strong negative relationship with age in the sample (r=-.49, 
p<.01, one-tailed) .  Given the wide age range of participants, a further 
regression analysis was used to adjust the ELCC score using age as a 
dependent variable. Pearson correlation revealed that the resulting age-
adjusted estimate of lifetime cognitive change (A-ELCC) score was not 
significantly correlated with age (r=.00, p  = .50, one-tailed). 
 
6. Episodic Memory: AMIPB: Story Recall Immediate and Delayed 
The Story Recall Immediate (SRI) and Story Recall Delayed 
(SRD) tests of the Adult Memory and Information Processing Battery 
(Coughlan & Hollows, 1985) were used to assess episodic memory. On 
this tests participants are asked to recall as much of a story as possible, 
both immediately and after a 30 minute delay. The score is based on 
the number of ideas correctly recalled. Each idea could receive a score 
between 0 and 2, depending on the accuracy of the recall 
(0=missed/incorrect; 1=partially correct; 2=correct),  for a maximum of 
58 points. This test was administered and scored following 
standardized procedures and using norms provided (Coughlan & 
Hollows, 1985).  
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7. Short-Term / Working Memory :Digit Span  
The Digit Span task is a simple test from the Wechsler Adult 
Intelligence Scale (Wechsler, 1997). Participants are asked to repeat 
small strings of numbers both forwards and backwards. Digit Span 
Forwards (DSF) is a measure of span of attention and verbal short-term 
memory and digit span backwards (DSB) a measure of simple working 
memory including both storage and processing. The score is based on 
the number of items correct for both DSF and DSB out of 30. The test 
is administered and scored using standard test procedures and norms 
(Wechsler, 1997). 
4.4.1.  Procedure 
Participants completed a series of short questionnaires and a 
cognitive assessment battery. For the majority of participants, this 
session took place before or after their scheduled clinic appointment 
and for others it  was scheduled on a separate day when convenient for 
the patient.  The questionnaires were given to the participants while 
they waited for their clinic appointment and took 10 to 15 minutes to 
complete. Participants completed the cognitive assessment battery with 
the researcher, a Registered Educational Psychologist (Canada). Before 
the cognitive assessment started, participants were asked to check their 
blood glucose. If below a value of 4 mmol/litre, the participant had a 
glucose drink (lucozade), provided by the Diabetes Centre as a 
standard protocol for treating hypoglycaemia. Testing started after 
further blood glucose check shows a level of blood glucose above 4 
mmol/litre. Despite this check, it  was discovered during the session 
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that some participants took on hypoglycaemia after the start of the test.  
These individuals were provided a glucose drink and were tested to 
ensure blood glucose was normal, however as noted above their results 
were excluded from the analysis. The blood glucose level at the time of 
testing was recorded for each participant. The participants’ responses 
to some tests were video-recorded for scoring purposes. For the 
majority of participants it  took approximately 50 minutes to complete 
the test battery. 
4.5.  Statistics 
4.5.1.  Within-Group Comparison 
To examine the impact of diabetes health variables on cognitive 
function the participants were divided into groups based on the 
diabetes health variables (HbA1c level, retinopathy severity) and 
presence of MCI. A healthy control group was not recruited as it  has 
already been established that there is a difference in specific areas of 
cognitive function between groups with and without diabetes.  Instead 
the study was designed to get a better understanding of the possible 
reasons for this difference. Further confirmation of a difference 
between groups with T1DM and healthy controls would not provide this 
information.  
4.5.2.  Power analysis 
Analysis of Variance 
A power calculation was completed using the R statistical 
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program (http://www.R-project.org) for one-way analysis of variance. 
The effect size entered was 0.3, the lowest effect size for cognitive 
domains in a meta-analysis of cognitive studies on T1DM in 
comparison to controls (Brands et al. ,  2005). A conservative estimate 
was used to cover all  cognitive domains in the proposed research. For a 
power of .8, with a significance level of .05, the sample size was 
estimated to be a minimum of 37 for each of three groups in the 
analysis or n=111. There were higher effect sizes reported for 
psychomotor efficiency (~0.6), cognitive flexibility (~0.5), fluid 
intelligence (~0.5), crystallized intelligence (~0.8); lower effect sizes 
were reported for working memory (~0.1), immediate memory (~0.1), 
and delayed memory (~0.2). Smaller size groups would be required for 
sufficient power for measures of intelligence, processing speed and 
executive function (cognitive flexibility) ranging from 7 to 14 
participants for each of 3 groups. A sample size of over 300 per group 
is required for sufficient power at an effect size of only 0.1 and over 
80 for an effect size of 0.2. These domains are included given their 
importance in ageing research and were included for exploratory 
purposes given the current study sample is older than the typical 
samples found in T1DM studies (Brands et al. ,  2005). 
Multiple Regression 
Power analysis for multiple regression was completed using the 
pwr package (Champely, 2009) for the R statistical program 
(http://www.R-project.org). The effect size for this calculation (f2) was 
calculated using a known R2  value (f2 = R2 /1- R2). There were no 
63 
estimations of R2 reported in the T1 literature for groups similar to the 
age range for this study. The R2  values used in the power calculations 
were taken from a regression analysis by Brismar and colleagues 
(2007) with an age range of 22 to 55 years of age. Table 4.9 provides 
the results of power calculations using the R2  values from the Brismar 
(2007) study for cognitive domains which will also be assessed in the 
current study using a power of .8 and significance level of .05 for both 
the target sample size of 150 and the actual sample size of 94. Given 
the actual sample size and low effect sizes for some cognitive domains, 
only measures of processing speed and general intelligence (premorbid 
IQ and fluid reasoning) were used in multiple regression analysis. 
 
Table 4.9 Number of Predictor Variables for Multiple Regression 
Analysis  
  
 
Cognit ive 
Domain 
R 2  value Effect  Size 
(f2)   
Target  
Sample Size 
n=150 
Actual  
Sample Size 
n=94 
   Number of  Predictors  
Perceptual  Speed 0.156 0.185 51 
 
13 
 
 General  
Inte l l igence 
0 .145 0.17 39 10 
Memory 0.11 0 .124 15 4 
Executive 0 .074 0.080 4 0  
Working Memory 0.072 0.078 4 0  
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4.6.  Transformation of variables for normal distribution 
Due to non-normal distribution of some variables, some 
transformations and/or minimization of outlier values were required. A 
number of methods were used to normalize the distribution for each 
variable to be entered into the general linear model analysis techniques 
based on methods described by Field (2005) including minimizing 
outliers based on the mean and standard deviation of the variable and 
using log and square root transformations. The details of required 
transformations are provided in Appendix N and when used indicated 
within each study chapter when necessary. 
4.7.  Summary 
 This chapter provided an introduction of the methodology 
common to the studies contained in this thesis. All or a sub-group of 
these participants took part in the studies that follow. The diabetes and 
cognitive variables are highlighted throughout these studies. General 
health variables and health habits are examined within the cognitive 
study in Chapter 5 and the MCI study in Chapter 6. Psychological 
variables are the focus of Chapter 7.  
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                                                                            Chapter 5
Predictors of Cognitive Function In Middle and Older Aged 
Adults With Type 1 Diabetes 
 
5.1.  Introduction 
Individuals with T1DM are encouraged to maintain strict glyceamic 
control to prevent onset of microvascular and macrovascular 
complications. Chronic hyperglycaemia and its related complications 
have been identified as a potential link to relative cognitive deficits in 
groups with T1DM (Wessels, Scheltens, Barkhof, & Heine, 2008). 
Many previous studies do not have access to long-term information 
about glycaemic control,  exclude participants with microvascular 
disease (a marker of poor glycaemic control),  or focus only on young 
adults.   
The purpose of this research study is to evaluate the relationship 
between glycaemic control (as measured by HbA1c), related diabetes 
complications, general health, and cognitive processing in a middle 
aged and older group with T1DM. This research study aims to 
determine whether signs of early cognitive ageing may be found in 
groups that have poorer diabetes health or general health and to 
identify the strongest diabetes health predictor of cognitive function. 
The strongest predictor was used as a way to determine comparison 
groups in the functional MRI study, as it  was presumed that this factor 
would also be most likely to have an impact on brain functioning.  
The first part of the study will compare individuals with T1DM, 
who have varying levels of long-term glycaemic control,  directly on 
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tasks representing a spectrum of cognitive processes that have been 
highlighted by both the T1DM and cognitive ageing research. The 
predictive value and relative importance of long-term glycaemic 
control on cognitive performance was evaluated along with the relative 
contribution of other diabetes complications and general health factors 
known or presumed to impact cognitive function. This study included a 
group of individuals with a higher mean age than is typically studied in 
T1DM (Brands et al. ,  2005) to maximize the potential for finding 
between-group cognitive differences, that may indicate signs of early 
cognitive ageing. 
5.2.  Study Questions  
Question 1: Do individuals who differ on glycaemic control and other 
diabetes health variables show significantly different scores on 
measures of cognitive processes?  
Question 2: Is cognitive function related to general health variables 
and health promoting habits? 
Question 3: Which diabetes health variables have the strongest 
predictive value on cognitive function? 
5.3.  Ethics 
A favourable ethical opinion was obtained (Appendix F) through 
the Tayside Committee on Medical Research Ethics A, an arm of the 
East of Scotland Research Ethics Service for the National Health 
Service (NHS). Approval to conduct the study on NHS Sites and with 
the assistance of NHS staff was sought through the NHS Research and 
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Development Office (Appendix G). Ethical approval was also sought 
and obtained through the University Teaching and Research Ethics 
Committee (UTREC) for the University of St.  Andrews (Appendix H).  
Access to past and present medical records, both paper and 
computerized files, was also required. As such, it  was necessary to 
seek approval to allow access to these records through the NHS 
Tayside Caldicott Guardian who is the person responsible to protect the 
confidentiality of patient information. Caldicott Guardian approval was 
obtained as required. The study also had to be registered with NHS 
Tayside Diabetes Managed Clinical Network (MCN) and the Scottish 
Diabetes Research Network (SDRN) to acquire access rights to 
computerized patient records for participants through the clinical 
management system SCI-DC (Scottish Care Information – Diabetes 
Collaboration) and to access the SDRN Research Register to obtain 
patient contact information for patients who had already provided 
permission to contact for any diabetes study. Approval to access paper 
medical records was secured with the respective medical records 
departments for each secondary care facility.  
5.4.  Methods  
The methods for the cognitive study are described in Chapter 4. 
Participants completed the diabetes health and well-being 
questionnaires and the cognitive battery. Diabetes and information 
about general health variables was collected from medical records as 
described. 
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5.5.  Statistical Analysis 
5.5.1.  Correlation 
Pearson correlation and Spearman’s rho were used for the 
correlation analysis to identify demographic, diabetes health variables 
and general health variables important for further analysis.  Diabetes 
health variables including mean HbA1c (and variants such as 
current/recent HbA1c and HbA1c standard deviation), diabetes burden 
(duration, age of onset),  and diabetes complications (retinopathy, 
microvascular disease, severe hypoglycaemic, insulin resistance) were 
examined for their relationship with cognitive processing scores and 
the inter-correlation between these variables. The complete results of 
this analysis are presented in (Appendix O) with specific correlations 
of interest highlighted within this chapter. One-tailed significance 
values are used to ensure identification of all  potential relationships of 
interest and variables to be controlled and included in further analysis.  
5.5.2.  Analysis of Variance 
Participants were split  into three similar sized groups based on 
tertile scores for frequency weighted mean HbA1c (Low ≤7.9%, 
Midrange 8.0-8.8%, High ≥8.9%). Between-group differences were 
investigated using general linear model analysis of variance (ANOVA) 
or analysis of covariance (ANCOVA) in all cognitive domains and on 
the age-adjusted estimate of lifetime cognitive change (A-ELCC) to 
examine main effects of mean HbA1c group and retinopathy severity. A 
factorial ANOVA was used to further explore the relationship between 
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mean HbA1c, retinopathy severity and cognitive function in areas in 
which a significant effect of either mean HbA1c or retinopathy severity 
was found. Planned comparisons were completed irrespective of the 
significance of the F-test given that these comparisons are hypothesis 
driven based on the results of previous research and the number of 
planned comparisons (2) is one less than the number of groups 
(Karpinski, 2011). Information from this analysis was used to identify 
potential diabetes health variables to use as predictors for multiple 
regression analysis. 
5.5.3.  Multiple Regression 
Mean HbA1c was entered into a multiple regression analysis with 
other diabetes factors chosen on basis of importance in previous 
regression analyses (e.g.,  duration of diabetes, microvascular diseases, 
severe hypoglycaemic events).  The dependent variables were scores on 
age-adjusted cognitive change and cognitive tasks. This analysis was 
used to determine the strongest predictor of cognitive processing 
scores. 
 
5.6.  Results 
Participant Demographics and Relation to Diabetes Health 
The demographic characteristics of the participants are presented 
in Table 5.1. Spearman’s rho was used to investigate the relationship 
between demographic variables and diabetes health variables with 
correlations of interest highlighted in the text.  This was used to 
identify potential demographic variables to control or include in 
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further analyses. The complete correlation table is provided in 
Appendix O for reference.  
Age  
Older Age is positively correlated with longer duration of 
diagnosis (rs=.381, p=.000), higher age of onset (rs=.271, p=.004), 
higher severity of retinopathy (rs=.276, p=.004), and greater total 
microvascular disease (rs=.310, p=.001). Age is also positively 
correlated to NART-IQ (rs=.222, p=.016). When controlling for NART-
IQ in partial correlation the relationship remains significant between 
age and higher severity of retinopathy (prs=.294, p= .002) and greater 
total microvascular disease (prs=.371, p= .000). It  will be important to 
control for age to when evaluating these values as predictors of 
cognitive function. Participant age was controlled in the analysis of 
cognitive function by using z-scores based on age norms.  
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Table 5.1 Participant Demographic and Diabetes Characteristics  
 
 
Gender 
Female gender was associated with higher eGDR (rs=.571, 
p=.000), which is indicative of lower insulin resistance. Female gender 
is also associated with lower waist-hip ratio values (rs=-.691, p=.000) 
and lower hypertension (rs=-.243, p=.009) which are the main factors 
used to calculate eGDR and suggests better overall general health in 
this group. Gender was included in multiple regression as it  has a 
relationship with general health variables in the study. 
  
Variable Range Mean Std. Error Std. Deviation 
Age (years) 45.0 - 80.7 58.7 .10 8.79 
Education (years) 9 – 25 14.2 .37 3.55 
Premorbid Intelligence 
(NART IQ) 
 
94 – 126 
 
114.2 
 
.71 
 
6.83 
Diabetes Duration 
(years) 
11.1 - 67.8 31.9 1.3 12.0 
Age of Onset (years) 4.6 - 59.1 26.8 1.2 11.2 
*Weighted Mean 
HbA1c (%) 
6 – 12 8.4 .10 .933 
Weighted HbA1c Std. 
Deviation (%) 
.36 – 2.7 .94 .04 .36  
*n=93 
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Education 
Higher years of education is related to lower current HbA1c 
value (rs=-.223, p=.02), lower recent HbA1c value (rs=-.191, p=.03), 
and lower total microvascular disease (rs=-.227, p=.014). However, 
education also has a positive relationship with NART-IQ (rs=.488, 
p=.000). Results of partial Spearman’s rho correlation indicate that the 
relationship between education and HbA1c values becomes 
insignificant when controlling for IQ for both current HbA1c values 
(prs=-.126, p=.114) and recent HbA1c (prs=-.127, p=.113). Age has a 
positive relationship with microvascular disease (rs=.310, p<.01). The 
relationship between education and microvascular disease remains 
when controlling for age (prs=-.213, p= .020). NART-IQ is included as 
a variable when evaluating predictors of cognitive function, given its 
relationship with education.  
Premorbid IQ 
Higher premorbid IQ (NART-IQ) is related to lower current 
HbA1c (rs=-.237, p=.011), however this relationship does not remain 
when controlling for participant education (prs=-.150, p=.075). Higher 
NART-IQ is also related to higher age of onset (rs=.190, p=.03), 
however this relationship does not remain when controlling for age 
(prs=.138, p=.094). Higher pre-morbid IQ is related to lower 
microvascular disease (rs=-.199, p=.03), and this relationship is 
strengthened when controlling for participant age (prs=-.289, p=.002). 
Higher NART-IQ is also related to lower long-term variability in 
HbA1c (rs=-.209, p=.02). This relationship remains when controlling 
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for participant age (prs=-.197, p=.029). NART-IQ is included as a 
predictor in the multiple regression analysis. 
5.6.1.  Glucose Control and Cognitive Function 
Question 1: Do individuals who differ on glycaemic control and other 
diabetes health variables show significantly different scores on 
measures of cognitive processes?  
 
Glycaemic Control 
Mean HbA1c .  For comparison of the effect of glucose control on 
cognitive function, three groups were formed based on based on tertile 
cut-off points for long-term (≥  10 years) frequency weighted mean 
HbA1c (Low ≤7.9% [n=29], Midrange 8.0-8.8% [n=34], High ≥8.9% 
[n=29]). There are 93 instead of 94 participants because there was 
limited long-term HbA1c data (5 years) available for one participant. 
This participant is included in analyses that do not depend on a value 
for mean HbA1c. Group comparison on demographic, diabetes and 
health variables are presented. The three mean HbA1c groups (Low, 
Midrange, High) did not differ by gender, IQ, education, age, age of 
onset of diabetes, duration of diabetes, anxiety, or depression (Table 
5.2). Groups were compared on their mean performance for all  
cognitive tests. Results are provided in Table 5.3. 
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Table 5.2 Comparison of Demographic Variables Between Mean HbA1c 
Groups  
 
  
 Mean HbA1c Group  
 
Variable  
Low HbA1c 
≤7.9 % 
mean (SD) 
 
 
Midrange 
HbA1c 
8.0-8.8% 
mean(SD) 
High 
HbA1c 
≥8.9% 
mean(SD) 
 
 
Signif icance 
 n=29 n=34 n=29  
Gendera  Female=13 
Male=16 
Female=19 
Male=15 
Female=17 
Male=13 
 
χ ²(2)=1.05,  p=0.59 
 
Ageb  
 
 
57.57(7.7)  
 
 
58.55(9.32)  
 
 
59.79(9.45)  
 
F (2 ,90)  =.462,  p=0.63 
 
NART-IQ b  
 
 
3 .14 (1 .2)T 
115(6.6)UT 
 
 
3 .09 ( .87)T 
116(5.2)UT 
 
 
3 .61 (1 .1)T 
112(8.2)UT 
 
 
F (2 ,90)  =2.31,  p=0.11 
(T)  
 
 
Educat ionc  
 
48.95 
 
 
50.29 
 
 
41.38 
 
 
H (2 )=1.98,  p=0.37 
 
 
Age of  
Onsetb  
 
26.11(9.96)  
 
24.57(9.4)  
 
29.63(13.8)  
 
F (2 ,90)  = 1 .69,  p=0.19 
 
 
 
Durat ion of  
Diagnosisb  
 
 
31.46 (10.5)  
 
33.98 (12.1)  
 
30.15(12.9)  
 
F (2 ,90)  =0.84,  p=0.43 
 
HADS 
Anxietyc  
 
47 .45 44.93 48.92 H (2)  = .36,  p=0.83 
 
HADS 
Depressionc  
 
 
39.29 
 
48.22 
 
53.07 
 
H (2)  = 4 .02,  p=0.13 
a .Chi  Square  ana lys is  (χ ²) :  g roup  numbers  ind ica ted  for  each  HbA1c leve l .   
b .ANOVA analys is (F ) :  mean  and  s tandard  devia t ion  ind ica ted  for  each  HbA1c leve l .   
c .Kruskal  Wal l i s  non-parametr ic  ana lys is  (H ) :  mean  rank  ind ica ted  for  each  HbA1c leve l .  
Note .  Transformat ions  were  used  for  ana lys is  of  NART-IQ (Reverse  & Square  Root)  and  
because  of  a  non-normal  d is t r ibu t ion  of  th is  var iab le .  For  ease  of  unders tanding ,  the  means  
d isp layed  for  bo th  the  unt ransformed var iab le  (UT)  and  the  t ransformed var iab le  (T)  wi th  the  
assoc ia ted  F  score .   
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Table 5.3 ANOVA Results for Cognitive Tests by Mean HbA1c Group  
 
 Mean HbA1c Group  
Cogni t ive  
Tes ts  
Low HbA1c 
≤7.9% 
Mean  (SD)  
Midrange  HbA1c 
8 .0-8 .8% 
Mean (SD)  
High  HbA1c 
≥8.9% 
Mean (SD)  
F p  
 n=29 n=34 n=30 
(n=29 TMT) 
  
A-ELCC .040  ( .91)  .197  ( .83)  - .267  (1 .1)  1 .98  .144  
TMT AZ .865  ( .37)  T  1 .02  ( .28)  T  .98  ( .34)  T  1 .90  .156  
TMT BZ .981  ( .49)  T  1 .23  ( .40)  T  1 .08  ( .45)  T  2 .46  .091  
SRI  Z   .012  ( .65)  .050  ( .96)  - .008  ( .68)  .045  .956  
SRD Z .145  ( .68)  .021  ( .88)  .030  ( .13)  .251  .779  
SDMT-W Z - .433  (1 .2)  - .175  ( .97)  - .311  ( .97)  .469  .627  
SDMT-O Z - .196  (1 .24)  .076  ( .944)  .123  (1 .1)  .748  .476  
Digi t  Span  Z  1 .38  ( .35)  T  1 .49  ( .36)  T  1 .35  ( .38)  T  1 .48  .233  
A-ELCC=Age-Adjus ted  Es t ima te  o f  L i fe t ime  Cogn i t ive  Change ;  TMT =  Tra i l  Mak ing  Tes t ;  
SRI  =  S to ry  Reca l l  Immedia te ;  SRD =  S to ry  Reca l l  De layed ;  SDM T-W /SDM T-O= Symbol  
D ig i t  Moda l i t i e s  Tes t  W r i t t en  (W ) /  Ora l  (O) .   
N .B .  T rans fo rma t ions  ( ind ica ted  by  T)  were  used  fo r  ana lys i s  o f  TM T A & B  and  Dig i t  
Span  Z  sco res  (Square  Roo t )  because  o f  a  non-normal  d i s t r ibu t ion  o f  these  va r i ab les .  Fo r  
cons i s t ency  and  ease  o f  compar i son  ac ross  t e s t s  the  t r ans fo rmed  TMT scores  were  r eve r sed  
to  be  in  l ine  w i th  the  o the r  cogn i t ive  t e s t  s co res  fo r  wh ich  a  lower  sco re  i s  r e l a ted  to  
poore r  pe r fo rmance .  
 
Results indicated no significant differences between groups 
based on the omnibus F test for any cognitive measure. Hypothesis 
testing was completed through planned comparisons and a trend was 
identified for age-adjusted lifetime cognitive change (A-ELCC). 
Planned comparisons revealed that the High mean HbA1c group showed 
a trend towards a lower A-ELCC score, than the Midrange mean HbA1c 
group, t(90)=1.97, p=.052, two-tailed, d=.42. The A-ELCC score for 
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the High mean HbA1c group was below 0, suggesting relative cognitive 
decline ( x¯= -.27, SE=.20). In comparison, the A-ELCC score for the 
Midrange HbA1c group was above 0, indicating cognitive stability or 
improvement ( x¯=.20, SE=.14). Although the score for the High mean 
HbA1c group was below 0, this score was within one standard 
deviation of the mean indicating overall performance was still  within 
the average range of functioning. 
Alternative Measures of HbA1c and Cognitive Function 
 
Relationship with Mean HbA1c. Pearson correlation was used to 
examine the relationship between current HbA1c (value on test date) 
and recent HbA1c (frequency weighted mean most recent  5 years) and a 
frequency weighted standard deviation (HbA1c SD) between measures, 
with measures of diabetes health and with measures of cognitive 
function (Appendix O). The measures of HbA1c are highly interrelated. 
Mean HbA1c was correlated with current HbA1c (r=.580,  p=.000), 
recent HbA1c (r=.826,  p=.000), and HbA1c standard deviation (r=.492,  
p=.000) with the highest correlation value for the 5 year measure of 
HbA1c. This indicates limited differentiation between the long-term 
and recent mean values of HbA1c with more differentiation from the 
current value of HbA1c. 
 
Relationship with Diabetes Complications.  All HbA1c values have a 
relationship with measures of diabetes complications. Higher current 
HbA1c is related to higher retinopathy (rs=.274,  p  =.004) and total 
microvascular disease (r=.202,  p  =.026) although not duration of 
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diagnosis (r=.003,  p  =.49) nor age of onset(r=-.002,  p  =.49). Higher 
recent HbA1c is related to higher retinopathy (rs=.333,  p=.001) and total 
microvascular disease (r=.350,  p=.000) and not duration of diagnosis 
(r=-.020,  p  =.42) nor age of onset (r=.029,  p  =.39). In comparison, mean 
HbA1c has a slightly stronger relationship with both retinopathy 
(rs=.365,  p=.000) and total microvascular disease (r=.470,  p=.000) and 
also does not have a significant relationship with duration of diagnosis 
(r=-.050,  p  =.32) nor age of onset (r=-.024,  p  =.41). HbA1c SD was not 
related to any of these diabetes health variables or measures of 
diabetes burden. HbA1c based on long-term period shows a relatively 
stronger relationship with diabetes complications suggesting it  is,  
among the three measures, the best indicator of overall diabetes health.  
 
Relationship with Cognitive Processes.  Results of Pearson correlation 
indicated both current and recent HbA1c were correlated to scores on a 
test of immediate story recall,  whereas mean HbA1c was not. Higher 
current HbA1c (r=.186,  p=.02) and higher recent HbA1c (r=.172,  p=.049) 
were both significantly related to higher scores on immediate story 
recall,  with a slightly stronger correlation for current HbA1c. Mean 
HbA1c was not correlated with immediate story recall (r=.091, p=.19) 
and ANOVA results (Table 5.7) indicated no significant differences 
between Low, Midrange and High HbA1c groups. Episodic memory is 
an area that has not been highlighted in previous T1DM research. 
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HbA1c Group Comparison of Cognitive Processes. Both current HbA1c 
and recent HbA1c were split  into the same three groups based on 
HbA1c value (Low=≤7.9%, Midrange = 8.0-8.8%, High≥8.9%). As a 
result,  many participants changed groups (Table 5.4). For current 
HbA1c, 55 percent of participants stayed in the same group to which 
they were assigned based on mean HbA1c (51/93). Forty-five percent 
of participants (42/93) moved up or down one or two groups. For 
recent HbA1c, 63 percent of participants stayed in the same group to 
which they were assigned based on mean HbA1c (59/93). Thirty-seven 
percent of participants (34/93) moved up or down one or two groups. 
Although there is moderate correlation between alternative measures of 
HbA1c, changing the definition of HbA1c based on current or more 
recent values made a notable change of group assignment, affecting 
over one third of the group as originally defined by a 10-year 
frequency weighted HbA1c. The choice of how to measure HbA1c has 
not been of particular concern in previous T1DM research (i.e. choice 
of long-term or short-term value is not explained), but appears to affect 
potential group composition and therefore would likely lead to 
different results.  
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Table 5.4 Number and Percentage of Participants With Change in 
Mean HbA1c Group Based on Alternative HbA1c Measurement  
HbA1c Measure Same Change 1 Group Change 2 Groups 
  Up Down Up Down 
Current HbA1c 
Percentage 
51  
54.8% 
22 
23.7% 
13 
14.0% 
3 
3.2% 
4 
4.3% 
Recent HbA1c 
Percentage 
59 
63.4% 
18 
19.4% 
12 
12.9% 
2 
2.2% 
2 
2.2% 
Tota l  n=93 
 
ANOVA was used to examine the relationship between current and 
recent HbA1c group and demographic variables (Table 5.5 & Table 
5.6). There was a significant difference between groups for NART IQ 
and years of education when using current HbA1c. These two variables 
were controlled in analyses using current HbA1c. There were no 
significant differences between groups on demographic variables using 
recent HbA1c; therefore no control variables were required. 
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Table 5.5 Comparison of Demographic Variables Between Current 
HbA1c Groups  
 
 Current HbA1c Group  
 
Variable 
Low HbA1c 
≤7.9 % 
 
 
Midrange 
HbA1c 
8.0-8.8% 
 
High 
HbA1c 
≥8.9% 
 
 
 Significance 
 n=32  n=37 n=25  
Gendera  Female=16 
Male=16 
Female=22 
Male=15 
Female=11 
Male=14 
  
χ²(2)=1.52, p=.47 
 
Ageb  
 
58.84(8.8) 
 
58.83(8.16) 
 
58.18(9.94) 
 
F  (2,91) =.05, p=.95 
 
NART-IQb  
 
 
3.02 (1.1)T 
116(5.6)UT 
 
 
3.09 (.996)T 
115(4.9)UT 
 
 
3.86 (.92)T 
110 (7.3)UT 
 
F  (2,91) =5.94, 
p=.004 (T)** 
 
 
Educationc  
 
52.48 
 
51.82 
 
34.72 
 
 H(2)=7.59, p=.022* 
 
Age of 
Onsetb  
 
25.26(8.96) 
 
29.23(12.9) 
 
25.14(10.94) 
 
 F(2,91) = 1.45, 
p=.24 
 
Duration of 
Diagnosisb  
 
33.58 
(11.20) 
 
29.62 
(12.05) 
 
33.04(12.75) 
 
F(2,91) =1.11, p=.34 
 
HADS 
Anxietyc  
48.13 48.85 44.70 H(2)=.375, p=.83 
 
HADS 
Depressionc  
45.63 46.11 51.96 H(2)=.933, p=.63  
a .Chi  Square  ana lys is  (χ ² ) :  g roup  numbers  ind ica ted  for  each  HbA1c leve l .   
b .ANOVA analys is (F ) :  mean  and  s tandard  devia t ion  ind ica ted  for  each  HbA1c leve l .   
c .Kruskal  Wal l i s  non-parametr ic  ana lys is  (H ) :  mean  rank  ind ica ted  for  each  HbA1c 
leve l .  Note .  Transformat ions  were  used  for  ana lys is  of  NART-IQ (Reverse  & Square  
Root)  because  of  a  non-normal  d is t r ibu t ion  of  th is  var iab le .  For  ease  of  unders tanding ,  
the  means  d isp layed  for  bo th  the  unt ransformed var iab le  (UT)  and  the  t ransformed 
var iab le  (T)  wi th  the  assoc ia ted  F  score .  *p< .05 ,  **p< .01  
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Table 5.6  Comparison of Demographic Variables Between Recent 
HbA1c Groups  
 
 Recent HbA1c Group  
 
Variable 
Low HbA1c 
≤7.9 % 
 
 
Midrange 
HbA1c 
8.0-8.8% 
 
High 
HbA1c 
≥8.9% 
 
 
 Significance 
 n=33  n=33 n=28  
Gendera  Female=17 
Male=16 
Female=15 
Male=18 
Female=17 
Male=11 
  
χ²(2)=1.42, p=.49 
 
Ageb  
 
58.01(8.4) 
 
59.29 (8.8) 
 
58.69(9.4) 
 
F  (2,91) =.17, p=.84 
 
NART-IQb  
 
 
3.07 (1.1)T 
115(6.7)UT 
 
3.15 (.96)T 
115(5.9)UT 
 
3.64 (.997)T 
112(7.6)UT 
 
F  (2,91) =2,59, p=.08 
 
 
Educationc  
 
51.30 
 
52.12 
 
37.57 
 
 H(2)=5.37, p=.068  
 
Age of 
Onsetb  
 
25.66(9.29) 
 
26.30(13.0) 
 
28.69(11.27) 
 
 F(2,91) = .596, 
p=0.55 
 
Duration of 
Diagnosisb  
 
32.36 
(11.61) 
 
33.0 (12.58) 
 
29.99(11.88) 
 
F(2,91) =.513, 
p=0.60 
 
HADS 
Anxietyc  
48.36 45.83 48.45 H(2)=.192, p=.91  
 
HADS 
Depressionc  
43.30 47.82 52.07 H(2)=1.60, p=.45 
 
a .Chi  Square  ana lys is  (χ ²) :  g roup  numbers  ind ica ted  for  each  HbA1c leve l .  b .ANOVA 
analys is (F ) :  mean  and  s tandard  devia t ion  ind ica ted  for  each  HbA1c leve l .  c .Kruskal  
Wal l i s  non-parametr ic  ana lys is  (H ) :  mean  rank  ind ica ted  for  each  HbA1c leve l .  Note .  
Transformat ions  were  used  for  ana lys is  of  NART-IQ (Reverse  & Square  Root)  because  
of  a  non-normal  d is t r ibu t ion  of  th is  var iab le .  For  ease  of  unders tanding ,  the  means  
d isp layed  for  bo th  the  unt ransformed var iab le  (UT)  and  the  t ransformed var iab le  (T)  
wi th  the  assoc ia ted  F  score .   
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ANOVA was used to investigate the relationship between HbA1c 
level and results on the different cognitive tasks. There were no 
differences between groups using either current or recent HbA1c on the 
age-adjusted estimate of lifetime cognitive change (A-ELCC), the oral 
version of Symbol Digit Modalities (SDMT-O), Story Recall-Delayed 
or the Trail Making Tests (TMT-A & B). Mean HbA1c will be used in 
multiple regression focused on these cognitive processes.  
Results of the ANOVA and ANCOVA using Story Recall 
Immediate (SRI) and Delayed (SRD), including mean HbA1c, recent 
HbA1c and current HbA1c, are shown in Table 5.7. Overall ANCOVA 
results (controlling for education and NART IQ) are significant only 
for current HbA1c and SRI. There is a trend towards a significant 
difference between the current HbA1c groups on SRD. Planned 
comparisons revealed that the low current HbA1c group showed 
significantly lower scores on the SRI test ( x¯=-.26, SE=.13) than the 
high current HbA1c group ( x¯ =.33, SE=.16), t(89)=-2.83,  p=.006. As 
well,  planned comparisons revealed that the low current HbA1c group 
showed significantly lower scores on the SRD test ( x¯=-.17, SE=.13) 
than the high current HbA1c group ( x¯ =.32, SE=.15), t(89)=-2.40,  
p=.018. The score for the low current HbA1c group was below the 
mean (0) for both SRI and SRD, but within one standard deviation 
based on the normative sample, indicating average performance. When 
comparing across means, qualitatively, using mean HbA1c, the High 
group has the lowest SRI score, whereas for both the recent and current 
HbA1c groupings the low group has the lowest SRI score. Current 
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values of HbA1c were used in the multiple regression for this cognitive 
process. 
Table 5.7 ANOVA and ANCOVA Results for Story Recall Immediate (I) 
and Delayed (D) by HbA1c Group (Mean, Recent and Current) 
 
 HbA1c Group   
 Low HbA1c 
≤7.9% 
Midrange  HbA1c 
8 .0-8 .8% 
High HbA1c 
≥8.9% 
F p  
Mean HbA1c  
Group Number  
n=29 n=34 n=30   
S tory  Recal l  I  
Mean (SD)  
.012  ( .65)  .050  ( .96)  - .008  ( .68)  .045  .956  
S tory  Recal l  D  
Mean (SD)  
.145  ( .68)  .021  ( .88)  .030  ( .69)  .251  .779  
Recent  HbA1c 
Group Number  
n=33 n=33 n=28   
S tory  Recal l  I  
Mean (SD)  
- .14  ( .78)  .13  ( .70)  .06  ( .84)  1 .03  .362  
S tory  Recal l  D  
Mean (SD)  
- .02  ( .74)  .14  ( .68)  .06  ( .86)  .361  .698  
Current  HbA1c 
Group Number  
n=32 n=37 n=25   
S tory  Recal l  I  
Mean (SE)  
- .255  ( .13)  .036  ( .12)  .332  ( .16)  4 .08  .020* 
Story  Recal l  D  
Mean (SE)  
- .170  ( .13)  .081  ( .12)  .317  ( .15)  2 .97  .057  
*  p<.05 .  Note .  ANCOVA contro l l ing  years  of  educat ion  and  NART IQ used  in  
compar ing  curren t  HbA1c groups .  
 
The Digit Span Test ANOVA results (Table 5.8) indicate that 
there were differences between recent HbA1c groups, F(2,91)=8.26, 
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p=.001, d=.29. Planned comparisons indicate that the high recent 
HbA1c group showed lower mean Digit Span performance ( x¯ =1.28, 
SD=.37) than the midrange recent HbA1c group ( x¯ =1.60, SD=.35), 
t(91)=3.716,  p=.000, two-tailed, d=.78. There were no overall 
differences on Digit Span when using current HbA1c, F(2,89)=1.68, 
p=.192 controlling for NART IQ and education. When mean HbA1c 
was used, there were also no differences between groups, 
F(2,90)=1.48, p=.23. All scores on the Digit Span task were greater 
than one standard deviation above the mean indicating better than 
average performance on this task in comparison to the normative 
sample. Recent HbA1c values will be used in the multiple regression 
analysis for this cognitive process. 
ANOVA results indicated no difference between groups on the 
Symbol Digit Modalities Test-Written (SDMT-W) for either recent 
HbA1c groups, F(2,90)=1.72, p=.19, or the current HbA1c groups, 
F(2,89)=.77, p=.47 (Table 5.9). Planned comparisons did however 
reveal a trend towards lower scores for the low recent HbA1c group ( x¯
=-.513, SD=1.15) than the high recent HbA1c group ( x¯ =-.014, 
SD=1.16), t(90)=-1.65, p=.052, d=-.35, controlling for unequal 
variance (Levene Statistic=3.98, p< .05). These scores were within one 
standard deviation below the mean of the normative population 
indicating average performance. 
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Table 5.8 ANOVA Results for Digit Span by HbA1c Group (Mean, 
Recent and Current)  
 
 HbA1c Group   
 Low HbA1c  
≤7.9% 
Midrange  HbA1c 
8 .0-8 .8% 
High HbA1c 
≥8.9% 
F p  
Mean HbA1c  
Group Number  
n=29 n=34 n=30   
Dig i t  Span  
Mean (SD)  
1 .38  ( .35)   1 .49  ( .36)   1 .35  ( .38)   1 .48  .233  
Recent  HbA1c 
Group Number  
n=33 n=33 n=28   
Dig i t  Span  
Mean (SD)  
1 .33  ( .29)  1 .60  ( .35)  1 .28  ( .37)  8 .26  .001* 
Current  HbA1c 
Group Number  
n=32 n=37 n=25   
Dig i t  Span  
Mean (SE)  
1 .33  ( .06)  1 .46  ( .05)   1 .45  ( .07)  1 .68  .192  
NB Digi t  span  z  scores  were  t ransformed (square  root )  for  ana lys is .   
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Table 5.9 ANOVA Results for Symbol Digit Modalities - Written by 
HbA1c Group (Mean, Recent and Current)  
 
 HbA1c Group   
 Low HbA1c  
≤7.9% 
Midrange  HbA1c 
8 .0-8 .8% 
High HbA1c 
≥8.9% 
F p  
Mean HbA1c  
Group Number  
n=29 n=34 n=30   
SDMT-Wri t ten  
Mean (SD)  
- .433  (1 .2)  - .17( .97)  - .311  ( .97)   .469  .627  
Recent  HbA1c 
Group Number  
n=33 n=33 n=27   
SDMT-Wri t ten  
Mean (SD)  
- .513  (1 .15)  - .319  ( .759)  - .014  (1 .17)  1 .722  .185  
Current  HbA1c 
Group Number  
n=32 n=37 n=24   
SDMT-Wri t ten  
Mean (SE)  
- .439  ( .18)  - .314  ( .16)  - .089  ( .21)  .768  .467  
 
5.6.2.  Measures of Diabetes Health  
 
The influence of measures of diabetes health (i .e. retinopathy, 
microvascular disease, insulin resistance, severity of hypoglycaemia) 
and measures of disease burden (duration of diagnosis, age of onset) 
has been investigated for their relationship with cognitive deficit  in 
previous T1DM studies (Brands et al. ,  2005). In this study, results of 
Spearman’s rho correlation indicate that higher severity of retinopathy 
is related to lower scores on the age-adjusted estimate of lifetime 
cognitive change (A-ELCC), rs=-.188,  p=.04, a test of perceptual speed, 
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Trail Making Test-A (TMT-A), r=-.227,  p  =.014 and a test of executive 
function, Trail Making Test-B (TMT-B), r=-.187,  p =.04). Results of 
this study showed that higher severity on a measure of total 
microvascular disease was also related to lower scores on age-adjusted 
estimate of lifetime cognitive change (A-ELCC), r=-.209, p=.02, TMT-
A (r=-.258,  p=.006), TMT-B (r=-.264,  p=.005), Symbol Digit Modalities 
– Written (SDMT-W), r=-.307,  p=.001, and Symbol Digit Modalities-
Oral,  r=-.275,  p=.004. An estimate of insulin resistance (eGDR) and 
self-rating of average number of hypoglycaemic events per year which 
required assistance did not show significant correlation with any 
cognitive task. Having diabetes for a longer duration was related to 
lower scores on the TMT-A (r=-.205,  p=.02), the TMT-B (r=-.238,  p=.01) 
and SDMT-O (r=-.172,  p=.049). Although earlier age of onset is 
correlated with longer duration of diagnosis (r=-.715,  p=.000) in this 
study, age of onset was not correlated with any of the cognitive tests.  
The diabetes health variables with significant correlations to cognitive 
tests are explored further.  
Retinopathy and Microvascular Disease  
 
Higher severity of retinopathy and a higher combined rating of 
microvascular disease are correlated with lower scores in some 
cognitive domains including perceptual speed, executive function and 
estimated lifetime cognitive change, as indicated above. ANOVA was 
used to compare groups varying on severity of retinopathy 
(Mild/Observable; Referable; Proliferative) on the cognitive tests.  
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ANOVA was used to compare retinopathy groups on demographic 
variables (Table 5.10). 
Table 5.10 Comparison of Demographic Variables Between Retinopathy 
Severity Groups  
 Ret inopathy Group  
 
Variable  
Mild/  
Observable   
 
 
Referable  
 
Prol iferat ive 
 
 
Signif icance 
 n=40  n=21 n=33  
Gendera  Female=20 
Male=20 
Female=12 
Male=9 
Female=17 
Male=16 
  
χ²(2)=.289,  p=.86 
 
Ageb  
 
 
55.85(8.4)  
 
 
60.80 (7 .66)  
 
 
60.72 (9 .21)  
 
F  (2 ,91)  =3.78,  p=.026* 
 
NART-IQ b  
 
 
3 .21 (1 .0)T 
115(5.7)UT 
 
 
3 .23 (1 .04)T 
115(7.9)UT 
 
 
3 .37 (1 .16)T 
113 (7 .5)UT 
 
 
F  (2 ,91)  =.24,  p=.79 (T) 
 
 
Educat ionc  
 
52.33 
 
 
47.38 
 
 
41.73 
 
 
 H (2 )=2.77,  p= .25 
 
 
Age of  
Onsetb  
 
26.43(11.47)  
 
33.48(11.32)  
 
22.96(9.07)  
 
 F(2,91)  = 6 .28,  p=.003** 
 
 
 
Durat ion of  
Diagnosisb  
 
 
33.58 (11.20)  
 
29.62 (12.05)  
 
33.04(12.75)  
 
F(2,91)  =1.11,  p=.34 
 
HADS A c  
 
55.08 49.31 37.17 H (2 )=8.03,  p= .018* 
 
HADS 
Depressionc  
 
51 .29 52.93 39.45 H (2 )=4.56,  p= .102  
a .Chi  Square  ana lys is  (χ ² ) :  g roup  numbers  ind ica ted  for  each  HbA1c leve l .   
b .ANOVA analys is (F ) :  mean  and  s tandard  devia t ion  ind ica ted  for  each  HbA1c leve l .   
c .Kruskal  Wal l i s  non-parametr ic  ana lys is  (H ) :  mean  rank  ind ica ted  for  each  HbA1c leve l .  
Note .  Transformat ions  were  used  for  ana lys is  of  NART-IQ (Reverse  & Square  Root)  
because  of  a  non-normal  d is t r ibu t ion  of  th is  var iab le .  For  ease  of  unders tanding ,  the  
means  d isp layed  for  bo th  the  unt ransformed var iab le  (UT)  and  the  t ransformed var iab le  
(T)  wi th  the  assoc ia ted  F  score .  *p< .05 ,  **p< .01  
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Results indicated that there were differences between retinopathy 
groups in age, F(2,91)=3.78, p=.026, with the mild/observable 
retinopathy group younger ( x¯ =55.85, SD=8.4) than the proliferative 
retinopathy group ( x¯=60.71, SD=9.2, p<.05), based on Tukey HSD post 
hoc test.  There was also a difference between retinopathy groups in age 
of onset,  F(2,91)=6.28, p=.003, with the referable retinopathy group 
showing later age of onset (mean = 33.48, SD=11.3) than the 
mild/observable group ( x¯ = 26.43, SD=11.5, p=.042) and the 
proliferative group ( x¯= 22.96, SD=9.1, p=.002), based on Tukey HSD 
post hoc test.  Finally there was a difference between retinopathy 
groups based on anxiety level,  H(2)=8.00, p=.018. Post-hoc testing 
using Mann-Whitney U indicated that the proliferative retinopathy 
group (Mean Rank =29.09) showed significantly lower anxiety ratings 
than the mild/observable retinopathy group (Mean Rank=43.53), 
U=399, p=.004 ,  r=-0.34. Lower anxiety may lead to an advantage for 
the proliferative retinopathy groups on cognitive tasks, as such it  is not 
a factor that would lower cognitive scores in this group. The 
relationship between and anxiety, diabetes health variables and 
cognitive test results will be further explored in the chapter on 
psychological variables (Chapter 7). As well,  all  cognitive scores have 
already been adjusted for age. Only age of onset will be used as a 
covariate in ANCOVA. 
Results of the ANOVA for cognitive function, controlling for age 
of onset are displayed in Table 5.11.  
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Table 5.11 Results Of ANOVA Comparison Of Cognitive Tests By 
Retinopathy Level Controlling for Age of Onset 
 
 Ret inopathy  Level   
Cogni t ive  
Tes ts  
Mild /  
Observable  
Mean  (SE)  
Referable  
Mean (SE)  
Pro l i fe ra t ive  
Mean (SE)  
F p  
 n=40 n=21 n=33 
(n=32 TMT) 
  
A-ELCC .304  ( .15)  - .252  ( .21)  - .174  ( .17)  3 .42  .037* 
TMT AZ 1 .03  ( .05)  T  .942  ( .07)  T  .878  ( .06)  T  2 .07  .132  
TMT BZ 1 .21  ( .07)  T  1 .07  ( .10)  T  .991  ( .08)  T  2 .21  .115  
SRI  Z   - .014  ( .12)  .055  ( .18)  .026  ( .14)  .058  .944  
SRD Z .059  ( .12)  .148  ( .17)  .001  ( .13)  .213  .809  
SDMT-W Z - .186  ( .17)  - .211  ( .239)  - .498  ( .19)  .834  .438  
SDMT-O Z .156  ( .17)  .199  ( .24)  - .309  ( .19)  2 .00  .141  
Digi t  Span  Z  1 .42  ( .06)T 1 .30  ( .08)  T  1 .47  ( .06)  T  1 .28  .282  
A-ELCC=Age-Adjus ted  Es t ima te  o f  L i fe t ime  Cogn i t ive  Change ;  TMT =  Tra i l  Mak ing  Tes t ;  
SRI  =  S to ry  Reca l l  Immedia te ;  SRD =  S to ry  Reca l l  De layed ;  SDM T-W /SDM T-O= Symbol  
D ig i t  Moda l i t i e s  Tes t  W r i t t en  (W ) /  Ora l  (O)  
N .B .  T rans fo rmat ions  ( ind ica ted  by  T)  were  used  fo r  ana lys i s  o f  TMT A & B  and  Dig i t  
Span  Z  sco res  (Square  Roo t )  because  o f  a  non-normal  d i s t r ibu t ion  o f  these  va r i ab les .  Fo r  
cons i s t ency  and  ease  o f  compar i son  ac ross  t e s t s  the  t r ans fo rmed  TMT scores  were  reve rsed  
to  be  in  l ine  w i th  the  o the r  cogn i t ive  t e s t  s co res  fo r  wh ich  a  lower  sco re  i s  r e l a ted  to  
poore r  pe r fo rmance .  
 
It  was expected that those with highest severity retinopathy 
would show the poorest cognitive performance compared to those with 
lower severity of retinopathy. Both the Referable and Proliferative 
Retinopathy groups showed an age-adjusted estimate of lifetime 
cognitive change (A-ELCC) score below 0, indicating a decline in 
cognitive function from estimated premorbid IQ. In contrast the 
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Mild/Observable Retinopathy group showed a mean A-ELCC score 
above 0 indicating stability or improvement from an estimate of 
premorbid IQ. There was a significant difference between groups that 
varied on retinopathy severity for the mean A-ELCC, F(2,88)=4.438, 
p=.015, shown in Figure 5.1, when controlling for age, age of onset of 
diabetes and anxiety rating. 
 
Figure 5.1. Mean age-adjusted estimate of lifetime cognitive (A-ELCC)  
change z score by retinopathy group controlling for age, age of onset,  
and anxiety.  
 
 
Planned comparison indicated that the Proliferative retinopathy group 
showed lower mean A-ELCC score ( x¯ =-0.27, SE=.17), than the 
mild/observable retinopathy group ( x¯ =0.36, SD=.15), t(88)=2.66, 
p=.009). The score for the referable retinopathy group ( x¯ =-0.21, 
SD=.21) was not different from that of the proliferative retinopathy 
group. 
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Results of omnibus F test indicated no significant difference 
between retinopathy groups on a test of perceptual speed, TMT A, 
F(2,89)=2.07, p=.13, however planned comparisons indicated a 
significant difference between the proliferative retinopathy group ( x¯
=.878, SE=.06) and the mild/observable retinopathy group, ( x¯=-1.03, 
SE=.05), t(89)=2.01, p=.048. Similarly, there was no overall 
significant difference between groups on a test of executive function, 
TMT-B, F(2,89)=2.22, p=.115, however planned comparisons indicated 
that the proliferative retinopathy group showed weaker performance ( x¯
=.991, SE=.08), than the mild/observable retinopathy group, ( x¯=1.21, 
SE=.07),  t(89)=-2.06, p=.043.  
No significant differences were found between groups on mean 
scores for a test of perceptual speed (SDMT-O & W) or on the tests of 
verbal episodic memory, Story Recall Immediate or Delayed or short-
term/working memory (Digit Span).  
Retinopathy and mean HbA1c 
 
Higher mean HbA1c is correlated with higher retinopathy 
(rs=.365,  p =.000), and greater overall microvascular disease (rs  =.470, p 
=.000). Could it  be that HbA1c is related to cognitive deficits through 
its relationship with these complications? Factorial ANOVA was used 
to look the possible interaction between severity of retinopathy and 
level of mean HbA1c. Because of low group numbers, the retinopathy 
group was split  into two – those with no/mild/observable retinopathy 
(Lowest Retinopathy; n=39) and those with referable/proliferative 
retinopathy (Highest Retinopathy; n=54). The HbA1c groups remained 
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the same (Low, n=29; Midrange n=34; High, n=30). The total number 
is 93 instead of 94 because there was no mean HbA1c data for 1 
participant. Group size was uneven with a significant discrepancy 
confirmed by chi square analysis, χ²(2)=6.20, p=.045, two-tailed, in 
frequency of group membership, likely reflecting the discrepancy 
between the size of the Lowest and Highest retinopathy groups with 
High HbA1c (Table 5.12). 
 
Table 5.12 Group Size for Factorial ANOVA Mean HbA1c (3) and 
Retinopathy Severity (2)  
 
 Mean HbA1c Group  
Retinopathy 
Severity 
Low 
≤7.9% 
Midrange 
8-8.8% 
High 
≥8.9% 
Total 
Lowest 17 14 8 39 
Highest 12 20 22 54 
Total 29 34 30 93 
 
When considering the age-adjusted estimate of lifetime cognitive 
change (A-ELCC), there was a significant main effect based on 
retinopathy group, F(1,87)=5.661, p=.020 with the highest retinopathy  
group showing a lower A-ELCC score ( x¯ =-.195, SD=.13) than the 
lowest retinopathy group ( x¯=.287, SD=.16). The mean A-ELCC score 
for the highest retinopathy group was below 0, indicating decline from 
estimated premorbid IQ, whereas the score for the lowest retinopathy 
group was above 0 indicating overall stability or improvement from 
estimated premorbid IQ levels. There was a no significant effect of 
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HbA1c group on mean A-ELCC score, F(2,87)=.786, p=.46. Although, 
there was no significant interaction between severity of retinopathy 
and mean HbA1c, F(2,87)=.734, p=.48, planned comparisons revealed 
that those within the highest retinopathy group who also had high mean 
HbA1c showed a lower mean A-ELCC score ( x¯=-.482, SD=1.12) than 
those in the lowest retinopathy group who also had high mean HbA1c 
( x¯ =.323, SD=.672), F(1,89)=7.21, p=.009. Results are displayed in 
Figure 5.2. These groups are much different in size, with only 8 in the 
lowest retinopathy/high HbA1c group compared to 22 in the highest 
retinopathy/high HbaA1c group. However, the estimates for mean A-
ELCC score for the lowest retinopathy group are nearly identical 
across all  mean HbA1c groups despite the larger size of the midrange 
mean HbA1c group (n=14) and the low mean HbA1c group (n=17), 
suggesting that more participants would not necessarily have 
significantly influenced the level of mean performance for this 
particular group. Furthermore, there is a numerically smaller variance 
in scores for the lowest retinopathy group with high mean HbA1c 
(SD=.67) than for those in the highest retinopathy group with high 
mean HbA1c (1.12) indicating greater consistency between scores in 
the former group. This also suggests a higher group number would not 
necessarily influence the outcome for this group on this variable. Post 
Hoc Tukey tests indicated no other significant differences between 
mean A-ELCC scores. In the Highest retinopathy group, those with 
Midrange HbA1c achieved a mean above 0, indicating stability or 
improvement from an estimate of premorbid IQ. Those groups with low 
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and high mean HbA1c groups achieved means below 0 indicating 
decline from an estimate of premorbid IQ suggesting that when high 
levels of retinopathy are present both extremes of blood glucose may 
increase risk of cognitive decline. 
 
 
Figure 5.2. Mean age-adjusted estimate of lifetime cognitive change by 
mean HbA1c group and retinopathy severity.  
 
 
On a test of processing speed, Trail Making Test-A (TMT-A), 
factorial ANOVA indicated a main effect of mean HbA1c, 
F(2,86)=3.16, p=.047. Planned comparisons indicate that the low mean 
HbA1c group shows lower mean score on TMT-A ( x¯ =.84, SE=.060) 
than the high mean HbA1c group ( x¯=1.03, SE=.056), p<.05. There was 
also a significant effect of retinopathy level,  F(1,86)=6.17, p=.015, 
with those in the highest retinopathy group showing a lower mean 
score on TMT-A ( x¯ =.877, SE=.045) than those in the lowest 
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retinopathy group ( x¯ =1.05, SE=.054). There was no significant 
interaction between mean HbA1c group and retinopathy level, 
F(2,86)=1.13, p=.327. However, there was a trend towards a difference 
between TMT-A scores for those in the Low HbA1c group depending 
on the retinopathy group, F(1,88)=3.84, p=.053, with those in the 
highest retinopathy group ( x¯ =.701, SD=.318) showing a lower mean 
TMT A score than those in the lowest retinopathy group ( x¯ =.982, 
SD=.362). Possibly highlighting a degree of vulnerability for those 
with low mean HbA1c as well.  These scores are above the mean and 
well within the average range. 
On a test of executive function, the Trail Making Test B (TMT-
B), factorial ANOVA indicated a main effect of mean HbA1c, 
F(2,86)=3.32, p=.041. However, planned comparisons indicate no 
significant differences between the High mean HbA1c group and the 
Low or midrange mean HbA1c groups. There was a non-significant 
interaction between mean HbA1c group and retinopathy level, 
F(2,86)=.084, p=.92. There were no differences in mean HbA1c scores 
based on level of retinopathy or vice versa. 
5.6.3.  General Health Variables and Cognitive Function 
Question 2: Is cognitive function related to general health variables 
and health promoting habits? 
People with diabetes are also at increased risk general health 
variables (i .e.  hypertension, high cholesterol,  high BMI). Could it  be 
that people with relatively weaker cognitive function have greater 
general health variables or differ in health promoting habits (i .e.  
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exercise, cognitive activity)? To investigate this possibility, non-
parametric correlation Spearman’s rho was used to determine if there 
were any significant relationships between cognitive function and these 
health factors outlined in Table 5.13. Significant correlations are 
highlighted below. One-tailed correlation significance was used. The 
complete correlation table is provided in Appendix O.  
 
Table 5.13 General Health Variables for Analysis of Cognitive 
Impairment  
 
Cardiovascular  Cholesterol  Obesi ty  Health  Habits  
Systo l ic  BP  Tota l  Choles tero l  BMI Exerc ise   
(Less /Same/More)  
Dias to l ic  BP HDL Choles tero l  Wais t /Hip  Rat io  Rate  of  Perce ived  
Exer t ion  (Low to  
modera te  /  S t rong)  
 Tr ig lycer ides   Cogni t ive  Act iv i ty   
(Less /Same/More)  
 
Results of Spearman’s rho correlation indicate that higher self-
rating on a perceived exertion scale, when participants rated how much 
they typically exert themselves in physical activity on a scale of 1 to 
10, correlated with a better age-adjusted estimate of lifetime cognitive 
change score (A-ELCC), rs  =.237,  p  =.02. Results of partial correlation 
indicate that this relationship was maintained when controlling for 
participant education, prs  =.247, p= .012, NART-IQ, prs  =.236, p=.015, 
or age, prs  =.234, p= .015. 
Greater self-reported daily cognitive activity in comparison to 
age peers was related to higher scores on Digit Span, a task of short-
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term/working memory, rs  =222,  p  =.02 and higher IQ scores, rs  =.182,  
p  =.04. The relationship between the task of short-term/working 
memory and the self-rating of cognitive activity becomes a non-
significant trend when controlling for NART-IQ, prs  =.165, p= .057.  
 Higher HDL (good) cholesterol levels were related to lower scores 
on the Digit Span test,  rs  =-.175, p  =.046, however this became a non-
significant trend when controlling for participant age, prs=-.168, 
p= .054. Story Recall Delayed (SRD) had a negative relationship with 
waist-hip ratio, rs=-.177, p=.046, however this relationship became 
non-significant when controlling for participant age, prs  =-.138, 
p= .097 and NART-IQ, prs=-.102, p= .17. Given that many of these 
correlations values that became non-significant when considering other 
factors, these general health variables and health promoting habits 
were not included as predictors in further analysis. 
 
5.6.4.  Question 3 
Which diabetes health variables have the strongest predictive value on 
cognitive function? 
Finally, measures of diabetes health and diabetes burden found 
significant in the preceding analyses or influential in previous studies 
were entered into a multiple regression analysis to determine which 
factors were best at predicting cognitive function (i.e.,  A-ELCC, TMT-
A & B, SDMT-O &W, SRI, SRD and Digit Span). Using backward 
stepwise entry with an exclusion criteria of p< .055, age, female 
gender, NART-IQ, retinopathy/micovascular disease, 
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mean/recent/current HbA1c, severe hypoglycaemia, and duration of 
diagnosis were entered into the multiple regression analysis. Predictors 
were limited due to the number of subjects and issues of 
multicollinearity between predictors (e.g. duration of diagnosis and age 
of onset; retinopathy and microvascular disease; education and IQ; 
mean/recent/current HbA1c). In this case, one predictor was chosen if 
it  had the highest correlation with cognitive function. Based on the 
finding of significant correlation (Appendix O), the dichotomous 
variable retinopathy was used as the predictor in the analysis of age-
adjusted estimate of lifetime cognitive change. For all  other cognitive 
tests, microvascular disease had the strongest correlation with these 
tests and was therefore used in these regression analyses instead of 
retinopathy. Age of diagnosis was left out of the final analysis given 
its high correlation with duration of diagnosis and the fact it  loaded on 
the same dimension when it  was included in the model, causing a 
problem of multicollinearity. Age of diagnosis was not correlated with 
any of the cognitive domains tested (Appendix O). Duration of 
diagnosis is included in the regression as it  is correlated with scores on 
the Trail Making Test – A (r=-.205,  p <.05), Trail Making Test-B (r=-
.238,  p <.05) and Symbol Digit Modalities (r=-.172,  p <.05). Although 
severe hypoglycaemia was not found to be a significant predictor of 
cognitive deficit it  was included due to the relationship between lower 
mean HbA1c levels and an increased risk of hypoglycaemia (Cryer, 
2010).  
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The results of the final 2 steps of this analysis for each cognitive 
test are presented in Table 5.14. The best predictors of the age-adjusted 
estimate of lifetime cognitive change (A-ELCC) were retinopathy, 
severe hypoglycaemic events and female gender, explaining 17% of the 
variability in the A-ELCC score (r2=.174). These variables were 
retained as significant predictors in the final step of the model and is a 
significant predictor of cognitive change (A-ELCC), F(1,91)=6.017, 
p=.001, with a combination of higher retinopathy (ß=-.259, t(89)=-
2.671, p=.009), female gender (ß=-.290, t(89)=-2.962, p=.004), and 
higher frequency of hypoglycaemic events (ß=-.201, t(89)=-2.049, 
p=.043) predictive of a lower A-ELCC z score. 
Total microvascular disease burden was found to be the sole 
predictor on processing speed tasks. Microvascular disease was 
retained as a significant predictor in the final step of the model and is 
a significant predictor of the TMT-A score, F(1,90)=8.53, p=.004, with 
a higher level of microvascular disease related to lower TMT-A score 
(ß=-.294, t(90)=-2.92, p=.004). However, this factor on its own 
explains a small percentage (8.7%) of the TMT-A score (r2=.087).  
The best predictor on another test of perceptual speed, Symbol 
Digit Modalities – Oral (SDMT-O) is a combined score for 
microvascular disease. Microvascular disease was retained as a 
significant predictor in the final step of the model and is a significant 
predictor of the SDMT-O score, F(1,90)=8.02, p=.006) with higher 
microvascular disease score related to lower SDMT-O score (ß=-.286, 
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t(90)=-2.833, p=.006). However, this factor on its own explains a small 
percentage (8.2%) of the SDMT-O score (r2=.082).  
The best predictor on a written version of Symbol Digit 
Modalities – Written (SDMT-W) is a combined score for microvascular 
disease. Microvascular disease was retained as a significant predictor 
in the final step of the model and is a significant predictor of the 
SDMT-W score, F(1,90)=10.26, p=.002, with higher microvascular 
disease score related to lower SDMT-W score (ß=-.320, t(90)=-3.202, 
p=.002). However, this factor on its own explains a small percentage 
(10.2%) of the SDMT-W score (r2=.102).Total microvascular disease 
has a slightly stronger relationship to the written version of the SDMT 
which required a paper and pencil response in the form of writing the 
numbers corresponding with the symbols, than the oral version of the 
SDMT, which only required saying the numbers corresponding with the 
symbols. The best predictors of the episodic memory scores were 
current HbA1c and NART-IQ. Together, these variables accounted for 
13.5% of the variance in SRI scores, F(1,90)=7.10, p=.001, r2=.135, 
and 13.1% of the variance in SRD scores, F(1,90)=6.87, p=.002, 
r2=.131. 
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Table 5.14 Predictors of Scores on Tests of Cognitive Processing  
  
Cognit ive  
Test  
 
Predictors  
 
B  
 
S .E .  
 
Beta  
 
F  
 
p  
 
R 2  
A-ELCC a  
Step  4  
(Constan t )  
Age  
Female  Gender  
Ret inopathy  
Hypo 2  
- .264    
.009  
- .558   
 - .538  
- .371  
.642  
.011  
.186  
.194  
.188  
 
.080  
- .295  
- .281  
- .195  
 
 
 
 
4 .648  
.682  
.434  
.004  
.007  
.052  
 
 
 
 
.174  
A-ELCC  
Step 5  
(Constan t )  
Female  Gender  
Ret inopathy  
Hypo 2  
  .744  
-  .549  
- .496  
- .383  
.200  
.185  
.186  
.187  
 
- .290  
- .259  
- .201  
 
 
 
6 .017  
.000  
.004  
.009  
.043  
 
 
 
.169  
TMT-A b  
Step  6  
(Constan t)  
Female  Gender  
Micro  Tota l  
  1 .173  
  - .095  
 - .231  
.074  
.066  
.076  
 
- .161  
- .307  
 
 
5 .348  
.000  
.154  
.003  
 
 
.107  
TMT-A  
Step 7  
(Constan t )  
Micro  Tota l  
1 .116  
 - .221  
.063  
.076  
 
- .294  
 
8 .526  
.000  
.004  
 
.087  
TMT-B b  
Step  3  
(Constan t )  
Age  
Female  
NART-IQ  
Micro  Tota l  
Mean HbA1c 
-1 .591  
- .009  
- .163  
.022  
- .252  
.115  
.910  
.005  
.087  
.007  
.116  
.055  
 
- .178  
- .181  
.338  
- .245  
.218  
 
 
 
 
 
5 .201  
.084  
.096  
.063  
.001  
.033  
.042  
 
 
 
 
 
.232  
TMT-B  
Step 4  
(Constan t )  
Female  
NART-IQ 
Micro  Tot  
Mean HbA1c 
-1 .615  
- .184  
.019  
- .320  
.109  
.919  
.087  
.006  
.110  
.056  
 
- .204  
.283  
- .311  
.207  
 
 
 
 
5 .675  
.083  
.037  
.005  
.005  
.054  
 
 
 
 
.207  
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Table  5 .14  (cont . )  
Cognit ive  
Test  
 
P red ic tors  
 
B  
 
S .E .  
 
Beta  
 
F  
 
p  
 
R 2  
SDMT b  
Step  6  
(Constan t )  
NART-IQ 
Micro  Tot  
-3 .048  
   .028  
  - .667  
1 .814 
.015  
.242  
 
.184  
- .279  
.  
 
6 .923  
096 
.072  
.007  
 
 
.135  
SDMT 
Step 7  
(Constan t )  
Micro  Tot  
   .242  
 - .765  
.199  
.239  
 
- .320  
 
10 .255 
.227  
.002  
 
.102  
Digit  Span c  
Step  5  
(Constan t )  
Female  
NART-IQ 
-1 .233 
- .079  
.024  
.566  
.067  
.005  
 
- .110  
.444  
.  
 
12 .056 
.032  
.241  
.000  
 
 
.209  
Digit  Span 
Step 6  
(Constan t )  
NART-IQ 
-1 .276 
   .024  
.566  
.005  
 
.444  
 
22 .622 
.027  
.000  
 
.197  
SRI d  
Step  5  
(Constan t )  
NART-IQ  
Current   HbA1c 
Dura t ion  
-6 .224  
   .038  
   .206  
.006     
1 .638  
.012  
.073  
.006  
 
.334  
.288  
.093  
 
 
 
5 .034  
.000  
.002  
.006  
.341  
 
 
 
.144  
SRI 
Step 6  
(Constan t )  
NART- IQ  
Current  HbA1c 
-6 .005  
   .038   
.205  
1 .621 
  .012   
.073  
 
.332  
.288  
 
 
7 .100  
.000  
.002  
.006  
 
 
.135  
SRD d  
Step  5  
(Constan t )  
Age  
NART-IQ  
Current  HbA1c 
-5 .591  
  - .010  
   .041    
.183  
1 .580  
  .009  
  .012   
.071  
 
- .117  
.375  
.264  
 
.  
 
5 .046  
.001  
.248  
.001  
.012  
 
 
 
.144  
SRD 
Step 6  
(Constan t )  
NART-IQ  
Current  HbA1c 
-5 .766            
.038   
.177  
1 .576 
  .011   
.071  
 
.346  
.255  
 
 
6 .868  
.000  
.001  
.015  
 
 
.131  
a .  age ,  f ema le ,  NART-IQ,  r e t inopa thy  ( low/h igh) ,  mean  HbA1c ,  du ra t ion ,  seve re  hypo  
( low/h igh)  
b .  age ,  f ema le ,  NART-IQ,  mic rovascu la r  to ta l ,  mean  HbA1c ,  du ra t ion ,  seve re  hypo  ( low/h igh)  
c .  age ,  f ema le ,  NART-IQ,  mic rovascu la r  to ta l ,  r ecen t  HbA1c ,  du ra t ion ,  seve re  hypo  
( low/h igh)  
d .  age ,  f ema le ,  NART-IQ,  mic rovascu la r  to ta l ,  cu r ren t  HbA1c ,  du ra t ion ,  seve re  hypo  
( low/h igh)  
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On the test of cognitive flexibility (TMT-B) demographic 
variables (female gender & NART-IQ) emerged as the significant 
predictors along with total microvascular disease. Mean HbA1c was 
retained in the final model, but was just below the threshold for 
significance. These factors explain 20.9% of the variance in TMT-B 
score (r2=.209). Microvascular disease was retained as a significant 
predictor in the final step of the model and is a significant predictor of 
the TMT-B score, F(1,90)=5.68, p=.000, with a higher level of 
microvascular disease related to lower TMT-B score (ß=-.311, t(87)=-
2.907, p=.005) along with NART-IQ (ß= .283, t(87)=-2.869, p=.005) 
predictive of higher TMT-B score and female gender (ß=-.204, t(87)=-
2.116, p=.037), predictive of lower TMT-B score.  This task also has a 
perceptual speed component, joining alternating numbers and letters as 
quickly as possible with a pencil line. The only significant predictor 
remaining for the working memory task, Digit Span, was NART-IQ, 
explaining 19.7% of the variance in this score, F(1,90)=22.62, p=.000. 
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5.7.  Discussion 
5.7.1.  Question 1 
Do individuals who differ on glycaemic control and other diabetes 
health variables show significantly different scores on measures of 
cognitive processes?  
Results showed that severity of microvascular disease, 
specifically retinopathy, was the diabetes health variable that most 
consistently differentiated group scores on the cognitive processing 
measures. Those with proliferative retinopathy showed lower scores 
than those with low levels of retinopathy on an estimate of lifetime 
cognitive change, processing speed, and executive function (set-
shifting). These areas are typically found to differentiate the T1DM 
group from control groups (Brands et al. ,  2005). This is consistent with 
findings that retinopathy was identified as one of the key predictors of 
cognitive change in a large longitudinal study (Jacobson et al. ,  2011). 
When retinopathy was evaluated together with glycaemic control,  it  
was noted that severity of retinopathy also led to greater vulnerability 
to the extremes of glycaemic control.  Those with proliferative 
retinopathy and the highest level of mean HbA1c showed the greatest 
decline on the estimate of lifetime cognitive change. There was a trend 
for those with proliferative retinopathy and the lowest level of mean 
HbA1c on processing speed.  
Dividing the group based mean HbA1c on its own did not 
indicate differences on cognitive processing scores.  The is in line with 
results of other cross-sectional studies (Brismar et al. ,  2007; Zihl et 
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al. ,  2010). Using alternative measures (recent and current) highlighted 
the importance of the particular measurement of HbA1c on the results.  
Those with low current HbA1c showed lowest scores on the measures 
of episodic memory. Those with high recent HbA1c showed lowest 
scores on short term/working memory. Those with low recent HbA1c 
showed a trend towards the lowest scores on a measure of processing 
speed. This suggests that there may be disadvantages at both extremes 
of HbA1c for this older group that has not been highlighted in studies 
of younger adult groups (Jacobson et al. ,  2007, 2011). 
Results also highlight the potential that differences in motor 
speed rather than cognitive processing may have influenced some of 
the findings from studies in groups with T1DM. Based on previous 
studies, it  was expected that a differentiation in performance based on 
mean HbA1c would especially be apparent on tasks of processing speed 
(Brands et al. ,  2006; Jacobson et al. ,  2007 & 2011;).  However, the 
tasks used in this study did not have as strong a motor component as 
ones used in some previous studies that required a more complex fine 
motor control,  specifically fitting a small key in a hole in Grooved 
Pegboard (Lafayette Instrument Co., 2002). Fine motor speed may be 
especially important to take into consideration with older adults groups 
who would have greater incidence of peripheral nerve damage. In fact,  
neuropathy and measures of nerve conduction have been highlighted as 
predictors of cognitive function in previous studies (Ryan, 2005; 
Brismar et al.  2007). It  may be that the difference between those with 
T1DM and controls in the DCCT/EDIC study (Jacobson et al. ,  2007 & 
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2011) is based more on a difference in physical motor speed rather than 
cognitive processing speed.   
It  is important to note that cognitive results emphasized that all   
relative deficits in cognitive processing scores were within the average 
range based on age within the study group. This indicated that 
differences highlighted between groups were mild. Differences in 
cognitive measure and differences how HbA1c is measured may explain 
differences in results of cognitive studies in this group. More emphasis 
will need to be placed on differentiating these factors in future studies 
to gain a clear picture of the impact of HbA1c on cognitive processes.  
5.7.2.  Question 2 
Is cognitive function related to indicators of general health variables 
and health promoting habits?  
Results of this study indicate that greater perceived exertion in 
exercise was correlated to higher scores on the estimate of lifetime 
cognitive change even when considering IQ, education and age. 
Cognitive research studying the T1DM group has not yet included 
potential cognitive protective factors. There is some evidence that 
exercise has a positive influence on cognitive function. Cotman & 
Berchtold (2002) suggest that exercise has molecular and cellular 
effects that influence brain plasticity, especially in ageing. In a review 
of the available literature, Kramer, Bherer, Colcombe, Dong, & 
Greenough (2004), conclude that the results are mixed as to the effects 
of factors such as fitness on preserving cognitive function into old age. 
Although, protective factors have not been studied in T1DM studies of 
108 
cognition, these factors have been investigated in some studies of 
T2DM and cognition with some initial support.  Bruce and colleagues 
(2008), in a prospective study of cognitive change after 7 years, found 
that engaging in any amount of exercise in the past two weeks was a 
protective factor against cognitive decline in an older T2DM group. 
The identification of the relationship between higher perceived 
exertion and a higher estimate of cognitive change (less decline) in the 
study group suggests that exercise may be a potential modifiable factor 
that can be advised in the treatment of adults with T1DM. 
There were no markers of general health related to cognitive 
processes when taking into consideration other factors like premorbid 
IQ. Although some previous studies have identified general health 
variables as predictors of cognitive function in such as BMI and 
hypertension (Brismar et al. ,  2007; Brands et al. ,  2006) as well as 
cardiovascular events in longitudinal analysis of older samples (Van 
Duinkerken, 2011), other studies have not found strong evidence for 
measures of macrovascular health implicated in cognitive change over 
the long-term (Jacobson et al. ,  2011). It  may be that because the study 
group is middle aged and older, the presence of pre-cursors of 
cardiovascular disease are common across the whole group and some of 
these health factors are controlled by medication (e.g. blood pressure 
and cholesterol),  reducing the importance of these variables in 
differentiating cognitive performance between groups.  
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5.7.3.  Question 3 
Which diabetes health variables have the strongest predictive value on 
cognitive function? 
When diabetes health variables and demographic characteristics 
were combined in analysis, retinopathy or microvascular disease were 
found to be the strongest predictors in many cognitive processing areas 
including the estimate of lifetime cognitive change, all  measures of 
processing speed and executive function. This finding is in line with 
previous studies. Retinopathy and renal disease were identified as 
independent predictors of cognitive change scores over time in a large 
longitudinal study (Jacobson et al. ,  2011), however mean HbA1c was 
also identified as being and independent predictor of cognitive 
function, unlike results of this study. Other microvascular diseases 
including neuropathy have also been identified as a significant 
predictor of cognitive scores (Brismar et al. ,  2007).  
Results indicated that mean HbA1c was not an independent 
predictor of cognitive differences in a group of middle-aged to older 
adults with T1DM. This is in line with results of the cognitive study by 
Brismar and colleagues (2007) and the conclusion of a study of adults 
over age 50 (Brands et al. ,  2006) indicating that chronic exposure to 
hyperglycaemia was not sufficient to have considerable structural 
impact on the brain. Although mean HbA1c is not an independent 
predictor of cognitive function, current HbA1c and NART-IQ were the 
best predictors of episodic memory scores. This aspect of memory has 
not been highlighted in other T1DM research, however this may be a 
110 
cognitive process more important in ageing populations and appears to 
be related to the particular measure of HbA1c chosen (i.e. current 
value). 
Results showed that a higher frequency of self-reported severe 
hypoglycaemic events was identified as a significant predictor of 
estimated lifetime cognitive change (A-ELCC). Previous findings that 
recurrent hypoglycaemia relayed no long-term risk in cognitive 
functioning is based on a large prospective study of relatively younger 
adults (Jacobson et al. ,  2007 & 2011). However, this was consistent 
with recent findings from a prospective study that older adults with 
frequent severe hypoglycaemic events were more likely to show 
cognitive decline (Van Duinkerken et al. ,  2011) and the suggestion that 
older adults may be more vulnerable to this factor. There may be risks 
for older adults with T1DM in cognitive functioning at both extremes 
of glycaemic control that are not apparent at younger ages. Maintaining 
glycaemic control near normal, with the trade-off of more frequent 
hypoglycaemic events may have some negative cognitive outcomes for 
this group.  
5.7.4.  Conclusions 
What do the results tell  us about cognitive ageing in T1DM and its 
relationship with theories of healthy cognitive ageing? 
Study results indicate that middle aged and older individuals 
with T1DM perform at a level that is within the average in relation to 
the information on the normative population for these tests. Overall,  
their performance does not distinguish them as deficient as a group in 
111 
comparison to their age peers. Although differences were identified in 
cognitive processing for groups with greater severity of microvascular 
disease, measures of current and recent HbA1c, and recurrent 
hypoglycaemia, relative deficits were within the average range. This 
indicates that there are not evident signs of early cognitive ageing 
based on results of cognitive testing within the group as a whole. This 
is in line with the finding that only moderate cognitive deficits were 
identified between older groups with T1DM and controls (Van 
Duinkerken, 2011; Brands et al. ,  2006). Although the group did not 
show significant deficits overall,  further examination of the 
participants in the cognitive study who did show cognitive processes 
significantly below the mean will be investigated to determine whether 
there may be a higher incidence of mild cognitive impairment (MCI) in 
the sample compared to the general population and the diabetes health 
variables that are predictive of MCI in Chapter 6. Increased incidence 
of MCI especially in the middle-aged adults with T1DM would provide 
evidence of early cognitive ageing in this group. 
The maintenance of cognitive performance is present despite 
evidence from structural brain imaging of adolescents with T1DM that 
deficits in gray and white matter are identified even from a young age 
(Perantie et al. ,  2007). The cognitive reserve theory indicates that 
maintenance of cognitive function despite brain insults is accomplished 
through strong neural networks and neural compensation, or use of 
alternative brain networks when the ones typically used begin to fail 
(Stern, 2009).  Similarly, STAC theory posits that the brain uses 
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scaffolding to compensate for structural brain changes in an effort to 
maintain cognitive function (Park & Reuter-Lorenz, 2009). According 
to these theories, cognitive performance may be maintained through 
functional brain changes that could be detected using functional MRI 
(fMRI). This means that it  is possible early or accelerated brain ageing 
may be occurring even when cognitive function is maintained. 
Accelerated cognitive ageing has been dismissed as a possibility in 
groups with T1DM (Ryan, 2005); however, this conclusion is based 
only on cognitive testing. Research on cognitive ageing provides 
evidence that maintenance of cognitive function can occur even though 
there are signs of brain ageing (Reuter-Lorenz & Park, 2010). 
Identification of predictors of cognitive function provides targets for 
group comparison in fMRI that are most likely to show functional brain 
changes. Severity of microvascular disease, retinopathy in particular, 
was the most common predictor of differences across cognitive 
processing tasks. Groups were constructed based on high and low 
severity of retinopathy for comparison in the fMRI study presented in 
Chapter 8. 
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                                                                             Chapter 6
Mild Cognitive Impairment 
 
6.1.  Introduction 
The presence of mild cognitive impairment (MCI) has been 
identified as a factor that increases a person’s risk for developing 
dementia later in life (Petersen, 2011). It  signifies a marked deviation 
from the course of the normal cognitive ageing process. In a recent 
review, Petersen (2011) reports that for groups over 65, the prevalence 
rate for MCI is between 10 to 20%. Other researchers have reported an 
incidence rate from 3 to 19% (Gauthier et al. ,  2006). Meta-analysis of 
prospective population studies of people with diabetes have indicated a 
1.5 to 2 times higher risk of Alzheimer’s disease and a 2 to 2.5 times 
higher risk of vascular dementia, however the proportion of people 
with T1DM in these studies is not specified and will primarily be a 
T2DM population due to the higher incidence of this disease in the 
diabetes population (Biessels et al. ,  2006). Given the higher risk of 
MCI in prospective population studies of diabetes and the association 
with factors common in T1DM such as insulin use, long duration, early 
onset and complications, it  was hypothesized that those with T1DM 
may also show an increased incidence of MCI. If greater MCI is 
present in this primarily middle-aged study sample, this would provide 
evidence of early cognitive ageing in this group.  
6.2.  Study Aims  
This investigation explored the evidence for MCI within the total 
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cognitive study sample (n=94) based on presence of objective cognitive 
impairment greater than 1.5 SD below the mean for age. Although 
having a diagnosis of MCI was an exclusion criteria in the study 
sample, there were still  individuals who displayed deficits in areas of 
cognitive function that would meet the objective criteria for MCI. The 
study set out to explore whether the group who could be identified with 
MCI was different from those who show lower levels of cognitive 
impairment or no cognitive impairment in systematic ways that would 
explain the differences (i.e. older age, lower education, lower IQ) and 
whether this group would show indications of diabetes health variables 
(i .e.  more microvascular complications, chronic hyperglycaemia, 
recurrent hypoglycaemic events, greater insulin resistance) or greater 
disease burden (i.e. longer duration, earlier onset) as in previous 
studies of MCI in primarily T2DM populations. 
6.3.  Study Questions   
 
1. What is the incidence and nature of MCI in the study sample?  How 
does this compare to the incidence of MCI in the general 
population? 
2. Are there differences in the age, education or general intelligence 
of the participants in the study sample who show MCI in 
comparison to those who show lower levels of cognitive 
impairment?  
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3. Are there differences in general health variables and health habits 
in those who show MCI in comparison to those who show lower 
levels of cognitive impairment?  
4. Are there differences in diabetes health variables for those with 
MCI and in comparison to those who show lower levels of 
cognitive impairment? What are the strongest predictors of MCI? 
 
6.4.  Methods 
6.4.1.  Identification of MCI 
Petersen (2004) distinguishes between MCI with memory deficits,  
a-MCI, amnestic type with memory only (single domain) or with other 
cognitive deficits (multiple domain), and those with a cognitive 
impairment in a cognitive area other than memory na-MCI or non-
amnestic in a single domain or multiple domains. Petersen (2004) 
indicates that these different variations of MCI have different levels of 
risk for advancing to Alzheimer’s or other types of dementia, with the 
presence of amnestic types of MCI increasing risk of Alzheimer’s and 
vascular dementia and the non-amnestic types of MCI more commonly 
a precursor of other types of dementia (e.g. fronto-temporal dementia 
and dementia with lewy bodies) although other researchers have found 
that these distinctions in type of MCI do not predict types of dementia 
accurately (Fischer et al. ,  2007). Petersen (2004) proposes several 
criteria to define amnestic type MCI : 
• Memory complaint usually corroborated by an informant 
• Objective memory impairment for age 
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• Essentially preserved general cognitive function 
• Largely intact functional activities 
• Not demented 
(Petersen, 2004,p.189) 
Petersen (2004) suggests that a cutoff to determine an objective 
cognitive impairment compared to age in previous studies has been 
greater than 1.5 SD below the mean for age, however he cautions that 
this is to be used in conjunction with the other criteria. Other research 
groups have operationalized this objective impairment to greater than 
1.0 SD below the mean (Ganguli,  Dodge, Shen, & DeKosky, 2004). 
Petersen (2004) also describes non-amnestic MCI, which includes 
objective cognitive impairment in any other cognitive domainThe 
criteria for MCI include five components. Some of the evidence for 
meeting these criteria is primarily subjective or self-rated and other 
evidence is primarily objective or age norm-referenced. Table 6.1 
provides the MCI criteria adapted from Peterson (2004). In this table, 
the MCI criteria are divided into type (subjective or objective) and 
operationalized by providing the evidence necessary to meet each 
criterion. Subjective cognitive complaints were not assessed as 
explained below. 
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Table 6.1 Operationalized Criteria for Mild Cognitive Impairment 
 
Criteria for MCI 
Subjective Objective (Norm-Referenced) 
1. Person complains of memory 
and/or other cognitive 
difficulties  (cognitive complaints 
are noted be the person themselves 
and may or may not be noticed by 
others) 
 
1. Presence of an objective 
cognitive impairment .  (memory 
or other cognitive function in at 
least one area greater than 1.5 SD 
below mean for age) 
2. Intact functional activities  
(person reports that they can 
perform general activities of daily 
living independently or 
dependence is solely due to   
physical disability) 
2. Preserved general cognitive 
function  (evidence of average to 
above average IQ for age - rule 
out that the reason for impairment 
is below average cognitive 
function) 
 
 3. No Dementia  (rule out those 
who meet norm-referenced criteria 
for dementia) 
*based on amnest ic  MCI cr i ter ia ,  Petersen (2011;  2004) 
 
Objective Cognitive Impairment.  Results of the cognitive study 
provided detailed information about the presence of objective cognitive 
impairment in the study sample, the key inclusionary objective criteria 
118 
for MCI. The percentage of participants who meet this criteria, could 
be verified by examining participants’ cognitive function level in 
relation to age across various domains including memory, processing 
speed, executive function, and an estimate of cognitive change. In the 
literature, evidence of objective cognitive impairment has been defined 
in research by using an inclusion value starting at greater than 1 SD 
below the mean (Ganguli et al. ,  2004), however it  is more common to 
use a strict inclusion value of greater than 1.5 SD below the mean 
(Petersen, 2011) to diagnose MCI.  
 
Preserved General Cognitive Function.  In the present study, all  
participants have preserved general cognitive function. Specifically, all  
participants had average to above average general intelligence (i.e. 
NART IQ within 1 SD of the mean or > 1SD above the mean).  
 
Intact Functional Activities. Information on functional activities was 
not specifically collected; however, all  participants lived 
independently (i.e. in their own home) and maintained primary 
responsibility for their own diabetes care (i .e.  insulin injections, blood 
glucose monitoring).  
 
No Dementia.  A diagnosis of dementia was an exclusion criteria for the 
study, and as such no participant in the study was diagnosed with 
dementia. A diagnosis of MCI was also an exclusion criteria, however, 
some participants showed cognitive impairment in cognitive testing. 
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Subjective Cognitive Complaints.  There was evidence that components 
of the subjective MCI criteria were met, but this was not confirmed. In 
particular, information on subjective cognitive complaints were not 
systematically collected and only provided in anecdotes by some 
participants. Some researchers do not believe this is an essential 
component of the diagnosis of MCI and rather view this factor as an 
indicator of higher risk for progression of MCI to dementia (Mitchell,  
2008a; Mitchell,  2008b).  
6.4.2.  Statistical Analysis 
To answer these questions, age norm-referenced z scores for each 
participant in the total study sample (n=94) were counted as meeting 
the minimal objective criteria for cognitive impairment (CI) if the z 
score was greater than 1SD below the mean in any cognitive domain. 
The nature of the cognitive impairments was defined for this group by 
counting the number of participants who showed specific impairments 
in memory, processing speed, executive function or an estimate of 
cognitive change. A separate count was taken of participants who met 
the more strict criteria for objective cognitive impairment (CI), which 
is >1.5 SD below the mean for age (MCI). The characteristics of the 
MCI group were further explored and compared to the groups with Low 
CI (>1to 1.5SD below the mean) or no CI (within 1SD of the mean or 
above). Groups were compared on age, education, IQ, various diabetes 
health variables, and disease burden using group frequency measures 
(observation, and chi square). Spearman’s Rho and Pearson correlation 
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were also used to examine the relationships between CI group, 
demographic, diabetes, and health variables. Groups representing the 
three levels of cognitive function (defined in Table 6.2) are compared 
using the general linear model (GLM) including correlation, ANOVA, 
and ANCOVA. Multiple regression is used to determine the best 
predictors of high cognitive impairment. 
 
Table 6.2 Groups for GLM Statistical Analysis  
 
Level of Cognitive 
Impairment 
Group Name and Group Size 
 
Group Inclusion Criteria 
MCI 
n=25 
One or more cognitive domains  
> 1.5 SD below the mean for age 
Low CI 
n=18 
One or more cognitive domains > 1SD 
to 1.5 SD below the mean for age 
No CI 
n=51 
All cognitive domains within 1 SD or 
>1SD above the mean for age 
 
Planned comparisons were completed irrespective of the 
significance of the F-test given that these comparisons are hypothesis 
driven based on the results of previous research and the number of 
planned comparisons (2) is one less than the number of groups 
(Karpinski, 2011). 
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6.5.  Results 
6.5.1.  Question 1 
What is the incidence and nature of MCI in the study sample?   
Using the least strict criteria for cognitive impairment, a majority of 
participants of the total study sample (43 out of 94) showed at least 
one cognitive domain that was greater than 1 SD below the mean 
(46%). Of this group (n=43), 12 (28%) showed a memory impairment 
(story recall and/or digit span), 29 (67%) showed an impairment in 
processing speed (Trail Making Test A and/or Symbol Digit Modalities 
Test),  17 (40%) showed an impairment in executive function (Trail 
Making Test B) and 12 (28%) showed significant cognitive decline for 
age (A-ELCC). The percentage within each cognitive domain >1SD 
below the mean is displayed in Figure 6.1 .  The total percentage is 
greater than 100% of the group because 18 participants have 
impairment in two or more cognitive domains and were counted in each 
domain. 
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Figure 6.1. Percentage of participants with cognitive impairment (CI) 
greater than 1SD below mean (n=43) by cognitive domain. 
 
Using the criteria for MCI recommended by Petersen (2011), 
objective cognitive impairment greater than 1.5 SD below the mean, 25 
out of the total study sample of 94 (27%) met the criteria for an 
objective cognitive impairment. Of this subgroup 5 (20%) show 
impairment in the memory domain, 11 (44%) show impairment in 
processing speed, 14 (56%) in executive function, and 7 (28%) show 
evidence of cognitive decline. The percentage within each cognitive 
domain >1.5 SD below the mean is displayed in Figure 6.2. The total 
percentage is greater than 100% of the group (n=25) because 11 
participants (44%) showed more than one area of objective cognitive 
impairment.  
28%!
67%!
40%!
28%!
Memory!
Processing!Speed!
Executive!Function!
Cognitive!Change!
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Figure 6.2. Percentage of participants with cognitive impairment (CI) 
greater than 1.5 SD below mean (n=25) by cognitive domain. 
 
How does the incidence of MCI in the study sample compare to the 
incidence of MCI in the general population? 
 
Twenty-seven percent of the sample met the objective criteria for 
cognitive impairment for the identification of MCI established by 
Petersen (2004). The total cognitive study sample ranges in age from 
45 to just over 80, however the majority (81%) of this sample are under 
the age of 65 with a mean age of 58.7 years. MCI incidence is 
generally determined for those over 65 with an upper estimate of the 
incidence in the general population of 20% (Petersen, 2004). It  is 
presumed there would be a lower incidence for middle-aged adults.  In a 
normal distribution, under 7% of the population would have cognitive 
function >1.5 SD below the mean, indicating that this T1DM study 
population shows greater incidence of MCI than expected in the 
20%!
44%!
56%!
28%!
Memory!
Processing!Speed!
Executive!Function!
Cognitive!Change!
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general population. As well,  the incidence of MCI (27%), for 
participants is slightly higher than the upper incidence of MCI reported 
in previous population research. These numbers may not be comparable 
as MCI was not confirmed in this study sample through direct 
confirmation of other diagnostic criteria, however, these participants 
would likely meet the full criteria for MCI as this relatively young 
group does meet the other objective criteria for MCI (i.e.,  no dementia 
and preserved general cognitive function) and meets subjective criteria 
for MCI (i.e. preserved daily functioning). The high rate of MCI in this 
primarily middle-aged sample suggests the possibility that there is a 
higher incidence of MCI generally in the T1DM population. 
6.5.2.  Question 2 
Are there differences in age, education or general intelligence of the 
participants in the study sample who show MCI in comparison to those 
who show lower levels of cognitive impairment? 
Could the group of participants who meet criteria for MCI show 
these impairments because they are older or have less years of 
education or lower intelligence than other participants?  
Age 
Eighty-four percent (21/25) of the group with objective cognitive 
impairment >1.5 SD below the mean (MCI, n=25), were under the age 
of 65. This was not different than the age distribution in the total study 
sample (n=94) with 81% under the age of 65. In addition, only 2 of the 
participants with multiple domains of high objective cognitive 
impairment in the sample (n=11) are over the age of 65 also suggesting 
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that advanced age is not the primary reason this group showed higher 
cognitive impairment.  
The total study sample (n=94) was split  into three groups that 
varied on incidence of objective cognitive impairment (No CI, Low CI 
and MCI) as indicated in Table 6.2. Correlation using Spearman’s rho 
indicated that there is no relationship between age and CI group (rs = 
.079, p  =.46, two-tailed). ANOVA was also used to compare three 
groups on mean  age. Results of this ANOVA are displayed in Table 6.3. 
The three groups do not differ in mean age, F(2,91)=.20, p=.817.  
 
Table 6.3 ANOVA Comparison of Mean Age and General Intelligence 
Between Cognitive Impairment Groups  
 
Demographic   
Factors  
No CI 
Mean 
(SD) 
Low CI  
Mean 
(SD) 
MCI 
Mean 
(SD) 
F  p  
 n=51 n=18 n=25   
 
Age 
 
58.17 (9 .2)  
 
58.83 (8 .1)  
 
59.54 (8 .7)  
 
.203 
 
.817 
General  
Inte l l igence 
 
2 .95 ( .80)  T 
117 (4 .7)  UT 
3.56 (1 .32)  T 
112 (7 .8)  UT 
3.72 (1 .1)  T 
111 (7 .9)  UT 
5.91 .004* 
*p<.01  
N.B.  Genera l  In te l l igence  var iab le  was  reversed  and  square  root  used  to  normal ize  
the  d is t r ibu t ion  for  ANOVA. Transformed (T)  means  and  s tandard  devia t ions  as  
wel l  as  unt ransformed (UT)  means  are  used  in  the  tab le  to  express  da ta ,  a long  wi th  
the  F  score  and  s igni f icance  re la t ing  to  the  t ransformat ion .  
 
To determine whether the type of cognitive impairment (i .e.,  memory, 
executive function, processing speed or cognitive decline) in the MCI 
group was differentially distributed across participant age groups in the 
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whole study sample (n=94), the number of participants who could be 
classified under each domain was grouped into three age categories, 
under 55, 55 to 65 and over 65.  
 
Table 6.4 provides information on a count of the number showing 
impairments in each cognitive area and the percentage of the total 
study sample (n=94) within each age group. Participants with multiple 
cognitive impairments were counted in more than one group.  
 
Table 6.4 Percentage of Participant Age Groups with Cognitive 
Processes Greater than 1.5SD Below The Mean  
 
 
Age  
Group 
n=to ta l  in  
whole  
group 
(94)  
 
Memory  
n=5 
 
Process ing  
Speed  
n=11 
 
Execut ive  
Funct ion  
n=14 
 
Age-Adjus ted  
Cogni t ive  
Change   
n=7 
 
Mul t ip le   
Domains  
n=11 
 n  % of  
age 
group 
n % of  
age 
group 
n % of  
age 
group 
n % of  
age 
group 
n % of  
age 
group 
Under  55 
n= 37 
2 5% 5 14% 6 16% 2 5% 5 14% 
55-65 
n=39 
2 5% 4 10% 6 15% 4 10% 4 10% 
Over 65 
n=18 
1 6% 2 11% 2 11% 1 6% 
 
2  11% 
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There is a similar incidence of objective memory impairments 
across the age groups. Participants under age 55 showed a 3-4% higher 
incidence of impairment in processing speed than older participants. 
Participants under age 65 showed a 4-5% higher incidence of 
impairment in executive function than participants over age 65. The 
incidence of estimated cognitive decline was highest in the 55 to 65 
year old age group. Those with multiple domains of cognitive 
impairment were found across all age groups, with a slightly higher (3-
4%) incidence in the under 55 age group. Overall,  participants showed 
the highest incidence of objective cognitive impairment in the areas of 
executive function and processing speed. 
Education and Intelligence 
Could the group with MCI have lower education or lower 
intelligence?  The sample was divided into three groups that varied on 
incidence of objective cognitive impairment (No CI, Low CI, and MCI) 
as indicated in Table 6.2. Spearman’s rho correlation was used to 
determine whether there was a relationship between education or 
general intelligence and CI. Groups were also compared on these 
variables using the Kruskal-Wallis Test (education) and ANOVA 
(general intelligence) to determine whether there were differences in 
general intelligence (IQ) between groups.  
Regarding education, results show that the cognitive impairment 
groups did not differ in this factor. Spearman’s rho correlation 
indicated that there was no significant relationship between years of 
education and CI group (rs= -.162, p =.120, two-tailed). The result of the 
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Kruskal-Wallis non-parametric test is displayed in Table 6.5 for 
education, as this variable is not normally distributed. The three groups 
do not differ in years of education, H(2)=2.67, p=.262.  
Regarding general intelligence, results show that the cognitive 
impairment groups did differ in this aspect. Spearman’s rho correlation 
indicated that there is a significant relationship with general 
intelligence and CI group (rs = -.374, p =.000, two-tailed). Results of the 
ANOVA are displayed in Table 6.3 for general intelligence. This 
analysis confirmed CI groups do differ on general intelligence, 
F(2,91)=5.91, p=.004. Post Hoc Tukey HSD comparison indicated that 
the MCI group had significantly lower mean IQ ( x¯  =111) than the No 
CI group ( x¯  =117), p=.001. Although lower, the mean IQ level in the 
MCI group is at the upper end of the average range, and does not 
suggest that there is a general intellectual deficit  in this group.  
 
 
Table 6.5 Kruskal-Wallis Non-Parametric Comparison of Mean Rank of 
Education Between Cognitive Impairment Groups  
 
Demographic  
Factors 
No CI 
Mean Rank 
(Mdn/SD) 
Low CI  
Mean Rank 
(Mdn/SD) 
MCI 
Mean Rank 
(Mdn/SD) 
H  (p) 
 n=51 n=18 n=25   
Education 50.95 
(15.0/3.1) 
47.94 
(13.5 /4.2) 
40.14 
(12.0 /3.9) 
2.67 .262 
Note .  In  repor t ing  Kruskal -Wal l i s  the  mean ranks  used  in  the  ana lys is  a long  wi th  
the  s imple  mean scores  and s tandard  devia t ions  for  compar ison .   
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6.5.3.  Question 3 
Are there differences in general health variables and health habits in 
those who show high levels of objective cognitive impairment in 
comparison to those who show lower levels of objective cognitive 
impairment?  
People with diabetes are also at increased risk for general health 
problems (i.e. cardiovascular disease, hypertension, high cholesterol).  
Could it  be that people with MCI have poorer general health or differ 
health habits? To investigate this possibility, non-parametric 
correlation Spearman’s rho was used to determine if there were any 
significant relationships between assignment to the cognitive 
impairment groups and obesity, cholesterol,  or cardiovascular health 
indicators. Results of Spearman’s rho correlation indicate no 
relationship between CI level and these general health variables shown 
in Table 6.6.  
 
Table 6.6 Spearman’s Rho Correlation and Significance of 
Relationships Between General Health Variables and CI Group  
 
Variable  WHR Systo l ic  
BP 
Dias to l ic  
BP  
High  BP BMI 
 
Tota l  
Chol .  
HDL 
Chol  
CI  
Group 
- .065  
( .537)  
.171  
( .100)  
- .006  
( .958)  
.097  
( .353)  
.018  
( .860)  
.058  
( .576)  
.043  
( .678)  
N.B.  two- ta i led  s igni f icance  va lues  repor ted ;  CI  Group =  Cogni t ive  Impairment  
Group;  WHR = Wais t  Hip  Rat io ;  Chol=Choles tero l ;  BMI=Body Mass  Index  
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Results of T-Tests indicate that level of cognitive impairment 
(No CI vs MCI) was not related to measures of cardiovascular health, 
cholesterol levels shown in Table 6.7.  
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Table 6.7 T-Test Comparison of Health Variables Between CI Groups  
Heal th  Variables  No CI  
x¯  (SD)  
MCI 
 x¯  (SD)  
t  (74)  
 
Sig.  (p ,  
2- ta i led)  
Effect  
Size  (r)  
 n=51 
§n=50 
n=25 
§n=24 
§df=73 
†df=72 
  
BMIb  
Untransformed 
1.43 (0 .06)  
26.90 (3 .43)  
1 .43 (0 .07)  
27.23(4.84)  
- .175 .862 .020 
Systol ic  BP 134.6 (15.71)  139.1 (13.17)  -1 .22 .226 .14 
Diastol ic  BP 72.86 (10.96)  72.96 (13.10)  - .034 .973 .004 
Total  Cholesterol c  
Untransformed 
2.10 ( .18)  
4 .46 ( .77)  
2 .14 ( .22)  
4 .65 ( .95)  
- .862 .392 .10 
HDL Cholesterol  1 .69 1 .81 -1 .05 .296 .12 
Note :  Transformat ions  were  used  to  normal ize  d is t r ibu t ion  for  parametr ic  tes t ing :  a .  
min imized  one  out l ie r  to  mean +  3SD;  b .  log  t ransformat ion ,  c . square  root  
t ransformat ion;  Untransformed means  and  s tandard  devia t ions  were  repor ted  for  Tota l  
Choles tero l  and  BMI for  communica t ing  in  te rms of  a  more  eas i ly  unders tood  metr ic .   
 
Regarding health habits,  higher cognitive impairment was related 
to lower cognitive activity (rs  =-.278,  p=.007, two-tailed). This 
correlation remained when controlling for participant age, IQ and 
education through partial correlation, prs  =-.248, p=.018, two-tailed. 
There was no significant relationship between greater self-reported 
exercise involvement to be related to lower levels of cognitive 
impairment, rs  =-.144,  p  =.12, two-tailed.  
6.5.4.  Question 4 
Are there differences in diabetes health variables for those with MCI in 
comparison to those who show lower levels of cognitive impairment?  
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Could the group of participants with MCI show poorer diabetes 
health (i .e.  more microvascular complications, higher mean HbA1c, 
more severe hypoglycaemic events, greater insulin resistance) or 
greater disease burden (i.e. longer duration, earlier onset)?  This is 
expected based on the results of research in T2DM and MCI (Roberts et 
al. ,  2008) and consistent with the findings of the cognitive study. To 
answer this question, the sample was divided into three groups that 
varied on incidence of objective cognitive impairment (No CI, Low CI, 
and MCI) as indicated in Table 6.2. Spearman’s rho correlation was 
used initially to determine any relationships between these variables 
and CI group. The results of this analysis are provided in Table 6.8.  
 
Table 6.8 Spearman’s Rho Correlation and Significance of 
Relationships Between Diabetes Health Variables and CI Group  
 
Variab le  Micro  
Tota l  
Mean 
HbA1c 
Hypos/  
Year   
Insu l in  
Res is t  
Dura t ion  
 
Onset  
CI  Group  .372  
( .000)** 
.130  
( .213)  
.194  
( .061)  
- .061  
( .561)  
.210   
( .042)*  
- .162  
( .120)  
*=p<.05 ,  (2- ta i led) ,  **=p<.01  (2- ta i led)  
N.B.  CI  Group =  Cogni t ive  Impairment  Group;  Micro  Tota l  =  Combinat ion  score  of  
re t inopathy ,  neuropathy  and  nephropathy;  Hypos/Year  =  Dichotomous  var iab le  of  
Low and High  average  number  of  severe  hypoglycaemic  events  per  year ;  Insu l in  
Res is t  =  Insu l in  Res is tance  based  on  es t imated  g lucose  d isposa l  ra te  (eGDR).  
 
The three cognitive impairment (CI) groups (No CI, Low CI and 
MCI) were also compared using ANOVA on diabetes health variables 
(i .e. ,  microvascular disease, mean HbA1c, and insulin resistance) and 
indicators of disease burden (i.e.,  duration of diabetes and age of 
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onset).  ANCOVA was used to control for variables that might influence 
significant relationships. Linear regression was used for the 
comparison of the categorical variable hypoglycaemic events with 
assistance per year. Microvascular disease, duration and age of onset 
were identified as factors related to MCI in previous research (Roberts 
et al. ,  2008). Hypoglycaemic events and insulin resistance were 
included as they are included as variables in this cognitive study. The 
results of the omnibus ANOVA tests are presented in Table 6.9. 
Results for each diabetes variable are discussed in turn.  
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Table 6.9 ANOVA Comparison of Demographic and Diabetes Factors 
for Cognitive Impairment Groups  
Diabetes    
Factors  
No CI 
Mean 
(SD) 
Low CI  
Mean 
(SD) 
MCI 
Mean 
(SD) 
 
F  
 
p  
  
n=51 
 
n=18 
 
n=25 
  
 
Microvascular  
Disease 
 
.71 ( .25)  T 
 
.84 ( .33)  T 
 
 
.94 ( .28)  T 
 
 
6 .23 
 
.003* 
Mean HbA1c 8.3  ( .77)  8 .4  ( .94)  8 .7  ( .96)  1 .54 .220 
 
Severe  Hypo 
Events  
.37 ( .49)  .33 ( .49)  .64 ( .49)  3 .01 .054 
Insul in  
Resis tance  
.77 ( .13)  T 
 
.72 ( .12)  T 
 
.76 ( .16)  T 
 
.946 .392 
Durat ion of  
Diagnosis  
30.21(11.77)  29.35(9.63)  37.1(11.98)  3 .45 .036* 
Age of  Onset  27.8  (11.0)  29.5  (11.7)  22.4  (10.4)  2 .77 .07 
*p<.05  **p<.01;   
Note .  The  var iab le  “Microvascular  Disease”  t ransformed us ing  square  root  used  to  
normal ize  the  d is t r ibu t ion  for  ANOVA. The  var iab le  “ Insul in  Res is tance  used  a  Log 
10  t ransformat ion .  Transformed (T)  means  and  s tandard  are  used  in  the  tab le  to  
express  da ta ,  a long  wi th  the  F  score  and  s igni f icance  re la t ing  to  the  t ransformat ion .  
Severe  Hypo Events  i s  a  d ichotomous  var iab le .  
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Microvascular Disease 
A higher severity of microvascular disease has been related to 
the incidence of MCI in the T2DM population  (Roberts et al. ,  2008). 
Results of the current study indicate a significant relationship between 
measures of microvascular disease and CI group. Higher cognitive 
impairment levels are related to higher severity of retinopathy (rs  = 
.224, p=.030, two-tailed) and a higher combined microvascular disease 
rating (rs  = .372, p=.000, two-tailed). The MCI group was compared to 
the No CI group on level of the microvascular disease retinopathy 
(none/mild, observable, referable, proliferative). The same divisions of 
retinopathy (Table 4.6) used in the cognitive study. 
  Figure 6.3 shows a comparison of the percentage of participants 
from the MCI (n=25) and No CI (n=51) groups categorized within each 
retinopathy severity level.  A greater proportion of participants had 
proliferative retinopathy (highest severity) in the MCI group (56%) 
compared to the No CI group (24%). Results of chi square statistic 
indicated that there is a significant association between the level of 
cognitive impairment and level of retinopathy, χ²(2)=8.22, p=.016. This 
seems to represent the fact that there is a lower than expected 
frequency of participants in the No CI group with proliferative 
retinopathy and a greater than expected frequency of participants in the 
MCI group with proliferative retinopathy. The rates of mild/observable 
retinopathy were comparable in the two groups. A greater proportion of 
participants in the No CI group (29%) showed referable retinopathy 
(2n d highest severity category) in comparison to the MCI group (12%). 
136 
There was a slightly higher than expected frequency of participants 
from the No CI group with referable retinopathy and a slightly lower 
than expected frequency of participants from the MCI group with 
referable retinopathy. There seemed to be a trade-off between the two 
highest severity categories of retinopathy (referable and proliferative), 
the MCI group with more participants in the highest of the two 
categories (proliferative) and the No CI group with more participants 
in the less severe of the two categories (referable). 
 
 
 
Figure 6.3 .  Percentage of participants at each retinopathy level in the 
MCI vs NO CI groups.  
 
Results of ANOVA indicate a significant difference between 
groups with varying levels of cognitive impairment for total 
microvascular disease (combination of retinopathy, neuropathy and 
nephropathy), F(2,91) = 6.23, p=.003, with a medium effect size, 
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d=0.37. Planned comparison, assuming unequal variance, indicate that 
the MCI group showed a higher level of microvascular disease than the 
No CI group, t(91)= -3.424,  p=.001, two-tailed, d=0.76 shown in 
Figure 6.4. The MCI group showed more severe levels microvascular 
disease than those participants with no cognitive impairment. There 
was a significant linear trend for microvascular disease severity across 
levels of cognitive impairment F(1,91)=11.73, p<.01. 
 
 
 
Figure 6.4. Microvascular disease by cognitive impairment (CI) group. 
 
Higher microvascular disease is correlated with demographic 
factors including age (rs  = .310, p=.002, two-tailed), education (rs  =  
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-.227, p  =.028, two-tailed), as well as diabetes health variables 
including mean HbA1c (rs  = .444, p=.000, two-tailed), and insulin 
resistance (rs  = -.340, p=.001, two-tailed), as well as indicators of 
diabetes burden including duration of diagnosis (rs  = .405, p=.000, 
two-tailed), and a trend towards a relationship with general 
intelligence (rs  = -.199, p  =.055, two-tailed) and age of onset (rs  = -
.190, p=.067, two-tailed). Using ANCOVA, when controlling for each 
of these factors, the significant relationship between microvascular 
disease and level of cognitive impairment remained significant. The 
results of the ANCOVA are displayed in Table 6.10 
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Table 6.10 ANCOVA Microvascular Disease and CI Group with 
Demographic and Diabetes Health Covariates  
 
 
Covariates  
Microvascular Disease by CI Group 
Controlling for Covariate 
No CI 
Mean (SE) 
Low CI 
Mean (SE) 
MCI 
Mean (SE) 
(df)  
F  
p 
value 
None .708 
(.035) 
.844 
(.077) 
.936 
(.055) 
(2,90) 
6.23 
.003* 
Age .713 
(.037) 
.843 
(.062) 
.928 (.052) (2,90) 
6.01 
.004* 
Education .710 
(.038) 
.846 
(.064) 
.931 
(.055) 
(2,90) 
5.84 
.004* 
General 
Intelligence 
.715  
(.039) 
.838 
(.065) 
.926 
(.056) 
(2,90) 
4.73 
.011* 
Mean 
HbA1c 
.731  
(.035) 
.843 
(.058) 
.901 (.050) (2,89) 
4.25 
.017* 
Insulin 
Resistance  
.721 
(.037) 
.819 (.062) .940 (.053) (2,88) 
5.83 
.004* 
Duration of 
Diagnosis 
.720 
(.037) 
.862 
(.062) 
.899 
 (.053) 
(2,90) 
4.54 
.013* 
Age of 
Onset 
.711 
(.038) 
.851 
(.064) 
.926 
(.055) 
(2,90) 
5.52 
.005* 
*p<.01  Note .  Two var iab les  were  t ransformed to  normal ize  for  GLM analys is  
inc luding  Microvascular  Disease  (square  root )  and  Insu l in  Res is tance  (Log) .  
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Together, the results indicate that higher cognitive impairment in this 
T1DM group is related to higher severity rating of microvascular 
disease, a common diabetes complication. 
Increased severity of microvascular disease is also related to 
higher systolic blood pressure (rs  =.204,  p=.049, two-tailed). ANCOVA 
indicated that a significant relationship between microvascular disease 
and cognitive impairment remained when controlling for these 
indicators of cardiovascular health, including systolic blood pressure, 
F(2,90)=5.45, p=.006. Controlling for this general health variable did 
not change or alter the relationship between microvascular disease and 
cognitive impairment. 
 
Mean HbA1c 
Mean HbA1c is also used as a diabetes health variable with lower 
values, an indication of tighter glucose control,  related to fewer 
diabetes complications including retinopathy. The MCI group was 
compared to the No CI group on level of mean Hba1c (Low </=7.9%, 
Midrange 8.0-8.8%, High >8.8%), the same divisions used in the 
cognitive study.  
Mean HbA1c levels were not significantly related to levels of 
cognitive impairment (rs  = .130, p=.213). Figure 6.5 shows a 
comparison of the percentage of participants from the MCI (n=25) and 
No CI (n=50) groups categorized within each mean HbA1c level.  
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Figure 6.5 Percentage of participants at each mean HbA1c level in the 
MCI and No CI group  
 
There are 50 instead of 51 participants in the No CI group because 
mean HbA1c could not be calculated for 1 participant. There was a 
higher proportion in MCI group (44%) compared to the No CI group 
(26%) that fell in the highest category of mean HbA1c (mean HbA1c 
≥8.9%) showing a trend towards higher levels of blood glucose (i.e. 
lower glucose control) in this group. However, 32% of both the MCI 
and No CI groups were classified in the Low HbA1c category. Eighteen 
percent more of the No CI group (42%) are classified in the Midrange 
HbA1c group (mean HbA1c 8.0-8.8%) than the MCI group (24%). Most 
participants in the No CI group are classified in the Low and Midrange 
HbA1c range (74%) and most of the MCI group (68%) are classified in 
the Midrange to High HbA1c range. However, results of chi square 
analysis indicated that there is no significant association between the 
level of cognitive impairment and level of mean HbA1c, χ²(2)=3.19, 
0%!5%!
10%!15%!
20%!25%!
30%!35%!
40%!45%!
50%!
Low!!!!!!!!!!!!!!!!!!!!!!!!!!(<7.9%)! Midrange!(8.0S8.8%)! High!!!!!!!!!!!!!!!!!!!!!!!(>!8.9%)!
P
er
ce
n
ta
ge
!o
f!C
I!G
ro
u
p
!
Mean!HbA1c!Group!
No!CI!(n=50)!!MCI!(n=25)!
142 
p=2.03, indicating that there was no difference between the observed 
and expected frequencies for level of mean HbA1c between the 
cognitive impairment groups. 
Results of ANOVA indicated that the cognitive impairment 
groups did not differ in mean HbA1c level, F  (2,89)=1.54, p=.22, with 
a small effect size, d=0.2. Planned comparisons indicated only a trend 
that the MCI group show higher mean HbA1c values than the No CI 
group, t(90)=-1.76, p=.083, two-tailed, with a medium effect size, 
d=0.4.  
This trend may be better explained by other factors. Mean HbA1c 
is correlated with total microvascular disease (rs  = .444, p  =.000, two-
tailed). ANCOVA revealed that when controlling for microvascular 
disease the relationship between mean HbA1c and CI group is not 
significant, F(2,89)=.098, p=.91, with a lower F value than for the 
original ANOVA, F(2,89)=1.54, p=.22. Planned comparisons indicated 
there was no significant difference between the MCI and No CI groups, 
t(89)=.369, p=.71 or between the MCI and Low CI group, t(89)=.036, 
p=.97, after controlling for microvascular disease. 
Although there are some results that indicate the MCI group shows 
higher HbA1c than the group with no cognitive impairment, this 
association seems to be better explained by other factors such as the 
increased severity of microvascular complications in those with higher 
HbA1c. 
Severe Hypoglycaemic Events 
The occurrence of severe hypoglycaemic events is another indicator 
143 
of level of diabetes glucose control.  Severe hypoglycaemic events are 
experiences of extremely low blood glucose, which require another 
person’s assistance for recovery. A greater number of severe events is 
an indicator of frequent extreme low blood glucose. Although severe 
hypoglycaemic events have an immediate impact on cognitive function, 
large studies have not identified this as a risk factor for cognitive 
impairment in the long-term (Jacobson et al. ,  2011). The MCI group 
was compared to the No CI group on average number of severe 
hypoglycaemic events per year (Low ≤ .06 events per year, High >.06 
hypoglycaemic events per year),  the same divisions of hypoglycaemia 
used in the cognitive study. The variable was dichotomized as it  was 
not normally distributed with a large range of values. 
There was a trend for those with higher cognitive impairment to 
have a higher average number of hypoglycaemic events per year 
(rs=.194, p=.061, two-tailed). The No CI and MCI group were also 
compared on incidence of hypoglycaemic events. Results of chi square 
analysis indicates that there is a significant association between level 
of average hypoglycaemic events per year and the presence of objective 
cognitive impairment, χ²(1)=4.83,p=.028. The odds of being in the 
severe hypo group with MCI is 1.78. The odds of being in the severe 
hypo group with no CI is 0.59. Based on the odds ratio (1.78/.59=3.02), 
those in the MCI group are 3 times more likely to experience a higher 
average of severe hypoglycaemic events per year than those in the No 
CI group. In this T1DM sample there is a relation between having more 
frequent severe hypoglycaemic events and higher levels of cognitive 
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impairment. However, recurrent hypoglycaemia has been generally 
dismissed as a cause for cognitive deficit  in T1DM based on the results 
of large longitudinal studies (Jacobson et al. ,  2011).  
Insulin Resistance 
Although insulin resistance has been debated as a possible factor 
affecting cognitive function in T1DM and insulin dose (positively 
related to insulin resistance) was one of the factors related to higher 
levels of MCI in type 2 diabetes research, there was no significant 
relationship between level insulin resistance and level of cognitive 
impairment, rs  = -.061, p=.56, two-tailed in this study sample. ANOVA 
comparison revealed no significant differences between CI groups in 
level of insulin resistance, F(2,89)=.946, p=.39, with a small effect 
size, d=0.2. Insulin resistance is not revealed as an important factor in 
relation to cognitive impairment in this T1DM sample. 
Duration of Diagnosis 
Higher cognitive impairment was also correlated with longer 
duration of diagnosis, rs=.210, p=.042, two-tailed, an indicator of 
greater disease burden. ANOVA results indicate a significant 
difference between groups with varying levels of cognitive impairment 
for duration of diagnosis F(2,91) = 3.45, p=.036, with a small effect 
size, d=0.3, shown in Figure 6.6 
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Figure 6.6. Mean duration of diagnosis by cognitive impairment (CI) 
group. 
 
Planned comparisons indicate that the MCI group showed longer mean 
duration of diabetes than the No CI group, t(91) = -2.42, p=.018 (two-
tailed), d=0.5 and the Low CI group, t(91) = -2.15, p=.035 (two-tailed), 
d=0.5. These results indicate that those with the highest level of 
cognitive impairment in the study group have been diagnosed with 
diabetes for longer than those with no or low levels of objective 
cognitive impairment.  
Having diabetes longer also means that these participants are 
likely older, and have more severe complications, factors that may also 
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increase the likelihood of higher cognitive impairment. It  may be that 
one of these factors is actually the reason for the difference between 
the MCI and Low CI groups. Given that duration of diagnosis is 
significantly correlated with participant age (r=.448, p= .000, two-
tailed), and microvascular disease (rs=.405, p =.000), it  could be that 
the difference in duration of diagnosis between the groups is due to one 
of these factors. Using ANCOVA, when controlling for participant age, 
there was still  a significant difference between CI groups on duration 
of diagnosis, F(2,90)= 3.5, p=.034.  
 Spearman’s rho correlation indicated that longer duration of 
diabetes is associated with indicators of cardiovascular health, lower 
diastolic blood (rs  = -.396, p=.000, two-tailed), and lower blood 
pressure (rs  = -.205, p=.047, two-tailed). ANCOVA results indicate the 
relationship between MCI and duration of diagnosis remains when 
controlling for indicators of cardiovascular health, including diastolic 
blood pressure, F (2,90)=3.76, p=.027 and incidence of high blood 
pressure, F(2,90)=3.83, p=.025.  
The people with diabetes longer also had a higher severity of 
microvascular disease. Results of the ANCOVA indicates that when 
controlling for microvascular disease, the difference between groups on 
duration of diagnosis becomes insignificant,  F(2,90)= 1.87, p=.16 This 
suggests that the relationship between longer duration of diagnosis and 
greater cognitive impairment may be explained by a higher level 
microvascular disease.  
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Mean HbA1c is not correlated with duration of diagnosis in the 
study sample (rs=-.001, p=.99), however is a variable of interest in this 
study. Results of the ANCOVA indicated that the significant difference 
between MCI groups based on duration of diabetes remains when 
controlling for mean HbA1c, F(2,89)= 3.18, p=.046.  
Results indicate that longer duration of diagnosis is related to 
higher levels of cognitive impairment, however this may be explained 
by greater incidence of microvascular disease in this group. 
Age of Onset 
Although the omnibus F indicated no significant difference 
between cognitive impairment groups based on age of diabetes onset,  
F(2,91) = 2.78, p=.068, with a small effect size, d=0.3, there was a 
trend towards a difference. Planned comparisons indicate that the MCI 
group were diagnosed with diabetes at a younger age than the No CI 
group, t(91)= 2.05, p=.043, d=0.5 and the  Low CI group, t(91)= 2.06, 
p<.042, d=0.5 shown in Figure 6.7. 
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Figure 6.7 Mean age of onset by cognitive impairment (CI) group. 
 
Age of onset is an indicator of greater disease burden related to 
duration of diagnosis, and possibly increased risk of microvascular 
complications. Although age of onset is highly correlated with duration 
of diagnosis (r  =-.715, p<.000, two-tailed), it  may measure factors that 
are somewhat different because age of onset it  is not significantly 
correlated with microvascular disease (rs=-.190, p=.067). Younger age 
of diabetes onset is correlated with younger participant age in this 
sample (r=.305 ,  p=.003). If those with early onset of diabetes tend to 
be younger it  is not likely that age is a factor in the differences in age 
of onset between the MCI and Low CI groups. Using ANCOVA, when 
controlling for participant age, the associated F value for CI group 
becomes significant, F(2,90)= 3.51, p=.034. This suggests that there is 
a significantly lower age of onset in the highest cognitive impairment 
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group than for groups with lower levels of cognitive impairment when 
participant age is taken into consideration.  
ANCOVA results indicated that when controlling for 
microvascular disease, there is no significant difference between age of 
onset for CI groups, F(2,90)=2.14, p=.124. Similarly, the difference in 
age of onset between the MCI and Low CI groups is not significant 
when controlling for mean HbA1c, F(2,89)=2.8, p=.066. The fact that 
the relationship between age of onset and cognitive impairment level is 
attenuated with the addition of these diabetes health variables suggests 
that these indicators of poor diabetes health might better explain this 
relationship. 
 
What are the main predictors of MCI identification? 
Finally, diabetes factors with a significant relationship to CI group 
were entered into a multiple regression analysis to determine which 
factors were best at predicting MCI group versus Low/No CI group 
membership. Using backward stepwise entry with an exclusion criteria of 
p< .055, Logistic regression was used to examine which factor or group 
of factors was most predictive of MCI group membership. The following 
factors were entered: Age, NART-IQ (crystallized IQ), microvascular 
disease, long-term HbA1c, duration of diagnosis, the dichotomized 
variable severe hypoglycaemic events. Given the aim to explore signs of 
accelerated ageing, participant age was also included. Duration of 
diagnosis was chosen over age of onset (which are highly correlated,  r=-
.715, p= .000, two-sided), as it  had a slightly higher effect size when 
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comparing CI groups to prevent multicollinearity of variables in the 
analysis. The results of the final step of logistic regression are displayed 
in Table 6.11. The results indicate that the best predictors of MCI group 
membership were greater microvascular disease (effect size r=.42), and 
lower crystallized IQ score (effect size r=.40), retained as significant 
predictors in the final step of the regression model. Together the final 
model explained 36% of the variance in membership in the MCI group. 
The final model predicted CI group membership with 78.9% accuracy.  
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Table 6.11 Results of backwards stepwise logistic regression for 
predicting MCI group membership   
Step Predictors  B (SE) Wald exp b  p χ²  R 2  
1 Constant ,  Age,  
IQ,  Durat ion,  
Micro,  Hypo (2)  
   < .001 26.01 
(df=5) 
.40 
2  Constant ,   
IQ,  Durat ion,  
Micro,  Hypo (2)  
   < .001 26.01 
(df=4) 
.40 
3  Constant ,  IQ,  
Micro,  Hypo (2)  
   < .001 24.14 
(df=3) 
.38 
4  Constant ,  Micro,  
IQ 
   < .001 22.58 
(df=2) 
.36 
 Constant  -6 .839  
(1 .66)  
17.06  < .001   
 Micro  3 .698  
(1 .26)  
8 .67 40.363 .003   
 IQ .947 
( .335)  
7 .97 2 .577 .005   
Note :  Predic tors  and  Model  coeff ic ien ts  a re  provided  for  each  s tep .  Beta  va lues  for  
each  var iab le  a re  provided  for  the  las t  s tep .   
Nagelkerke  R 2repor ted  
Micro :  Microvascular  Disease  (Sqr t  t ransformed)   
IQ:  NART IQ (Reverse  Sqr t  t ransformed) 
Hypo (2) :  Dichotomized  hypoglycaemic  events  (≤ . 06 /year  or  > .06/year)  
 
The analysis was run again with only participants under 65, 
leaving n=41 in the No CI group and n=21 in the MCI group. Results are 
displayed in Table 6.12. The findings were consistent with the results of 
the first analysis. The best predictors of MCI group membership were 
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greater microvascular disease (r=.30), and lower crystallized IQ score 
(r=.20), retained as significant predictors in the final step of the 
regression model (Table 4). Together the final model explained 41% of 
the variance in membership in the MCI group. The final model predicted 
CI group membership with 80.6% accuracy.  
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Table 6.12 Results of Backwards Stepwise Logistic Regression For 
Predicting MCI Group Membership For Participants Under Age 65  
Step Predictors  B (SE) Wald exp b  p χ²  R 2  
1 Constant ,  Age,  
IQ,  Durat ion,  
Micro,  Hypo(2)  
   < .001 24.60 
(df=5) 
.45 
2  Constant ,   
IQ,  Durat ion,  
Micro,  Hypo(2)  
   < .001 24.12 
(df=4) 
.45 
3  Constant ,  IQ,  
Micro,  Hypo(2)  
   < .001 22.95 
(df=3) 
.43 
4  Constant ,  Micro,  
IQ 
   < .001 21.43 
(df=2) 
.41 
 Constant  -7 .181  
(1 .91)  
14.097  < .001   
 Micro 4 .378 
(1 .53)  
8 .238 79.71 .004   
 IQ .907 
( .402)  
5 .102 2.48 .024   
Note :  Predic tors  and  Model  coeff ic ien ts  a re  provided  for  each  s tep .  Beta  va lues  for  
each  var iab le  a re  provided  for  the  las t  s tep .   
Nagelkerke  R 2repor ted  
Micro :  Microvascular  Disease  (Sqr t  t ransformed)   
IQ:  NART IQ (Reverse  Sqr t  t ransformed) 
Hypo (2) :  Dichotomized  hypoglycaemic  events  (≤ .06 /year  or  > .06/year)  
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6.6.  Discussion 
6.6.1.  Question 1 
What is the incidence and nature of MCI in the study sample?  How 
does this compare to the incidence of MCI reported in research of the 
general population? 
 
Despite the fact that most of the study group was middle-aged, 
the incidence of MCI is relatively high (27%). Population studies have 
shown MCI incidence of up to 20% in people over the age of 65 (2011).  
This suggests a possibility that a higher percentage of people may be 
classified with MCI in T1DM groups at a relatively younger age than in 
studies of the general population over the age of 65. The high 
incidence of MCI in this primarily middle-age group (mean 58.7) 
suggests that there are early signs of cognitive ageing in this group. 
The nature of cognitive impairment in the group with MCI was 
primarily in the domains of executive function and processing speed. A 
particular deficit  in processing speed has been found in those with MCI 
in the general diabetes population (Arvanitakis et al. ,  2004; Toro et al. ,  
2009). Performance on delayed recall and executive function tests have 
also been related to progression to dementia (Gauthier et al. ,  2006). 
The risk of dementia has been studied in the general diabetes 
population, which is composed primarily of those with type 2 diabetes 
(Biessels et al. ,  2006; Bruce, Harrington, Davis, Davis, & Fremantle, 
2001). There is a higher incidence of vascular dementia than  
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Alzheimer’s disease for those with primarily T2DM (Biessels et al. ,  
2006), although both are elevated in relation to the general population. 
The incidence of dementia in groups with T1DM has not been 
specifically examined. Indications in this study of a high risk of MCI 
in this group, suggest the need to examine this group more closely in 
this respect.  
6.6.2.  Question 2 
Are there differences in the age, education or general intelligence of 
the participants in the study sample who show MCI in comparison to 
those who show lower levels of objective cognitive impairment?  
 
Results showed that the group with MCI was the same age as 
those with lower levels or no cognitive impairment and most were 
under the age of 65. Although those with MCI did show lower 
premorbid IQ however, this was in the upper average range and not 
likely to impact cognitive processing.  That the average IQ in the MCI 
group was high highlights the general strong general intelligence 
within in the study group and suggests that this group should not be 
particularly vulnerable to early MCI. The cognitive impairment focused 
on the middle-aged adults in the group highlights the relatively early 
cognitive impairment in the T1DM group compared to those in the 
general population. Early incidence of MCI contributes to evidence of 
an early cognitive ageing process in this group.  
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6.6.3.  Question 3.  
Are there differences in general health variables and health habits in 
those who show MCI in comparison to those who show lower levels of 
objective cognitive impairment?  
Regarding health habits,  cognitive impairment was related to 
lower level of self-reported daily cognitive activity even when age, IQ 
and education were taken into account. However, this could be a result 
or cause of cognitive impairment. Those with lower cognitive activity 
may be more vulnerable to cognitive impairment or those with 
cognitive impairment may engage in less daily cognitive activity. 
Although the direction of the relationship is uncertain, 
recommendations for engaging in cognitive activity may benefit in 
prevention of MCI in this group.  
There were no general health variables that could better explain 
the relationships between microvascular disease and diabetes duration 
with cognitive impairment, even though these were correlated with 
measures of cardiovascular health including systolic and diastolic 
blood pressure. As most of this older T1DM group had hypertension 
(84%) with 78% on blood pressure medication, it  may be difficult to 
determine if there is an effect of cardiovascular health on cognitive 
impairment in this sample as found in the results of the cognitive 
study. 
6.6.4.  Question 4.  
Are there differences in diabetes health variables for those who show 
MCI in comparison to those who show lower levels of objective 
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cognitive impairment? What are the main predictors of MCI 
identification? 
Results suggest that there is a relationship between the incidence 
of MCI in the study sample and indicators of sub-optimal diabetes 
control.  The group with MCI had more severe microvascular disease 
(d=0.76), were 3 times more likely to experience a higher average of 
severe hypoglycaemic events per year, longer diabetes duration (d=0.5) 
and younger age of onset (d=0.5) than the group with no cognitive 
impairment. The finding that those with higher cognitive impairment 
also experience more frequent severe hypoglycaemic events further 
highlight this may be a particular vulnerability for older adults.  It  may 
also be that those with microvascular disease are more vulnerable to 
the effects of recurrent severe hypoglycaemic events. A final 
regression analysis retained only one diabetes health variable as 
predictive of high cognitive impairment including, higher severity of 
microvascular disease along with a measure of general cognitive 
intelligence, NART IQ. These results highlight the importance of blood 
glucose control within an optimal range to both limit microvascular 
disease, and prevent exposure to recurrent severe hypoglycaemic 
events. Limiting these complications may help in limiting early 
cognitive impairment for those with T1DM. 
6.6.5.  Conclusions 
What do the results tell  us about cognitive ageing in T1DM and its 
relationship with theories of cognitive ageing? 
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The risk of MCI has not been previously identified in groups with 
T1DM. Results suggest that middle-aged adults with T1DM may be at 
higher risk for MCI, just as those with T2DM.  Park & Reuter-Lorenz 
(2009) suggest an early need for scaffolding with some chronic 
diseases. The need for early scaffolding is expected in T1DM, as there 
is evidence of early structural brain differences in this group (Perantie 
et al. ,  2007). Park and Reuter-Lorenz (2009) suggest early use of 
scaffolding leads to more vulnerability to accelerated ageing and 
higher levels of cognitive impairment. It  was clear that those 
individuals with greater indication of vascular disease, greater severity 
of microvascular disease, were at most risk of MCI. This may initiate 
an early need for scaffolding processes in these individuals to offset 
impacts on the brain. The identification of MCI in this primarily 
middle-aged group provides evidence of early cognitive ageing in this 
group. In Chapter 8, the brain functioning of those with retinopathy 
will be directly compared to investigate evidence that this scaffolding 
process may be occurring at an earlier stage for those with high 
severity retinopathy.  
The STAC theory (Park& Reuter-Lorenz, 2009) highlights 
activities that would promote “scaffolding enhancement” include new 
learning, engagement, exercise and cognitive activity. The cognitive 
reserve theory suggests a higher level of reserve for those engaged in 
these lifestyle-enhancing activities (Stern, 2002; 2006). The correlation 
with increased cognitive activity and lower cognitive impairment 
suggests a potential route for prevention of cognitive impairment in 
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this group. Engagement in these activities is enhanced through 
psychological wellbeing. The influence of psychological variables on 
diabetes control and cognitive function will be explored in Chapter 7. 
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                                                                           Chapter 7
The Influence Of Personal and Psychological Variables on 
Diabetes Health Variables and Cognitive Function 
 
7.1.  Introduction 
Results of the cognitive study highlighted that severity of 
microvascular disease was the strongest predictor of cognitive function 
and MCI in the study group. As well results highlighted personal health 
habits (cognitive activity, exercise) that could be of potential benefit in 
the treatment of those with T1DM for maintenance of optimal cognitive 
function in ageing. There are a number of psychological variables that 
can support adherence to treatment or healthy lifestyle choices. 
Psychological variables could influence the relationship between 
T1DM and cognition through influence on self-management and 
glycaemic control.  These factors could potentially support maintenance 
of cognitive function in ageing for individuals with T1DM.  For 
example, diagnosis of clinical depression has been related to reductions 
in scores on cognitive tasks demanding high processing resources 
(specifically processing speed and working memory tasks) for both 
younger and older populations (Tsourtos, Thompson, & Stough, 2002; 
Nebes et al. ,  2000). These modifiable factors may potentially work 
together with the scaffolding process (Park & Reuter-Lorenz, 2009) 
and minimize the effects of disease and ageing on cognitive function or 
increase overall level of cognitive reserve (Stern, 2002; 2006).  
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7.2.  Study Questions  
1. What percentage of the study group rate clinical symptoms of 
anxiety and depression? How does this compare to the incidence in the 
general population?  
2. Do measures of well being relate to demographic variables? 
3. Do measures of well-being relate to diabetes health variables? 
4. Do measures of well being relate to cognitive function? 
7.3.  Materials and Method 
Standardized questionnaires were administered to participants 
before completing the cognitive assessments to investigate various 
psychological variables potentially important in optimal cognitive 
function, glycaemic control and minimizing diabetes complications. 
These include depression, anxiety and well being. Each participant 
completed the following questionnaires either on their own or with the 
chief investigator.  
 
1. Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 
1983). This is a measure of anxiety and depressive symptoms 
experienced. Participants are asked to rate how they have been feeling 
over the past week on a 14-item scale with 7 items about depression 
(HADS D) and 7 about anxiety (HADS A). Higher scores indicate 
higher psychological distress. Scores below from 0 to 7 are considered 
normal, 8-10 mild, and 11 and more moderate to severe and probable 
cases of mood disorder. 
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2. Well-Being Questionnaire–28 (WBQ: Bradley, 1994). This 
questionnaire includes questions regarding positive and negative well 
being, energy and stress, and attitudes related to diabetes. This 
measure was specifically developed for evaluation of individuals with 
diabetes. This is not a norm-referenced measure, but designed for 
tracking patient changes over time. 
7.4.  Statistical Analysis 
 
Spearman’s rho and Pearson’s correlation were used in a 
correlation analysis to examine the relationship between ratings of 
anxiety, depression, general and diabetes well-being with diabetes 
health variables and cognitive test scores. Chi square was used to look 
at group composition based on retinopathy level.  ANOVA was used to 
further explore relationships highlighted in the correlation analysis. 
Multiple regression was used to determine significant predictors of 
well-being and cognitive function. 
7.5.  Results 
7.5.1.  Question 1 
What percentage of the study group rate clinical symptoms of anxiety 
and depression? How does this compare to the incidence in the general 
population?  
Ratings from the Hospital Anxiety and Depression scale (HADS) 
indicate that just under a quarter of participants rated above normal 
symptoms for HADS A (23.4%) and much less for the HADS D 
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(10.6%). Of these participants, only a small percentage showed 
probable clinical levels (moderate or severe) of anxiety or depression 
(HADS score ≥  11), displayed in Table 7.1. Anxiety ratings indicated 
just over 8% showed ratings of moderate anxiety (HADS score 11-14) 
and only 3% showed ratings of severe anxiety (HADS score 15-21). 
Over three quarters of participants had ratings within the normal range 
(HADS score 0-7) for anxiety with fewer than 12% of participants 
reported mild values for anxiety (HADS score 8-10). Depression 
ratings indicate that only 2 participants rated high levels of depression, 
and both were at the moderate level.  The majority of people in the 
study sample, about 90%, rated themselves to have normal values for 
depression with just over 8% rated themselves to be in the mild range.  
Table 7.1 Percentage of Participants within Categories for HADS 
Anxiety and Depression Ratings  
 
 HADS Anxiety  HADS Depression 
Category  
(Score Range) 
 
n 
 
% 
  
n 
 
% 
Normal (≤  7) 72 76.6  84 89.4 
Mild (8-10) 11 11.7  8 8.5 
Moderate (11-14) 8 8.5  2 2.1 
Severe (≥  15) 3 3.2  0 0 
Total 94 100  94 100 
 
Participants received average ratings overall on HADS A and 
HADS D. The mean anxiety rating for the study sample was within the 
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normal range ( x¯=4.99, SD = 4.3) with a range from 0 to 17. The mean 
anxiety rating was slightly higher and showed higher variability than 
the mean rating for depression ( x¯=3.41, SD = 2.8) with a range from 0 
to 11.  
The present study included a self-selected sample, who was not 
formally identified with psychological disorders, although some 
(14.9%) participants were currently or recently using medication for 
depression (14/94), none were taking anti-anxiety medication. The 
mean for anxiety was not significantly higher ( t  (92)=-1.58, p=.12) for 
those taking anti-depressants ( x¯=6.64, SD = 4.63) compared to those 
who did not take this medication ( x¯ =4.7, SD = 2.8). The range of 
anxiety scores was narrower for those who were taking anti-depressants 
(0-14) than for those who were not taking this medication (0-17). The 
mean depression score was significantly higher ( t  (92)=-2.40, p<.05) 
for those taking anti-depressants ( x¯ =5.07, SD = 2.97) compared to 
those who do not take this medication ( x¯=3.13, SD = 2.77). The range 
of depression scores was narrower for those who were taking anti-
depressants (1-10) and only included those in the normal and mild 
range, compared to those who were not taking this medication (0-11), 
including the 2 participants in the moderate range.  
 To determine whether there are any patterns in the items 
typically endorsed by participants in this T1DM group, an item 
analysis was undertaken. Results are displayed in Figure 7.1. Most of 
the group endorsed items relating to positive well being. Over 60% of 
participants gave scores of 0 for items relating to humor, cheer and 
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enjoyment in relaxing activities (a score of 0 indicates the participant 
does not have any problem in the area). The negatively endorsed items 
may relate to physical health of the group. There were two items in 
particular that elicited scores of 1 or more (showing some level of 
difficulty) for the majority of the study sample participants including, 
“I feel slowed down” and “I still  enjoy the things I used to enjoy”. It  
appears that ratings are related to physical limitations of middle-aged 
and older adults with T1DM. Over one quarter of participants endorsed 
scores over 1 indicating problems occurred very often or all  the time 
for the item “I feel slowed down”. This is also reflected in 
participants’ responses to the Well-Being Questionnaire (WBQ). On the 
WBQ Energy Scale, most participants indicated some issues with 
energy only sometimes feeling “energetic, active, and vigorous” (49%), 
sometimes feeling sluggish (55%), and sometimes feeling tired (44%). 
Results of Spearman’s Rho correlation indicated that there was a high 
negative correlation between HADS depression scores and the WBQ 
general energy (rs=-.645, p<.01). 
 Results on the WBQ General Negative Well-Being Scale reinforced 
that high scores of depression in the study group were not derived from 
items relating to high psychological distress. Most participants did not 
endorse having “crying spells or feeling like it” (62%), and 44% 
indicated that they did not feel “down hearted and blue” at all  and 40% 
indicated that they sometimes felt this way over the past week. 
Although it  may be assumed that managing diabetes may relate to 
greater negative feelings, symptoms of depression did not appear to be 
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related to dealing with diabetes for most. On the WBQ Diabetes 
Negative Well-Being Scale with only 36% endorsing scores over 0 for 
“talking or thinking about my diabetes gets me upset or feeling 
downhearted” and only 35% endorsed scores over 0 for “because of my 
diabetes I get depressed”.  
Turning to anxiety, items endorsed did not represent high 
psychological distress. Items endorsed by the study group on the HADS 
A scale are shown in Figure 7.2, the majority of participants report 
scores of 1 or more on most items relating to general worries and 
tension. Reported anxiety is related to general worries and tension 
rather than attacks of anxiety. Participants endorsed a score of 1 for 
sometimes feeling “tense or wound up” (46%), sometimes “worrying 
thoughts go through my mind” (34%), have some difficulty “sitting and 
feeling relaxed” (43%), sometimes get a frightened feeling like 
butterflies in the stomach” (41%), and sometimes “feel restless as if I 
have to be on the move” (35%). Most participants did not endorse 
items concerning anxiety attacks without a known cause including, “I 
get a sort of frightened feeling as if something awful is about to 
happen” (60% -not at all),  “I get sudden feelings of panic” (66% - not 
at all) or having frightened feelings like butterflies in the stomach 
(52% -not at all).  Participants endorsed scores over 1 regarding 
“feeling restless as if I  have to be on the move” (28%). Only a few 
endorsed scores over 1 for having a “frightened feeling like butterflies 
in the stomach” (7%) or having “sudden feelings of panic” (12%). This 
was also reflected in participants’ responses on the WBQ on the 
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General Negative Well-Being Scale. Most indicated that they did not 
“feel afraid for no reason at all” (78%) and did not “get upset easily or 
feel panicky” (58%). In contrast on the WBQ Diabetes Negative Well-
Being, most endorsed feeling some “worry about the management of 
my diabetes” (70%), and indicated endorsement of the item “because of 
my diabetes I worry about the future (63%).  
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Figure 7.1 Percentage of participants’ endorsement of scores (0-3) on HADS D items. 
  
45%$
81%$ 69%$
18%$
72%$ 64%$ 83%$49%$
14%$ 28%$
55%$
16%$ 30%$ 15%$6%$ 5%$ 3%$ 21%$ 11%$ 4%$ 1%$0%$ 0%$ 0%$ 6%$ 1%$ 2%$ 1%$
0%#
50%#
100%#
I$still$e
njoy$th
e$
things$
I$used$t
o$enjoy
$
I$can$la
ugh$an
d$see$
the$fun
ny$side
$of$
things$ I$feel$ch
eerful$
I$feel$a
s$if$I$am
$
slowed
$down$
I$have$l
ost$inte
rest$in$
my$app
earanc
e$
I$look$f
orward
$with$
enjoym
ent$to$t
hings$
I$can$en
joy$a$go
od$
book$o
r$radio
$or$TV$
progra
mme$
HADS%D%Items%%
0$1$2$3$
169 
 
 
Figure 7.2 Percentage of participants’ endorsement of scores (0-3) on HADS A 
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How does the incidence of anxiety and depression in the study sample 
compare to the incidence in the general population? 
In the study sample, a greater percentage of the group gave 
normal ratings of anxiety (76.6%) and depression (89.4%) symptoms in 
comparison to a UK normative study (Crawford et al. ,  2001). In the 
UK population study, normal ratings of anxiety were attained by a 
smaller percentage of participants (66.6%) with a higher number 
classified in the mild range of problems with anxiety (20%) than in the 
study sample (11.7%). In the UK normative sample (Crawford et al. ,  
2001). the mean anxiety rating of the population ( x¯=6.14, SD=3.76) 
was slightly higher than that of the study sample ( x¯=4.99, SD = 4.3) 
and the mean depression rating ( x¯=3.68, SD=3.0) in the UK sample 
was similar to that of the study sample ( x¯=3.41, SD = 2.8). The rates 
of probable clinical disorders of anxiety and depression are also 
slightly lower than the rates found in normative studies. The rate of 
moderate and severe anxiety in the UK population sample (Crawford et 
al. ,  2001) was 12.6% (11.7% in the study sample) and depression was 
3.6% (2.1% in the study sample). 
 
7.5.2.  Question 2 
Do measures of well being relate to demographic variables? 
Spearman’s rho correlation coefficient was used to explore the 
relationships between well-being and diabetes health. Full correlation  
tables are provided in Appendix P. Correlations of interest are 
highlighted in text. 
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Age 
Participant age was consistently correlated with measures of well 
being across measures with the exception of diabetes stress and HADS 
depression (Table 7.2). One-tailed correlation was used for this 
exploratory analysis.  
 
Table 7.2 Correlation Between Ratings of Well-Being and Participant 
Age  
Variable  Age 
HADS-Anxiety  - .289 ( .002)** 
HADS-Depression - .143 ( .09)  
WBQ General  Negat ive Well-Being - .327 ( .001)** 
WBQ General  Energy .302 ( .001)** 
WBQ General  Posi t ive  Well-Being .304 ( .001)** 
WBQ General  Stress  - .393 ( .000)** 
WBQ Diabetes  Negat ive Well-Being - .243 ( .009)** 
WBQ Diabetes  Stress  - .129 ( .11)  
WBQ Diabetes  Posi t ive  Well-Being .239 ( .010)* 
WBQ General  Well-Being .406 ( .000)** 
WBQ Diabetes  Well-Being .264 ( .005)** 
Spearman’s  rho,  one-ta i led correla t ion values ,  *p<.05,  
**p<.01 
 
Middle-aged and older adults appear to have a positive outlook in 
general.  Specifically, measures of positive well-being on the WBQ 
(general energy, general positive well-being, general well-being, 
diabetes positive well-being and diabetes well-being) were related to 
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older age. Measures of anxiety and negative well-being (HADS A, 
diabetes negative well-being, general stress, general negative well-
being) were related to younger age.  
Education   
Of the demographic variables, education has a positive relationship 
with WBQ general positive well-being (rs  =.215,  p  =.019), with higher 
education related to higher ratings of positive well-being. This 
relationship was strengthened when controlling for participant age (prs  
=.252,  p  <.01).  
Gender 
 Is there a difference between ratings of well-being for women 
and men as in previous studies?  There are a near equal number of 
females (n=49) and males (n=45) in the study sample. Female gender 
was related to higher ratings on the WBQ general negative well being 
(rs  =-.265,  p=.005) and diabetes negative well-being (rs  =-.180,  
p<.05). There was no significant relationship between female gender 
and ratings of depression, HADS D (rs  =-.077,  p=.23) or anxiety, 
HADS A (rs  =-.154,  p=.07). Because of low numbers of participants 
who rated themselves to have above normal (Mild/Moderate/Severe) 
ratings on the HADS, ratings were recoded into low normal (score=0-
3), high normal (score=4-7) and above normal (score=8 and above). A 
chi square analysis appears to reflect that there is a higher than 
expected percentage of women that rate themselves in the above 
normal range on the HADS A scale and fewer than expected men that 
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rated themselves above the norm (χ²(2)=7.3, p<.05). The numbers and 
percentages of men and women in each HADS category are presented 
in  
 
Table 7.3.  
 
Table 7.3 Percentages of Men and Women in Each Category on the 
HADS Anxiety Scale  
 HADS A Category   
 Low Normal  
(Score  =  0-3)  
n  (%)  
High  Normal  
(Score  =  4-7)  
n  (%)  
Above Normal  
(Score  =  8+)  
n  (%)  
Tota l  
n  (%)  
Female 
 
Count  
Exp 
% Gender  
% HADS 
19  
21.9  
38.8  
45.2  
13 
15.6  
26.5  
43.3  
17 
11.5  
34.7  
77.3  
49 
49 
100 
52.1  
Male  Count  
Exp 
% Gender  
% HADS 
23 
20.1  
51.1  
54.8  
17 
14.4  
37.8  
56.7  
5  
10.5  
11.1  
22.7  
45 
45 
100 
47.9  
Exp=Expected  Frequency;  HADS=Hospi ta l  Anxie ty  and  Depress ion  Scale  
 
7.5.3.  Question 3 
Do measures of well being relate to diabetes health variables? 
Spearman’s rho correlation, partial correlation and multiple 
regression were used to explore the relationships between diabetes 
health variables and psychological well being.  
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Duration and Onset 
Those with diabetes for longer had a more positive outlook. Some 
measures of positive well-being related to duration and age of onset.  
Longer duration was related to higher diabetes positive well-being 
(rs= .253, p=.007). This relationship remained when controlling for age 
(prs= .180, p<.05). Older age of onset was related to higher feelings of 
general energy (rs= .174, p=.047)  and general well-being (rs= .199, 
p=.03); however, these relationships were not significant when 
controlling for age for either general energy (prs= .101, p=.34) or 
general well-being (prs= .102, p=.34). Those with younger age of onset 
showed higher general negative well-being (rs=-.176, p<.05), and 
greater general stress (rs- .249, p<.01), however these relationships 
were not significant when controlling for age for either general 
negative well-being (prs=-.096, p=.36) or general stress (prs=- .161, 
p=.12). 
Glycaemic Control 
Does well-being relate to better outcomes on glycaemic control? 
Results showed that higher long-term (mean HbA1c) values related to 
higher scores on the HADS D (rs= .187, p=.036), greater diabetes stress 
(rs= .222, p=.016), and lower diabetes well-being (rs=- .174, p=.048). 
These relationships remained when controlling for age; HADS D 
(prs= .205, p<.05), diabetes stress (prs= .238, p<.05), and diabetes well 
being (prs=- .208, p<.05). 
Higher recent HbA1c (5 year mean) was related to lower diabetes 
positive well-being (rs= .182, p=.039), lower diabetes well-being 
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(rs= .204, p<.05), and higher diabetes stress (rs= .181, p=.040). These 
relationships remained when controlling for age: diabetes positive 
well-being (prs=- .195, p<.05), diabetes well-being (prs=- .219, p<.05), 
and diabetes stress (prs= .186, p<.05). Higher current values of HbA1c 
were particularly associated with lower diabetes positive well-being 
(rs=- .176, p=.045). This relationship remained when controlling for 
age (prs=-.179, p<.05). 
 Results of Kruskal-Wallis (Table 7.4) analysis indicated that when 
participants were divided into groups based on mean, recent, and 
current HbA1c, although there was a linear pattern for HADS D scores 
between groups (low HbA1c group lowest HADS D scores compared to 
the high HbA1c group), there was no significant difference between 
the HADS scores for each group. It  was also observed that for those 
with low HbA1c, the HADS D mean rank was numerically higher for 
groups with more recent HbA1c, whereas for both the Midrange and 
High HbA1c groups, the HADS D mean rank was numerically lower 
for groups with more recent HbA1c. This suggests the question of 
whether mood may be more closely related to mean HbA1c for those 
with tight control. 
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Table 7.4 Kruskal-Wallis comparison of HADS D scores for Mean, 
Recent and Current HbA1c groups.  
 
 HbA1c Group   
 Low HbA1c  
≤7.9% 
Midrange  HbA1c 
8 .0-8 .8% 
High HbA1c 
≥8.9% 
H p  
Mean HbA1c (n)  n=29 n=34 n=30   
HADS D 
Mean Rank 
Mdn (SD) 
 
39.29 
 
2 .0  (2 .6)  
 
48.22 
 
3 .0  (2 .7)  
 
53.07 
 
3 .0  (3 .2)  
 
4 .02  
 
0 .13  
Recent  HbA1c (n)  n=33 n=33 n=28   
HADS D 
Mean Rank 
Mdn (SD) 
 
43.30 
 
2 .0  (2 .9)  
 
47.82 
 
3 .0  (2 .3)  
 
52.07 
 
3 .0  (3 .4)  
 
1 .03  
 
0 .36  
Current  HbA1c (n)  n=32 n=37 n=25   
HADS D 
Mean Rank 
Mdn (SD) 
 
45.63 
 
3 .0  (2 .9)  
 
46.11 
 
2 .0  (2 .8)  
 
51.96 
 
3 .0  (3 .1)  
 
1 .60 
 
0 .45  
 
 
 
Multiple regression, using backwards stepwise entry, was used 
to investigate significant predictors of HADS D scores (Table 7.5). 
Age, retinopathy level,  and mean HbA1c were entered into the 
analysis. In the final step of the model, mean HbA1c was retained as 
the sole significant predictor of HADS D scores, with a non-significant 
trend for retinopathy level to have a significant added influence on 
HADS D scores, F(2,90)=3.725, p<.05. 
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Table 7.5 Multiple Regression Results: Significance of Age, Mean 
HbA1c and Retinopathy as Predictors of HADS Depression Score  
 
 B SE B ß t  p  
Step  1       
Cons tan t  - .476  3 .388   - .140   
Age  - .043  .034  - .131  -1 .243  .22  
Ret inopathy  Level  -1 .026  .658  - .176  -1 .560  .12  
Mean HbA1c .828  .337  .267  2 .460 .016* 
Step  2       
Cons tan t  -2 .950  2 .750  -1 .073  .29  
Ret inopathy  Level  -1 .248  .635  - .214  -1 .966  .052  
Mean HbA1c .839  .338  .271  2 .486 .015* 
Analys is  uses  mul t ip le  regress ion  wi th  backwards  s tepwise  en t ry  
R 2=.092 for  S tep  1 ;  ∆  R 2=- .016  for  S tep  2  (ps= .22) ; ,  *p<.05  
 
Insulin Resistance 
A negative relationship was identified between anxiety and insulin 
resistance. Lower insulin resistance (i.e.,  higher estimated glucose 
disposal rate) was related to higher HADS anxiety scores (rs= .280, 
p=.003), higher general negative well-being (rs= .267, p=.005) and 
higher feeling of general stress (rs= .183, p=.040). Female gender and 
age are both related to higher anxiety. The relationship with anxiety 
remained when controlling for female gender, HADS A (prs= .237, 
p<.05) and when controlling for age (prs=.282, p<.01); however, the 
relationship became non-significant for general negative well-being 
(prs= .146, p=.08) and general stress (prs= .121, p=.13). It  could be that 
one or more of the factors used in the calculation of eGDR are 
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influencing the relationship with HADS A. These include waist-hip 
ratio (WHR) and current HbA1c. These factors have a relationship in a 
negative direction HADS A. WHR is not significantly related to 
anxiety (rs=-.118, p=.26) and neither is current HbA1c (rs=-.049, 
p=.64).  
Retinopathy and Microvascular Disease 
A negative relationship was also found between microvascular 
complications (retinopathy) and anxiety scores. Higher severity of 
retinopathy was correlated with lower HADS A scores (rs=-.288, 
p=.002), higher general positive well-being (rs= .214, p=.019), lower 
general stress (rs=-.241, p=.010) and higher general well-being 
(rs= .250, p=.007). Using partial Spearman’s correlation, when 
controlling for age, this relationship remained significant for HADS A 
(prs=-.227, p<.05). However, it  was not significant for general 
positive well-being (prs= .143, p=.085), general stress (prs=-.151, 
p=.074), or general well-being (prs=-.159, p=.064). Similarly, greater 
overall microvascular disease was related to lower HADS anxiety (rs=-
.260, p=.006), lower general negative well-being (rs=-.205, p=.024), 
and lower general stress (rs=-.173, p=.048). Using partial Spearman’s 
correlation, when controlling for age, this relationship was attenuated; 
however, it  remained significant with HADS A (prs=-.187, p<.05,) and 
not with general negative well-being (prs=- .115, p=.28), or general 
stress (prs=- .059, p=.58).  
Using chi square, Low Severity Retinopathy - LSR 
(none/mild/observable retinopathy) and High Severity Retinopathy 
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HSR (referable/proliferative retinopathy) groups were compared across 
ratings for HADS A. Given that most participants’ ratings were in the 
normal range, HADS ratings were recoded to groupings of low normal 
HADS score (0-3) high normal HADS score (4-7) and above normal 
HADS score (≥8). The counts, expected frequencies and percentages 
are presented in Table 7.6. Results of chi square statistic indicated that 
there is a significant association between normative rating of HADS 
anxiety and level of retinopathy, χ²(2)=6.50, p<.05. This seems to 
represent the fact that,  for those in the LSR group, there was a lower 
than expected number with low normal HADS A scores and a higher 
than expected number with high normal and above normal HADS A 
scores. In contrast,  for those in the HSR group there was a higher than 
expected number with low normal HADS A scores and a lower than 
expected with high normal and above normal HADS A scores. For 
those with maximal retinopathy, the majority of the group (56%) had 
low normal HADS anxiety score, whereas 30% with minimal 
retinopathy had a low normal anxiety score. A higher percentage of 
those with minimal retinopathy had high normal anxiety scores 
(37.5%) than those with maximal retinopathy (27.8%). A higher 
percentage of the group with minimal retinopathy had above average 
HADS A scores (32.5%) than the group with maximal retinopathy 
(16.7%).  
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Table 7.6 Chi Square Cell Counts for HADS A by Retinopathy and by 
Age  
 
 HADS A Category   
 Low Normal  
(Score  =  0-3)  
n  (%)  
High  Normal  
(Score  =  4-7)  
n  (%)  
Above Normal  
(Score  =  8+)  
n  (%)  
Tota l  
n  (%)  
Min 
Ret  
 
Count  
Exp 
% Min Ret  
12  
17.9  
30.0  
15 
12.8  
37.5  
13 
9 .4  
32.5  
40 
40 
100 
Max 
Ret  
Count  
Exp 
% Max Ret  
30 
24 
55.6  
15 
17.2  
27.8  
9  
12.6  
16.7  
54 
54 
100 
Min  Ret=Minimal  Ret inopathy  (None/Mild /Observable) ;  Max Ret  =  Maximal  
Ret inopathy  (Referab le /Pro l i fe ra t ive) ;  U60=Under  Age 60;  60+=Over  Age 60;  
Exp=Expected  Frequency;  HADS=Hospi ta l  Anxie ty  and  Depress ion  Scale  
 
Age, retinopathy and hypertension (high blood pressure or 
taking blood pressure medication) were entered into multiple 
regression to determine significant predictors of HADS A score, as all  
three have been show to have a significant relation to HADS A in 
correlation. Although these factors are all  positively correlated to each 
other, (i .e. ,  age and hypertension, rs=.244; age and retinopathy, 
rs=.276; retinopathy and hypertension, rs= .289, p< .01) there were no 
issues of multicollinearity identified to limit regression analysis (i .e.  
VIF=1.1; Tolerance<1; each variable loads highly on a separate 
dimension). In the final step of the analysis, age and hypertension 
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remained as significant predictors of HADS A score, F(2,91)=8.219,  
p<.01. The beta values for each step of the regression analysis are 
presented in Table 7.7.  
 
Table 7.7 Multiple Regression Results: Demographic and Health 
Predictors of HADS-Anxiety Score  
 
 B SE B ß t  p  
Step  1       
Cons tan t  13 .808 2 .833  4 .878  .000** 
Age - .101  .050  - .207  -2 .033  .045* 
Ret inopathy  Level  - .815  .888  - .095  - .918  .361  
Hyper tens ion  -2 .886  1 .184 - .248  -2 .439  .017* 
Step  2       
Cons tan t  14 .155 2 .805  5 .045  .000** 
Age - .111  .048  - .229  -2 .307  .023* 
Hyper tens ion  - .313  1 .153  - .269  -2 .712  .008** 
Analys is  uses  mul t ip le  regress ion  wi th  backwards  s tepwise  en t ry  
Ret inopathy  Level  (Minimal /Maximal) ;  Hyper tens ion  (Yes /No)  
R 2=.161 for  S tep  1 ;  ∆  R 2=- .008  for  S tep  2  (ps= .36) ; ,  *p<.05  **p<.01  
 
7.5.4.  Question 4 
Do immediate measures of well being relate to cognitive function? 
General Intelligence 
There was a positive relationship between IQ scores and some of 
the indicators of well being. Those with higher IQ had higher ratings 
on the WBQ for general energy (rs  =.175,  p=.045), general positive 
well being (rs  =.222,  p=.016), and general well-being (rs  =.190,  
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p=.03). These relationships were no longer significant when 
controlling for participant age through a Spearman’s rho partial 
correlation for general energy (prs  =.116,  p=.13, one-tailed), general 
positive well being (prs  =.165,  p=.06, one-tailed), or general well 
being (prs  =.111,  p=.15, one-tailed). Those with higher IQ had lower 
scores on one indicator of negative well being, the HADS D rating (rs  
=-.219,  p<.05, one-tailed). This relationship remained when 
controlling for participant age (prs  =-.194,  p<.05, one-tailed). 
Cognitive Domains 
 The results of Spearman’s rho correlation, one-tailed (Appendix 
P) indicated that well-being scores were related to a restricted number 
of cognitive domains and age-adjusted cognitive change. The measure 
of executive function, Trail Making Test B (z score based on age 
norms) was negatively correlated with diabetes negative well being 
(rs=- .220, p=.02). This relationship remained when controlling for age 
(pr s=-.279, p<.01).  
When investigating the diabetes factors that are predictive of the 
TMT-B score, it  was found that microvascular disease was the only 
significant predictor of TMT-B scores. Microvascular total,  age, and 
diabetes negative well-being score were entered into multiple 
regression. Both microvascular disease and diabetes negative well-
being remained significant predictors of TMT-B score, F(2,90)=5.772, 
p<.01, explaining 11.4% of the variance in the TMT-B score, r2= .114 
for final model. 
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Table 7.8 Well-Being, Demographic and Diabetes Health Predictors of 
TMT-B Score  
 B SE B ß t  p  
Step  1       
Cons tan t  1 .883  .331   5 .688  .000** 
Age - .009  .006  - .167  -1 .551  .124  
Micro  Tota l  - .209  .107  - .205  -1 .960  .053  
WBQ DNWB .048 .019  - .253  -2 .466  .016* 
Step  2       
Cons tan t  1 .391  .096   14 .434 .000** 
Micro  Tota l  - .264  .101  - .258  -2 .603  .011* 
WBQ DNWB - .040  .019  - .209  -2 .103  .038* 
Analys is  uses  mul t ip le  regress ion  wi th  backward  s tepwise  
Micro  Tota l  =  Microvascular  Tota l  (combined  re t inopathy ,  neuropathy ,  
nephropathy) ;  WBQ DNWB = Wel l -Being  Ques t ionnai re  Diabetes  
Negat ive  Wel l -Being   
R 2= .137 for  S tep  1  ∆  R 2=- .023  for  S tep  2  (ps= .12) ,  *p<.05  **p<.01   
 
The test of short-term/working memory, Digit Span (z score 
based on age norms) had a positive relationship with well-being sores 
including general positive well being (rs= .256, p=.006), general 
energy (rs= .215, p=.02), and general well being (rs= .196, p=.03) and 
had a negative relationship with HADS D (rs=- .274, p=.008). Results 
of partial correlation using Spearman’s rho indicate that these 
relationships remain when controlling for age for general positive well 
being (prs= .240, p<.05), general energy (prs= .197, p<.05), general 
well-being (prs= .173, p<.05), and HADS D (prs=- .237, p<.05).  
Multiple regression was used to identify significant predictors of 
the Digit Span score (Table 7.9). Age, NART IQ and HADS D were 
entered into the analysis. In the final step of the model, NART IQ 
remained as the only significant predictor of Digit Span scores, 
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F(2,91)=13.51, p< .01, explaining 23% of the variance in the score, 
r2=.229 for final model. There was a trend towards significance for the 
GPWB score (ß=.181,  p=.057) 
Table 7.9 Multiple Regression: Well-Being, Age and IQ As Predictors 
of Digit Span Scores  
 
 B SE B ß t  p  
Step  1       
Cons tan t  -1 .225  .570   -2 .150  .034* 
Age - .002  .004  - .046  - .466  .642  
NART IQ .022  .005  .420  4 .389 .000** 
WBQ GPWB .028 .014  - .192  1 .979 .051  
S tep  2       
Cons tan t  -1 .274  .558   -2 .285  .025* 
NART IQ .022  .005  .411  4 .396 .000** 
WBQ GPWB .027 .014  .181  1 .931 .057  
Analys is  uses  mul t ip le  regress ion  wi th  backward  s tepwise  en t ry  
WBQ GPWB = Wel l -Being  Ques t ionnai re  Genera l  Pos i t ive  Wel l -Being  
R 2=.231 for  S tep  1  ∆  R 2=- .002  for  S tep  2  (ps= .64) ,  *p<.05  **p<.01  
 
 
Results of Spearman’s rho correlation indicated that the age-
adjusted estimate of cognitive change (A-ELCC) was related to a 
number of aspects of well being (Table 7.10). When controlling for 
age, the relationship of the A-ELCC score with HADS A, general 
energy, general well being, and diabetes negative well being becomes 
non-significant. The only significant relationships that remain are 
negative relationships between A-ELCC and general negative well 
being and general stress. 
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Table 7.10 Correlation Between Ratings of Well-Being and Age-
Adjusted Lifetime Cognitive Change  
 
Variable  A-ELCC A-ELCC & Age 
HADS-Anxiety  - .189 ( .04)** - .128 ( .22)  
HADS-Depression - .145 ( .08)  - .113 ( .28)  
WBQ General  Negat ive Well-Being - .255 ( .007)** - .209 ( .04)* 
WBQ General  Energy .175 ( .046)* .118 ( .26)  
WBQ General  Posi t ive  Well-Being .104 ( .16)  .060 ( .57)  
WBQ General  Stress  - .243 ( .009)** - .216 ( .04)* 
WBQ Diabetes  Negat ive Well-Being - .221 ( .016)* - .203 ( .050) 
WBQ Diabetes  Stress  - .112 ( .14)  - .114 ( .28)  
WBQ Diabetes  Posi t ive  Well-Being .  109 ( .15)  .071 ( .50)  
WBQ General  Well-Being .235 ( .01)* .186 ( .07)  
WBQ Diabetes  Well-Being .214 ( .02)** .152 ( .15)  
Spearman’s  rho used for  ALCC; Spearman’s  rho part ia l  correla t ion used for  
ALCC & age,   
one-ta i led correla t ion values ,  *p<.05,  **p<.01 
 
Multiple regression was used to identify significant predictors of 
the A-ELCC score (Table 7.11). Age, NART IQ, retinopathy severity 
and General Negative Well-Being (GNWB) were entered into the 
analysis. In the final step of the model, retinopathy severity and 
GNWB remained as the only significant predictors of A-ELCC scores, 
F(2,91)=6.756, p< .01, explaining 13% of the variance in the score, 
r2=.129 for final model. 
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Table 7.11 Multiple Regression: Retinopathy, Well-Being, Age and IQ 
As Predictors of Age-Adjusted Estimate of Lifetime Cognitive Change  
 
 B SE B ß t  p  
Step  1       
Cons tan t  - .461  1 .673   - .275  .784* 
Age - .002  .012  - .016  - .143  .887  
NART IQ .009  .014  .067  .650  .517  
Ret  Level  - .537  .199  - .280  -2 .694  .008** 
WBQ GNWB - .106  .047  - .240  -2 .281  .025* 
Step  2       
Cons tan t  - .511  1 .627   -314  .754  
NART IQ .009  .014  .064  .638  .525  
Ret  Level  - .545  .190  - .284  -2 .863  .005** 
WBQ GNWB - .104  .044  - .236  -2 .350  .021* 
Step  3       
Cons tan t  .521  .167   3 .120  .002  
Ret  Level  - .556  .189  - .289  -2 .940  .004** 
WBQ GNWB - .109  .044  - .247  -2 .507  .014* 
Analys is  uses  mul t ip le  regress ion  wi th  backward  s tepwise  en t ry  
Ret  Level=Ret inopathy  Level  x2  (Minimal -None/Mild /Observable  and  Maximal  –  
Referable  & Pro l i fe ra t ive  
WBQ GNWB = Wel l -Being  Ques t ionnai re  Genera l  Negat ive  Wel l -Being   
R 2= .133 for  S tep  1  ∆  R 2= .000 for  S tep  2  (ps= .89) ,  ∆  R 2=- .004  for  S tep  3  (ps= .53) ,  
*p<.05  **p<.01   
 
7.6.  Discussion 
7.6.1.  Question 1 
What percentage of the study group is classified within each category 
on the HADS anxiety and depression scale?   
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Results indicated that this middle-aged to older group with 
T1DM showed many indications of positive psychological well being. 
Although in the current study, most of the participants indicated 
ratings of anxiety and depression within the normal range, there is a 
higher percentage within the normal range in the study group than 
found in the normative population (Crawford et al. ,  2001). Although 
there is research relating higher levels of depression to those with 
T1DM, there was a similar percentage that were classified in the 
normal range for depression in the UK study sample as in the study 
sample.  
Only a small percentage of participants showed high levels 
(moderate or severe) of anxiety or depression that would indicate a 
probable clinical disorder, despite the fact that these study participants 
have a chronic disease that involves significant day-to-day 
management, dietary, and lifestyle limitations. The incidence of 
moderate and severe levels of anxiety and depression is lower than a 
previous clinic study (Lloyd et al. ,  2000) that found more than a 
quarter of the adults with diabetes (Type 1 & 2) rated anxiety and/or 
depression at the moderate and severe level.  However, the clinic study 
did include a wide age range (18-80) and the current study is focused 
on middle age to older adults.  Since well being is found to increase 
with age into the late 60s (Carstensen et al. ,  2011) one reason for the 
slightly lower rates of clinically significant depression and anxiety 
may be the focus on this older age group. The current study sample 
was self-selected and included those with T1DM only. The previous 
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study may have included some with diagnosed psychological disorders, 
however the current study did not. In a study comparing older adults 
(mean age = 61.6) with T1DM and controls (Brands et al. ,  2006), the 
researchers also concluded that the group with diabetes did not show a 
difference in level of psychological distress and a lower rate of 
depression than reported in other studies. 
7.6.2.  Question 2 
Do measures of well being relate to demographic variables? 
 
In the study sample, participant age had the strongest 
relationship to participant’s ratings on the well-being scales. With few 
exceptions, older age was related to higher ratings of positive well 
being and lower ratings of negative well-being.  This reflects a well-
established finding highlighted in the longitudinal study of a non-
clinic sample, with steady gains in emotional well being from age 20 
into the late 60s only leveling in the 70s and a linear gain in emotional 
stability into the 9t h  decade (Carstensen et al. ,  2011). One theory is 
that this difference could be due to changes in emotion regulation 
between older and younger adults (Urry & Gross, 2010). As well,  
another study of T1DM reported that older age is a protective factor 
associated with lower HADS anxiety and depression scores (Collins et 
al. ,  2009). This highlights the fact that despite dealing with a chronic 
disease, this group shows similar positive relationship between age 
and well being that is a hallmark of normal ageing. This highlights the 
need to separate groups by age when estimating the rates of anxiety 
and depression in this population. 
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In the study sample, women had higher ratings of general 
negative well-being and diabetes specific ratings of negative well-
being. These scales both include items relating to worry and sadness. 
Women also rated themselves above the average on the HADS A 
compared to men. However there was no significant relationship with 
HADS D and there were not as clear findings regarding ratings of 
anxiety as there has been in previous studies. This is not consistent 
with study on the UK normative sample for the HADS (Crawford et al. ,  
2001). In the population study, women rated themselves higher on both 
the anxiety and depression scales, even when controlling for age. As 
well in a study of anxiety and depression symptoms in diabetes, female 
gender was associated with higher anxiety scores, however was not a 
significant predictor of anxiety scores (Collins, et al. ,  2009). Older 
age may diminish the sex differences on anxiety and depression ratings 
identified in younger age groups. 
7.6.3.  Question 3 
Do measures of well-being relate to diabetes health variables? 
Duration was related to a better sense of diabetes-specific well-
being. This includes feeling adjusted to diabetes, feeling satisfied and 
positive with diabetes management and feeling can cope with diabetes 
challenges. It  is not known whether this evaluation of diabetes well-
being is particular to middle-aged and older adults or is a function of 
becoming more accepting of diabetes over time. Consultants and 
patients can capitalize on this positive outlook in self-management 
goals. 
190 
In the current study, measures of mean, recent and current 
glycaemic control were specifically related to measures of diabetes 
well-being. Those with higher HbA1c showing lower diabetes well-
being and greater diabetes stress. These scales includes specific items 
about satisfaction and feelings of diabetes management suggesting a 
correspondence between participants’ feelings about the management 
and their actual HbA1c value. An association with depression scores 
was identified for one measure of HbA1c, the long-term mean, and not 
for more recent or current values. Van Tilburg and colleagues (2001) 
found that that Beck Depression Inventory scores, below the cut-off 
for clinical depression, were positively related to current HbA1c 
values for a small group with T1DM. They suggested less self-
monitoring of blood glucose may mediate this relationship. The fact 
that current HbA1c and depression scores are not correlated for this 
older group of adults with long-duration of diabetes suggests that 
evaluation of depressed mood is likely not linked to evaluation of 
current management of HbA1c and having more depressive symptoms 
is likely not enough to influence current HbA1c. The finding in one 
previous study showed that therapeutic treatment of depression does 
not result in better HbA1c values over the course of a year 
(Georgiades et al. ,  2007), suggesting that depression isn’t directly 
influenced by a persons’ current level of control over diabetes. 
Participants’ ratings on the WBQ Diabetes Negative Well-Being Scale 
also indicate that most of the study participants did not feel depressed 
about diabetes. This also suggests that immediate evaluation of 
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depressive symptoms is not directly influenced by current values of 
glycaemic control.  It  may be that depression is a result of chronic 
hyperglycaemia as suggested by Van Tilburg and colleagues (2001). 
This is a topic for a future prospective study.   
In multiple regression mean HbA1c was retained as the sole 
significant positive predictor of HADS D scores. Even though 
retinopathy is positively correlated with HbA1c, there was a trend for 
retinopathy to have a negative association with HADS D scores in the 
final model.  Results of meta-analysis indicate that depression is 
associated with a higher level of complications in T1DM (De Groot, 
Anderson, Freedland, Clouse, & Lustman, 2001), however the authors 
did note that three studies showed trends towards inverse 
relationships, with lower depression associated with higher 
complications.  
Both retinopathy and a combined measure of microvascular 
disease were negatively related to HADS A, even when controlling for 
age. When the group was split  by retinopathy level those with high 
severity retinopathy had low normal HADS A scores and more than 
expected had high normal and above normal (mild/moderate) HADS A 
scores. The opposite pattern was found for those with low severity of 
retinopathy. It  is possible that for those with T1DM, having some 
concern about health may promote better health. “Optimism and 
positive thinking can derail us is if  they lead us to ignore or discount 
important cues and warnings.” (Norem & Chang, 2002, p.998). In their 
study on the psychological aspects of adolescents with diabetes, Dusan 
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and colleagues (2010) found that teenagers with good metabolic 
control (<7.5%) had more problems with anxiety, relied on others more 
in dealing with stress, and used optimism and positive attitude as a 
coping style. The authors suggest it  confirms the hypothesis that 
anxiety has a protective influence through fear of chronic 
complications and can be “conditionally called ‘functional’ anxiety” 
(Dusan et al. ,  2010, p.1792). Results suggest that some level of worry 
may expected and beneficial to a patient with chronic disease who has 
high need for self-responsibility for monitoring and management and 
significant consequences for sub-optimal management. This is also 
supported by the finding that a higher than expected number of 
participants with high severity of retinopathy had low normal HADS A 
scores. The idea of functional anxiety may apply here with those with 
low worry related to higher severity of complications, however this 
would need to be investigated in a prospective study. 
To look at the importance of age in the prediction of anxiety 
scores, age was included in regression analysis along with retinopathy 
and hypertension. It  was found to have a significant negative 
relationship with retinopathy level.  Results highlighted that both age 
and hypertension were significant negative predictors of HADS A 
scores. Both older age and having hypertension were related to lower 
anxiety scores. These results highlight the importance of the positive 
relationship between age on well being even in this group with a 
chronic health condition and is also suggestive of the possibility of a 
functional role of anxiety symptoms of worry.  
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These results highlight the importance of using clinical 
interview in the study of anxiety disorders and diabetes to differentiate 
those with anxiety disorder and those with functional worry stemming 
from the management of a chronic disease with significant 
consequences to future quality of life. In a systematic review of 
screeners for depression, researchers concluded that the HADS and 
other similar self-rating scales identified a high rate of false positives 
and emphasized that these types of tools are not diagnostic in and of 
themselves and not intended for the purpose of assessing symptom 
severity (Roy, Lloyd, Pouwer, Holt,  & Sartorius, 2011). It  may be that 
a “normal range” of anxiety for those with T1DM (as measured by 
self-report),  encompasses a higher range of scores on the HADS than 
for people without a chronic disease requiring high self – management. 
Since the HADS is used as a quick screen for depression and anxiety 
in hospital settings, the negative evaluation of above normal scores 
may lead to over-identification of problems and advice and treatments 
that may not lead to the best diabetes health outcomes for patients. 
Further identification and clarification of this functional level of 
worry for groups with T1DM may help to better tailor advice that 
would ultimately promote better disease self-management. 
7.6.4.  Question 4 
Do immediate measures of well being relate to cognitive function? 
 In the current study, well-being scores were related to two of the 
individual cognitive domains including executive function and short-
term/working memory as well as the overall estimate of lifetime 
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cognitive change (A-ELCC). Both total microvascular disease and a 
measure of diabetes-specific negative well being on the WBQ are 
significant negative predictors of executive function score. For short-
term/working memory scores, only NART IQ remained as a significant 
positive predictor with a trend towards an additional positive 
significance for a measure of general positive well being. Both 
retinopathy level and a measure of general negative well being was 
predictive of lower estimate of lifetime cognitive change (indicating 
greater cognitive decline). These results highlight the importance of 
psychological variables in understanding cognitive function. 
There is one study of cognition in older adults with T1DM that 
also includes measures of psychological well being (Brands et al. ,  
2006). These researchers did not find a relationship between the well-
being measures they used and measures of cognitive function, however 
different measures of well being were used. The measures highlighted 
are those tailored specifically for people with diabetes (WBQ), also 
speaking to the importance of designing population-specific measures 
to evaluate well being in this group 
7.6.5.  Conclusions 
What do the results tell  us about cognitive ageing in T1DM and its 
relationship with theories of cognitive ageing? 
 These results speak to the positive outlook of older adults that 
can be harnessed when setting treatment goals within this group. These  
encouraging results may be related to the older age of this T1DM 
group given the finding in ageing studies that well being increases 
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through the late 60s (Carstensen et al. ,  2011). Psychological well-
being is a component of successful ageing (Young, Frick, & Phelan, 
2009), and these results highlight an aspect of successful ageing in 
this group despite daily living and management of a chronic disease. 
The possibility that there may be a functional level of anxiety that is 
related to less severe microvascular complications and an overall 
positive outlook in this group, requires careful balance to promote 
worry that is helpful and not debilitating. 
The relationship between feelings of negative well being and 
cognitive function in this group was specifically identified in areas 
identified in ageing research (working memory and executive function) 
and related to cognitive decline. This speaks to the importance of 
monitoring and addressing well being to promote the best cognitive 
outcomes in ageing for this group.  
 STAC theory (Park & Reuter-Lorenz, 2009) suggests that new 
learning, cognitive engagement, and exercise promote scaffolding or 
the brain’s ability to make functional changes that maintain cognitive 
function. Cognitive reserve theory identifies leisure activities, social 
experiences, and exercise among factors that increase cognitive 
reserve (Tucker & Stern, 2011). Given the positive attitudes and well-
being identified in this group, this general sense of well-being may 
potentially facilitate engagement in these activities in this middle-aged 
to older adult group. Results from both the cognitive study and the 
investigation of MCI support the positive role of exercise and 
cognitive activity on cognitive function in this group.  The fact that 
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well-being is also related to key areas of cognitive function identified 
in ageing research, suggests a role for a focus on well-being in 
minimizing cognitive changes. 
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                                                                          Chapter 8
Evidence of Functional Brain Ageing in T1DM with 
Microvascular Disease 
 
8.1.  Introduction 
In comparing younger and older groups with T1DM, although 
older groups show areas of greater deficit ,  these cognitive deficits are 
not thought to be beyond the trajectory expected in the normal ageing 
process (Ryan, 2005). As well,  when comparing older individuals with 
T1DM to age-matched controls,  Brands and colleagues (2006) 
concluded that T1DM does not have a significant impact on the brain 
structure or cognitive function. Functional neuroimaging has the 
potential to identify brain functioning that suggests an early ageing 
process even when there appears to be little observable change in 
cognitive function. 
 In the normal brain ageing process, changes in brain function 
have been viewed as a scaffolding process to compensate for structural 
brain changes (Park & Reuter-Lorenz, 2009). Preservation of cognitive 
function may be seen despite the presence of functional brain 
differences between young and old groups through functional 
compensation or preservation of cognitive performance through 
recruitment of non-task related brain areas (Rajah & D'Esposito, 
2005). For example, a move from neural specificity in younger 
adulthood to differentiation in ageing can support maintenance of 
cognitive processes (Cabeza, 2002). Baltes & Lindenberger (1997) 
suggest this process of de-differentiation is highlighted by the link 
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between sensory and intellectual function in ageing suggesting these 
processes are distinct in younger adults and become entwined in 
ageing. There are several researchers that highlight common changes 
found in normal brain ageing detailed below. 
8.1.1.  Default Mode Network in Ageing 
The default mode network (DMN) includes the medial prefrontal 
and lateral parietal regions of the brain that are connected and more 
active during rest,  and suppressed during tasks. The intrinsic activity 
in these regions is correlated, jointly elevated at rest,  and diminished 
during active cognition. Damoiseaux and colleagues (2008) identified 
posterior and anterior resting state networks that showed lower 
activity in older compared to younger adults.  The posterior part of the 
DMN includes the posterior cingulate and bilateral superior parietal 
regions. The anterior part of the DMN includes the superior and 
middle frontal gyri,  posterior cingulate, bilateral middle temporal 
gyrus, and bilateral superior parietal regions.  Their research showed 
that decreased activity in the anterior DMN was associated with 
cognitive decline. Buckner, Andrews-Hanna, and Schacter (2008) 
indicate that the core regions identified as part of the DMN based on 
Brodmann’s Area classification include the ventral medial prefrontal 
cortex (vmPFC; BA 24, 10, 32), posterior cingulate/retrosplenial 
cortex (BA 29/30, 23/31), inferior parietal lobule (BA 39/40), lateral 
temporal cortex (BA 21), dorsomedial prefrontal cortex (dmPFC; BA 
24/32/10/9) and the hippocampal formation (hippocampus, 
parahippocampal cortex, entorhinal cortex). In a study of task-
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associated deactivation of the DMN in older adults,  Persson, Lustig, 
Nelson, & Reuter-Lorenz (2007) found that older adults did not 
decrease resting state activation as much as younger adults in medial 
frontal,  anterior cingulate and posterior cingulate  when engaged in a 
task.  
 
8.1.2.  Posterior-Anterior Shift in Ageing (PASA) 
 Ageing researchers have found that there is a reduction of 
activity in occipital and temporal areas that go along with increases in 
frontal activity in normal ageing (Davis et al. ,  2008). This activity is 
independent of task difficulty and is compensatory (i.e. prefrontal 
cortex activity is correlated positively with cognitive task performance 
and negatively correlated with occipital activations). These researchers 
suggest that decreases in occipital areas reflect deficits in sensory 
processing. They suggest the same pattern happens in task-related 
deactivation of the DMN. Older adults deactivate anterior regions of 
the DMN to a greater extent than posterior regions of the DMN.  
8.1.3.  Neuroimaging in Ageing Summary 
A recent review by Reuter-Lorenz and Park (2010) summarized 
the findings of neuroimaging studies of younger groups 18-30 and 
older groups aged 65 and older. Differences between the younger and 
older groups included less task-induced deactivation of the DMN (i.e.,  
maintenance of DMN activation) with increased task difficulty, 
prefrontal overactivation (i.e.,  stronger and/or more sites of frontal 
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activation) and less connectivity and less overall activity in resting 
state. Waiter and colleagues (2008) found that older adults who 
showed cognitive decline (“decliners”) showed an absence of 
activation that was significantly negatively or positively correlated 
with task difficulty. Those who maintained cognitive function over 
time (“sustainers”) showed a similar pattern of negative posterior 
correlations and positive frontal correlations with an increase in task 
difficulty as the pattern shown in the whole group and in comparison 
to younger adults.   
8.1.4.  Accelerated Brain Ageing 
Given that evidence of brain ageing is not directly reflected in 
observable cognitive change, the question remains unclear whether the 
effects of long-term hyperglycaemia, specifically retinopathy, could 
indicate an increase in microvascular burden in the brain that relates to 
signs of accelerated ageing in individuals with T1DM. Do individuals 
with retinopathy show premature brain ageing of vulnerable areas? If 
there are signs of accelerated ageing, functional performance in these 
middle age participants (45 to 65) with T1DM should look similar to 
the research on functional activation and deactivation in older adult 
groups. 
Specifically: 
•  Prefrontal overactivation - stronger, more sites: inferior frontal 
gyrus, dorsolateral PFC (Davis et al. ,  2008) 
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•  Less task induced deactivation of default network - default 
activation during task:  medial PFC, posterior cingulate, 
precuneus, inferior parietal (Persson et al. ,  2007) 
•  Less connectivity in default network - less activity in resting 
state (Damoiseaux et al. ,  2008) 
•  Pattern comparable to “decliners” on the Waiter and colleagues 
(2008) inspection time task  
8.2.  Study Aims  
Results of the cognitive study suggest that it  may only be with 
the presence of blood-sugar related changes in small blood vessel 
integrity, as in retinopathy and other microvascular diseases, that 
patients with T1DM experience mild changes in cognitive function. 
This finding was further tested through functional neuroimaging to 
determine whether there is evidence of accelerated cognitive ageing in 
this group. In this study, a subgroup of participants from the cognitive 
study with and without microvascular disease (retinopathy) with 
varying levels of blood glucose control was selected for follow-up 
using functional magnetic resonance imaging (fMRI).  
8.3.  Study Questions 
1. Does neural activation (as indicated by the blood oxygen level 
dependent (BOLD) response in fMRI), when completing a cognitive 
task and at rest,  differ between groups with high severity 
retinopathy and those with low severity retinopathy?  
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2. Does BOLD activation in the high severity retinopathy group 
resemble patterns found in normal ageing? 
8.4.  Ethics 
A favourable ethical opinion was obtained (Appendix Q) through 
the Tayside Committee on Medical Research Ethics A, an arm of the 
East of Scotland Research Ethics Service for the National Health 
Service (NHS). Approval to conduct the study on NHS Sites and with 
the assistance of NHS staff was sought through the NHS Research and 
Development Office (Appendix Q). Ethical approval was also sought 
and obtained through the University Teaching and Research Ethics 
Committee (UTREC) for the University of St.  Andrews.  
 
8.5.  Methods  
8.5.1.  Participants 
A subgroup of 30 participants from the Cognitive Study who 
were evenly sampled from those who have high severity retinopathy 
(referable and proliferative retinopathy) and low severity retinopathy 
(none/mild/observable retinopathy) between the ages of 45 and 65 
were recruited to take part in the neuroimaging study. Potential 
participants were contacted by phone. Participants who were interested 
in the study and who met the inclusionary/exclusionary criteria 
received an information sheet detailing their participation. If the 
participant agreed, a time for MRI scan was arranged. Informed 
consent was completed before the MRI scanning session. 
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Inclusion Criteria 
The same inclusionary criteria used for the cognitive study (Study 1) 
applied to the neuroimaging study (Study 2), however only participants 
between 45 and 65 years old were invited to take part.   
Exclusion Criteria  
The same exclusionary criteria used for the cognitive study (Study 1) 
applied to the neuroimaging study (Study 2).  Participants were 
excluded if they had conditions or characteristics that would preclude 
MRI scanning including: 
• metal implants, foreign metal objects in body 
• medical devices (e.g. pacemaker, surgical clips) 
• pregnancy 
• internally implanted insulin pump or external (tube/tubeless) 
insulin pump that cannot be safely removed for a period of 60 
minutes. 
• currently taking part in other clinical or research MRI scanning 
• recent surgery (past 6 weeks) 
Emotional or physical limitation to entering the MRI scanner 
• Fear of confined spaces (i .e. ,  Claustrophobic) 
• Physical limitation that impedes ability or comfort to stay still  
lying down for extended time in the scanner (e.g. tremors) 
8.5.2.  Procedure  
The sequence of events in the MRI procedure is graphed in a 
flow chart in Appendix S. MRI scanning took place at the Clinical 
Research Centre (CRC) at Ninewells Hospital,  Dundee.   
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Blood Glucose Testing 
After signing consent, participants checked their blood glucose. 
If blood glucose was below 5mmol/l the participant had a glucose 
drink and biscuit and then re-checked blood glucose to ensure it  was 
over 5 mmol/l.  This was a higher threshold than used in the cognitive 
study to ensure that the risk of participants having a hypoglycaemic 
event in the scanner was low as they would be in the scanner for 
approximately 60 minutes.  
Training on Cognitive Tasks 
The researcher reviewed the sequence of events in the scanner 
with the participant and provided baseline training on the cognitive 
tasks that they will encounter during the fMRI experiments. The 
participant then completed training on the two tasks they would 
complete in the MRI scanner (Appendix T), until  the examiner and 
participant were confident that they understood the tasks.  
Preparation for MRI 
After completing the NHS Tayside MRI Patient Safety 
Questionnaire, and changing into scrubs, the radiographer and 
physicist prepared the participant for the scanning session.  The MRI 
physicist prepared the necessary equipment (headphones, goggles, 
response buttons) and ensured all the equipment was functioning 
correctly.  Corrective goggles were used for the participant to be able 
to view the computer screen, and was adjusted specifically to suit each 
participant’s vision.  
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Emergency Protocols 
Participants were provided with an emergency squeeze bulb in 
case they experienced any distress during scanning.  They were able to 
use this to alert the imaging staff that assistance was required or they 
would like to stop the scanning.  None of the participants had to use 
this emergency alert and all completed the MRI scanning. Once the 
participant entered the MRI and had first-hand experience of this 
environment, they were asked again if they were still  willing to 
proceed. If so, the MRI protocol was initiated. Participants could stop 
participation at any time, however all  completed the tasks.   
MRI scanning  
The radiographer provided instructions before each section of 
scanning to indicate the purpose of the sequence, and to tell  the 
participant what they would be required to do during the session (e.g.,  
lay still  with eyes closed, or asked to read instructions for the specific 
cognitive task). All of the fMRI imaging was completed in one 
session. The total scanning session was 60 minutes on average. The 
presentation of tasks was chosen to be similar to previous research 
protocols and to minimize scanner time for participants.   
8.5.3.  fMRI Data Acquisition 
Functional MRI tasks were chosen because they were key 
features of cognitive ageing, and were highlighted in this cognitive 
study and other studies of T1DM and cognition.  The tasks chosen had 
been well tested in other fMRI studies of diabetes and/or ageing 
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(Wessels et al. ,  2006; Waiter et al. ,  2008, 2009, Damoiseaux et al. ,  
2008).  This included a measure of working memory (n-Back), a 
measure of processing speed (inspection time), and resting state. The 
total time of each task was between 5 to 8 minutes to take into 
consideration the older age and physical limitations of some of the 
participants that would make it  physically difficult to stay focussed 
and still  for tasks for an extended time. The instructions and visual 
stimuli were presented on a computer monitor and viewed through 
goggles attached to the head coil.   The MRI physicist applied the 
necessary vision correction through the goggles prior to scanning.  
Participants were provided two pushbutton boxes, one for each hand to 
allow the software to log the timing and responses to the task. 
Working Memory: N-back 
During the n-back task, participants are shown English letters 
and asked to respond by pressing the right button to a specific target 
letter and the left button to all other letters. In the easy version of the 
task, for each letter shown and the participant was asked to press the 
right button when a target letter X appeared (0-back) and the left 
button to any other letter.  On the hard version of the task, to increase 
working memory load, the participant was asked to press the right 
button if the letter was the same as the one presented two trials back 
(2-back) and the left button to all other letters.  An example of the 
appropriate responses to a mock sequence of letters on the 2-back task 
is provided showing the trial;  letter and corresponding correct button 
push in Table 8.1  
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Table 8.1 2-Back Example  
 
Trial Letter 
Displayed 
Correct 
Button Response 
1 A L 
2 B L 
3 C L 
4 B R 
5 B L 
 
Dr. Stephen Nicholas, an MRI Physicist at the Clinical Research 
Centre (CRC) at Ninewells Hospital,  Dundee programmed the n-back 
task using Presentation software (Neurobehavioral Systems Inc.,  CA).  
To minimize scanner time and frustrations for participants on this task, 
only the 0-Back and 2-Back conditions were used. In the previous 
fMRI studies mentioned, these were the only contrasts on which a 
group with T1DM with and without retinopathy differed (Wessels et 
al. ,  2006) and the only contrast that differentiated groups in a study of 
cognitive ageing (Waiter et al. ,  2009). The task was presented in a 
block design interleaving 4 epochs each of 0-back and 2-back with 14 
trials in each block and an inter-stimulus interval (ISI) of 2.5 seconds 
(1 s letter,  1.5 s blank). Each block lasted 32.5 seconds including 5 
seconds for instructions at the beginning of each block. Each 
participant completed one run (4 epochs) of the n-back task. There was 
no fixation stimulus used.  Behavioural measures included response 
accuracy and reaction time. 
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The run was presented in the same order (0-back first,  2-back 
second for each epoch) such that all  participants started with the easy 
version of the task to ensure initial success and motivation. In both the 
0-back and 2-back blocks the probability of the item being a target was 
29% (4/14).  The occurrence of the target letter was different for each 
block to reduce the chances of learning a response set.   In the 2-back 
block, there was a 29% chance the letter would be a repeated letter 
(i .e.  a distractor letter seen before in the block either 1 back or 3 back) 
and a 43% chance (6/14) the letter would be new within the block.  
Resting State: Default Mode Network 
Resting state data was collected as in previous fMRI studies of ageing 
(Damoiseaux et al. ,  2008) in investigation of the default mode 
network. Participants were asked to lie still  in the scanner with their 
eyes closed while scanning proceeded with similar imaging parameters 
as in the n-back task.  
Processing Speed – Inspection Time  
Inspection time is a simple visual discrimination task.  Two 
parallel vertical lines of obviously different lengths are shown on a 
computer screen to the participant for less than a second. Participants 
were asked to indicate the side on which they saw the longer line 
shown in Figure 8.1 .  Trials were varied in difficulty by showing the 
line pairs for varying lengths of time, which affects the likelihood of 
accurate performance. Harder trials were associated with shorter 
stimulus duration. 
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Figure 8.1  Inspection time stimulus showing correct responses. Image 
from Waiter and colleagues (2008), reprinted with permission of 
author. 
 
The participant indicated the side on which they saw the longer line by 
pushing the left button with the left index finger if the longest line 
was on the left,  and by pushing the right button with the right index 
finger if the longest line was on the right.  
Participants were trained on the task before going into the scanner 
to provide familiarity with the task instructions and address any 
questions and provide practice to increase the chance of all  
participants responding correctly on this task.  The threshold of 
inclusion for the data of a particular participant was above a threshold 
of 90% correct (31.5/35) for highest duration (97ms) and above chance 
(17.5/35) on the shortest exposure. Waiter and colleagues (2009) also 
used a threshold of 90% correct (18/20) on the inspection time task for 
the 100 ms exposure, therefore the same threshold was used in this 
study. 
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Dr. Gordon Waiter, MRI Physicist at the University of Aberdeen, 
provided the Presentation software syntax as the basis for 
programming the inspection time task (Presentation software, 
Neurobehavioral Systems Inc.,  CA).  Waiter and his colleagues (2009) 
used this programming in their study, however they used a 1.5T 
Scanner and presented visual stimulus on a screen with a higher 
refresh rate than a typical computer screen.  In the original studies 
(Waiter et al. ,  2008, 2009) 2 inspection time runs of 20 trials were 
presented at each of eight durations (6, 12, 25, 37, 50, 75, 100 and 150 
ms). Only the time durations of 25, 37, 50 and 75 ms were included in 
analysis in the previous study (Waiter et al,  2008). The shortest time 
presentations were excluded because older adult groups did not show a 
difference in brain function at these levels of presentation and 
responding was below chance level.   The longest duration showed 
100% accuracy and also no differentiation between groups. For the 
purposes of the current study, the presentation of the task was 
shortened by eliminating the shortest duration presentations and some 
of the longest time presentations and optimized for the 3T scanner at 
the CRC by MRI Physicist,  Dr. Stephen Nicholas.  In the current study 
there were 5 stimulus durations used (15, 31, 48, 82, & 97 ms). More 
practically, at the shortest time (6ms) this presentation was not 
possible at the CRC due to a lower refresh rate of the computer screen 
available for stimulus presentation than available in the Waiter and 
colleagues study (2008).  
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The inspection time task is presented in an event-related design 
and optimized for the 3 T scanner. There was only one inspection time 
run in this study with 35 trials.  The trials are presented in the same 
random order for each participant. The inter-stimulus interval (ISI) is 
2 seconds. Behavioural measures included response accuracy and 
reaction time. 
8.5.4.  Brain Imaging Parameters 
Scanning was performed on a Magnetom Trio 3.0 T scanner 
(Siemens Healthcare, Erlangen, Germany), using a standard 12-channel 
phased array head coil.  The protocol for the structural and functional 
MRI is shown in Table 8.2. 
After the structural scans, T2*-weighted gradient-echo (GRE) 
echo-planar images (EPI) were obtained in the axial orientation for the 
n-back task with a repetition time (TR) of 2.5s and echo time (TE) of 
30 ms, slice thickness 3.0 mm, matrix 80, field of view (FOV) 240 x 
240 mm (in-plane resolution 3.0 x 3.0 mm), and flip angle of 90º. Fat 
saturation and parallel imaging (acceleration factor of 2) were used to 
minimize chemical shift and distortion artifacts.   There were 130 
volumes for the n-back task made up of 37 slices/volume. The total 
scanning time for the n-back task was 5 minutes and 39 seconds. The 
same parameters were used for the inspection time task and for the 
resting state data.  The differences were that for inspection time there 
was a shorter TR (2.2s) and there were 210 volumes collected for the 
inspection time task with 37 slices per volume. The total scanning time 
for the inspection time task was 7 minutes and 42 seconds.  There were 
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140 volumes collected for resting state fMRI.  The total scanning time 
was 5 minutes and 49 seconds. The Siemens System runs four 
“dummy” scans prior to the fMRI acquisition to ensure the fMRI signal 
has reached a steady state. These dummy scans do not form part of the 
data and the first synchronization pulse is only sent after these dummy 
scans have finished. Therefore, none of the acquisition volumes were 
discarded for data analysis. 
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Table 8.2 Imaging Parameters and Timing for Structural and Functional MRI Sequences  
 
MRI Sequence Purpose Imaging Sequence Imaging Orientation Time in Minutes 
Localiser Template figures for placing slices 
in correct position 
Low-resolution  GRE 3 plane 0.13 
Structural Scan 1: T1  High Resolution 3D images for 
morphometry. 
T1 3D MP-RAGE (magnetisation Prepared-Rapid 
Acquisition Gradient Echo). 1 mm isotropic resolution. 
Sagittal  4.26 
Structural  Scan 2: T2    Identification of  lesions T2 3D TSE (Turbo Spin Echo). 1 mm isotropic 
resolution 
Sagittal  4.43 
fMRI  
n-back run  
data acquisition for working 
memory task  
T2* GRE-EPI. Axial  5.39 
fMRI resting state run  Data  acquis i t ion  for  defaul t  
mode  ne twork   
T2* GRE-EPI  Axia l .   
 
5.59 
fMRI inspection time run 
 
Data acquisition for processing 
speed task 
T2* GRE-EPI Axial  7.42 
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8.5.5.  Statistical Analysis  
Behavioural Analysis 
 
SPSS Version 19.0 (SPSS Inc.,  Chicago, IL, www.spss.com) was used 
to perform statistical analysis on the reaction time and accuracy data 
from the cognitive tasks.  
Image Pre-processing 
 
Initially, DICOM files were converted to Nifti  format. SPM8 
software (www.fil.ion.ucl.ac.uk/spm) was used to analyze the images. 
Pre-processing steps and parameters for n-Back, resting state and 
inspection time included:  
1. Slice time correction: correction for acquisition delay between 
slices  (37 slices, slice order=interleaved, middle reference slice = 37). 
Repetition Time (TR) =2.5 s for n-Back and resting state. TR=2.2 s for 
inspection time. Echo Time (TE) =  30 ms 
2. Realignment: within subject registration motion correction 
realignment to first image of each series using rigid body affine 
transformation (translation <5mm for all  subjects)  
3. Normalization: warped to standard SPM 8 EPI template using 12-
parameter affine transformation with a 2x2x2 mm voxel size 
4. Smoothing: realigned and normalized images were smoothed with a 
6mm full width half maximum Gaussian kernel 
The first level within-subject analysis was completed following 
a General Linear Model approach.  Information about the timing of 
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stimuli and responses were obtained from the Presentation log file for 
both the n-Back and the Inspection Time tasks.  
N-back Random Effects Analysis  
First-level statistical analysis for the n-back epoch data, 
followed the same process described by O’Connor, Han, & Dobbins 
(2010).  Participants were treated as a random-effect and volumes as 
temporally-correlated time series. This was modeled by convolving a 
canonical hemodynamic response function (HRF) provided in SPM 8 
along with delta functions that mark the onset of each condition from 
the presentation of the stimulus letter of the n-back test.  Incorrect 
responses were grouped into a variable of no interest and not included 
in the analysis. Parameter estimates for the best-fit  canonical HRF for 
the easy and hard conditions of the n-back task were used in pairwise 
contrasts and stored separately as an image for each participant. 
Images were tested against the null hypothesis of no difference 
between conditions using one-tailed, repeated measures, t-tests. 
Activations were considered significant if they had a voxel-extent of 5 
or more and exceeded a threshold of p< .001.  
Second-Level random-effects analyses were performed to 
compare groups with high severity retinopathy (HSR) and low severity 
retinopathy (LSR). A factorial ANOVA was used to investigate the 
interaction of age (young/old) and retinopathy (LSR/HSR) on BOLD 
activation. Estimated by beta values of BOLD signal activity generated 
through the second-level fMRI analysis and extracted using MarsBaR  
(Brett,  Anton, Valabregue, & Poline, 2002) were used to examine the 
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direction of differences in regional brain activity between the LSR and 
HSR groups. 
 
Resting State Analysis 
Resting state analysis of functional connectivity was completed 
using the method described by O’Connor and colleagues (2010). Dr. 
Akira O’Conner at the University of St.  Andrews provided the 
MATLAB program for this analysis. Functional connectivity analysis 
was examined on timecourses from one 4mm diameter region of 
interest (ROI). The ROI was created using MarsBaR software (Brett  et 
al. ,  2002) to make a sphere around the central coordinate.   
The research defined seed ROI in the ventromedial prefrontal 
cortex (vmPFC) was chosen as it  had been identified as part of the 
Hippocampal-Cortical Memory System (HCMS; Vincent, Kahn, 
Snyder, Raichle, & Buckner, 2008). The Montreal Neurological 
Institute (MNI) coordinates of this region are x=0, y=51, z=-7; this is 
situated approximately in Brodmann area (BA) 10. This seed ROI is 
depicted on the brain image in Figure 8.2. 
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Following the method outlined (O’Connoret al. ,  2010), the seed 
region was entered as a covariate of interest along with sources of 
non-specific variance (a total of 18 including 6 movement parameters, 
signal from spheres in the left lateral ventricle, deep cerebral white 
matter in left hemisphere and averaged across the whole brain, along 
with 9 first order derivatives of these covariates) using the same 
threshold as the functional data, p<.001, 5 voxel extent. This shows 
areas whose activation covaries with the seed regions scan-by-scan 
after nonspecific effects are controlled. Connectivity for the whole 
group, low severity retinopathy group (n=15) and high severity 
retinopathy group (n=15) were analyzed separately. 
Inspection Time Random-Effects Analysis 
Analysis of the event-related inspection task followed the 
method described in the study by Waiter and colleagues (2008). 
vmPFC 
0,51,-7 
Figure 8.2 Location (including MNI coordinates) of the ventromedial 
prefrontal cortex (vmPFC) seed region used in resting state analysis.  
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Functional activity was modeled using one regressor for trials with 
correct responses and one for incorrect responses. The vector of 
stimulus onsets were convolved with a canonical hemodynamic 
response function provided in SPM 8, resulting in 10 predictors of 
brain activity for the inspection time run, 5 for correct responses and 5 
for incorrect responses.  
Second level random-effects analyses were performed to 
compare groups with high and low severity of retinopathy on easy and 
hard conditions of the Inspection Time tasks. Inspection Time analysis 
focused on BOLD activation associated with correct responses. 
Inspection time durations were weighted for increasing task difficulty 
for correctly answered trials using a linear weighting of inspection 
time durations in a manner comparable to Waiter and colleagues 
(2008). This weighting was recommended by Dr. Waiter as it  would 
provide a near linear weighting based on duration (-1.00,   -0.67,    
-0.25,    0.67,    1.25).  Regions of positive and negative correlation 
with inspection time difficulty were determined by providing a linear 
weighting for the 5 inspection time stimulus durations using the 
regressors associated with correct responses only. A significance level 
of p<.005 uncorrected, with a 10 voxel extent was used for voxel-wise 
multiple comparisons at the group level in line with the 
recommendation for using less strict threshold values to balance Type 
I and Type II errors in functional neuroimaging studies of complex 
cognitive processes (Lieberman & Cunningham, 2009).  
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8.6.  Results 
8.6.1.  Demographic Comparison of Retinopathy Groups 
Thirty participants were recruited for the neuroimaging section 
of the study according to the highest reported rating based on the 
Scottish Diabetic Retinopathy Grading Scheme (SDRGS; 2007).  Two 
groups were formed, with 15 participants each, the low severity 
retinopathy (LSR) group (none, mild or observable background 
diabetic retinopathy) and the high severity of retinopathy (HSR) group 
(referable background diabetic retinopathy/referable maculopathy, 
proliferative retinopathy or laser treated retinopathy).  The comparison 
of demographics between the two groups is presented in Table 8.3. 
There was no difference between groups in age, education, gender, or 
premorbid IQ. 
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Table 8.3 Comparison of Demographic Variables by Retinopathy 
Group  
 
 LSR (n=15) 
 
HSR (n=15) t  
(28) 
U  χ²(1)  p  
Age x¯  (SD) 
min-max yrs 
52.62 (5.43) 
45-62 
53.61 (5.66) 
45-64 
-.488   .64 
§Education 
(Mdn) 
min-max yrs  
13.0 
10-20 
11.0 
10-25 
 87.5  .30 
Female (n) 9 8   .136 .99 
†NART IQ 
x¯  (SD)  
min-max IQ 
3.42a(.601) 
113.9b(3.85) 
109-122 
3.38a(.980) 
113.7b(6.03) 
105-124 
.145 
 
  .88 
 
2- ta i led  s igni f icance  repor ted .  
§Educat ion  could  not  be  normal ized ,  ins tead  used  non-parametr ic  Mann Whitney  U.  
†NART IQ was  t ransformed for  ana lys is  due  to  non-normal  d is t r ibu t ion  (Reverse  
Square  Root) .  Both  t ransformed and  non- t ransformed means  are  provided  for  ease  of  
unders tanding .   
a .  Values  for  reverse  square  root ,  wi th  t  & p  va lue   
b .  Orig ina l ,  un t ransformed va lues  (not  used  in  ana lys is  –  t  &p  va lue  not  repor ted)  
 
The LSR and HSR groups were also compared on diabetes health 
variables reported in Table 8.4. It  was expected that the HSR group 
would have greater diabetes health variables than the LSR group.  
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Table 8.4 Comparison of Diabetes Variables by Retinopathy Group  
 
 LSR (n=15) 
x¯  (SD)  
HSR (n=15) 
x¯  (SD)  
t  (28)  p        
 
Duration Diagnosis 
min-max  years 
26.7 (10.5) 
11.5-43.1 
28.2 (10.3) 
13.8-49.0 
-.382 .70 
Age of Onset 
 
min-max years 
25.91 (10.8) 
7.0-41.8 
25.44 (10.2) 
4.6-46.0 
.120 .90 
Mean HbA1c 
min-max % 
7.9 (.80) 
6.0-9.0 
8.7 (.60) 
7.5-9.7 
-3.07 .02* 
†Micro. Disease 
 
min-max  
.562a (.28) 
.387b (.27) 
0.0-1.07 
.908a (.24) 
.879b (.51) 
0.4-2.13 
-3.65 .002** 
§Insulin Resistance 
(eGDR) 
min-max  
.806a (.13) 
6.68b (2.0) 
3.8-10.5 
.745a (.15) 
5.89b (2.2) 
2.8-10.6 
1.167 .26 
*p<.05 ,  **p<.01;  2- ta i led  s ignif icance  repor ted .   
†  Micro  Disease=Microvascular  Disease ,  was  t ransformed for  ana lys is  (Square  Root) .   
§  The  var iab le  insu l in  res is tance  was  t ransformed for  ana lys is  ( log  10) ,  lower  eGDR 
= grea ter  insu l in  res is tance  
For  a l l  t ransformat ions ,  bo th  t ransformed and  non- t ransformed means  are  provided   
a .  Values  for  reverse  square  root ,  wi th  t  & p  va lues  
b .  Orig ina l ,  un t ransformed va lues  (not  used  in  ana lys is  –  t  &p  va lue  not  repor ted)   
 
Although groups did not differ in duration or onset of diabetes, 
the HSR group had higher microvascular disease, t(28)=-3.65, p<.01, 
r= .57), and higher mean HbA1c, t(28)=-3.07, p<.05, r= .50) than the 
LSR group. Groups did not differ on insulin resistance, which 
primarily relies on general health variables (presence of hypertension 
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and waist-hip-ratio) in calculation of this value. Pearson chi square 
analysis indicated that groups did not differ on experience of severe 
hypoglycaemia requiring assistance (χ²(1)=.136, p=.50). The groups 
were similar in relation to general health variables (Table 8.5). 
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Table 8.5 Comparison of General Health Variables by Retinopathy 
Group  
 
 LSR (n=15) 
x¯  (SD)  
HSR (n=15) 
x¯  (SD)  
t  (28)  p        
 
Systolic BP 
min-max  
130.6 (13) 
105-157 
136.7 (13.2) 
120-167 
-1.27 .22 
Diastolic BP 
min-max  
74.6 (10.7) 
53-86 
70.7 (5.99) 
59-79 
1.24 .22 
Waist-Hip Ratio 
min-max  
.877 (.085) 
.72-1.0 
.874 (.099) 
.73.1.0 
.079 .94 
§BMI 
 
min-max  
1.41a (.07) 
26.1b (4.25) 
20.5-33.8 
1.46a (.06) 
28.9b (4.01) 
23.1-34.8 
-1.89 .06  
†Total Cholesterol 
 
min-max 
2.10a (.16) 
4.42b (.68) 
3.3-5.9 
2.19a (.14) 
4.80b (.61) 
3.7-5.8 
-1.65 .11 
HDL Cholesterol 
min-max  
1.81 (.38) 
1.2-2.3 
1.93 (.48) 
1.3-2.96 
-.795 .44 
§Triglycerides 
 
min-max  
- .162a (.19) 
.769b (.47) 
.43-2.3 
-.077a (.15) 
.884b (.30) 
.47-1.6 
-1.37 .18 
*p<.05 ,  2- ta i led  s igni f icance  repor ted .   
†  Tota l  Choles tero l  was  t ransformed for  ana lys is  (Square  Root) .   
§  The  var iab le  BMI,  Tr ig lycer ides ,  and  Choles tero l  Rat io  were  t ransformed for  
ana lys is  ( log  10)  
For  a l l  t ransformat ions ,  bo th  t ransformed and  non- t ransformed means  are  provided   
a .  Values  for  reverse  square  root ,  wi th  t  & p  va lue   
b .  Orig ina l ,  un t ransformed va lues  (not  used  in  ana lys is  –  t  &p  va lue  not  repor ted)   
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The LSR and HSR groups were also compared on their 
performance on cognitive tests shown in Table 8.6. In this small 
group, there is no significant difference between scores on the 
cognitive tests for the LSR compared to the HSR group. Groups were 
also compared on the Ravens Total score using non-parametric Mann-
Whitney U test.   There was no significant difference on Ravens score 
between the LSR group (Mdn=  44) and HSR groups (Mdn= 41), 
U=89.0, p=.35, one-tailed. Differences in brain function identified 
should not be due to difference in basic cognitive performance 
between groups. 
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Table 8.6 Performance on Cognitive Tests by Retinopathy Group  
 
 LSR (n=15) 
x¯  (SD)  
HSR (n=15) 
x¯  (SD)  
t  (28)  p        
 
§A-ELCC .274 (.66) .041 (.99) .757 .46 
†TMT-A 1.20a (.26) 
-.594b (.65) 
1.21a (.37) 
-.499b (.82) 
-.106 .92 
†TMT-B  1.08a (.39)  
- .497b (.67) 
1.17a (.58)  
- .082b 
(1.74) 
-.501 .61 
Story Recall Immed. .130 (.69) .180 (.67) -.201 .84 
Story Recall Delay .177 (.72) .215 (.67) -.149 .88 
Digit Span 1.37a (.38) 
.245b (1.1) 
1.46a (.36) 
.467b (1.1) 
-.621 .54 
Symbol Digit (W) -.085 (.857) .069 (1.1) -.424 .68 
Symbol Digit (O) .198 (.99) .422 (.83) -.675 .50 
2- ta i led  s igni f icance  repor ted .  
§A-ELCC=Age-Adjus ted  Es t imate  of  L i fe t ime Cogni t ive  Change  
TMT=Trai l  Making  Tes t ,  lower  scores  ind ica te  be t te r  per formance .   
†TMT tes ts  and  Digi t  Span  were  t ransformed for  ana lys is  due  to  non-normal  
d is t r ibu t ion  (Square  Root) .  Both  t ransformed and  non- t ransformed means  are  
provided  for  ease  of  unders tanding .  
a .  Values  for  reverse  square  root ,  wi th  t  & p  va lue   
b .  Orig ina l ,  un t ransformed va lues  (not  used  in  ana lys is  –  t  &p  va lue  not  repor ted)  
 
8.6.2.  Results 
N-back 
Of the 30 participants who took part in the fMRI scanning, not 
all  were included in the analysis of the working memory test.  Two 
participants from the LSR group and 1 participant from the HSR group 
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scored below chance on the 2-Back and were excluded from the 
random-effects analysis leaving 13 participants in the LSR group and 
14 in the HSR group. 
N-back Behavioural Results 
 To determine whether the participants experienced greater 
difficulty on the 2-back version than the 0-back version of the task, 
performance was compared for the hard and easy versions of the task. 
As expected, results of paired t-test showed that participants 
performed more accurately and quickly on the 0-back task when the 
working memory load was low than the 2-back task when the working 
memory load was high (Table 8.7). Results of Spearman’s rho 
correlation indicated that accuracy on the 0-back was not correlated 
with response time on the 0-back (rs=-.163 ,  p=.42).  In contrast,  
accuracy on the 2-back was negatively correlated with response time 
on the 2-back (rs=-.770 ,  p<.001) and 0-back (rs=.391 ,  p<.05). 
Therefore those with greater response time had less accurate 
responses. 
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Table 8.7  Results of Paired t-Test of Group Performance on 0-Back vs 
2-Back Task  
 
 0 Back  2 Back t (26) p 
2-tailed 
# Correct 53.52 (2.5) 42.41 (6.0) -12.37* .000 
Response Time 528.27 (73.4) 770.91 (106.8) 10.26* .000 
 
Results of t-test comparison of the LSR and HSR group on the n-back 
task are provided in Table 8.8. On the 0-back task, there was no 
difference between the LSR and HSR group on the number correct and 
no difference in the response time.  On the 2-back task, the LSR group 
performed more slowly on the 2-back task than the HSR group, 
t(25)=2.135, p< .05, two-tailed. Despite taking longer to respond, the 
LSR group performed no better than the HSR group on the 2-back task. 
 
Table 8.8 Accuracy and Response Time on N-Back Task for Low 
Severity Compared with High Severity Retinopathy Group  
 
N-
Back 
Measure LSR (n=13) 
 Mean (SD) 
HSR (n=14) 
Mean (SD) 
t  (25) p 
2-
tailed 
0 
 
# Correct 53.9 (0.3) 53.3 (0.9) .494 .62 
RT ms 514.7 (16.5) 545.2 (23.4) -1.26 .22 
2 # Correct 40.9 (1.8) 43.9 (1.5) -1.39 .18 
RT ms 815.3(33.5) 731.2 (25.8)  2.14 .02 
RT=Response  Time in  ms  *p< .05  
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Whole Group Results 
To determine the regions of activation and deactivation on the n-
back task, a whole group analysis was completed to determine BOLD 
activity with increasing task difficulty on the n-back task. Significant 
clusters at p< .001, uncorrected, 5 voxel extent are reported along with 
the MNI coordinates. Activations that were greater in the hard task (2-
back) than the easy task (0-back) are provided in Table 8.9.Significant 
activations were identified in bilateral frontal areas including a large 
area surrounding the middle frontal gyrus (~BA 6), left inferior frontal 
gyrus (~BA 11), and medial frontal gyrus (~BA 6). Areas in the 
occipital lobe showed activation including the right inferior occipital 
and left middle occipital (~BA 18), as well as the left cuneus (~BA 
17). Significant activation was shown in the superior temporal gyrus 
(~BA 13) in the temporal lobe and the postcentral gyrus (~BA 3) in the 
parietal lobe. 
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Table 8.9 Activations for the Whole Group with Increasing Task 
Difficulty on the N-back Task  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Frontal        
Middle Frontal Gyrus R 6 32 12 52 79812 7.35 
Inferior Frontal Gyrus L 11 -14 42 -20 9 3.93 
Medial Frontal Gyrus R 6 18 -20 52 11 3.35 
 L 6 -6 -12 72 13 3.30 
Occipital        
Inferior Occipital Gyrus R 18 42 -86 -12 30 3.61 
Cuneus L 17 -16 -90 8 22 3.56 
Middle Occipital Gyrus L 18 -36 -90 0 6 3.19 
Temporal        
Superior Temporal Gyrus R 13 52 -44 20 24 3.58 
Parietal        
Postcentral Gyrus L 3 -36 -36 66 17 3.45 
SPM clus ters  conta in ing  a t  leas t  5  s ign i f icant  voxels  (p  <001,  uncorrec ted) .  MNI 
coord ina tes  (x ,y ,z )  re fer  to  c lus ter  maxima repor ted  in  MNI space .  Lat .=  
la te ra l i ty ;  BA= approximate  Brodmann’s  a rea ;  Vox.=  number  of  s ign i f icant  voxels  
 
Significant deactivations, p< .001, 5 voxel extent were identified 
for the whole group on the hard version of the task (2-back) greater 
than the easy version of the task (0-back). MNI coordinates of cluster 
maxima are provided in Table 8.10. Significant deactivations were 
identified in the left medial prefrontal cortex and several areas of the 
temporal lobe including the left middle temporal gyrus (~BA 21 & 39) 
and bilateral superior temporal gyrus (~BA 22/38/41). In the posterior 
region, significant deactivation was identified in the left precuneus 
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(~BA 31) of the parietal lobe. Sub-lobar areas were also deactivated 
including bilateral insula (~BA 13), and claustrum. 
 
Table 8.10 Deactivations for the Whole Group with Increasing Task 
Difficulty on the N-back Task  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Frontal        
Medial Frontal Gyrus L - -10 50 2 936 4.83 
Temporal        
Middle Temporal Gyrus L 21 -48 2 -36 123 4.84 
  L 39 -52 -74 26 10 3.65 
Superior Temporal Gyrus L 38 -34 2 -24 17 4.10 
 R 22 56 -2 4 8 3.46 
 L 41 -48 -28 16 8 3.46 
Parietal        
Precuneus L 31 -8 -56 32 564 5.04 
Sub-Lobar        
Insula L 13 -42 -16 -8 45 4.04 
 R 13 48 -26 20 48 4.03 
 L 13 -40 -14 12 76 3.76 
Claustrum R - 36 8 8 6 3.64 
Lis ted  reg ions  a re  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted) .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  
of  s ign i f icant  voxels ;  
  
The images for the whole group results on activation and 
deactivation associated with increasing task difficulty are shown in 
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Figure 8.3. Large areas of activation can be seen in the frontal,  
parietal lobes, and cerebellum. Deactivation was focused in the medial 
frontal regions and temporal areas.   
 
  
 
 
  
a b 
Figure 8.3 Image of results  for the whole group n-back (a) activations and 
(b) deactivations with increased task difficulty (2-back >0-back),  
threshold p<.001 unc ,  5  voxel extent  
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Retinopathy group comparison  
 Random-effects analysis was performed to compare the HSR and 
LSR group in relation to activation on the hard (2-back) in comparison 
to the easy (0-back) version of the n-back task. If there are signs of 
accelerated ageing in the BOLD activation for the HSR group should 
be comparable to findings from functional ageing research including 
greater frontal activity and less DMN deactivation in comparison to 
the LSR group. 
There were no significant activations for the LSR group over the 
HSR group with increasing task difficulty at the significance level of 
p<.001,unc, 5 voxel extent. When comparing activations that are 
greater in the Hard (2-back) than the Easy (0-back) task, the HSR 
group showed significant differences in activations.  MNI coordinates 
of cluster maximum derived from the analysis are displayed in Table 
8.11.  
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Table 8.11 Activations for the HSR Group > LSR Group with 
Increasing Task Difficulty on the N-back Task  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Frontal        
Middle Frontal Gyrus L 11 -22 30 -14 44 4.18 
 L 9 -12 46 30 29 3.93 
 L 10 -6 58 14 88 3.83 
 R 9 10 54 24 16 3.76 
 R 10 6 56 12 7 3.40 
Superior Frontal Gyrus L 11 -10 52 -16 14 3.57 
Temporal        
Inferior Temporal Gyrus L 20 -56 -32 -22 12 4.01 
Parietal        
Precuneus L 31 -8 -56 32 8 3.45 
Limbic        
Anterior Cingulate L 32 -8 36 18 36 3.83 
 L 32 -10 36 -12 20 3.70 
Posterior Cingulate L 29 -6 -46 10 5 3.23 
Cerebellum        
Uvula L - -20 -86 -36 37 3.66 
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted) .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  
of  s ign i f icant  voxels ;  
 
The HSR group showed higher activation in several frontal areas 
including bilateral areas in the middle frontal gyrus (~BA 9/10/11) and 
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the superior frontal gyrus (~BA 11). Activations were also higher for 
the HSR group than the LSR group on the hard version (2-back) of the 
task in the inferior temporal gyrus (~BA 20) and the precuneus (~BA 
31) in the parietal lobe. Areas in the cingulate cortex also showed 
higher activation for the HSR group on this task including the left 
anterior cingulate cortex (~BA 32) and posterior cingulate cortex (~BA 
29) along with a region in the cerebellum.  
It  is possible that the significant difference identified in 
activation between the LSR and HSR group could be due to activation 
that is relatively higher in one group than the other, deactivation that 
is relatively less in one group than the other, or activation in one 
group and deactivation in the other. The cluster maxima were 
converted to a region of interest directly from the SPM output. Using 
the MarsBaR  toolbox (Brett et al. ,  2002), beta values were extracted 
for each of these regions to determine the reason for the difference 
between the LSR and HSR group in these particular regions.  Beta 
values are the estimated response amplitude difference between the 2-
back and 0-back tasks. A positive value therefore indicates activation 
and a negative value indicates deactivation. Figure  8 .4 displays the beta 
values extracted from the significant areas determined in the statistical 
analysis.  
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Figure 8.4 Beta  va lues  fo r s ignificant  ac tiva t ions HSR>LSR on  the  2back  working memory task. A nega t ive 
va lue indica tes  deact iva t ion. The  l ine  in  the middle of  the  graph denotes  the be ta value  of  0 . SFG= superior  
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Retinopathy Group by Age Comparisons  
If retinopathy is influencing accelerated ageing of brain 
function, then a young group with high severity of retinopathy should 
show brain function that can be related to a pattern shown in ageing 
when compared to an older group with low severity of retinopathy. The 
retinopathy groups were split  by age. ANOVA was used to compare the 
young group without retinopathy and the young group with retinopathy 
to the older group without retinopathy and the older group with 
retinopathy for activations greater on the hard versus easy versions of 
the n-back task. Table 8.12 provides sample size and mean age/SD and 
age range for the young and old groups with HSR and LSR. 
 
Table 8.12 Mean Age and Sample Sizes for Retinopathy Groups by Age  
 
 Young Old 
 LSR HSR LSR HSR 
n 6 7 6 8 
Mean Age  
(SD) 
48.19 
(2.86) 
48.32 
(2.17) 
57.49 
(3.15) 
57.75 
(3.64) 
Age Range 46-52 45-53 55-63 55-61 
 
On the hard versus the easy n-back task, there was a significant 
main effect of retinopathy and age (t (23), 3.48, p<.001,unc.,  5 voxel 
extent) and a significant interaction between age and retinopathy group 
F(1,23)=9.63, p<.005 .  Post Hoc comparison indicated that the young 
HSR group showed several areas of higher activation than the old LSR 
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group, t(23), 3.48, p<.001, unc., 5 voxel extent.  MNI coordinates for 
cluster maxima, are displayed in Table 8.13. To determine the 
direction of the differences in activation between groups, beta values 
were extracted for each area in the method described previously and 
are provided in Figure 8.5. Significant differences in activation for the 
HSR group greater than the LSR group included bilateral areas across 
the dorsolateral prefrontal cortex (BA 9), left inferior parietal lobule 
(BA 40), and right post-central gyrus (BA40).  The young HSR group 
also showed several areas of activations whereas the old LSR group 
showed deactivations including the areas of BA 9 in the left middle 
frontal gyrus and left precentral gyrus, the left superior temporal gyrus 
(BA38), the left middle occipital gyrus (BA 19, 37) and the 
cerebellum. There were no greater activations for the old LSR group 
over the young HSR group.  
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Table 8.13 Young HSR > Old LSR Group Activation with increasing 
task difficulty on N-Back Task  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Frontal        
Superior Frontal Gyrus L 9 -16 40 42 23 3.88 
Precentral Gyrus L 9 -36 20 42 9 3.51 
Middle Frontal Gyrus L 9 -34 14 30 7 3.42 
 R 9 42 30 40 7 3.27 
 L 9 -46 18 34 5 3.25 
Inferior Frontal Gyrus R 9 56 16 26 9 3.42 
Occipital        
Lingual Gyrus L 18 -12 -88 -18 82 4.27 
 L 17 -4 -92 -12  3.84 
Middle Occipital Gyrus L 19 -46 -86 -2 9 3.56 
 L 37 -54 -74 2 8 3.35 
Parietal        
Postcentral Gyrus R 40 54 -36 56 10 3.79 
 L 2 -54 -30 40 24 3.70 
Inferior Parietal Lobule L 40 -52 -38 50 10 3.34 
Temporal        
Superior Temporal Gyrus L 38 -36 24 -24 7 3.26 
Limbic        
Anterior Cingulate L 32 -8 36 18 8 3.68 
Cerebellum        
Declive L - -44 -70 -24 6 3.37 
Lis ted  reg ions  a re  SPM clus ters  conta in ing  a t  leas t  5  s ign i f icant  voxels  (p  <001,  
unc) .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI space .  Lat .=  
la te ra l i ty ;  BA= approximate  Brodmann’s  a rea ;  Vox.  =  number  of  s ign i f icant  voxels  
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on the n-Back task 
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8.6.3.  Resting State: Functional Connectivity Analysis 
The hippocampal-cortical memory system (HCMS) identified by 
Vincent and colleagues (2008) is a part of the default-mode network, 
is active during passive mental states, and is internally directed. 
Regions in this system include the ventral medial PFC (vmPFC), 
posterior inferior parietal lobule, retrosplenial cortex, posterior 
cingulate and lateral temporal lobe. The vmPFC (Brodmann’s Area 10) 
was chosen as a seed ROI for resting state analysis given that this area 
was highlighted in differences between the group with and without 
retinopathy. Resting state functional activity analysis can provide 
information on whether functional connectivity for the HSR group, and 
not the LSR group, is consistent with research on the DMN in ageing. 
This finding would provide evidence of accelerated ageing in the HSR 
group. 
Whole Group Results: Ventromedial Prefrontal Cortex Seed Region 
 
MNI coordinates and regions for clusters that show activation 
that is positively correlated with activation in the ventromedial 
prefrontal cortex (vmPFC) seed (x=0,y=51,z=-7) for the whole group 
is provided in Table 8.14. Activity in the vmPFC seed was positively 
correlated with activity in a large area surrounding the seed (~BA 10) 
and in the bilateral inferior (~BA 47), and left superior (~BA 6) 
frontal lobe. Large areas were also positively correlated with the 
vmPFC seed in the left precuneus (~BA 31), several areas of the 
temporal lobe (~BA 20/21/38/39), bilaterally in the parahippocampal 
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gyrus (~BA 28), the left anterior cingulate (~BA 32), and caudate area 
of the basal ganglia. Several areas of the cerebellum were also 
positively correlated with activation in this seed.  
 
Table 8.14 Functional Connectivity for Whole Group: Regions 
Demonstrating Positive Correlation with Ventral Medial Seed Region  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
F ronta l          
Media l  Fronta l  Gyrus  R 10  2  48  -6  10001 65535 
Infer ior  Fronta l  Gyrus  R 47  32  30  -18  155 5 .65  
 R  47  30  16  -18  37  4 .08  
 L  47  -36  34  -12  8  3 .66  
 L  47  -24  12  -16  6  3 .54  
Sup.  Fronta l  Gyrus  L  6  -10  26  62  6  3 .55  
Occip i ta l          
P recuneus  L  31  -2  -68  26  4717 6 .56  
Tempora l          
In fer ior  Tempora l  Gyrus  L  20  -60  -10  -26  1021 5 .70  
Fus i form Gyrus  R 20  58  -6  -28  423 5 .80  
Angular  Gyrus  L  39  -54  -70  32  944 6 .01  
Sup.  Tempora l  Gyrus  R 39  56  -62  26  835 5 .87  
 R  38  32  20  -38  122 4 .56  
Middle  Tempora l  Gyrus  R 21  66  -20  -16  9  3 .37  
Limbic         
Parahippocampal  Gyrus  L  28  -24  -18  -20  565 5 .48  
 R  28  24  -20  -20  313 5 .24  
Anter ior  Cingula te  L  32  -6  34  28  13  3 .45  
        
 
242 
Table  8 .14  (cont . )  
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Basa l  Gangl ia         
Caudate  L  -  -14  20  6  5  3 .42  
Cerebel lum        
Decl ive  L  -  -26  -90  -30  91  4 .89  
Cerebel la r  Tons i l  R  -  8  -48  -50  331 4 .81  
Pyramis  R  -  12  -90  -40  92  4 .45  
Tuber  R  -  50  -66  -40  109 4 .03  
 L  -  -34  -80  -38  6  3 .31  
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  
of  s ign i f icant  voxels ;  Sup .=super ior  
 
MNI coordinates and regions for clusters that show activation 
that is negatively correlated with activation in the vmPFC seed 
(x=0,y=51,z=-7) for the whole group are indicated in Table 8.15. 
Negative correlations were found in the right inferior frontal (~BA 
44), bilateral middle frontal (~BA 46), superior frontal (~BA 6), and 
bilateral precentral (~BA 6/9) gyri as well as a right sub-gyral area 
(~BA 10) in the frontal lobe. Areas of the left occipital lobe (~BA 
18/19), temporal lobe (~BA 19/37), parietal lobe (~BA 2/7/40), 
cingulate gyrus (~BA 30/31) were also indicated. Sub-lobar, brainstem 
and the cerebellum also showed negative correlation to the seed ROI 
activation.  
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Table 8.15 Functional Connectivity for Whole Group: Regions 
Demonstrating Negative Correlation with Ventral Medial Seed Region  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Fronta l         
In fer ior  Fronta l  Gyrus  R 44  54  16  12  2252 5 .79  
Middle  Fronta l  Gyrus  L  46  -46  38  26  1129 6 .32  
 R  46  40  48  20  263 4 .68  
 R  6  38  -2  48  7  3 .83  
 R   6  48  6  50  32  3 .69  
Precentra l  Gyrus  L   6  -52  -6  28  11  3 .59  
Precentra l  Gyrus  R 9  36  6  36  12  3 .58  
Occip i ta l         
Middle  Occip i ta l  Gyrus  L  19  -54  -68  -12  659 6 .01  
 L   19  -36  -88  14  28  3 .71  
Lingual  Gyrus  L  18  -16  -78  0  361  4 .91  
Cuneus  L  18  -2  -82  10  18  3 .36  
Tempora l         
Middle  Tempora l  Gyrus  R 37  56  -62  -6  123  4 .93  
 R  19  42  -78  18  105 4 .53  
Fus i form Gyrus  L  37  -48  -50  -20  9  3 .41  
Par ie ta l         
In fer ior  Par ie ta l  Lobule  L  40  -60  -36  44  11480 7 .39  
Pos tcent ra l  Gyrus  R 2  60  -32  42  4336 6 .49  
 L  7  -20  -52  72  7  3 .60  
Limbic         
C ingula te  Gyrus  L  31  -12  -30  38  56  4 .62  
 R  31  16  -32  42  52  3 .82  
Pos ter ior  Cingula te  R  30  18  -70  4  213  4 .21  
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Table  8 .15  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Sub-Lobar         
C laus t rum R -  36  -2  10  38  4 .23  
Thalamus  R -  10  -22  -2  15  3 .81  
 L  -  -20  -10  12  5  3 .36  
Lent i form Nucleus  L  -  -14  2  4  7  3 .50  
Insu la  R  13  40  -16  -12  13  3 .39  
Insu la  R  13  44  -38  18  7  3 .31  
Midbra in         
Bra ins tem L -  -4  -28  -10  7  3 .36  
Cerebel lum        
Decl ive  L  -  -30  -60  -28  347 5 .15  
 R  -  26  -68  -24  407 5 .06  
Inf .  Semi-Lunar  Lobule  R -  22  -74  -50  107 5 .07  
Inf .  Semi-Lunar  Lobule  L  -  -20  -72  -50  60  4 .31  
Tuber  L  -  -42  -58  -34  73  4 .39  
 R  !  48  -56  -32  7  3 .72  
Cerebel la r  Tons i l  L  !  -34  -56  -48  8  3 .76  
Culmen L -  -36  -44  -36  12  3 .61  
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  of  
s ign i f ican t  voxels ;  Inf=infer ior  
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Retinopathy Group Results Ventromedial Seed Region  
 Results were analyzed separately for the HSR and LSR groups to 
determine whether there were noticeable differences in the positive 
and negatively correlated activations for one or both of these groups in 
comparison to the pattern for the whole group. Less connectivity for 
the HSR group than the LSR or whole group would provide evidence 
of accelerated ageing in this group. Areas with positive correlation to 
activation in the vmPFC seed ROI for the LSR group are indicated in 
Table 8.16. The LSR group showed a similar pattern of positive 
correlation with activation in the ventromedial PFC seed to the whole 
group including a large area surrounding the seed in the right medial 
frontal gyrus (~BA 10), bilateral inferior frontal gyrus (~BA 47), left 
precentral gyrus (~BA 6) and right superior frontal gyrus (~BA 18), 
and similar bilateral regions as the whole group in the temporal lobe 
(~BA 21/38/39). A positive correlation was also seen for activation in 
bilateral parahippocampal gyrus (~BA 28/30/35) and right cingulate 
(~BA 18), bilateral thalamus, right caudate and bilateral areas of the 
cerebellum, also identified in the whole group analysis.  Areas near the 
hippocampus (BA 28), vmPFC (BA 10) and lateral temporal lobe (BA 
39) are positively associated with the HCMS, active in rest.  
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Table 8.16 Functional Connectivity for LSR Group: Regions 
Demonstrating Positive Correlation with Ventral Medial Seed Region  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Fronta l         
Media l  Fronta l  Gyrus  R 10  12  54  -2  7407 6 .33  
Inf .  Fronta l  Gyrus  R 47  32  30  -18  47  4 .28  
 R  47  24  14  -24  13  3 .57  
 L  47  -24  10  -16  5  3 .66  
Precentra l  Gyrus  L  6  -36  -22  70  8  3 .55  
Super ior  Fronta l  Gyrus  R 8  10  46  46  6  3 .69  
Tempora l         
Sup .  Tempora l  Gyrus  R 39  56  -60  26  718 4 .76  
 L  38  -40  18  -38  57  4 .51  
 R  38  30  18  -36  9  3 .64  
 L  38  -30  8  -32  15  3 .58  
Inf .  Tempora l  Gyrus  R 21  62  -4  -24  296 5 .56  
Middle  Tempora l  Gyrus  L  21  -64  -14  -18  293 4 .98  
Angular  Gyrus  L  39  -54  -70  32  588 4 .96  
Limbic         
C ingula te  Gyrus  R 31  4  -52  26  3847 5 .86  
Parahippocampal  Gyrus  L  35  -28  -20  -24  434 5 .07  
 R  28  24  -16  -26  209 4 .49  
 L  28  -16  -8  -16  8  3 .86  
 L  30  -14  -38  -8  15  3 .73  
 L   -26  -6  -14  10  3 .73  
Sub- lobar         
Thalamus  L  -  -2  -14  6  41  4 .27  
 R  -  2  -2  8  10  3 .75  
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Table  8 .16  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Basa l  Gangl ia         
Caudate  R   16  20  10  10  3 .60  
Cerebel lum        
Cerebel la r  Tons i l  L  *  -4  -56  -46  159 4 .57  
Uvula  R  -  22  -92  -34  22  4 .18  
Tuber  L  -  -20  -88  -42  53  3 .67  
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  of  
s ign i f ican t  voxels ;  Inf=infer ior ;  Sup=Super ior  
 
For the HSR group, activations that were positively correlated 
with activity in the vmPFC seed ROI (shown in Table 8.17) included a 
large area in the right medial frontal gyrus surrounding the seed (~BA 
10), right inferior part of the medial frontal gyrus (~BA 25), right 
middle frontal gyrus (~BA 11), and bilateral inferior frontal gyrus 
(~BA 47). Activations also included the right cuneus (~BA 17), 
several areas bilaterally in the temporal gyrus (~BA 20/21/38/39), left 
inferior parietal lobule (~BA 39), right posterior cingulate (~BA 30), 
bilateral anterior cingulate (~BA 24/25), bilateral parahippocampal 
gyrus (~BA 28/37) and several areas of the cerebellum.  
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Table 8.17 Functional Connectivity for HSR Group: Regions 
Demonstrating Positive Correlation with Ventral Medial Seed Region  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  
score  
   x  y  z    
Fronta l         
Media l  Fronta l  Gyrus  R 10  2  48  -8  3659 7 .26  
 R  25  2  20  -18  10  4 .76  
Middle  Fronta l  Gyrus  R 11  32  36  -18  59  4 .49  
Infer ior  Fronta l  Gyrus  L  47  -32  30  -14  50  4 .33  
 L   47  -40  22  -18  22  3 .66  
 R  47  28  12  -18  9  3 .47  
Occip i ta l         
Cuneus  R 17  12  102 0  9  3 .43  
Tempora l         
Middle  Tempora l  Gyrus  L  21  -56  -10  -22  163 4 .73  
 L  21  -46  10  -40  25  4 .02  
 R  39  56  -68  28  82  3 .94  
 R  21  58  4  -26  35  3 .87  
 R  38  44  12  -46  20  3 .75  
 L  21  -50  8  -32  5  3 .42  
Sup.  Tempora l  Gyrus  L  38  -36  16  -28  38  4 .45  
 R  38  44  22  -26  6  3 .31  
 R  38  34  22  -38  22  3 .30  
Infer ior  Tempora l  Gyrus  L  20  -52  -2  -40  8  3 .65  
 R  20  50  -12  -32  5  3 .50  
Par ie ta l         
In fer ior  Par ie ta l  Lobule  L  39  -46  -72  40  278 4 .44  
Limbic         
Pos ter ior  Cingula te  R  30  6  -52  16  1701 5 .07  
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Table  8 .17  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  
score  
   x  y  z    
Anter ior  Cingula te  L  25  -2  2  -10  19  3 .83  
 L  25  -6  10  -10  12  3 .82  
 R  25  4  12  -8  35  3 .68  
 R  24  8  28  16  12  3 .33  
Parahippocampal  Gyrus  R 37  36  -38  -10  25  4 .47  
 L  28  -22  -18  -22  13  3 .53  
 R  28  22  -26  -14  5  3 .50  
Sub-Lobar         
Hypotha lamus  R -  10  -6  -14  36  3 .82  
Basa l  Gangl ia         
Caudate  R  -  14  16  12  15  3 .79  
 L  -  -14  18  4  5  3 .39  
 R  -  14  26  4  10  3 .39  
Amygdala  L  -  -22  -8  -16  12  3 .68  
Cerebel lum        
Decl ive  L  -  -28  -88  -30  23  4 .17  
Cerebel la r  Tons i l  L  -  14  -50  -44  65  4 .15  
Uvula  R -  26  -82  -34  45  3 .61  
Pyramis  L  -  -10  -86  -42  6  3 .34  
 R  -  38  -76  -44  5  3 .24  
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  of  
s ign i f ican t  voxels ;  Sup .=super ior .  
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The HSR group showed similar regions of positive correlation 
with activation in the ventromedial PFC to the whole group and LSR 
group, however the activation was not as extensive within each 
particular region (smaller voxel extent with many areas under 10 
voxels) and was present across more areas. This can be seen when the 
images of positively correlated activations are combined in Figure 8.6. 
The figure shows the green areas (LSR) surrounding smaller yellow 
areas (LSR & HSR) showing combined centres of activation 
illustrating the larger extent of activation for the LSR group.  Small red 
areas, indicate activity outside these common centres of activation 
particular to the HSR group.  
 
    
Figure 8.6 Combined activation for LSR (green) and HSR (red) group 
positively correlated with activation in the ventromedial seed region. 
Yellow regions indicate combined areas of activation 
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For the LSR group, activations that were negatively correlated 
with activity in the vmPFC seed ROI (shown in Table 8.18) included 
the precentral gyrus (~BA 6/44), middle frontal (~BA 6/10/46), 
superior frontal (~BA 6), and inferior frontal gyri (~BA 9/47) in the 
frontal lobe. Other areas included areas such as bilateral middle 
occipital gyri (~BA 19) and left lingual gyrus and left cuneus (~BA 
18) in the occipital lobe. Areas in the temporal lobe included bilateral 
superior temporal gyrus (~BA 22) and the postcentral gyrus (~BA 
2/3/7). The inferior parietal lobule (~BA 40), bilateral cingulate cortex 
(~BA 24/30/31), sub-lobar areas and regions of the cerebellum were 
also negatively correlated with activation in the seed region in the 
LSR group.  
 
Table 8.18 Functional Connectivity for LSR Group: Regions 
Demonstrating Negative Correlation with Ventral Medial Seed Region  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Frontal        
Precentral Gyrus L 44 -48 10 12 1995 4.98 
 L 6 -44 -16 30 44 3.97 
Middle Frontal Gyrus L 46 -46 36 26 1025 5.64 
 R 10 46 48 -4 159 4.25 
 R 10 32 56 10 98 4.11 
 R 6 40 0 44 13 3.93 
 R 6 48 4 50 26 3.91 
 L 6 2 14 50 442 4.79 
Superior Frontal Gyrus R 6 26 6 60 152 4.62 
 L 6 -10 -10 72 21 3.86 
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Table  8 .18  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Inferior Frontal Gyrus R 9 50 6 36 25 3.64 
 R 9 44 10 24 18 3.55 
 L 47 -32 24 -10 5 3.40 
Occipital        
Middle Occipital Gyrus L 19 -54 -64 -12 268 4.88 
 R 19 38 -78 16 45 4.23 
Lingual Gyrus L 18 -16 -76 0 80 3.78 
Cuneus R 18 10 -76 14 28 3.94 
Temporal        
Superior Temporal Gyrus R 22 54 8 4 1227 5.65 
 L 22 -56 -12 8 59 4.05 
Parietal        
Inferior Parietal Lobule L 40 -40 -46 46 3051 5.92 
Postcentral Gyrus R 2 58 -30 44 2233 5.79 
 L 7 -20 -52 70 7 3.72 
 R 3 32 -36 70 5 3.72 
Limbic        
Cingulate Gyrus R 31 14 -24 40 18 3.52 
 L 24 -10 6 36 17 3.86 
 L 31 -14 -28 38 8 3.42 
 R 24 8 -4 46 6 3.79 
 R 24 8 8 36 10 3.63 
Posterior Cingulate R 30 20 -68 6 19 3.68 
Sub-Lobar        
Claustrum R - 36 -16 -6 5 3.21 
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Table  8 .18  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Midbrain        
Red Nucleus L - -6 -20 -12 6 3.48 
Cerebellum        
Declive R - 26 -68 -24 162 5.62 
 R - 8 -78 -24 124 4.31 
 L - -16 -58 -22 19 3.86 
 R - 10 -62 -18 13 3.48 
Pyramis L - -10 -76 -38 77 4.08 
Culmen L - -40 -50 -32 471 4.77 
 R - 36 -56 -32 78 4.88 
 L - -4 -66 -6 9 3.43 
Inf. Semi-Lunar Lobule R - 22 -72 -50 58 3.92 
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  <001,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion;  Vox.  =  number  
of  s ign i f icant  voxels .  
 
For the HSR group, activations that were negatively correlated 
with activity in the vmPFC seed ROI (shown in Table 8.19) included 
the precentral gyrus (~BA 6), middle frontal (~BA 6/46), superior 
frontal (~BA 6/9), and inferior frontal gyri (~BA 9/46). Other areas 
included those in the occipital region including the bilateral middle 
occipital gyri (~BA 19), left cuneus (~BA 17/18), and right precuneus 
(~BA 31).  
 
254 
Table 8.19 Functional Connectivity for HSR Group: Regions 
Demonstrating Negative Correlation with Ventral Medial Seed Region  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Fronta l         
P recentra l  Gyrus  L  6  -46  4  42  254 4 .48  
 R  6  32  8  34  27  4 .01  
 R  6  50  -8  28  8  3 .58  
Middle  Fronta l  Gyrus  L  46  -44  36  30  105 4 .25  
 R  6  28  -2  52  17  3 .78  
 R  6  22  14  62  25  3 .57  
 R  46  42  48  20  5  3 .34  
 R  6  40  4  58  5  3 .29  
Infer ior  Fronta l  Gyrus  L  9  -50  14  24  180 4 .65  
 L  46  -50  38  12  13  3 .67  
 L  46  -48  48  8  6  3 .63  
Super ior  Fronta l  Gyrus  L  9  -36  36  32  8  3 .43  
 L  6  -26  6  56  5  3 .34  
Occip i ta l         
Middle  Occip i ta l  Gyrus  R 19  56  -64  -10  44  3 .94  
 R  19  40  -82  8  20  4 .01  
 L  19  -38  -86  16  7  4 .03  
Cuneus  L  17  -18  -80  6  34  4 .12  
 L  18  -4  -82  24  8  3 .59  
Precuneus  R 31  24  -66  22  10  3 .47  
Tempora l         
Super ior  Tempora l  Gyrus  L  39  -52  -54  6  326  4 .63  
 L  22  -56  8  -4  44  4 .37  
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Table  8 .19  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Super ior  Tempora l  Gyrus  L  22  -62  -42  16  26  3 .56  
 R  22  64  -4  8  14  3 .83  
 R  22  56  -54  4  12  3 .96  
 L  22  -60  8  4  9  3 .82  
 R  22  58  14  -6  6  3 .34  
Middle  Tempora l  Gyrus  R 39  44  -78  20  7  3 .36  
Par ie ta l         
P recuneus  R 7  20  -66  44  1610 4 .99  
 L  7  -8  -76  48  42  4 .01  
Infer ior  Par ie ta l  Lobule  L  40  -62  -36  44  1918 5 .01  
Limbic         
C ingula te  Gyrus  R 32  10  18  46  674 4 .38  
 L  31  -14  -32  42  11  3 .50  
Sub-Lobar         
Insu la  R  13  48  10  2  366  5 .19  
Claus t rum L -  -34  6  2  48  4 .24  
 R  -  38  -8  10  19  4 .04  
Cerebel lum        
Decl ive  L  -  -30  -60  -28  23  4 .02  
Uvula  R -  18  -74  -42  8  3 .97  
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  5  s igni f icant  voxels  (p  < .001,  
uncorrec ted) .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima and  are  repor ted  in  
MNI space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  
of  s ign i f icant  voxels  
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Negatively correlated activation was also found in the temporal 
gyrus in regions including the bilateral superior temporal gyrus (~BA 
22), and middle/superior temporal gyrus (~BA 39). Other regions 
included the inferior parietal lobule (~BA 40), precuneus (~BA 7), and 
bilateral cingulate cortex (~BA 31/32). Sub-lobar areas included the 
claustrum and insula (~BA 13). Bilateral regions of the cerebellum 
were also indicated.  
Negative correlations were less focused for the HSR group 
showing in a greater number of activated areas with small extent size. 
This can be seen when the images of negatively correlated activations 
are combined in Figure 8.7. The figure shows the green areas (LSR) 
ranging across wider regions (higher extent values). Small red areas 
indicate scattered activity outside these common centres of activation 
particular to the HSR group. Yellow areas indicate sections negatively 
correlated with activation in the vmPFC for both the LSR and HSR 
groups.   
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Figure 8.7 Combined activation for LSR (green) and HSR (red) group 
negatively correlated with activation in the ventromedial seed region. 
Yellow regions indicate combined areas of activation   
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  When comparing images combining the positively (red) and 
negatively (green) correlated activity with the vmPFC seed (Figure 
8.8), it  is seen that the LSR looks similar to the whole group in the 
extent of areas correlated with the seed region. On the other hand the 
HSR group shows less extensive patterns of connectivity comparison 
to the whole group. More limited areas of activation were seen in the 
anterior part of the frontal lobes, posterior/parietal and temporal 
regions. Limited deactivation was seen in the posterior cerebellum. On 
the right and left sides of the cortex, there was limited activation in 
frontal and parietal areas and less extensive deactivation in 
sensory/motor areas. On the superior part of the cortex, there were less 
extensive areas of activation in frontal and parietal regions. There was 
a lack of deactivation seen in the cerebellum and more limited 
activation in frontal and posterior regions on the inferior surface. 
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a c b 
Figure 8.8 Activations associated with positive (red) and negative (green) correlation with activity in ventromedial 
seed for the whole group (a) LSR group (b) and HSR group (c).  The left side of the brain is  on the left side of each 
image. From left to right and top to bot tom the 8 images in each panel are left medial, right medial,  posterior, 
anterior, left la teral,  right lateral , inferior,  and superior 
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8.6.4.  Inspection Time 
Behavioural Results 
Of the 30 participants who took part in the fMRI scanning, not 
all  were included in the analysis of the inspection time test.    The 
threshold of inclusion for the data of a particular participant was 
above a threshold of 90% correct (31.5/35) for highest duration (97ms) 
and above chance (17.5/35) on the shortest exposure. Four participants 
from both the LSR group and the HSR group were excluded from the 
2n d level analysis leaving 11 participants in both the LSR group and 
HSR groups.  
Inspection Time performance was compared across levels of the 
task and between the HSR and LSR groups. Behavioural results were 
analyzed to determine any systematic differences between groups. 
Results of repeated measures ANOVA showed that there was a 
significant difference in accuracy with increasing accuracy as the 
length of stimulus exposure increased F(1.64, 34.52) = 36.2, p< .001 
(Greenhouse-Geisser corrected df used due to violation of assumption 
of sphericity). Contrasts between each increasing level of stimulus 
exposure were significantly different, 31ms > 15ms, F(1,21)=13.05, 
p<.01, r=.62; 47ms>31ms, F(1,21)=30.70, p<.001, r=.77; 81ms>47ms, 
F(1,21)=15.21,p<.01, r=.65. This was true for all  except the last 2 
given near perfect responses in both the 81 and 97 ms exposure, 
F(1,21)=.148, p=.70, r= .08, as shown in Figure 8.9 .  In line with 
Waiter and colleagues (2009), easy trials were defined as those at 
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ceiling (32/35) including 47, 81, and 97 ms and hard trials were 
defined as those above chance (17.5/35) and below ceiling (32/35) 
including 15 and 31. Note on 31 ms the LSR group achieved a mean of 
31.55 – at 90% - possibly 15 ms the only “hard” level for comparisons. 
 
 
Figure 8.9  Change in Accuracy with Increasing Stimulus Exposure on 
the Inspection Time Test 
 
Overall,  participant response time decreased with increasing 
stimulus exposure time, F(2.06, 43.24)=29.79,p<.001 (Greenhouse-
Geisser corrected df used due to violation of assumption of sphericity) 
shown in Figure 8.10 .  Contrasts between increasing level of stimulus 
exposure were significantly different, 31ms > 15ms, F(1,21)=18.05, 
p<.001, r= .68; 81ms>47ms, F(1,21)=12.68,p<.01, r=0.61 with a trend 
in this direction for 47ms>31ms, F(1,21)=4.30, p=.051, r=0.41. At the 
2 longest exposure levels, response time was equivalent, F(1,21)=.311, 
p=.58, r=.12. 
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Figure 8.10  Change in Response Time with Increasing Stimulus 
Exposure for the Inspection Time Test 
 
 
 
The LSR and HSR groups were compared on performance at 
each level of the inspection time test.  Results are displayed in Table 
8.20. Although the HSR group consistently displayed a numerically 
higher response time than the LSR group, this time was not 
statistically different. Results of t-test indicated there was no 
difference in the accuracy of responses between the LSR and HSR 
group at any stimulus duration.  
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Table 8.20 Comparison of Retinopathy Group on Inspection Time 
Accuracy and Response Time at each Stimulus Duration  
 
 
IT Stimulus 
Duration 
(ms) 
Measure LSR (n=11) 
 Mean (SD) 
HSR (n=11) 
Mean (SD) 
t  (20) p 
 
15 
 
# Correct 29.36 (4.4) 27.36 (4.6) 1.04 .32 
RT ms 426.97 (90.1) 473.09 (88.1) -1.21 .28 
31 # Correct 31.55 (2.3) 30.82 (2.3) .747 .46 
RT ms 393.75 (67.2) 444.97 (67.6) -1.78 .09 
47 # Correct 33.27 (1.8) 33.18 (2.3) .102 .92 
RT ms  388.64 (71.0) 431.82 (76.1) -1.38 .28 
81 # Correct 34.73 (.65) 34.36 (1.0) .994 .34 
RT ms  375.85 (56.9) 403.65 (60.9) -1.11 .28 
97 # Correct 34.73 (.47) 34.55 (1.0) .531 .60 
RT ms  377.3 (71.2) 406.62 (57.0) -1.07 .30 
IT=Inspect ion  Time;  RT=Response  Time in  ms  
 *p< .05 ,  2 - ta i led  
 
 
fMRI Group Results Inspection Time 
 
 Whole group results were examined to determine the areas of 
negative and positive correlation with task difficulty.  Cluster maxima 
greater than a voxel extent of 10 and threshold of p<.005, uncorrected 
were identified.  Those areas of activation with a negative correlation 
to stimulus duration (increasing difficulty) included primarily small 
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areas in the frontal regions (medial frontal gyrus, superior frontal 
gyrus, and cingulate cortex (Table 8.21) shown in Figure 8.11. 
Figure 8.11 Activation on Inspection Time task negatively correlated with 
increasing duration (increasing task difficulty) whole group 
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Table 8.21 Regions with negative correlation to stimulus duration 
(increasing task difficulty) on inspection time for whole group  
 
Region  Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x y  z    
Frontal        
Inferior Frontal Gyrus L 47 -40 18 -6 109 4.40 
Inferior Frontal Gyrus L 47 -32 20 -10  3.05 
Superior Frontal Gyrus R 8 6 30 50  3.15 
Superior Frontal Gyrus L - -30 48 6  2.88 
Middle Frontal Gyrus L 10 -38 54 8 19 3.22 
Medial Frontal Gyrus R 9 2 36 36 20 2.77 
Limbic        
Insula L 13 -40 16 8  3.20 
Cingulate Gyrus L 32 -4 24 42 226 3.63 
Cingulate Gyrus R 32 8 22 36  3.32 
Claustrum L - -32 18 4 12 2.90 
Brainstem        
Red Nucleus L - 0 -20 -20 23 3.59 
MNI coord ina tes  (x ,y ,z)  re fer  to  peak  voxels  wi th in  c lus ter  maximum repor ted  
p<.005,  10  voxel  ex ten t .  MNI space .  Lat .=  la te ra l i ty ;  BA= approximate  
Brodmann’s  loca t ion;  Vox.  =  number  of  s igni f icant  voxels ;  
 
There were several large areas indicating a positive correlation 
in BOLD activation with increasing stimulus duration (decreased 
difficulty), primarily in posterior regions (superior temporal gyrus, 
middle occipital gyrus, precuneus, posterior cingulate) and some 
frontal areas (superior and middle frontal gyrus). These areas are 
listed in Table 8.22 and shown in Figure 8.12 
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Figure 8.12 Activation on Inspection Time task positively correlated with 
increasing duration (decreasing task difficulty) whole group 
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Table 8.22 Regions with negative correlation to stimulus duration 
(increasing task difficulty) on inspection time for whole group  
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Frontal        
Inferior Frontal Gyrus L 47 -42 24 -20 39 3.21 
 L 47 -30 32 -20 28 3.02 
 R 46 44 38 8 12 2.83 
Medial Frontal Gyrus L 10 -12 58 20 2107 4.61 
 L 9 -14 42 36 20 3.16 
Middle Frontal Gyrus R 8 24 36 46 316 4.56 
 L 8 -26 30 42 1087 4.31 
 R 6 28 -10 56 31 3.80 
 L 6 -18 -12 64 14 3.54 
 R 8 48 16 46 23 3.06 
Superior Frontal Gyrus L 6 -16 -6 74 26 3.15 
Paracentral Lobule L 5 -24 -44 48 29 3.44 
Precentral Gyrus L 6 -60 0 10 38 3.92 
 R 4 58 -16 36 136 3.64 
 L 6 -42 -20 64 57 3.27 
 R 4 24 -24 54 13 3.01 
 L 6 -60 -12 40 25 2.92 
Temporal        
Fusiform Gyrus L 20 -46 -2 -26 20 3.31 
 R 20 40 -22 -28 14 3.18 
Inferior Temporal Gyrus R 20 44 -14 -34 16 3.57 
Middle Temporal Gyrus L 21 -44 8 -38 14 3.23 
 R 39 32 -60 26 21 2.94 
Superior Temporal Gyrus R 38 56 12 -20 19 3.50 
Superior Temporal Gyrus L 22 -44 -24 -8 16 3.06 
268 
 
Table  8 .22  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Parietal        
Postcentral Gyrus R 3 40 -28 58 25 3.01 
Precuneus L 31 -12 -54 28 24171 5.76 
Superior Parietal Lobule L 7 -22 -60 66 14 3.26 
Limbic        
Amygdala L - -30 -4 -28 169 4.16 
Anterior Cingulate R 32 14 46 -10 15 3.62 
 L 24 0 20 16 50 3.25 
Sub-Lobar        
Caudate L - -18 -6 22 24 3.21 
 L - -10 4 16 11 2.81 
Insula R 13 38 2 18 27 3.74 
 L 13 -34 -28 20 47 3.30 
 R 13 38 -10 18 11 3.26 
 L 13 -44 -10 8 14 3.01 
Lentiform Nucleus L - ' -18 -6 143 4.19 
 L - -20 6 8 110 3.59 
 L - -22 -10 2 17 3.40 
Thalamus L - -20 -26 6 23 3.31 
  L - -8 -14 2 22 3.24 
Cerebellum        
Cerebellar Tonsil L - -28 -44 -50 52 3.67 
  L - -48 -48 -42 16 3.18 
  R - 28 -54 -42 10 3.12 
Inferior Semi-Lunar Lobule L - -8 -72 -48 35 3.31 
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Table  8 .22  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Pyramis L - -44 -72 -42 40 3.34 
 R - 46 -68 -44 16 2.97 
Culmen R - 14 -48 -16 20 3.18 
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  10  s igni f icant  voxels  (p  <005 ,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  of  
s ign i f ican t  voxels ;  Inf=infer ior  
 
 
 
 
When comparing activation for the LSR and HSR group related 
to task difficulty there was greater activation for the LSR group when 
stimulus duration increased (decreasing task difficulty) in several 
areas. Cluster maxima are reported in Table 8.23 and shown in Figure 
8.13.  
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Figure 8.13 Activation on Inspection Time task positively correlated with 
increasing duration (decreasing task difficulty) LSR group >HSR group 
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Table 8.23  Regions with positive correlation to stimulus duration 
(decreasing task difficulty) on inspection time for LSR group>HSR group 
 
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Frontal        
Inferior Frontal Gyrus L 47 -40 24 2 21 3.44 
  R 47 32 30 8 24 3.30 
Medial Frontal Gyrus R 25 12 30 -14 59 3.69 
  R 9 4 46 26 36 3.49 
Middle Frontal Gyrus L 10 -40 40 12 12 2.94 
  R 10 30 36 20 13 2.87 
Superior Frontal Gyrus L 8 -24 22 56 28 3.44 
Occipital        
Inferior Occipital Gyrus R 18 40 -86 -8 14 2.92 
Fusiform Gyrus R 37 40 -44 -18 21 3.74 
  R 37 38 -62 -14 31 3.42 
Temporal        
Inferior Temporal Gyrus L 20 -36 -6 -40 42 3.81 
Middle Temporal Gyrus R 21 60 2 -18 28 3.58 
  L 21 -48 -50 2 11 3.33 
Sub-Gyral L 37 -44 -52 -10 41 3.94 
Superior Temporal Gyrus R 41 44 -36 -2 29 3.50 
  L - -46 -24 2 42 3.31 
  R 22 58 -42 12 27 3.25 
Parietal        
Inferior Parietal Lobule L 40 -34 -34 36 32 3.57 
  L 40 -34 -56 34 18 2.85 
Postcentral Gyrus L 40 -60 -22 22 31 3.31 
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Table  8 .23  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
   x  y  z    
Precuneus L 7 -18 -50 40 27 4.07 
  R 7 26 -48 42 61 3.89 
  L 7 -14 -58 50 16 2.82 
Limbic        
Anterior Cingulate R 24 2 26 12 42 3.86 
  L 24 -10 30 4 16 3.36 
  L 32 -4 40 0 12 3.14 
Cingulate Gyrus L 31 -20 -44 28 110 4.52 
  R 24 18 -2 48 107 4.11 
  R 31 12 -36 40 124 3.94 
  R 24 8 4 32 21 3.67 
  L 31 -10 -26 40 49 3.65 
  L 31 -24 -26 40 20 3.34 
  L 24 -14 -6 40 21 3.07 
Parahippocampal Gyrus L 19 -22 -58 -12 21 3.40 
  L 28 -20 -14 -14 10 3.02 
Uncus R 28 18 -2 -30 28 3.58 
Sub-Lobar        
Caudate L - -8 18 18 13 3.43 
Claustrum R - 32 -18 20 113 4.10 
Insula L 13 -32 16 18 24 3.46 
  R 13 38 -4 20 22 3.19 
Lentiform Nucleus L - -24 -14 10 13 2.80 
Cerebellum        
Culmen R - 10 -34 -34 186 3.81 
  R - 4 -32 -20 15 3.49 
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Table  8 .23  (cont . )  
Region Lat  BA MNI (x ,y ,z )  Vox.  Z  score  
  L - -18 -26 -24 19 3.26 
  R - 4 -58 -2 13 2.96 
Nodule L - -8 -64 -34 205 3.74 
Cerebellar Tonsil R - 22 -44 -42 65 3.66 
Lis ted  reg ions  are  SPM clus ters  conta in ing  a t  leas t  10  s igni f icant  voxels  (p  <005,  
uncorrec ted .  MNI coord ina tes  (x ,y ,z )  re fer  to  c lus te r  maxima repor ted  in  MNI 
space .  Lat .=  la te ra l i ty ;  BA= approximate  Brodmann’s  loca t ion ;  Vox.  =  number  of  
s ign i f ican t  voxels ;  Inf=infer ior  
 
  
The LSR group showed higher activation with decreasing stimulus 
duration  (increasing difficulty) in only one area in the cerebellum, the 
right culmen (x=12,y=-32,z=-12).  
8.7.  Discussion 
8.7.1.  N-Back 
Functional MRI results for the whole group indicated several 
areas of activation with increasing task difficulty on the n-back task. 
The group shows similar areas of activation with increasing task 
difficulty on a multi-scanner evaluation of the n-back using a similar 
block design (Gradin et al.  2010). Between group results indicate that 
the group with high severity of retinopathy showed greater activity 
than the group with low severity of retinopathy in several frontal areas 
and less deactivations in areas included in the default mode network. 
These regions are part of those identified through resting state analysis 
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to be part of the anterior default mode network (DMN) by Damoiseaux 
and colleagues (2008) including the superior and middle frontal gyri 
(BA 11) and near the areas involved in task-induced deactivations in 
the Persson and colleagues (2007) study including the left precuneus 
BA 31 (11 -52 49), and right medial frontal BA 9 (11 49 21). In 
general this is consistent with the finding of absent or less 
deactivation in DMN of older groups in comparison to younger groups.  
The combination of retinopathy and age indicated that younger 
people with high severity of retinopathy show activations in 
comparison to deactivations across a number of areas in relation to the 
older group with low severity of retinopathy, supporting the 
hypothesis of accelerated ageing. The fact that there were no areas of 
greater activity for the older adults with low severity of retinopathy 
over the younger adults with high severity of retinopathy also supports 
the idea that the retinopathy places an added burden to BOLD function 
over age.  
8.7.2.  Functional Connectivity: Resting State fMRI 
Resting state fMRI methods were used to explore the possible 
differences in functional connectivity between the low severity and 
high severity retinopathy groups and how these differences compare to 
the results found in ageing research.  A seed region was identified 
through research on the hippocampal cortical memory system, part of 
the default mode network (Vincent et al. ,  2008).  
Results for the whole group indicated both anterior and posterior 
regions active in resting state that included those identified by 
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Damoiseaux and colleagues (2008) in their study of functional 
connectivity in ageing. Investigation of the positive and negative 
correlations to activation in the vmPFC seed ROI indicated that,  
consistent with evidence in ageing research, the group with high 
severity retinopathy showed lower connectivity (less extensive 
connections, scattered smaller regions of activation) than the group 
with lower severity retinopathy or the group as a whole. They also 
showed a lack of correlations in the cerebellum which also contributes 
in the DMN (Habas et al. ,  2009). This is consistent with the evidence 
of less functional connectivity and less overall activity in resting state 
(Reuter-Lorenz, & Park, 2010) in normal cognitive ageing and the 
findings from Damoiseaux and colleagues (2008) of lower BOLD 
activity in older compared to younger subjects in the anterior and 
posterior resting state networks. A recent study of resting state in 
older adults with T1DM also came to the conclusion of decreased 
connectivity in resting state networks for individuals with proliferative 
retinopathy in comparison to controls (Van Duinkerken et al. ,  2011). 
8.7.3.  Inspection Time 
Although in similar regions, the activation positively correlated 
with task difficulty was not as extensive in frontal regions for the 
study group in comparison to the research by Waiter and colleagues 
(2008). There was  also more extensive activation in posterior regions. 
In the Waiter and colleagues (2008) study, they compared results of 
sustainers, those who had maintained cognitive function as measured 
at age 11, and decliners, those who showed a decline in cognitive 
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function since age 11, and results from a younger age group. Although 
not as extensive as in the Waiter and colleagues (2008) study, the low 
severity retinopathy group, like the sustainers, showed a positive 
correlation in activation with increasing stimulus duration (decreasing 
task difficulty). In the Waiter and colleagues (2008) study, the 
decliners showed an absence of positively correlated activity with 
decreasing task difficulty. There were no areas in which the high 
severity retinopathy group, like the decliners, showed greater 
activation over the low severity retinopathy group with decreasing task 
difficulty. The group with higher severity retinopathy showed a similar 
pattern to the decliner group and the low severity retinopathy a similar 
pattern to the sustainer group. This is in line with the hypothesis that 
the high severity retinopathy accelerates decline in brain function.  
8.7.4.  Conclusions 
What do the results tell  us about cognitive ageing in T1DM and its 
relationship with theories of cognitive ageing? 
In the Scaffolding Theory of Ageing and Cognition (STAC), 
Park and Reuter-Lorenz (2009) argue that increased prefrontal 
recruitment and low levels of default mode network engagement 
should be considered protective of cognitive function in ageing and 
increases the ability of the ageing brain to use complementary, and 
alternative neural circuits to achieve a cognitive goal. These 
researchers view this as “self-generated support of cognitive function” 
(Park & Reuter-Lorenz, 2009, p. 175). Indeed, in the current study 
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there was no difference between the cognitive performance of those 
with high and low severity retinopathy on either the inspection time or 
the n-back tasks completed in the fMRI. They suggest that middle-aged 
adults who show scaffolding that is like that of older adults may be at 
risk for poorer cognitive outcomes and age-related deficits and is a 
response to underlying vulnerability that may be sub-clinical.  In the 
study group, although matched in age, those with high severity of 
retinopathy appear to be more like older adults in their pattern of task 
activations/deactivations and functional connectivity. These results 
provide evidence of accelerated ageing in this group. 
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                                                                      Chapter 9
General Discussion 
9.1.  Conclusions 
The aim of this thesis was to evaluate the evidence of 
accelerated cognitive and brain ageing within a middle-aged to older 
adult group with T1DM and to identify modifiable protective factors of 
cognitive function. As such, diabetes health, general health, 
psychological factors and their relation to outcomes on cognitive 
processing tests were the focus of the cognitive study and 
investigation of MCI and psychological variables in the study group.  
The combined results of these studies led to the focus on 
microvascular disease, specifically retinopathy, in the neuroimaging 
investigation in the search for evidence of functional brain ageing in 
the group with higher severity of retinopathy. The common thread 
through these studies is maintaining a view on the normal cognitive 
and brain ageing process to understand how this chronic disease 
impacts both cognitive and brain function in ageing.  
Although the research into cognition in T1DM has emphasized 
the mild to moderate impact of this chronic disease on only specific 
aspects of cognitive function (Brands et al,  2005; Brands et al. ,  2006, 
Ryan, 2005), these conclusions have been primarily based on the 
results of cognitive testing and structural imaging and without the 
consideration of the normal ageing process. The cognitive reserve 
theory suggests that cognitive function is maintained through neural 
compensation, or the use of alternative brain networks (Stern, 2009). 
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The STAC model (Park & Reuter-Lorenz, 2009) suggests that the brain 
uses functional scaffolding to re-allocate and re-distribute neural 
resources with the aim to maintain cognitive function, and compensate 
for structural brain changes in ageing.  The STAC model emphasizes 
that functional changes are evident before cognitive ones and early 
scaffolding processes may be initiated when there is disease that 
affects brain structure. Functional brain changes then can minimize 
cognitive changes and compensate for structural changes. Ultimately, 
investigation of brain function is necessary to confirm evidence of 
accelerated ageing in adults with T1DM. This methodology has only 
been used in a limited way in previous T1DM research (Van 
Duinkerken et al. ,  2011; Wessels et al. ,  2006).  
The research involved four components. First,  cognitive testing 
was used to identify the strongest diabetes health predictor of 
cognitive function and to determine whether the group showed 
evidence of cognitive deficits below the norm for age. Mild deficits, 
within the normal range, were confirmed for those with higher severity 
of microvascular disease, specifically retinopathy. Second, results of 
the cognitive study were extended to focus on the group who met 
criteria for MCI, confirming that retinopathy is the strongest diabetes 
health predictor of MCI group membership. Third, psychological 
factors, both general and diabetes-specific, were explored in relation 
to diabetes health variables and potential influence on cognitive 
function to determine modifiable factors that show a relationship with 
cognitive function in this older adult group. Finally, a functional MRI 
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(fMRI) paradigm, including both cognitive tasks and resting state 
functional connectivity methods, was used to determine whether 
groups who differed on severity of retinopathy would show functional 
brain differences. This finding would support the presence of early 
scaffolding and therefore an accelerated ageing process. The 
conclusion supported through these studies is that the microvascular 
damage present in those with severe retinopathy engages an early 
scaffolding process that would serve to preserve cognitive function 
and limit cognitive impairment through the same process seen in 
normal ageing. Optimal management of diabetes and the prevention or 
minimization of microvascular disease, engaging in scaffolding 
enhancing activities (cognitive engagement, exercise) and attention to 
psychological well-being can enhance this scaffolding process leading 
to better cognitive outcomes. 
Together, results of the cognitive and neuroimaging studies 
highlight the importance of severity of microvascular disease in the 
prediction of cognitive function and brain function for middle aged 
and older adults with T1DM above other measures of diabetes health. 
There was some evidence that estimated cognitive decline and MCI 
were related to a higher frequency of hypoglycaemic events and that 
groups with low HbA1c levels had the weakest cognitive outcomes on 
some measures. This suggests there may be greater vulnerability of an 
older adult group to tight glycaemic control and related increase in 
risk of hypoglycaemia that has not previously been identified based on 
the studies of younger adult groups with T1DM. Having severe 
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retinopathy also appeared to lead to vulnerability to the extremes of 
long-term glycaemic control.  Results suggest that once microvascular 
complications are present, long-term glycaemic control on its own is a 
less important factor in differentiating cognitive function in this group 
than for younger adults who do not have as high an incidence of this 
severe microvascular complication.  Although tight control is advised 
to minimize microvascular disease, older adults may be more 
susceptible to an increased risk of hypoglycaemic events than their 
younger counterparts. Chronic low glucose may not be devoid of 
cognitive costs as suggested in studies of relatively younger groups 
(Jacobson et al. ,  2007 & 2010). The finding of a higher incidence of 
MCI and age-related cognitive impairment, in this primarily middle-
aged group supports the premise that an early process is occurring.  
Psychological factors, and specifically feelings related to diabetes, 
were explored as possible ways to optimize outcomes in ageing and the 
group showed positive well-being overall.  Diabetes well-being was 
found to have a positive relation with both cognitive function and 
glycaemic control and anxiety a negative relation with microvascular 
complications. Harnessing the positive attitudes present generally in 
older adults with T1DM, working to maintain positive attitudes 
regarding diabetes, and finding a “functional” level of worry can 
facilitate self-management, and support the control of microvascular 
disease that would support optimal cognitive outcomes. Finally, the 
results of fMRI confirm that there is early scaffolding apparent in 
groups with more severe retinopathy through the functional results that 
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show consistent similarities with findings in normal ageing. When 
compared to the group with low severity of retinopathy, results 
indicated an increase of frontal activity and limited deactivation of 
areas related to the default mode network (DMN) on the working 
memory task. A pattern similar to cognitive “decliners” (Waiter et al. ,  
2008) was seen on the inspection time task and limited functional 
connectivity was seen in resting state.  
The combination of neuropsychological testing and 
neuroimaging in this study highlight that mild differences in cognitive 
function in comparison to age norms are maintained by changes in 
brain function that keep pace with and provide effective scaffolding 
for the earlier cognitive ageing process in this group with 
consequences that are generally not debilitating.  Although deficits are 
mild, Wrighten, Piroli,  Grillo, and Reagan (2009) suggest that,  “the 
potential unfortunate outcome of these ‘mild’ cognitive deficits in T1D 
patients is a predisposition for more rapid deterioration of cognitive 
function in later life” (p.445) and the structural brain changes that 
underlie these cognitive changes are likely to have negative 
consequences for functioning over time. 
 These results highlight the potential areas for intervention and 
recommendations for preservation of cognitive function in this group. 
This includes maintaining glucose control to limit the onset and 
severity of microvascular disease and maintaining cognitive activity 
and engaging in exercise. Activities that promote positive emotional 
health and a functional level of worry about self-management will help 
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middle aged and older adults make or maintain these health habits that 
relate to better cognitive outcomes. 
9.2.   Limitations and Critique  
The fact that no control group was used in this study may be 
considered a limitation in methodology as the determination of 
cognitive deficits was not based on a matched cohort and brain 
functioning could not be compared on the same measures under the 
same parameters. However, this was an intentional choice to focus on 
the potential important diabetes health variables that may particularly 
affect cognitive function. As a method of comparison, cognitive results 
were translated to standardized z scores and evaluated in relation to 
results of the normative age group. Comparison was made to results of 
population studies, and care was taken to equate methodology as much 
as possible in the fMRI study. Another criticism is that with 94 
participants in the cognitive study there were a limited number of 
variables that could be included in multiple regression analysis. In 
contrast,  the DCCT/EDIC study (Jacobson et al. ,  2011) had over 1000 
participants, increasing the power to find relationships among 
variables. To overcome this limitation, care was taken to choose fewer 
predictors to include in regression analyses. In comparison, other 
studies of older adults in T1DM have used a small sample size (n≤40) 
and this is a relatively large group. Three studies have followed the 
same sample (Van Duinkerken et al. ,  2011; Brands et al. ,  2006, Brands 
et al. ,  2007) comparing this group over time, or to control groups and 
groups with T2DM. Another study compared cognitive functioning of 
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45 to 64 year olds (n=39) to controls of the same age and younger 
groups with T1DM 18 to 44 (Ryan, 2005). The large DCCT/EDIC 
study has thus far focused mainly on a relatively younger age group 
(Jacobson et al. ,  2007).  
The cross-sectional design with correlation-based statistics, does 
not allow for cause and effect inferences. The results lead to a 
discussion of relationships between variables, however the direction of 
these relationships and possible third variables involved are 
undetermined. A control for this included controlling for factors that 
might have a relationship with variables of interest.  
As well,  the measure of microvascular disease was a 
combination of retinopathy, neuropathy, and nephropathy due to low 
numbers with high severity of the two latter diseases. It  was therefore 
not possible to determine if one type of microvascular disease had a 
greater influence than another on cognitive function. In most cases the 
combined score of microvascular disease did have stronger 
correlational values to cognitive function than retinopathy on its own, 
suggesting that the addition of neuropathy and nephropathy ratings 
increased the predictive value over retinopathy alone. 
 Although the neuropsychological tests used in this study are the 
ones commonly used in other studies of individuals with T1DM, these 
tests notoriously are not pure measures of the cognitive processes they 
purport to measure. Although the cognitive processes identified in this 
study are those identified in research of these measures, other 
cognitive processes may also play a part in cognitive performance on 
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these tests, or may be primarily responsible (e.g. graphomotor speed 
on a processing speed task), limiting the assurance that a certain 
cognitive process is responsible. The cognitive tests used for 
neuroimaging are more pure measures of the cognitive processes they 
measure and are related to common areas of BOLD activation and 
deactivation. The addition of fMRI techniques moves the focus from 
the cognitive process to the brain function supporting the cognitive 
process.  
9.3.  Future Directions 
The relationships between diabetes variables, cognitive function, 
and brain function highlighted in this thesis suggest possible areas that 
need to be explored to better understand cognitive and brain ageing in 
T1DM. In future, a prospective study of older adults would follow a 
group across time to track actual changes in cognition and effects over 
time. This would also allow follow-up with those who met criteria for 
MCI to determine outcomes for this group and rate of progression to 
dementia.  
Experimental studies would allow the ability to determine cause 
and effect relationships on cognitive function and MCI for 
interventions including controlling blood glucose, cognitive activity, 
exercise, and methods to promote well-being. They would lead to 
confirmation of these relationships and more specific recommendations 
on ways to promote healthy cognitive ageing in this group. Creating a 
diabetes-specific age-normed measure to accurately identify anxiety 
and diabetes within the T1DM population and operationalizing the 
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functional level of anxiety suggested by the results of the current 
study, could contribute to tailoring patient guidance to improve self-
management. Future fMRI studies could focus on direct comparison of 
younger and older groups with and without retinopathy to more 
specifically identify differences related to ageing and the added impact 
of retinopathy.  
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Appendix A       
Cognitive Study: Consultant Patient Invitation Letter  
Dear  
With col leagues from the Universi ty  of  St .  Andrews we are  running a  
research s tudy in  the NHS Tayside Diabetes  Centres  looking to  see i f  there  
is  any effect  of  blood glucose level  control  on the way in  which people  with  
Type 1 diabetes  think and reason.  
We wonder  whether  you might  be wil l ing to  help  with  this  research,  
which involves  an interview, including some problem-solving tasks  and a  
quest ionnaire  about  how you are  feel ing.  I  am enclosing a  copy of  the  
information sheets  which provide some more information.  
Please t ry  and read through this  information sheet  thoroughly pr ior  to  
deciding whether  you would l ike  to  take part  in  th is  s tudy.  I t  is  ent i re ly  
your  choice whether  or  not  you do so and you do not  need to  give any 
reason for  not  par t ic ipat ing.  Please a lso note  that  such a  decis ion wil l  not  
affect  your  t reatment  in  any way.  
I f  you are  interested in  helping with  this  research project ,  or  i f  you 
would defini te ly  not  want  to  discuss  i t  when you at tend the c l inic ,  I  would 
be grateful  i f  you could contact  Harr ie t  Johnston,  research psychologis t ,  by 
phone or  by post ing the a t tached response card (s tamp included).  Her  
contact  detai ls  are  provided on the information sheet .   
I f  you would l ike  to  obtain  fur ther  information or  ta lk  about  th is  
s tudy please do not  hesi ta te  to  te lephone the number provided so that  
Harr ie t  can get  back to  you.  Many thanks for  giving this  your  a t tent ion.   
Yours  s incerely ,   
Dr.  Rory McCrimmon 
Honorary Consultant  Diabetologis t ,  Stra thmore Diabetes  Centre   
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University of S t  A ndrews 
School  o f  Psychology    
 
 
  
Te l :  +44  01382  496483  
Emai l :  h johnston1@nhs .ne t  
 
 
________,  2010 
 
Dear   
 
Tit le:  Thinking and Reasoning  in  Type 1  d iabetes  
 
We are  curren t ly  car ry ing  out  a  research  pro jec t  a t  the  _______ Diabetes  Centre  
and  are  wr i t ing  to  ask  i f  you  would  l ike  to  take  par t .  
 
In  the  pro jec t  we are  inves t iga t ing  the  impact  of  b lood  g lucose  leve l  cont ro l  on  a  
var ie ty  of  a reas  of  th inking  for  people  wi th  Type  1  d iabetes .  
 
The  enclosed  Par t ic ipant  Informat ion  Sheet  g ives  you  more  informat ion  about  the  
pro jec t  and  what  you  have  to  do  i f  you  dec ide  to  take  par t .  Before  you  dec ide  you 
might  want  to  d iscuss  th is  wi th  your  spouse  or  o ther  members  of  your  family .  You 
can  a lso  d iscuss  i t  wi th  the  s ta f f  a t  the  d iabe tes  cent re  or  contac t  me,  Harr ie t  
Johns ton ,  on  01382 496483 i f  you  have  any  ques t ions .  
 
I f  you  would  l ike  to  take  par t ,  p lease  contac t  me or  comple te  and  re turn  the  
enc losed  response  card .  If  you do  not  wish  to  take  part  then you do not  have  to  
do  anything.  
 
Once you re turn  the  response  card  and  you have  indica ted  tha t  you  are  in teres ted  
in  the  s tudy ,  you  wi l l  be  contac ted  by  the  researcher.  A  t ime wi l l  be  a r ranged  to  
meet  before  or  a f te r  your  regular ly  scheduled  appoin tment  a t  the  d iabe tes  c l in ic  or  
a t  another  t ime a t  your  convenience .  At  th is  meet ing  the  pro jec t  wi l l  be  expla ined  
to  you.  Af ter  hear ing  more  about  the  pro jec t  you  dec ide  whether  or  not  to  
cont inue .  I f  you  wish  to  par t ic ipa te  you  wi l l  be  asked  to  s ign  a  consent  form and 
comple te  a  number  of  puzz le - l ike  tasks  and  ques t ionnai res .  
 
If  you decide  to  part ic ipate  you can change your mind at  any t ime in  the  
future .  Thank you for  tak ing  the  t ime to  read  th is  le t te r  and  informat ion .  
 
 
Yours  S incere ly ,  
 
,  Researcher ,  Univers i ty  of  S t .  Andrews  
 
Superv isors :  
Dr .  Ar lene  Aste l l ,  CCl inPsychol ,  Senior  Lecturer ,  Univers i ty  of  S t .  Andrews  
Dr .  Rory  McCrimmon,  Honorary  Consul tan t  Diabeto logis t  & Senior  Lecturer  in  
Trans la t ional  Medic ine ,  S t ra thmore  Diabetes  Centre /NHS Tays ide          
February  23 ,  2010  
            v2  
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Participant Information Sheet 
Thinking and Reasoning in Type 1 diabetes 
 
 
You are  invi ted to  par t ic ipate  in  a  research project .  This  research is  par t  of  
an educat ional  qual if icat ion.  The fol lowing information is  to  help  you 
decide i f  you want  to  take part .  Read i t  careful ly  and discuss  i t  with  other  
people  i f  you want .  You can ask me any quest ions and I  wil l  do my best  to  
answer them. Take t ime to  decide whether  or  not  you wish to  take part .   
 
What is  the purpose of  the study? 
While  much is  known about  the  importance of  blood glucose level  control  in  
diabetes  for  the  maintenance of  physical  well  being,  recent  evidence 
indicates  that  i t  may also be important  in  maintaining thinking and 
reasoning ski l ls .  The aim of  th is  project  is  to  f ind out  whether  blood 
glucose control  levels  may have a  subt le  impact  on thinking and reasoning 
processes  for  individuals  with  diabetes .   
 
Why have I  been chosen? 
We bel ieve this  is  a  sui table  s tudy for  you.  This  project  is  for  people  with  
Type 1 diabetes  aged 45 and over  who have had diabetes  for  10 or  more 
years .  
 
Do I  have to  take part? 
I t  is  up to  you to  decide whether  or  not  to  take part .  I f  you do decide to  take 
part  you wil l  be  given this  information sheet  to  keep and be asked to  s ign a  
consent  form. If  you decide to  take part  you are  s t i l l  f ree  to  withdraw at  any 
t ime and without  giving a  reason.  A decis ion to  withdraw at  any t ime,  or  a  
decis ion not  to  take part ,  wil l  not  affect  the  care  you receive or  affect  your  
re la t ionship with  medical  s taff  looking af ter  you,  now or  in  the  future  
 
What wil l  happen if  I  decide to  take part?  
If  you decide to  take part  you wil l  complete  a  short  bat tery  of  problem-
solving,  and puzzle- l ike tasks with  the researcher ,  Harr ie t  Johnston.  These 
cognit ive  tasks  should take no more than 45 minutes  a l together.  You wil l  
a lso  be asked to  answer a  few short  quest ionnaires  about  how you are  
feel ing,  and interview quest ions about  your  diabetes ,  age and heal th  his tory 
which should take no more than 15 minutes.  As you require  an adequate  
glucose supply to  perform your best  on the cognit ive tasks ,  before  the 
assessment  you wil l  be  asked to  take a  blood glucose measurement  (using 
your  personal  monitor)  to  ensure  that  you are  not  experiencing 
hypoglycaemia.  I f  you are  below 4 mmol/ l i t re  glucose wil l  be  provided and 
a  second glucose reading wil l  be  required to  ensure  you are  able  to  begin 
the cognit ive tasks .  A current  wais t  and hip  measurement  wil l  a lso  required 
as  th is  is  not  regular ly  taken at  the  Diabetes  Centre  appointment .  You can 
take this  measurement  a t  the  session or  a t  home.  Test ing wil l  be  completed 
at  the  Diabetes  Centre  that  you usual ly  vis i t .  The session wil l  be  
coordinated with  your  usual  appointment  or  scheduled at  your  convenience.  
 
University of S t A ndrews 
School  o f  Psychology  
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During the interview we will ask to video-record your responses (voice and 
hands/response sheet) whilst you are performing some of the tasks. We will ensure 
that there will be nothing on these tapes that could identify you in person and that 
these tapes will be destroyed once they have been analysed.  
 
What are the possible disadvantages and risks of taking part? 
We do not  ant ic ipate  any heal th  r isks  from taking part  in  this  s tudy.  Due to  
the length of  the interview you may f ind tes t ing to  be t i r ing,  but  you wil l  be  
given plenty of  opportuni ty  to  take breaks.  We do not  ant ic ipate  any 
adverse e f fects  from taking part  in  th is  s tudy.  I f  you wish to  complain,  or  
have any concerns about  any aspect  of  the  way you have been approached 
or  treated during the course of  th is  s tudy,  the  normal National  Health  
Service  complaints  mechanisms should be avai lable  to  you.  
 
 
What are the possible benefits of taking part? 
There will be no direct benefit to you by taking part, and your individual results will 
not be revealed to you. However, we will make any future publications of the findings 
available to you. It is hoped that this research will improve our knowledge relating to 
Type 1 diabetes and may influence care practices and information provided to 
people with diabetes in the future. 
 
What if something goes wrong? 
If you believe that you have been harmed in any way by taking part in this study, you 
have the right to pursue a complaint and seek any resulting compensation through 
the University of St. Andrews who are acting as the research sponsor. Details about 
this are available from the research team. Also, as a patient of the NHS, you have 
the right to pursue a complaint through the usual NHS process. To do so, you can 
submit a written complaint to the Patient Liaison Manager, Complaints Office, 
Ninewells Hospital (Freephone 0800 0275507). Note that the NHS has no legal 
liability for non-negligent harm. However, if you are harmed and this is due to 
someone’s negligence, you may have grounds for a legal action against  NHS 
Tayside but you may have to pay your legal costs.  
 
What wil l  happen to the information col lected in the study? 
All  information which is  col lected about  you during the course  of  the  
research wil l  be  kept  s t r ic t ly  confident ia l .  Any information about  you that  
leaves the hospi ta l  wil l  have your  name and address  removed so that  you 
cannot  be recognized from i t .  You wil l  be  a l located an anonymous ID code 
during tes t ing which wil l  be  used in  place of  your  name on any future  
publicat ions.  Only group resul ts  or  anonymous individual  data  wil l  be  
communicated in  Harr ie t  Johnston’s  PhD thesis ,  research publicat ions or  a t  
professional  and public  conferences.   
 
Who is  organizing and funding the research? 
This  research is  being completed in  fulf i lment  of  PhD requirements  for  the  
School  of  Psychology at  the  Universi ty  of  St .  Andrews.  The research is  
supervised by Dr.  Arlene Astel l ,  a  chartered cl inical  psychologis t  and 
lecturer  a t  the  Universi ty  of  St .  Andrews,  and Dr.  Rory McCrimmon, a  
consul tant  diabetologis t  a t  the  Strathmore Diabetes  Centre ,  NHS Tayside in  
col laborat ion with  the other  Diabetes  Centres  within  NHS Tayside.  
 
What happens now? 
If  you agree to  take part  you wil l  be  asked to  complete  a  consent  form. If  
you decide not  to  take part ,  th is  wil l  have no bearing on your  future  care  or  
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treatment  f rom the NHS. If  you decide to  take part  we would l ike  
permission to  inform your GP.  However ,  i f  you do not  agree to  us  informing 
your  GP you can s t i l l  take part .  The Tayside Committee  on Medical  
Research Ethics ,  which has  responsibi l i ty  for  scrut iniz ing proposals  for  
medical  research on humans,  has  examined the proposal  and has  ra ised no 
object ions from the point  of  view of  medical  e thics .  I t  is  a  requirement  that  
the  research records are  made avai lable  to  monitors  f rom NHS Tayside/and 
the Regulatory Authori t ies  ( the la t ter  applicable  ONLY in drug tr ia ls)  
whose role  is  to  check that  research is  properly  conducted and the interests  
of  those taking part  are  adequately  protected.   
 
Contact  for Further Information 
 
Thank you for  reading this  information sheet .  I f  you have fur ther  have any 
further  quest ions feel  f ree  to  contact  me.  Dr.  Ewan Pearson,  a  consultant  
physician at  Ninewells  Hospita l  who is  not  involved in  this  s tudy,  is  a lso  
avai lable  to  provide an independent  opinion about  taking part .  You can 
reach him at  01382 740081  
 
I f  you have understood the contents  of  th is  sheet  and wish to  take part ,  
e i ther  contact  Harr ie t  Johnston by leaving a  message at   01382 496483,  by 
email  hjohnston1@nhs.net ,  or  t ick the appropria te  box on the enclosed 
response card and return in  the envelope provided.   
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Response Card   
 
 
 
 
 
 
School of  Psychology, Universi ty of  St.  Andrews 
St.  Mary 's Col lege 
South Street,  St.  Andrews 
Fife,  Scot land, KY16 9JP  
 
Study: Thinking and reasoning in Type 1 diabetes 
 
Please check appropriate box and return in envelope provided 
 
  Yes. I  would l ike to be contacted for more information about th is 
study. 
 
  Preferred Contact Telephone Number(s)  
_____________________ /  __________________ 
 
Preferred Contact Time:   AM ___________________     PM 
_____________________ 
 
  No. I  do not want further contact regarding th is study.  
 
ID # __________  
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Appendix E          
Cognitive Study: Inclusion Exclusion Telephone Interview 
 
Inclusion Criteria  
How old are you?  __________________ 
  age over 45  
When were you diagnosed with diabetes? 
  duration 10 or more years ___________ 
Is English your first language? If not, are you comfortable with both 
speaking and reading in English?  ______________ 
  English speaker 
Exclusion Criteria 
Currently or in the past have you had any condition or injury affecting 
your thinking, reasoning or memory skills such as head injury, coma, 
stroke, epilepsy, dementia etc.  
 Injury or disease directly affecting the brain ___________________ 
Have you been diagnosed with a mental health or thought disorder for 
which you require medication (e.g. anxiety, depression, schizophrenia) 
 Psychiatric disorder ________________ 
Do you drink alcohol?  If so how many units per week?  
 Drug or Alcohol problem/addiction _____________ 
Do you have any difficulties with your hearing or vision? _______ If 
yes, do you wear glasses/hearing aids that correct for this? 
  Uncorrected hearing/vision ___________ 
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Appendix F          
Cognitive Study: NHS Ethics Favourable Opinion 
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Appendix G         
Cognitive Study: NHS Research and Development Approval 
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Appendix H       
Cognitive Study UTREC Ethics Approval           
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Harriet  Johnston <hnj2@st-andrews.ac.uk>  
 
PS5381_Approval  
 
psyethics <psyethics@st-andrews.ac.uk>  14 Apri l  2009 16:26  
To:  hn j2@st-andrews.ac.uk 
Cc:  Ar lene Aste l l  <a ja3@st-andrews.ac.uk> 
14 Apri l  2009  
  
  
  
Ethics Reference No:   
Please  quote  th is  ref  on  a l l  
correspondence  
 PS5381 
Project  Tit le:  Long-term g lycaemic contro l  o f  d iabetes and 
i ts  re la t ionship wi th  cogni t ive funct ion in  Type 
1 d iabetes mel l i tus  
Researchers Name(s):   Harr ie t  Naomi Johnston  
Supervisor(s):   Dr A Aste l l  
  
Thank you for  submit t ing your  applicat ion which was considered at  the  
Psychology School  Ethics  Committee  meet ing on the 14 Apri l  2009.  The 
fol lowing documents  were reviewed: 
  
Ethical Application Form                                  
Participant Information Sheet                           
Consent Form                                                 
External Permissions                                         
Letters to Parents/Children/Headteacher etc…          
Questionnaires                                                              
Enhanced Disclosure Scotland and Equivalent            
(as necessary) 
 
The Universi ty  Teaching and Research Ethics  Committee  (UTREC) 
approves this  s tudy from an ethical  point  of  view. Please note  that  where 
approval  is  g iven by a  School  Ethics  Committee  that  committee  is  par t  of  
UTREC and is  delegated to  act  for  UTREC. 
  
Approval  is  g iven for  complet ion within  the  s ta ted t ime period.  Projects ,  
which have not  commenced within  the  t ime given must  be re-submit ted 
to  your  School  Ethics  Committee .   
  
You must  inform your School  Ethics  Committee  when the research has  
been completed.  I f  you are  unable  to  complete  your  research within  the 
val idat ion period,  you wil l  be  required to  wri te  to  your  School  Ethics  
Committee  and to  UTREC (where approval  was given by UTREC) to  
request  an extension or  you wil l  need to  re-apply.  
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Any ser ious adverse  events  or  s ignif icant  change which occurs  in  
connect ion with  this  s tudy and/or  which may al ter  i ts  e thical  
considerat ion,  must  be reported immediately  to  the School  Ethics  
Committee ,  and an Ethical  Amendment  Form submit ted where 
appropria te .  
  
Approval  is  g iven on the understanding that  the  ‘Guidel ines  for  Ethical  
Research Pract ice’  (http://www.st-
andrews.ac.uk/media/UTRECguidelines%20Feb%2008.pdf)  are  
adhered to .  
  
Yours  s incerely 
  
  
On behalf  of  the  Convenor of  the  School  Ethics  
Committee           OR           Convener  of  UTREC 
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Appendix I        
Cognitive Study: Diabetes Questionnaire 
 
Part ic ipant  ID Number ______ Age ________  
Gender   M /   F  (c irc le)  
How many years  of  formal  educat ion have you taken from the t ime you 
s tar ted pr imary school? 
____________________________________________________ 
Year  of  diabetes  diagnosis  ____________   
Age at  d iabetes  diagnosis  __________ 
How many hypoglycaemic events  have you experienced that  have required 
assis tance or  hospi ta l izat ion?  (es t imate  number per  year  i f  f requent  
occurrence)  
Total  number = _  ____   OR   Est imate  of  number per  year    =   _____ 
How many hypoglycaemic comas have you experienced and when did these 
occur?  Include tota l  number?  (es t imate  number per  year  i f  f requent  
occurrence)  
Total  number = ____ OR     Est imate  of  number per  year    =   ____ 
What  medicat ions or  types  of  medicat ions do you use current ly?  
______________________________________________________ 
Do you have any other  medical  condit ions?  I f  so  l is t  
_____________________________________________________ 
What  is  your  level  of  physical  act ivi ty  compared to  others  of  your  age?  
Circle  One  
Much Less   Less   Same As More   Much More 
What  is  your  level  of  cognit ive act ivi ty  (e .g .  work,  school ,  puzzles ,  reading)  
compared to  others  of  your  age?  Circle  One 
Much Less   Less   Same As More   Much More 
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Appendix J          
Cognitive Study: Follow-Up Interview 
 
Are you a smoker?  
Current __  Past__       Never___     
 
You said you exercise (much less, less, same as, more, much more) 
than other people your age. What type of exercise do you do? How 
much and how often per week? 
 
Over the last 2 weeks what was your highest exertion level out of all  
your  physical activities. Rate of perceived exertion is how hard you 
think your body is working based on increased heart rate, increased 
breathing rate, increased sweating and muscle fatigue 
__  0  -  Nothing at  a l l  
__ 1  -  Very l ight  (gentle  walking –  50% effort)  
__ 2  -  Light  (60% effort)  
__ 3  -  Moderate  
__ 4  -  Some what  s t rong (70% effor t  –  s teady pace)  
__ 5  –  s t rong (80% effor t)  
__ 6  
__ 7  -  Very s trong (90% effor t)  
__ 8  
__ 9  
__ 10 -  Very,  very s trong -  maximal  (100% effort)  
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You said you do (much less, less, same as, more, much more)  
cognitive or thinking activities than others your age. What type of 
thinking activities do you do? How much and how often per week?  
 
Do you drink alcohol ? 
Yes   ___   No ___   
How much per week? _____ 
 
Waist ____   Hip  _____ 
 
Current Blood glucose ____ 
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Appendix K     
Method of Frequency Weighted Mean and Standard Deviation HbA1c 
Calculation 
First,  a method was operationalized to deal with duplicate 
information on the SCI-DC record. Due to the possibility of clerical 
errors leading to improbable values and duplication of values on SCI-
DC (McAlpine, October 21, 2009) the HbA1c values needed to be 
checked and corrected for potential errors. First the record of 
individual HbA1c scores was cleaned (i.e. removing duplicates values 
recorded on the same day, removing dates with no recorded values, and 
removing improbable values). An improbable value was considered an 
HbA1c value that was at or below the lower limit (<4%) of the normal 
range of HbA1c for a person without diabetes (4 to 6%). The target 
HbA1c for someone with diabetes is 6.5 to 7.5% (Diabetes UK, 
2011b). If different values were recorded for the same day, the higher 
of these values was retained to be consistent with local convention 
detailed in an email communication by the Managed Care Network 
(MCN) Data Facilitator for SCI-DC  (McAlpine, October 21, 2009). 
When different values were recorded for the same week all values were 
retained and weighted by the number of days between readings. In this 
way a reading a few days apart has less weight in the overall mean 
than readings that are months apart.  This was done to reduce the 
potential for loss of actual HbA1c values in the data cleaning process.  
 Next the frequency of the records was determined for each 
value. This was number of months or part months between the mid 
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point of one reading and the midpoint of the next. If the absolute 
number of months between readings was used, this would leave the 
first reading with no weighting. Therefore to be able to assign a 
weight to the first reading it  was assumed that the number of days 
between first HbA1c value and the one preceding it  would 
approximately be the same as the actual number of days between the 
first and second HbA1c readings. It  was then also necessary to 
estimate the number of days between the last reading and the next 
reading which was assumed to be the same as the number of days 
between the second-last and last reading. In this way an estimated 
weight based on the days between one actual or dummy reading and 
the next reading was assigned for each HbA1c value as illustrated in 
the following table. 
 
Method to determine frequency weighting for HbA1c values 
 
 
HbA1c 
Record No. 
 
1  
 
2  
 
3  
 
4  
 
5  
 
6  
 
7  
 
8  
 
9  
 
10  
 
11  
 
12  
 
Days 
from last  
record 
 
 
0  
 
 
X1 
 
 
X2 
 
 
X3 
 
 
X4 
 
 
X5 
 
 
X6 
 
 
X7 
 
 
X8 
 
 
X9 
 
 
X10 
 
 
0  
 
Mid point  
of  days 
between 
records 
 
 
X2-
X1 
 2  
 
X2-
X1 
 2  
 
X3-
X2 
 2  
 
X4-
X3 
 2  
 
X5-
X4 
 2  
 
X6-
X5 
 2  
 
X7-
X6 
 2  
 
X8-
X7 
 2  
 
X9-
X8 
 2  
 
X10-  
X9 
  2      
 
X11-
X10 
  2  
 
X11-
X10 
  2  
N.B.  shaded  boxes  indica te  HbA1c va lues  for  which  months  be tween readings  was  
es t imated   
Finally, the frequency weighted mean HbA1c was calculated. Each 
HbA1c value was multiplied by the value for days between readings. 
These values were then summed and divided by the sum of days 
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between readings. These values were also used to determine a 
frequency weighted standard deviation of HbA1c scores shown in the 
following equations. 
 
       ∑ xi wi     
    ∑ wi 
x= HbA1c Value ;  w= Number of days between readings  
∑ xi2 wi  
                         
∑  wi / n 
 
x= HbA1c Value ;  w= Number of days between readings; 
n=number of readings 
  
Frequency Weighted Mean = 
Frequency Weighted SD = 
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Appendix L  
Sample Items for Cognitive Tests in a Visual Format  
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Trail Making A – Sample 
 
 
Trail Making B – Sample 
 
  
A 
B 3 
2 
4 C 
5 D 
E 
Start 
End 
1 
2 
4 5 
3 
7 6 
9 8 
10 
Start 
End 
1 
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Symbol Digit Modalities Test - Sample 
 
KEY 
    ∆ =  ~ ¬ —  
 1 2 3 4 5 6 7 8 9  
 
 
¬    ∆ ¬ = ~  —  ¬ 
8 1 3 6 4 8 5 7     
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Raven’s Standard Progressive Matrices – Sample 
 
 
 
 
 
 
 
  
1 3 2 
4 5 6 
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Appendix M   
Cognitive Test Raw Score to Standard Score Conversion 
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Cogni t ive  Tes t  Raw Score   S tandard  Score  Convers ion  
Symbol  Dig i t  
Modal i t ies  Tes t :  
Wri t ten  
Number  i tems 
correc t ly  wr i t ten  
wi th in  90  second t ime 
l imi t .  Maximum  score  
110  
 
Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
and  years  of  educat ion  (Smith ,  
1982)  
Symbol  Dig i t  
Modal i t ies  Tes t :  
Wri t ten  
Number  i tems 
correc t ly  spoken 
wi th in  90  second t ime 
l imi t .  Maximum  score  
120  
 
Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
and  years  of  educat ion  (Smith ,  
1982)  
Tra i l  Making  Tes t  
(A&B) 
Seconds  to  comple te  Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
(Spreen  & Strauss ,  1998) .  
 
NART-IQ Number  of  e r rors  in  50  
i tems 
Errors  conver ted  to  WAIS Ful l  
Sca le  IQ score  equiva len t  us ing  
NART-2 Convers ion  tab le  
(Nelson  & Wil l i son ,  1991)  
 
Ravens  S tandard  
Progress ive  Matr ices  
(Ravens  SPM) 
 
Tota l  correc t  in  20  
minute  t ime l imi t .  
Maximum = 60  
Used  in  ca lcu la t ion  of  ELCC  
Es t imated  Life t ime 
Cogni t ive  Change  
(ELCC) 
NART-2 number  
correc t  and  Ravens  
SPM number  correc t  in  
20  minutes  
S tandard ized  res idual  (z  score)  -  
regress ion-based  d i f fe rence  to  
ad jus t  curren t  ab i l i ty  (Ravens  
SPM) for  pr ior  ab i l i ty  (NART-2;  
Deary ,  Whal ley ,  and  Crawford ,  
2004)  
 
Age-Adjus ted  
Es t imated  Life t ime 
Cogni t ive  Change  
(A-ELCC) 
 
ELCC and Par t ic ipant  
Age  
S tandard ized  res idual  (z  score)  
regress ion-based  d i f fe rence  to  
ad jus t  ELCC for  par t ic ipant  age  
AMIPB Story  Recal l  
Immedia te  (SRI)  
Number  of  s tory  ideas  
reca l led  correc t ly  
immedia te ly  a f te r  
hear ing  a  s tory .   
28  ideas   
maximum 2  
poin ts / idea  maximum 
score  =  58  
 
Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
(Coughlan  & Hol lows,  1985)  
AMIPB Story  Recal l  
Delayed  (SRD) 
Number  of  s tory  ideas  
reca l led  correc t ly  30  
minutes  a f te r  hear ing  a  
s tory  
28  ideas   
maximum 2  
poin ts / idea  maximum 
score  =  58  
 
Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
(Coughlan  & Hol lows,  1985)  
AMIPB Story  Recal l  
Reta ined  
(SRD/SRI)  X 100 Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  age  
(Coughlan  & Hol lows,  1985)  
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Table  M (cont . )  
 
Cogni t ive  Tes t  Raw Score   S tandard  Score  Convers ion  
Digi t  Span  Forward  
(DSF)  
DSF Tota l  Score  
number  correc t  of  
8  Tr ia ls  x  2  
I tems/Tr ia l  
Maximum = 16  
 
 
Dig i t  Span  Backward  
(DSB) 
DSB Tota l  Score  =  
number  correc t  of  
8  Tr ia ls  x  2  
I tems/Tr ia l  
Maximum = 14  
 
 
Dig i t  Span   DS Scaled  Score  =  
DSF Tota l  Score  +  
DSB Tota l  Score .  
Maximum 30 
Z  score  ca lcu la ted  based  on  mean 
and  s tandard  devia t ion  for  sca led  
scores  (Wechs ler ,  1997)  
 
 
340 
Appendix N      
Required Transformations for Normalization Of Study Variables 
 
To preserve the variable and number of data points for each 
analysis transformations were tried in the following order  
1. Variable Transformation 
log 10 (Log) ,  square root (SQRT) and reciprocal (Rec) transformation  
2.Minimizing Outliers  
If an outlier was ≥3SD from the mean, the score was changed to mean 
+ 2.5, 3.0 or 3.5 SD if transformation failed as long as the relative 
position of the outlier was maintained (i.e. did not change positions 
with the next nearest score).  
3. Non-parametric Statistics 
Used if transformations and minimizing outliers failed.  
The results of the successful transformation are shown in the following 
table. A transformation was considered successful if the distribution 
looked normal and the z values for skewness and kurtosis were below 
2 SD above the mean as recommended by Field (2005). If 
transformation and minimizing outliers did not normalize the 
distribution,  
non-parametric statistics were used
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Table N.1 
Check for Normal Distribution of Cognitive Test Variables and Required Transformation 
 
V a r i a b l e  P r e -  
T r a n s f o r m a t i o n  
 
 
P o s t -   
T r a n s f o r m a t i o n  
 S k e w n e s s  ( S )  K u r t o s i s  ( K )  O u t l i e r   T r a n s f o r m a t i o n  S k e w n e s s  ( S )  K u r t o s i s   ( K )  
 S  S E  z S  K  S E  z K  ≥3 S D  T r a n s f o r m a t i o n / M i n i m i z e  O u t l i e r  S  S E  z S  K  S E  z K  
A d j - L C C  - . 7 1   . 2 4 9  - 2 . 8  1 . 8  . 4 9 3  3 . 7  z = - 3 . 7  C h a n g e d  o u t l i e r  v a l u e  t o  m e a n  + 2 . 5  S D   
= - 2 . 4 9  ( T A d j _ C o g _ C h a n g e )  
- . 4 2  . 2 4 9  1 . 7  . 8 0  . 4 9 3  1 . 6  
T M T - A Z  1 . 5  . 2 4 9  6 . 1  4 . 6  . 4 9 5  9 . 2  z = 4 . 2  C h a n g e d  o u t l i e r  v a l u e  t o  m e a n  + 3 . 5  S D  =  3 . 0 9  
&  S Q R T  T r a n s f o r m a t i o n  ( S Q R T T _ T M T A Z )  
- . 1 1 8  . 2 5 0  . 4 7  . 8 5  . 4 9 5  1 . 7  
T M T - B Z  1 . 4  . 2 4 9  5 . 5  1 . 9  . 4 9 5  3 . 8  z = 4 . 3  
z = 4 . 2  
C h a n g e d  o u t l i e r  v a l u e s  t o  m e a n  +  3  S D  = 3 . 8 2  &  
S Q R T  T r a n s f o r m a t i o n  ( S Q R T T _ T M T B Z )  
. 3 3  . 2 4 9  1 . 3  . 3 0  . 4 9 5  . 6 1  
S R I - Z  - . 0 8  . 2 4 9  - 0 . 3  - . 1 5   - 0 . 3          
S R D - Z  - . 2 3  . 2 4 9  - 0 . 9  - . 3 2   - 0 . 7          
S R R - Z  - . 5 5  . 2 4 9  - 2 . 2  2 . 0  . 4 9 3  4 . 1   N o n - p a r a m e t r i c         
S D M T W Z  . 0 3  . 2 4 9  . 1 2  - . 0 5   - 0 . 1          
S D M T O Z  . 1 2  . 2 4 9  . 4 7  . 1 6   . 3 1          
D S - Z  . 5 6  . 2 4 9  2 . 3  . 0 7  . 4 9 3  . 1 3   S Q R T  T r a n s f o r m a t i o n  ( S Q R T _ D S _ S c a l e Z )  - . 1 8  . 2 4 9  . 7 3  . 1 3  . 4 9 3  . 2 7  
N A R T  I Q  - . 7 5  . 2 4 9  - 3 . 0  . 6 5  . 4 9 3  1 . 3   R e v e r s e  a n d  S Q R T  T r a n s f o r m a t i o n  ( S Q R T _ R I Q )  - . 2 5  . 2 4 9  . 9 9  . 3 0  . 4 9 3  . 6 0  
E d u c a t i o n  . 6 7 9  . 2 4 9  2 . 7 3  . 0 1 1  . 4 9 3  . 0 2 2   N o n - p a r a m e t r i c        
N . B .  A d j - L C C :  A g e - A d j u s t e d  L i f e t i m e  C o g n i t i v e  C h a n g e ;  T M T - A Z :  T r a i l  M a k i n g  T e s t  A  z - S c o r e ;  T M T - B Z :  T r a i l  M a k i n g  T e s t  B  z - S c o r e ;  S R I - Z :  S t o r y  R e c a l l  I m m e d i a t e  
z - S c o r e ;  S R D - Z :  S t o r y  R e c a l l  D e l a y e d  z - S c o r e ;  S R R - Z :  S t o r y  R e c a l l  R e t a i n e d  z - S c o r e ;  S D M T  W - Z :  S y m b o l  D i g i t  M o d a l i t i e s  T e s t  W r i t t e n  z - S c o r e ;  S D M T  O - Z :  S y m b o l  
D i g i t  M o d a l i t i e s  T e s t  O r a l  z - S c o r e ;  D S - Z :  D i g i t  S p a n  z  S c o r e .  B e c a u s e  T M T  v a l u e s  a r e  c o u n t e r - i n t u i t i v e  ( a  h i g h e r  s c o r e  i n d i c a t e s  p o o r e r  p e r f o r m a n c e )  b o t h  T M T  
v a r i a b l e s  w e r e  r e v e r s e d  a f t e r  t r a n s f o r m a t i o n  w h e n  u s e d  i n  t h e  s t a t i s t i c a l  a n a l y s i s  t o  b e  i n  a l i g n m e n t  w i t h  t h e  d i r e c t i o n  o f  t h e  o t h e r  c o g n i t i v e  v a r i a b l e s .  
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Table N.2   
Check for Normal Distribution of Demographic and Diabetes &  Health Variables and Required Transformation 
 
V a r i a b l e  P r e -  
T r a n s f o r m a t i o n  
 
 
P o s t -   
T r a n s f o r m a t i o n  
 S k e w n e s s  ( S )  K u r t o s i s  ( K )  O u t l i e r   T r a n s f o r m a t i o n  S k e w n e s s  ( S )  K u r t o s i s   ( K )  
 S  S E  z S  K  S E  z K  z  T r a n s f o r m a t i o n / M i n i m i z e  O u t l i e r  S  S E  z S  K  S E  z K  
A g e  o f  
O n s e t  
. 4 8  . 2 4 9  1 . 9 4  - . 0 0 2  . 4 9 3  . 0 0 4          
D u r a t i o n  o f  
D i a g n o s i s  
. 4 7  . 2 4 9  1 . 8 9  - . 0 7 2  . 4 9 3  - . 1 5          
M e a n  
H b A 1 c  
. 4 1  . 2 4 9  1 . 6 3  1 . 5 3  . 4 9 5  3 . 0 8  3 . 0  C h a n g e d  o u t l i e r  v a l u e  t o   
m e a n  +  3 S D  = 1 1 . 2  ( T M e a n _ H b A 1 c )  
. 1 2  . 2 5 0  0 . 4 8  . 3 9  . 4 9 5  0 . 7 9  
I n s u l i n  
R e s i s t a n c e  
( e G D R )  
. 9 1  . 2 5 1  3 . 6 5  . 2 5 1  . 4 9 8  0 . 5 0  2 . 4  L o g  T r a n s f o r m a t i o n  ( L o g  e G D R )  . 0 3 4  . 2 5 1  0 . 1 4  . 1 5 0  . 4 9 8  0 . 3 0  
A g e  . 4 7  . 2 4 9  1 . 9 6  - . 4 9  . 4 9 3  1 . 0          
M i c r o v a s c .  
D i s e a s e  
. 9 3 4  . 2 4 9  3 . 7 5  . 7 1 4  . 4 9 3  1 . 4 5  4 . 6  S q u a r e  R o o t  T r a n s f o r m a t i o n   
( S Q R T _ M i c r o )  
- . 2 6 7  . 2 4 9  - 1 . 0 7  . 6 6 8  . 4 9 3  1 . 3 5  
B M I  . 5 8 7  . 2 4 9  2 . 3 6  . 0 7 2  . 4 9 3  0 . 1 5  3 . 1  L o g  T r a n s f o r m a t i o n  ( L o g  B M I )  . 2 5 2  . 2 4 9  1 . 0 1  - . 3 9 7  . 4 9 3  - 0 . 8 1  
W a i s t - H i p  
R a t i o  
- . 1 5  , 2 5 1  - 0 . 6 0  - . 7 3 1  . 4 9 8  - 1 . 4 7          
D i a s t o l i c  - . 0 1 3  . 2 4 9  - 0 . 0 5  . 0 0 0  . 4 9 3  0          
S y s t o l i c  . 3 3 5  . 2 4 9  1 . 3 6  . 0 3 5  . 4 9 3  0 . 0 7          
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T a b l e  N . 2  ( c o n t . )  
V a r i a b l e  P r e -  
T r a n s f o r m a t i o n  
 
 
P o s t -   
T r a n s f o r m a t i o n  
 S k e w n e s s  ( S )  K u r t o s i s  ( K )  O u t l i e r   T r a n s f o r m a t i o n  S k e w n e s s  ( S )  K u r t o s i s   ( K )  
 S  S E  z S  K  S E  z K  z  T r a n s f o r m a t i o n / M i n i m i z e  O u t l i e r  S  S E  z S  K  S E  z K  
C h o l e s t e r .  . 5 6 9  . 2 4 9  2 . 2 9  . 0 6 1  . 4 9 3  0 . 1 2  2 . 7  S Q R T  T r a n s f o r m a t i o n  ( S Q R T  C h o l e s )  . 3 4 9  . 2 4 9  1 . 4 0  - . 2 0 7  . 4 3 9  - 0 . 4 7  
H D L   . 4 3 9  . 2 4 9  1 . 7 6  - . 0 6 4  . 4 9 3  - . 0 1 3          
C h o l e s t e r  
R a t i o  
. 9 0 1  . 2 4 9  3 . 6 2  . 5 5 4  . 4 3 9  1 . 2 6  3 . 4  L o g  T r a n s f o r m a t i o n  ( L o g  C h o l R a t i o )  . 2 6 4  . 2 4 9  1 . 0 6  - . 4 9 0  . 4 3 9  - 1 . 1 2  
T r i -
g l y c e r i d e s  
1 . 7 6  . 2 4 9  7 . 0 7  3 . 8 2  . 4 9 3  . 7 4 8  4 . 1  L o g  T r a n s f o r m a t i o n  ( L o g  T r i g )  . 2 9 4  . 2 4 9  . 1 8 1  - . 0 9 4  . 4 9 3  - 0 . 1 9  
N B  M i c r o v a s c .  D i s e a s e :  M i c r o v a s c u l a r  D i s e a s e  c o m b i n e d  r a t i n g  o f  s e v e r i t y  r e t i n o p a t h y ,  n e u r o p a t h y  a n d  n e p h r o p a t h y ;  C h o l e s t e r . =  T o t a l  C h o l e s t e r o l ;  H D L  =  H D L  
C h o l e s t e r o l ;  C h o l e s t e r .  R a t i o  =  C h o l e s t e r o l  R a t i o  ( T o t a l  C h o l e s t e r o l / H D L  C h o l e s t e r o l  
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Table O.1 
Correlation between Demograhphic and Diabetes Health Variables 
 
Var iab le  Dura t ion  
o f  
D iagnos i s  
Age  a t  
Onse t  
HbA1c  
Cur ren t  
Mean   
HbA1c  
HbA1c   
Recen t  
HbA1cSD Highes t  
Re t inopa thy  
Mic ro  
To ta l  
Insu l in  
Res i s t ance  
(eGDR)  
Hypo  
He lp  
Age  .381  
( .000)**  
.271  
( .004)**  
- .011  
( .46 )  
.099   
( .17 )  
.028   
( .40 )  
- .076  
( .23 )  
.276  
( .004)**  
.310  
( .001)**  
- .035  
( .37 )  
.000  
 ( .50 )  
Educa t ion  - .083   
( .21 )  
.077   
( .23 )  
- .223  
( .02 )*  
- .145  
( .08 )  
- .191  
( .03 )*  
- .113  
( .14 )  
- .142  
 ( .09 )  
- .227  
( .014)*  
.048   
( .33 )  
- .138  
( .09 )  
Gender  
(Female )  
.137  
( .093)  
- .120   
( .13 )  
- .017   
( .44 )  
.068   
( .26 )  
.058   
( .29 )  
.072   
( .25 )  
- .002   
( .49 )  
- .056  
( .30 )  
.571  
( .000)**  
- .008   
( .47 )  
NART IQ  - .040  
( .31 )  
.190   
( .03 )*  
- .237  
( .011)*  
- .143  
( .09 )  
- .167  
( .054)  
- .209  
( .02 )*  
- .047   
( .33 )  
- .199  
( .03 )*  
.140  
( .091)  
- .097  
( .18 )  
Spearman’s  rho  one- ta i led  s igni f icance  used  *p< .05 ,  **p<.01   
Level  of  insu l in  res is tance  based  on  es t imated  g lucose  d isposa l  ra te  (eGDR) –  h igher  eGDR is  re la ted  to  lower  insu l in  res is tance  
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Table O.2  
Correlation of Diabetes Health Variables with Cognitive Tests  
a .  Pearson’s  corre la t ion  one- ta i led  used*p<.05 ,  **p<.01  
b .  Spearman’s  rho  one- ta i led  used*p<.05 ,  **p<.01  
TMT corre la t ions  were  reversed  for  ease  of  compar ison  wi th  o ther  cogni t ive  tes ts  
Level  of  insu l in  res is tance  based  on  es t imated  g lucose  d isposa l  ra te  (eGDR) –  h igher  eGDR is  re la ted  to  lower  insu l in  res is tance  
 
 
 
 
 
 
Var iab le  Age-
Adjus ted  
Cog  Change  
TMTA TMTB SRI  SRD SRR  SDM T-W  SDM T-O Dig i t  Span  
Dura t ion  o f  
D iagnos i s a  
- . 034  ( .37 )  - .205  ( .02 )*  - .238  ( .01 )*  .088  ( .20 )  .051  ( .31 )  - .033  ( .38 ) b  - .125  ( .12 )  - .172  
( .049)*  
- .016  ( .44 )  
Age  o f  Onse t a  . 038  ( .36 )  .123  ( .12 )  .126  ( .11 )  - .088  ( .20 )  - .080  ( .22 )  - .020  ( .43 ) b  . 067  ( .26 )  .059  ( .29 )  .096  ( .18 )  
Insu l in  
Res i s t ance  
(eGDR) a  
- .008  ( .47 )  - .094  ( .19 )  - .039  ( .36 )  .063  ( .28 )  .077  ( .23 )  .137  ( .10 ) b  . 079  ( .23 )  .036  ( .37 )  .024  ( .41 )  
Hypo  He lp b  - .106  ( .15 )  - .077  ( .23 )  - .046  ( .33 )  - .026  ( .40 )  .000  ( .50 )  .086  ( .21 )  - .007  ( .47 )  .043  ( .34 )  - .102  ( .16 )  
H ighes t  
Re t ionopa thy b  
 
- .188  ( .04 )*  - .227  
( .014)**  
- .187  ( .04 )*  .016  ( .44 )  - .024  ( .41 )  - .154  ( .070 )  - .152  ( .07 )  - .168  ( .054)  .109  ( .15 )  
Mic rovascu la r  
To ta l a  
- . 209  ( .02 )*  - .258  
( .006)**  
- .264  
( .005)**  
- .023  ( .41 )  - .099  ( .17 )  - .190  ( .03 ) b *  - .307  
( .001)**  
- .275  
( .004)**  
- .063  ( .27 )  
Mean  HbA1c a  - .171  ( .051 )  .006  ( .48 )  .010  ( .46 )  .091  ( .19 )  .044  ( .34 )  - .150  ( .08 ) b  - .052  ( .31 )  - .014  ( .45 )  .005  ( .48 )  
HbA1c  
Recen t a  
- . 141  ( .09 )  .064  ( .27 )  .050  ( .32 )  .172  ( .049)*  .105  ( .16 )  - .153  ( .07 ) b  . 048  ( .33 )  .044  ( .34 )  - .016  ( .44 )  
HbA1c  
Cur ren t a  
- . 125  ( .11 )  .098  ( .18 )  - .047  ( .33 )  .186  ( .02 )*  .150  ( .07 )  - .156  (07 ) b  - .011  ( .48 )  - .026  ( .40 )  - .080  ( .22 )  
G lucose  on  
Tes t  Da te a  
- .136  ( .10 )  - .052  ( .32 )  - .252  
( .008)**  
- .058  ( .29 )  - .076  ( .24 )  - .036  ( .37 ) b  - .093  ( .19 )  - .070  ( .26 )  - .220  
( .018)*  
HbA1c  SD a  - .079  ( .23 )  .024  ( .41 )  .025  ( .41 )  - .005  ( .48 )  - .044  ( .34 )  - .024  ( .41 ) b  - .065  ( .27 )  - .006  ( .48 )  - .089  ( .20 )  
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Table O.3 
Correlation between Diabetes Health Variables 
 
Var iab le  Mean  HbA1c  HbA1c  
Recen t  
HbA1c  
Cur ren t  
G lucose  
on  Tes t  
Da te  
HbA1cSD Dura t ion  
o f  
D iagnos i s  
Age  a t  
D iagnos i s  
Insu l in  
Res i s t ance  
(eGDR)  
Highes t  
Re t inopa t
hy  
Mic rovascu la r  
To ta l  
HbA1c  
Recen t a  
. 826  
( .000)**  
         
HbA1c  
Cur ren t a  
. 580  
( .000)**  
.794  
( .000)**  
        
G lucose  On  
Tes t  Da te a  
. 273  
( .005)**  
.282  
( .003)**  
.249  ( .009 )         
HbA1c  SD a  .492  
( .000)**  
.373  
( .000)*  
.181  ( .040 )  .261  
( .006)**  
      
Dura t ion  o f  
D iagnos i s a  
. 050  ( .32 )  - .020  ( .42 )  .003  ( .49 )  .176  
( .048)*  
.138  ( .09 )       
Age  o f  Onse t a  . 024  ( .41 )  .029  ( .39 )  - .002  ( .49 )  - .174  
( .049)*  
- .230  
( .013)*  
- .715  
( .000)**  
    
In su l in  
Res i s t ance  
(eGDR) a  
- .292  
( .002)**  
- .390  
( .000)**  
- .500  
( .000)**  
- .167  
( .058)  
- .119  
( .129)  
.001  ( .50 )  - .034  ( .37 )     
H ighes t  
Re t inopa thy b  
. 365  
( .000)**  
.333  
( .001)**  
.274  
( .004)**  
.073  ( .25 )  .080  
( .223)  
.367  
( .000)**  
- .148  ( .08 )  - .311  
( .001)**  
  
Mic rovascu la r  
To ta l a  
. 470  
( .000)**  
.350  
( .000)**  
.202  
( .026)**  
.103  ( .17 )  .156  
( .067)  
.345  
( .000)**  
- .145  ( .08 )  - .320  
( .001)**  
.817  
( .000)**  
 
Hypo  He lp b  - .056  ( .30 )  - .010  ( .46 )  .149  ( .08 )  - .249  
( .009)**  
.040  ( .35 )  - .011  
( .46 )  
- .044  ( .34 )  .033  ( .38 )  - .059  
( .29 )  
.042  ( .34 )  
a .Pearson’s  one- ta i led  s igni f icance  used  *p< .05 ,  **p<.01  
b .Spearman’s  rho  one- ta i led  s igni f icance  used  *p< .05 ,  **p<.01   
Level  of  insu l in  res is tance  based  on  es t imated  g lucose  d isposa l  ra te  (eGDR) –  h igher  eGDR is  re la ted  to  lower  insu l in  res is tance  
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Table O.4 
Correlation between General Health Variables and Cognitive Tests 
 
Var iab le  NART-IQ  TMTA TMTB SRI  SRD SDM T-W  SDM T-O Dig i t  Span  Age-
Adjus ted  
Cogn i t ive  
Change  
W ais t -H ip  
Ra t io   
- .060  ( .28 )  .164  ( .06 )  .095  ( .19 )  - .170  ( .05 )  - .177  
( .046)*  
- .040  ( .35 )  - .016  ( .44 )  - .035  ( .37 )  .103  ( .17 )  
Body  Mass  
Index   
- .114  ( .14 )  .077  ( .23 )  .103  ( .16 )  - .159  ( .06 )  - .135  ( .10 )  .084  ( .21 )  .097  ( .18 )  .018  ( .43 )  - .126  ( .11 )  
Sys to l i c  BP  - .038  ( .36 )  - .069  ( .26 )  - .013  ( .45 )  - .100  ( .17 )  - .105  ( .18 )  - .107  ( .15 )  - .058  ( .29 )  - .060  ( .28 )  .048  ( .32 )  
D ias to l i c  BP  .013( .45 )  .161  ( .06 )  - .023  ( .41 )  - .091  ( .19 )  - .058  ( .29 )  .023  ( .41 )  - .006  ( .48 )  - .051  ( .31 )  .052  ( .31 )  
H igh  BP  - .057  ( .29 )  - .099  ( .17 )  - .011  ( .46 )  - .077  ( .23 )  - .108  ( .15 )  - .051  ( .32 )  - .043  ( .34 )  - .036  ( .37 )  .006  ( .48 )  
To ta l  Cho les  .000  ( .50 )  .120  ( .13 )  - .038  ( .36 )  .016  ( .44 )  .011  ( .46 )  .071  ( .25 )  - .009  ( .47 )  - .096  ( .18 )  - .082  ( .22 )  
HDL .037  ( .36 )  - .041  ( .35 )  - .037  ( .36 )  .152  ( .07 )  .144  ( .08 )  .048  ( .32 )  .054  ( .31 )  - .175  ( .046)*  .008  ( .47 )  
To ta l /HDL 
Ra t io  
- .035  ( .37 )  .099  ( .17 )  .021  ( .42 )  - .099  ( .17 )  - .100  ( .17 )  - .004  ( .49 )  - .055  ( .30 )  .096  ( .18 )  - .045  ( .33 )  
T r ig lyce r ides  - .061  ( .28 )  .056  ( .30 )  .070  ( .25 )  - .114  ( .14 )  - .128  ( .11 )  - .071  ( .25 )  - .047  ( .33 )  .133  ( .10 )  .034  ( .37 )  
RPE - .021  ( .42 )  .074  ( .25 )  .088  ( .21 )  - .070  ( .26 )  .031  ( .39 )  - .044  ( .35 )  .091  ( .21 )  .082  ( .23 )  .237  ( .02 )*  
Exerc i se   . 037  ( .36 )  .135  ( .10 )  .123  ( .12 )  .031  ( .38 )  .082  ( .22 )  .007  ( .47 )  .053  ( .31 )  .120  ( .13 )  .161  ( .06 )  
Cogn i t ive  
Ac t iv i ty  
.182  ( .04 )*  .071  ( .25 )  .108  ( .15 )  .036  ( .37 )  .089  ( .20 )  .093  ( .19 )  .104  ( .16 )  .222  ( .02 )*  .118  ( .13 )  
Spearman’s  rho  one- ta i led  s igni f icance  used  *p<.05  
TMT corre la t ions  were  reversed  for  ease  of  compar ison  wi th  o ther  cogni t ive  tes ts  
RPE:  Ra te  o f  Pe rce ived  Exer t ion  in  exe rc i se  on  a  sca le  o f  0  (no  e f fo r t )  to  10  (max imal  e f fo r t )  
Exerc i se :  Se l f - r a t ing  in  compar i son  to  age  pee r s  –  Less  Exerc i se  (0 ) ,  Same  Exerc i se  (1 ) ,  More  Exerc i se  (2 )  
Cogn i t ive  Ac t iv i ty :  Se l f - r a t ing  in  compar i son  to  age  pee r s  –  Less  Cogn i t ive  Ac t iv i ty  (0 ) ,  Same  Cogn i t ive  Ac t iv i ty  (1 ) ,  More  Cogn i t ive  Ac t iv i ty  (2 )  
To ta l  Cho les :  To ta l  Cho les te ro l ;  HDL –  High-dens i ty  l ipopro te in  (h ighe r  sco res  ind ica te  be t t e r  hea l th ) ;   
H igh  BP  :  Sys to l i c  >140  and  o r  D ias to l i c  >90  
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Table P.1 
Inter-correlations between HADS and WBQ scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 H A D S  A  H A D S  D  G N W B  G E  G P W B  G S  D N W B  D S  D P W B  G W B  
HADS-Depress  .631            
W BQ Genera l  
Nega t ive   
W el l -Be ing  (GNW B) 
.702   .486          
W BQ Genera l  Energy  
(GE)  
- .462  
 
- .645  - .529         
W BQ Genera l  
Pos i t ive   
W el l -Be ing  (GPW B)  
- .492  
 
- .702  - .517  .673        
W BQ Genera l  S t re s s  
(GS)  
.660  
 
.503  .644  - .480  - .540       
W BQ Diabe tes  
Nega t ive   
W el l -Be ing  (DNW B) 
.550  
 
.458  .502  - .390  - .417  .436      
W BQ Diabe tes  S t re s s  
(DS)  
.485  
 
.449  .401  - .352  - .367  .424  .674     
W BQ Diabe tes  
Pos i t ive  W el l -Be ing  
(DPW B)  
- .387  
 
- .409  - .266  .420  .494  - .194  - .451  - .371    
W BQ Genera l  
W el l -Be ing  (GW B)  
- .681  - .718  - .767  .815  .843  - .817  - .515  - .446  .416   
W BQ Diabe tes   
W el l -Be ing  (DW B)  
- .531  - .480  - .438  .456  .530  - .410  - .819  - .766  .788  .546  
Spea rman’s  rho  one-s ided  co r re la t ion  va lues .  A l l  va lues  s ign i f i can t  a t  p<.01  
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Table P.2 
Correlation of Psychological Variables with Demographic and Diabetes Health Variables 
 
 
  
V a r i a b l e  A g e  E d u c a t i o n  G e n d e r  D u r a t i o n  o f  
D i a g n o s i s  
A g e  o f  
O n s e t  
H y p o  
H e l p  
I n s u l i n  R e s i s t  
( e G D R )  
H i g h e s t  
R e t i n o p a t h y  
M i c r o v a s c u l a r  
T o t a l  
M e a n  
H b A 1 c  
R e c e n t  
H b A 1 c  
C u r r e n t   
H b A 1 c  
H A D S - A n x i e t y  - . 2 8 9  
( . 0 0 2 ) * *  
- . 0 0 3  
( . 4 9 0 )  
- . 1 5 4  
( . 0 7 0 )  
- . 1 0 6     
( . 1 5 )  
- . 0 9 5  
( . 1 8 )  
. 1 6 2  
( . 0 6 )  
. 2 8 0  
 ( . 0 0 3 ) * *  
- . 2 8 8  
( . 0 0 2 ) * *  
- . 2 6 0   
( . 0 0 6 ) * *  
- . 0 2 5  
( . 4 1 )  
- . 0 7 3  
( . 2 4 )  
- . 0 4 9  
( . 3 2 )  
H A D S - D e p r e s s  - . 1 4 3  
( . 0 9 )  
- . 1 7 0  
( . 0 5 1 )  
- . 0 7 7  
( . 2 3 )  
- . 0 7 9  
( . 2 3 )  
- . 0 7 4  
( . 2 3 )  
. 0 9 2  
( . 1 9 )  
. 1 0 3  
 ( . 1 7 )  
- . 1 8 5   
( . 0 3 8 ) *  
. 0 0 3   
( . 4 9 )  
. 1 8 7  
( . 0 3 6 ) *  
. 1 0 7  
( . 1 5 )  
. 0 9 7  
( . 1 8 )  
W B Q   
G e n e r a l  
N e g a t i v e   
W e l l - B e i n g  
- . 3 2 7  
( . 0 0 1 ) * *  
. 0 8 7   
( . 2 0 )  
- . 2 6 5  
( . 0 0 5 ) * *  
- . 0 5 3  
 ( . 3 1 )  
- . 1 7 6  
( . 0 4 3 ) *  
. 0 4 5  
( . 3 6 )  
. 2 6 7  
 ( . 0 0 5 ) * *  
- . 1 7 0  
 ( . 0 5 0 )  
- . 2 0 5   
( . 0 2 4 ) *  
- . 0 1 6  
( . 4 4 )  
- . 0 2 2   
( . 4 2 )  
- . 0 9 6  
( . 1 8 )  
W B Q  
G e n e r a l  E n e r g y  
. 3 0 2  
( . 0 0 2 ) * *  
. 1 1 1   
( . 1 4 )  
. 1 2 0  
( . 1 2 )  
. 0 7 1  
 ( . 2 5 )  
. 1 7 4  
( . 0 4 7 ) *  
- . 0 9 0  
( . 1 9 )  
- . 1 0 1  
 ( . 1 7 )  
. 1 5 6  
 ( . 0 6 7 )  
. 0 7 8   
( . 2 3 )  
- . 0 7 3  
( . 2 4 )  
- . 1 5 3  
( . 0 7 0 )  
- . 0 8 2  
( . 2 2 )  
W B Q   
G e n e r a l  P o s i t i v e   
W e l l - B e i n g  
. 3 0 4  
( . 0 0 1 ) * *   
. 2 1 5  
( . 0 1 9 ) *  
. 1 1 8  
( . 1 3 )  
. 1 3 4  
 ( . 1 0 )  
. 1 0 3  
( . 1 6 )  
- . 1 2 1  
( . 1 2 )  
- . 0 6 4  
 ( . 2 7 )  
. 2 1 4  
( . 0 1 9 ) *  
. 0 4 2   
( . 3 4 )  
 - . 0 8 1  
( . 2 2 )  
- . 0 9 1  
( . 1 9 )  
- . 0 8 2  
( . 2 2 )  
W B Q   
G e n e r a l  S t r e s s  
- . 3 9 3  
( . 0 0 0 ) * *  
. 0 8 5   
( . 2 1 )  
- . 1 4 9  
( . 0 8 )  
- . 0 4 1  
 ( . 3 5 )  
- . 2 4 9  
( . 0 0 8 ) * *  
. 0 3 1  
( . 3 8 )  
. 1 8 3  
 ( . 0 4 0 ) *  
- . 2 4 1   
( . 0 1 0 ) *  
- . 1 7 3   
( . 0 4 8 ) *  
. 1 1 2  
( . 1 4 )  
. 0 1 7  
( . 4 4 )  
. 0 2 0  
( . 4 3 )  
W B Q   
D i a b e t e s  
N e g a t i v e   
W e l l - B e i n g  
- . 2 4 3  
( . 0 0 8 ) *  
- . 0 8 7  
( . 2 0 )  
- . 1 8 0  
( . 0 4 1 ) *  
- . 0 7 3  
 ( . 2 4 )  
- . 0 6 7  
( . 2 6 )  
. 1 0 4  
( . 1 6 )  
. 1 3 1  
 ( . 1 1 )  
- . 0 6 8   
( . 2 6 )  
. 0 2 0   
( . 4 2 )  
. 1 3 1  
( . 1 1 )  
. 1 4 9  
( . 0 7 5 )  
. 0 8 9  
( . 2 0 )  
W B Q  
D i a b e t e s  S t r e s s  
- . 1 2 9  
( . 1 0 8 )  
. 0 5 3  
 ( . 3 1 )  
- . 0 3 3  
( . 3 8 )  
- . 0 6 0  
 ( . 3 0 )  
- . 0 3 6  
( . 3 7 )  
. 0 0 8  
( . 4 7 )  
. 1 0 2  
 ( . 1 7 )  
- . 0 4 7   
( . 3 3 )  
. 0 2 5   
( . 4 1 )  
. 2 2 2  
( . 0 1 6 ) *  
. 1 8 1  
( . 0 4 0 ) *  
. 1 0 1  
( . 1 7 )  
W B Q  
D i a b e t e s  
P o s i t i v e  W e l l -
B e i n g  
. 2 3 9  
( . 0 1 0 ) *  
. 0 8 8   
( . 2 0 )  
. 0 6 3  
( . 2 7 )  
. 2 5 3  
 ( . 0 0 7 ) *  
- . 0 8 2  
( . 2 2 )  
- . 1 2 2  
( . 1 4 )  
- . 1 1 4  
 ( . 1 4 )  
. 1 1 7   
( . 1 3 )  
. 1 0 4  
( . 1 6 )  
- . 1 3 3  
( . 1 0 )  
- . 1 8 2  
( . 0 3 9 ) *  
- . 1 7 6  
( . 0 4 5 ) *  
W B Q  G e n e r a l  
W e l l - B e i n g  
. 4 0 6  
( . 0 0 0 ) * *  
. 0 4 4   
( . 3 4 )  
. 1 6 1  
( . 0 6 1 )  
. 1 0 9  
 ( . 1 5 )  
. 1 9 9  
( . 0 3 ) *  
- . 0 6 4  
( . 2 7 )  
- . 1 4 9   
( . 0 8 )  
. 2 5 0  
( . 0 0 7 ) * *  
. 1 5 0   
( . 0 7 5 )  
- . 0 9 0  
( . 2 0 )  
- . 0 8 1  
( . 2 2 )  
- . 0 5 5  
( . 3 0 )  
W B Q   
D i a b e t e s   
W e l l - B e i n g  
. 2 6 4  
( . 0 0 5 ) *  
. 0 4 4   
( . 3 4 )  
. 1 2 7  
( . 1 1 )  
. 1 4 9  
 ( . 0 8 )  
. 0 2 5  
( . 4 1 )  
- . 1 0 3  
( . 1 6 )  
- . 1 3 5   
( . 1 0 )  
. 1 0 9   
( . 1 5 )  
. 0 4 9   
( . 3 2 )  
- . 1 7 4  
( . 0 4 8 ) *  
- . 2 0 4  
( . 0 2 4 ) *  
- . 1 5 2  
( . 0 7 )  
Spea rman’s  rho  one- ta i l ed  s ign i f i cance  l eve l  ind ica ted  *p<.05 ,  **p<.01  
Leve l  o f  in su l in  r e s i s t ance  i s  based  on  e s t ima ted  g lucose  d i sposa l  r a te  ( eGDR)  –  h ighe r  r a t ing  o f  eGDR i s  r e l a ted  to  lower  in su l in  r e s i s t ance  Gender :  
Female  (0 )  M ale  (1 )  
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Table P.3 
Correlation of Psychological Variables with Cognitive Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V a r i a b l e  N A R T  
I Q  
T M T  A  T M T  B  S t o r y  
R e c a l l  
I m m e d i a t e  
S t o r y  
R e c a l l  
D e l a y e d  
S y m b o l  D i g i t  
W r i t t e n  
S y m b o l  D i g i t  
O r a l  
D i g i t  
S p a n  
A g e - A d j u s t e d  
C o g n i t i v e  
C h a n g e  
H A D S - A n x i e t y  - . 1 0 2  
( . 1 6 )  
. 0 8 5  
( . 2 1 )  
- . 0 4 2  
( . 3 4 )  
- . 0 7 9   
( . 2 3 )  
. 0 0 2   
( . 4 9 )  
. 1 1 0   
( . 1 5 )  
. 1 3 7   
( . 0 9 )  
- . 1 1 4  
( . 1 4 )  
- . 1 8 0  
( . 0 4 ) *  
H A D S - D e p r e s s  - . 2 1 9  
( . 0 2 ) *  
. 1 0 3  
( . 1 6 )  
- . 1 1 2  
( . 1 4 )  
- . 0 2 8    
( . 4 0 )  
- . 0 4 8   
( . 3 2 )  
- . 0 7 2   
( . 2 5 )  
- . 0 3 3   
( . 3 8 )  
- . 2 7 4  
( . 0 0 8 ) * *  
- . 1 4 5  
( . 0 8 )  
W B Q   
G e n e r a l  N e g a t i v e   
W e l l - B e i n g  
- . 0 5 9  
( . 2 9 )  
- . 0 6 0   
( . 2 8 )  
- . 0 4 1  
( . 3 5 )  
- . 0 6 9   
( . 2 6 )  
- . 0 0 6   
( . 4 8 )  
. 0 5 9   
( . 2 9 )  
. 0 3 7  
( . 3 6 )  
 
- . 1 1 1  
( . 1 4 )  
- . 2 5 5  
( . 0 0 7 ) * *  
W B Q  
G e n e r a l  E n e r g y  
. 1 7 5  
( . 0 4 5 ) *  
. 0 6 7  
( . 2 6 )  
. 1 1 1  
( . 1 4 )  
. 0 4 2  
 ( . 3 4 )  
. 0 5 1   
( . 3 1 )  
. 0 3 0   
( . 3 9 )  
- . 0 0 7  
( . 4 7 )  
. 2 1 5   
( . 0 2 ) *  
. 1 7 5  
( . 0 4 6 ) *  
W B Q   
G e n e r a l  P o s i t i v e   
W e l l - B e i n g  
. 2 2 2  
( . 0 1 6 ) *  
. 0 7 8  
( . 2 3 )  
. 0 6 3  
( . 2 7 )  
. 0 6 6   
( . 2 7 )  
. 0 4 9   
( . 3 2 )  
. 0 2 8  
( . 4 0 )  
- . 0 6 8  
( . 2 6 )  
. 2 5 6  
( . 0 0 6 ) * *  
. 1 0 4  
( . 1 6 )  
W B Q   
G e n e r a l  S t r e s s  
- . 1 2 2  
( . 1 2 )  
- . 0 1 7   
( . 4 4 )  
- . 0 1 5  
( . 4 4 )  
- . 0 0 5   
( . 4 9 )  
. 0 4 8  
( . 3 2 )  
- . 0 5 4  
( . 3 0 )  
- . 0 1 0  
( . 4 6 )  
- . 0 4 8  
( . 3 2 )  
- . 2 4 3 * *  
( . 0 0 9 )  
W B Q   
D i a b e t e s  
N e g a t i v e   
W e l l - B e i n g  
- . 1 4 4  
( . 0 8 )  
- . 0 2 7   
( . 4 0 )  
- . 2 2 0  
( . 0 2 ) *  
. 0 3 8   
( . 3 6 )  
. 0 5 6   
( . 3 0 )  
- . 0 0 2   
( . 4 9 )  
. 0 3 1  
( . 3 9 )  
- . 1 4 5  
( . 0 8 )  
- . 2 2 1  
( . 0 1 6 ) *  
W B Q  
D i a b e t e s  S t r e s s  
. 0 7 8   
( . 2 3 )  
. 0 1 5  
( . 4 4 )  
- . 0 8 7  
( . 2 1 )  
. 0 6 2  
( . 2 8 )  
. 0 9 4   
( . 1 8 )  
. 0 3 4   
( . 3 7 )  
. 1 0 5  
( . 1 6 )  
. 0 5 1  
( . 3 1 )  
- . 1 1 2  
( . 1 4 )  
W B Q  
D i a b e t e s  P o s i t i v e  
W e l l - B e i n g  
. 0 2 8   
( . 3 9 )  
. 0 3 6  
( . 3 7 )  
. 0 7 2  
( . 2 5 )  
- . 0 3 9  
( . 3 5 )  
- . 0 4 2  
 ( . 3 4 )  
- . 0 8 6  
( . 2 1 )  
 
- . 0 9 8  
( . 1 8 )  
. 1 1 8  
( . 1 3 )  
. 1 0 9  
( . 1 5 )  
W B Q  G e n e r a l  
W e l l - B e i n g  
. 1 9 0  
( . 0 3 ) *  
. 0 6 1  
( . 2 8 )  
. 0 7 4  
( . 2 5 )  
. 0 3 8   
( . 3 6 )  
. 0 1 0   
( . 4 6 )  
. 0 4 5  
( . 3 3 )  
- . 0 1 5  
( . 4 4 )  
. 1 9 6   
( . 0 3 ) *  
. 2 3 5  
( . 0 1 ) *  
W B Q   
D i a b e t e s   
W e l l - B e i n g  
. 0 4 7   
( . 3 3 )  
. 0 5 7  
( . 2 9 )  
. 1 6 2  
( . 0 6 )  
- . 0 4 6   
( . 3 3 )  
- . 0 7 9   
( . 2 2 )  
. 0 2 4  
( . 4 1 )  
- . 0 6 0  
( . 2 8 )  
. 1 2 4  
( . 1 2 )  
. 2 1 4  
( . 0 2 ) *  
Spea rman’s  rho  one- ta i l ed  s ign i f i cance  ind ica ted  *p<.05 ,  **p<.01  
TMT cor re la t ions  were  reve r sed  fo r  ease  o f  compar i son  wi th  o the r  cogn i t ive  t e s t s  
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Appendix Q               
fMRI Ethics Documentation 
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Appendix R              
fMRI Study Participant Information Sheet and Consent Form  
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Part ic ipant Information Sheet 
Thinking and Reasoning in Type 1 diabetes: An Exploratory 
Neuroimaging Study  
 
You are invi ted to part ic ipate in a research project.  This research is part  of  
an educat ional qual i f icat ion. The fo l lowing information is to help you 
decide i f  you want to take part.  Read i t  careful ly  and discuss i t  wi th other 
people i f  you want.  You can ask me any quest ions and I  wi l l  do my best to 
answer them. Take t ime to decide whether or not you wish to take part .   
 
What is the purpose of the study? 
While much is known about the importance of b lood glucose level  contro l  in 
d iabetes for the maintenance of physical  wel l  being, recent evidence 
indicates that i t  may also be important in maintain ing th inking and 
reasoning ski l ls .  The aim of th is project is  to f ind out whether b lood 
glucose contro l  levels and changes in b lood vessel regulat ion may have a 
subt le impact on brain structure and funct ion for indiv iduals with d iabetes.  
 
Why have I  been chosen? 
This is  a fo l low-up study of the same research quest ion using cognit ive 
tasks. You are invi ted to take part  in th is study because you took part  in 
the cognit ive component of  th is study.  
 
Do I have to take part? 
I t  is  up to you to decide whether or not to take part .  I f  you do decide to 
take part  you wi l l  be given th is information sheet to keep and be asked to 
s ign a consent form. I f  you decide to take part  you are st i l l  f ree to withdraw 
at any t ime and without g iv ing a reason. A decis ion to withdraw at any 
t ime, or a decis ion not to take part ,  wi l l  not af fect the care you receive  or 
af fect  your re lat ionship with medical  staf f  looking after you, now or in the 
future  
 
What wil l  happen if  I  decide to take part? 
I f  you decide to take part  you wi l l  have a magnet ic resonance imaging 
(MRI) structural  and funct ional scan at the Cl in ical  Research Centre (CRC) 
at Ninewel ls Hospita l ,  Dundee. The scan i tsel f  wi l l  take up to 60 minutes 
spl i t  in to 2 sect ions, including a 45 minute brain MRI and a 15 minute MRI 
of  a major b lood vessel in the chest.  The preparat ion for the scan (outs ide 
the scanner) can take up to 60 minutes as wel l .  The tota l  t ime required for 
the study wi l l  be a maximum of 2 hours for both the preparat ion and 
scanning t ime together.  The structural  and funct ional scans are completed 
together with in th is s ingle session.  
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In preparat ion for the MRI scan, you wi l l  go through a safety quest ionnaire,  
and i f  you are considered safe to enter the MRI sui te by the imaging staf f ,  
you wi l l  be given tra in ing on the di f ferent tasks you wi l l  be asked to 
complete whi le in the scanner.  As you require an adequate glucose supply 
to perform your best on the cognit ive tasks, before the scan you wi l l  be 
asked to take a blood glucose measurement (using your personal monitor)  
to ensure that you are not exper iencing hypoglycaemia. I f  you are below 4 
mmol/ l i t re,  g lucose wi l l  be provided and a second glucose reading wi l l  be 
required to ensure you are ready to begin the cognit ive tasks.   
 
For those using external (removable) insul in pumps, p lease note that an 
insul in pump is not MRI safe and i t  must be removed before you enter the 
MRI scanner.  For th is study, that would be for  a per iod of  up to 60 minutes 
whi le you are in the MRI scanner.  I f  you use a removable insul in pump and 
would l ike to take part  in th is study, p lease check with your physic ian. I f  
removing the insul in pump for th is per iod of t ime is not advised, i t  wi l l  not 
be safe for you to part ic ipate in th is study.  
 
Once these safety checks and tra in ing have been completed, you wi l l  then 
change into a hospita l  gown or scrubs and l ie in an MRI scanner.  You wi l l  
be asked to l ie  very st i l l  dur ing imaging. Dur ing the functional scans you 
wi l l  be asked to complete two th inking tasks, s imi lar to the ones you 
completed in the “Thinking and Reasoning in Type 1 diabetes” study. 
Dur ing sect ions of the study we wi l l  ask you to perform these th inking tasks 
seen through goggles on a computer screen which require a f inger button 
press response including: 
 
•  Responding to remembered let ters 
•  Comparison of s imple v isual images 
 
You wi l l  be given c lear instruct ions and pract ice pr ior to going into the 
scanner on how to complete these tasks and you wi l l  be able to l is ten to 
and speak to the person carry ing out your scan, who wi l l  remind you of 
what you have to do, before the scanning starts.  The task instruct ions wi l l  
a lso be presented for you to read r ight before the task begins. 
 
What is Magnetic Resonance Imaging? 
Magnetic Resonance Imaging (or MRI) uses a high strength magnetic field and non-
ionising radiofrequency radiation to obtain images of the inside of the body. An MRI 
scanner looks a little like a CT scanner. MRI scans are painless, although it is possible 
that you might experience a minor amount of discomfort as a result of lying still on the MRI 
table.  
 
What is fMRI? 
Functional Magnetic Resonance Imaging (or fMRI) is a specific type of MRI scan which 
concentrates on the brain. It provides information about which parts of the brain are being 
used when people perform different tasks such as listening to noises, looking at pictures or 
patterns or performing simple mental tasks. 
 
What are the possible disadvantages and risks of taking part? 
The MRI scanner is  loud and al though you wi l l  be given earplugs to reduce 
the noise, you wi l l  s t i l l  hear i t .  You must l ie  as st i l l  as possib le dur ing 
imaging. Some people f ind th is uncomfortable and feel  a l i t t le  st i f f  
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afterwards. I f  you exper ience feel ings of  c laustrophobia,  we suggest that 
you do not take part .  
 
There are a number of  safety hazards involved in enter ing an MR scanner.  
We reduce the r isks involved as much as possib le with our robust safety 
measures. These have ensured that NHS Tayside has provided a safe MRI 
service for over 10 years.  Please speak to one of the people l is ted below i f  
you would l ike more information. Your scan wi l l  be checked by a 
Consultant Radiologist .  I f  an unexpected abnormal i ty  is  d iscovered, i t  
could have an impact on future appl icat ions that you make for mortgages, 
l i fe insurance, health insurance or other serv ices. 
 
We do not ant ic ipate any adverse effects f rom taking part  in th is study. I f  
you wish to complain,  or have any concerns about any aspect of  the way 
you have been approached or t reated dur ing the course of th is study, the 
normal Nat ional Health Service complaints mechanisms should be 
avai lable to you. 
  
 
What are the possible benefits of taking part? 
There are no direct advantages to you. However,  we wi l l  make any future 
publ icat ions of  the f indings avai lable to you. I t  is  hoped that th is research 
wi l l  improve our knowledge re lat ing to Type 1 diabetes and may inf luence 
care pract ices and information provided to people with d iabetes in the 
future. An anatomical  image of your brain wi l l  be acquired and shown to a 
Consultant Radiologist .  I t  is  unl ikely but possib le that th is image wi l l  reveal 
an abnormal i ty  that you were unaware of.  Should th is happen, the 
Consultant Radiologist  wi l l  d iscuss the f indings with you, inform your GP i f  
necessary and recommend whether further invest igat ions are appropr iate 
or not.   
 
What if you have any concerns or complaints? 
Every reasonable precaut ion has been taken to ensure th is research is 
conducted safely and effect ively,  in l ine with NHS good pract ice. However,  
you should feel  f ree to d irect any concerns or complaints to Dr.  Ar lene 
Astel l  (01334 462056) at  the Universi ty of  St Andrews who is supervis ing 
th is project and who wi l l  l ia ise on your behalf  with the o ther Higher 
Educat ion and NHS bodies part ic ipat ing in the research. Should you have 
any immediate concerns whi lst  undergoing a scan, however,  then please 
don’t  wait  -  ra ise them immediately with the NHS staf f  who are there to 
assist  you. Of course, th is does not supersede the usual NHS complaints 
processes, in which case you can also submit  a wr i t ten complaint  to the 
NHS Tayside Pat ient L ia ison Manager,  Complaints Off ice, Ninewel ls 
Hospita l ,  Dundee, or use Freephone number 0800 0275507. Whi lst  there is  
no legal l iabi l i ty  for  non-negl igent harm ar is ing from the study, th is should 
not in any way deter you from using the above channels to register,  
d iscuss and resolve any problems, nor does i t  af fect  your legal r ights in the 
event that anyone organis ing or carry ing out the research is shown to be at 
faul t .  
 
What wil l  happen to the information collected in the study? 
All  information col lected about you dur ing the course of the research wi l l  
be kept str ic t ly  conf ident ia l .  Any information about you that leaves the 
hospita l  wi l l  have your name and address removed so that you cannot be 
recognized from i t .  You wi l l  be al located an anonymous ID code dur ing 
362 
test ing which wi l l  be used in p lace of your name on any future publ icat ions. 
Only group results or anonymous indiv idual data wi l l  be communicated in 
Harr iet  Johnston’s PhD thesis,  research publ icat ions or at  professional and 
publ ic  conferences.  
 
Who is organizing and funding the research? 
This research is being completed in fu l f i lment of  PhD requirements for the 
School of  Psychology at the Universi ty of  St.  Andrews. The research is 
supervised by Dr.  Ar lene Astel l ,  a chartered c l in ical  psychologist  and 
lecturer at  the Universi ty of  St.  Andrews, and Dr.  Rory McCrimmon, a 
consultant physic ian at the Strathmore Diabetes Centre,  NHS Tayside in 
col laborat ion with the other Diabetes Centres with in NHS Tayside. Funding 
for neuroimaging is provided through an Anonymous Trust research award 
jo int ly  held with Dr.  Stephen Nicholas, MRI Physic ist  at  the Cl in ical  
Research Centre and Professor Graeme Houston, Consultant Radiologist .   
 
What happens now? 
I f  you agree to take part  you wi l l  be asked to complete a consent form. I f  
you decide not to take part ,  th is wi l l  have no bearing on your future care or 
t reatment f rom the NHS. I f  you decide to take part  we would l ike 
permission to inform your GP. However,  i f  you do not agree to us informing 
your GP you can st i l l  take part.  The Tayside Committee on Medical  
Research Ethics, which has responsib i l i ty  for  scrut in iz ing proposals for 
medical  research on humans, has examined the proposal and has ra ised no 
object ions from the point  of  v iew of medical  eth ics.  I t  is  a requirement that 
the research records are made avai lable to monitors from NHS Tayside/and 
the Regulatory Author i t ies ( the lat ter appl icable ONLY in drug tr ia ls)  whose 
role is  to check that research is proper ly conducted and the interests of  
those taking part  are adequately protected.  
 
Contact for Further Information 
 
Thank you for reading th is information sheet.  I f  you have any further  
quest ions feel  f ree to contact Harr iet  Johnston at  01382 496483. 
 
You may also contact Dr.  Ar lene Astel l ,  who is the academic supervisor of  
th is PhD research, for further information. You can reach Dr.  Astel l  at  
01334 462056.  
 
Dr.  Ewan Pearson, a consultant physic ian at Ninewel ls Hospita l  who is not 
involved in th is study, is  a lso avai lable to provide an independent opin ion 
about taking part .  You can reach him at 01382 740081.  
 
 
I f  you have understood the contents of  th is sheet and wish to take part ,  
e i ther contact Harr iet  Johnston by leaving a message at  01382 496483, or 
by emai l  h johnston1@nhs.net   
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Patient Ident i f icat ion Number:___________ 
CONSENT FORM  
 
Title of Project: Thinking and Reasoning in Type 1 diabetes: An 
Exploratory Neuroimaging Study 
 
Name of Researcher:  Harr iet  Johnston 
 
                Please init ial  box  
 
 
________________________         ____________________   ___________             
Name of Part ic ipant                               S ignature  Date 
_ 
________________________      ____________________   ___________              
Name of Person Taking Consent    S ignature             Date  
 
1.  I  conf i rm that I  have read and understand the information 
sheet dated . . . . . . . . . . . . . . . . . . . . . . . . . . . .  (vers ion __) for the above 
study and have had an opportuni ty to consider the 
information, the opportuni ty to ask quest ions, and have had 
these answered sat isfactor i ly .  
 
 
 
 
 
 
2.  I  understand that my part ic ipat ion is voluntary and that I  am 
free to withdraw at any t ime, without g iv ing any reason, 
without my medical  care or legal r ights being affected. 
 
 
  
 
3.  I  understand that re levant sect ions of my medical  notes and 
data col lected dur ing the study may be looked at by the 
named researchers from the Universi ty of  St.  Andrews and 
from NHS Tayside where i t  is  re levant to my taking part  in 
th is research. I  g ive permission for these indiv iduals to 
have access to my records. 
 
 
 
 
 
  
 
4.  I  agree to my GP being informed of my part ic ipat ion in the 
study. 
 
 
  
 
 
5.  I  agree to be informed of incidental  f indings i f  d iscovered on 
the MRI scan  
 
 
 
6. I  agree to take part  in the above study.   
 
  
 
 
  
 
364 
Appendix S                 
fMRI Study Procedure Flowchart 
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Appendix T         
Participant Training for fMRI 
 
Schedule participant to arrive 45 minutes to an hour before the scan time. 
Need to get to MRI staff by 20 minutes before the scanning appointment so 
keep track of the time.  
 
1. Consent Form (Make sure ID # is on top):  
• The document quoted in the first point is the one I sent in mail or 
email 
• Need to initial every box and sign/date bottom of form to participate 
• Person taking consent sign/date bottom line 
•  
2. Blood Glucose 
• Need value 5 or more if  below give lucozade or digestives  (lucozade 
if lower than 4) and retest at end of training 
• Record blood glucose value(s) 
 
3. MRI Procedure: 
 
Tell the participant information about what will happen during the exam 
 
a. Radiographer or assistant will go through the questions on the MRI 
Safety Questionnaire to make sure safe to go in MRI 
 
b. Change into scrubs and put belongings in locker 
 
c. Radiographer and physicist will get you ready on the scanner bed. For 
the first scan a cage goes around your head with googles so that you can 
see the thinking tasks on a computer screen. The physicist will  adjust 
the goggles to correct your vision. The machine also makes a very loud 
noise so you will be given earphones to protect your ears. You won’t be 
able to talk to us while in the scanner so if you want to stop at any time 
you will have a bulb to squeeze to contact the radiographer. You will be 
given a trigger to hold in each hand to make responses on the thinking 
tasks. 
 
d. The first scan will be of your brain that takes a total of 45 minutes. For 
the first 20 minutes you will have structural scans of your brain to see 
the different parts.  You just keep your head as still  as possible – your 
eyes can be open or closed.  
 
e. The second set of scans, for the next 20 minutes, will be the functional 
MRI. This shows differences in the activity in your brain when you do a 
thinking task that is easy and one that is a bit harder. There are two 
different tasks and one scan to show what your brain is doing while at 
rest and you will just keep your eyes closed for that one. 
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f. The third part,  for about the last 5 minutes, is a scan of the white matter 
tracts in your brain that connect one part to another. In this scan you 
will feel vibrations as if your head is shaking in different directions – 
this is normal. 
g. Next you will get out of the scanner to stretch for a few minutes after 
this the radiographer will prepare you for the chest scan. This scan takes 
about 15 minutes. For this scan a cage is put around your chest.  You will 
be given instructions to hold your breath for short periods of time or to 
breathe normally. 
 
4. fMRI Task Training  
 
For both tasks open the Presentation software on the Dell computer (needs 
to be plugged in). Go into the Open Experiment tab and choose Nback. 
When ready to start the scenario, put in the participant ID # when 
prompted. Then Start Scenario 
 
a. Nback  
Verbal instructions: The first task is a memory task called the Nback. 
You will see one letter presented on the computer screen every second. 
On the first task, the 0back, you will press the button on the right (L on 
the keypad) every time you see the letter X, when you see any other 
letter you will press the button on the left (A on the keypad). This is the 
easy task. On the second task, the 2 back, you will be asked to press the 
right button (L) every time you see a letter that is the same as 2 letters 
before. You press the left button (A) for every other letter.  For example 
(Show example on sheet included with these instructions) if the letters 
are A, B, C, B, B you would press the left button for A, B, and C then 
the right button for the next B because you saw a B two letters back, and 
left for the next B because it  is only the same as the letter 1 letter back 
or 3 letters back, but not 2 letters back. The best way to do this is to 
repeat the first set of three letters (A, B, C), then update with the next 
set of 3 letters (B C B) then the next (CBB) and then you can compare 
the first letter with the third to know if you should press right or left 
button. I’m going to show you on the computer so that you can try it  for 
yourself.   
 
Make sure you press one of the buttons every time you see a letter.  I  
want you to get as many right as possible, but don’t worry if you make a 
mistake just go on to the next letter – because they keep going. The 
important thing is to keep focused and try your best on the task because 
I’m just interested in what your brain is doing when you are doing the 
easy 0back compared to when you do the harder 2back. 
 
Let the task run through until  you are sure the person understands. At 
first the trainer says the responses out loud while the person presses the 
button, and once they get the hang of it  let them do it  on their own and 
watch the responses to make sure they are getting it  right – if  not give 
more instructions as necessary until  the person learns the task). For the 
368 
2back repeat the letters out loud to show how to update the 3 letters to 
determine what button to press – if  they make mistakes encourage them 
to just focus on the letter presented and start again from there. Press 
esc to stop task once participant gets the hang of it .  You can run 
through one more trial if  necessary by loading the experiment again and 
changing the participant ID a bit (add letter a after the number).  
 
 
b. Inspection Time 
Change to the Inspection Time Presentation file 
 
Instructions: On the computer screen you will first see a small cross – 
this is just a sign to tell  you to wait for the next picture. Next you will 
see two lines attached by a line at the top. One line is twice as long as 
the other. You have to press the right button (L on the keypad) if the 
longer line is on the right  (Show the picture with the long line on the 
right).  You have to press the left button (A on the keypad) if the longer 
line is on the left (Show the picture with the long line on the left).  What 
makes it  more difficult is that you will be shown the pictures very 
quickly and it  will show for varying times, less than a second so 
sometimes it  will  be harder to see than others. After one of these 
pictures is shown then the lines are masked out with a forest of other 
lines to be you can’t see it  anymore, because even when you take an 
image out of your view  - you may still  have an afterimage – like when 
you look at a lightbulb and can still  see it  when you turn away – to make 
sure that this doesn’t happen, the lines are masked after you see them 
with this picture called the forest (Show the forest picture). Once you 
see this picture – the forest - it  is a signal that you have been shown one 
of the two lines and that you should make a response (even if it  was too 
fast for you to see).  
 
On this task it  is important to answer correctly. How quickly you answer 
isn’t important, although you need to make a response by the time you 
see the forest – even if your not 100% sure which one is longer. I will 
let you try it  for yourself until  you get the hang of it .  (Instruct to press 
the buttons if necessary).  
 
5. Get ready for MRI 
Once training has been done take the participant through to the 
radiographer/assistant.  Remember - need to get to MRI staff by 20 
minutes before the scanning appointment 
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Appendix U                     
MRI Patient Safety Questionnaire 
